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1 Summary  
Flustra foliacea is a marine bryozoan found in the waters of Nova Scotia, the North 
Sea and the White Sea (Russia) and has been a rich source of mono- and 
diterpenoids and 32 indole alkaloids. Most of the Flustra alkaloids are brominated 
and possess prenyl (3,3-dimethylallyl) and/or tert-prenyl (1,1-dimethylallyl) groups 
located at various positions. The chemical synthesis of Flustra alkaloids and 
subsequent biological evaluation of the synthetic natural products and analogues 
was the subject of this thesis work. 
a. Synthesis of flustramine C, dihydroflustramine C and debromo analogues 
Flustrabromine (1) was synthesized from tryptamine (124) with an overall yield of 
29% in 5 steps. The natural product 1 was deformylated to deformylflustrabromine 
(3) in excellent yield. In the key step, 3 was subjected to Lindel’s oxidative 2-tert-
prenyl rearrangement conditions. On reaction with NBS at 0 °C cyclization and 
sigmatropic [1,5] shift of the 2-tert-prenyl group was induced to result in rac-
flustramine C (5) in a one pot transformation. No brominated side products were 
detected. Formation of 5 is most straight forward and possibly biomimetic.  
32% aq. NaOH,
EtOH, rf, 48 h
N
X
N
N
H
NH
X
NBS, THF,
0 °C, 1 h
rac-
5
: X = Br (71%)
6
: X = H (71%)
3
: X = Br (99%)
4
: X = H (97%)
DIBAL-H,
THF, rt, 24 h
N
H
X
N
rac-
7
: X = Br (93%)
8
: X = H (74%)
H
N
H
N
X
1
: X = Br
2
: X = H
O
N
X
N
H
base,
prenylbromide
rac-
9
: X=Br
(flustramine A)  
Scheme 1: NBS-induced oxidative rearrangement of 2-tert-prenyltryptamines. 
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Rac-flustramine C (5) was diastereoselectively reduced by DIBAL-H to result in rac-
dihydroflustramine C (7, 93%). However, prenylation of 7 did not lead to the 
formation of rac-flustramine A (9). Instead, degradation occurred.  
Application of Lindel’s rearrangement conditions on 3 worked well. Secondary amine 
3 upon reaction with NBS underwent cyclization/rearrangement to furnish rac-
debromoflustramine C (6). Similarly, reduction of 6 furnished rac-
debromodihydroflustramine C (8) for the first time (Scheme 1). 
Reaction of deformylflustrabromine (3) with NBS, NCS, and NIS furnished rac-
flustramine C (5) in every case with reaction times of 20-60 minutes, 2 d, and 3-7 
hours, respectively. The individual enantiomers of rac-flustramine C (5) were 
separated on a chiral HPLC column. The optical rotation for the enantiomer of 5 with 
the lower retention time (6.2 min) was [α]
D
21.6 = +153 ° (c = 7.9 mg/mL, CHCl
3
) while 
the enantiomer of 5 with the higher retention time (8.1 min) showed an optical 
rotation of [α]
D
21.8 = –155 ° (c = 8.1 mg/mL, CHCl
3
). The hypervalent iodine reagent 
PIFA (Phenyliodo(III)bis(trifluoroacetate)) formed 5 in low yield (5%). 
b. Scope of the NBS-induced rearrangement on 2-tert-prenyltryptamines  
The scope of Lindel’s oxidative 2-tert-prenyl rearrangement reaction was evaluated 
on structurally varied derivatives. NBS-induced cyclization and prenyl shift on 10 to 
furnish the dimethylated amidinium salt 12. The debromo analog 11 behaved in the 
same way to result in formation of 13. The salts 12 and 13 were diastereoselectively 
reduced by NaBH
4
 to form the N
a
-methyl-dihydroflustramine C (14) and debromo 
analogue 15, respectively. In the next case study, the methyl group at the aliphatic 
amino group was omitted. Reaction of 16 via NBS-induced oxidative cyclization and 
rearrangement of the 2-tert-prenyl group resulted in pyrrolo[2,3-b]indole 17 in 
moderate yield (Scheme 2). 
However, N
b
-formylated precursor 18 failed to undergo oxidation on reaction with 
NBS. The behavior of N
b
,N
b
-dimethyl indole 20 was surprising. Compound 20 was 
treated with NBS to generate transient bromoindolenine 21 which was characterized 
by NMR spectroscopy. After work-up with 2 M NaOH, 3-bromo-2-tert-prenylindole 
(22) and HBr salt of the starting material (23) were the only isolated products 
(Scheme 3). 
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Scheme 2: Presence/absence of alkyl substitution did not influence the 
cyclization/prenyl shift sequence. 
 
 
Scheme 3: NBS failed to rearrange the 2-tert-prenyl group when the aliphatic side 
chain contained either a formamide or a tertiary amine. 
The above results indicated that the bromine substituent is not required for the 
oxidative transformation. The methyl group at indole N-1 or an aliphatic amine do not 
disturb the cyclization/prenyl shift sequence whereas presence of the proton at the 
side-chain amine is necessary. However, if the side chain beared an amide or a 
tertiary amine moiety, no formation of pyrrolo[2,3-b]indoles was observed. 
c. Synthesis of rac-flustramine A 
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The doubly prenylated indole 175 was deformylated to 24. Secondary amine 24 was 
reacted with NBS in THF to undergo oxidative ring closure/sigmatropic [1,5] shift of 
2-tert-prenyl group to form the amidinium salt 25. The salt 25 was subsequently 
reduced by NaBH
4
 to furnish rac-flustramine A (9) in a combined yield of 28% over 
the last two steps (Scheme 4). 
 
Scheme 4: Synthesis of rac-flustramine A (9) from 24. 
d. Study on doubly prenylated indole under non oxidative conditions 
Doubly prenylated 26 was thermally stable and attempts to rearrange the prenyl 
group from indole N-1 under microwave conditions failed. In one experiment, DMF 
was used to add a formyl group to 27 whereas TFA salt 28 was formed in another 
experiment (Scheme 5). 
 
Scheme 5: Doubly prenylated indoles were thermally stable. 
e. Attempts towards the synthesis of debromoflustramine E 
It was envisaged that the regularly prenylated precursor 31 upon reaction with NBS 
would furnish debromoflustramine E (32). Danishefsky’s protocol worked for the 
indole derivative 29 albeit in low yields. Hydrazinolysis of 29 followed by formylation 
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resulted in the formamide indole 30 in 81% over two steps. Although amide 30 was 
reduced with DIBAL-H to furnish 31, efforts to obtain pure 31 were not fruitful as 31 
degraded readily (Scheme 6). 
 
Scheme 6: Synthesis of 2-prenyl-methyltryptamine (31).  
h. Biological evaluation of Flustra alkaloids and analogues 
Compounds deformylflustrabromine (3), flustramine C (5), and Li-74, 175, and 24 
were thoroughly screened against a panel of different 42 human cancer cell lines. 
N
a
-prenyl-deformylflustrabromine (24) showed highest cytotoxicity with a geometric 
mean IC
50
 value of 5.14 µM (Table 9). Compounds 175, 3, Li-74, and 5 showed 
geometric mean IC
50
 values of 21.2, 30.5, 36.7, and 43.4 µM, respectively. When 
tested for antimicrobial activity, compounds 24 and 26 showed IC
50
 values of 5.9, 7.7 
µM, and 22.6, 7.7 µM against the gram positive bacteria Micrococcus luteus and 
Mycobacterium phlei, respectively. An IC
50
 of 29 µM was observed for compound 26 
against the gram negative bacterium E.coli. None of the compounds were antifungal. 
For bacterial biofilm inhibition, all the compounds were tested at concentrations of 1, 
5, and 25 µM. Only compound 29 was active.  
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2 Introduction 
2.1 Natural products 
Natural product chemistry is important for medicine. From 1981 to 2010, 1130 new 
chemical compounds were approved as drugs with natural products (47) and natural 
product derivatives (247) being the major contributors. The majority of the newly 
approved medicinal agents were anticancer, antibacterial, antiviral, antihypertensive, 
and anti-inflammatory drugs in a number of 128, 118, 110, 79, and 51, respectively. 
Starting from 1940s to date, 48.6% of the small molecules used against Cancer were 
either natural products or derived from them.1 
Marine organisms produce a wide variety of natural products in response to the 
challenging environmental conditions. These natural products often exhibit high 
structural diversity and complexity. With interesting biological activities, they 
represent the leading scaffolds in drug discovery and development. Pharmaceutical 
research involving marine natural products gained interest only in the last three 
decades. Didemnins2 are a class of marine natural products with impressive in vitro 
and in vivo cytotoxicity (in concentrations below nM) resulting in the first human 
clinical trials in U.S. (up to Phase II).3 Another example is bryostatin 1 from the 
bryozoan Bugula neritina.4 Bryostatin 1 has been in at least 80 human clinical trials 
from which 20 trials completed phase I and phase II.5 Dolastatin 10 and its analogue 
symplostatin 1 isolated from the marine cyanobacterium Symploca sp. VP642 are 
microtubule inhibitors with effective depolymerisation ability on murine mammary 
tumors.6 The synthetic derivative soblidotin is in clinical trials phase II and more 
active than the natural product Dolastatin 10.7 Sponge derived compounds 
discodermolide (from Discodermia dissoluta), ecteinascidin 743 (from Ecteinascidia 
                                            
1.  D. J. Newman, G. M. Cragg, J. Nat. Prod. 2012, 75, 311–335. 
2.  K. L. Rinehart, J. B. Gloer, R. G. Jr. Hughes, H. E. Renis, J. P. McGovren, E. B. Swynenberg, D. 
A. Stringfellow, S. L. Kuentzel, L. H. Li, Science 1981, 212, 933–935. 
3.  M. D. Vera, M. M. Joullié, Med. Res. Rev. 2002, 22, 102–145 
4.  G. R. Pettit, C. L. Herald, D. L. Doubek, D. L. Herald, E. Arnold, J. Clardy, J. Am. Chem. Soc. 
1982, 104, 6846–6848. 
5.  A. Clamp, G. C. Jayson, Anti-Cancer Drugs 2002, 13,673–683. 
6. H. Luesch, R. E. Moore, V. J. Paul, S. L. Mooberry, T. H. Corbett, J. Nat. Prod. 2001, 64, 907–
910. 
7.   D. J. Newman, G. M. Cragg, J. Nat. Prod. 2004, 67, 1216–1238. 
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turbinata), applidine (from Trididemnum solidum) and kahalalide F (from Elysia 
rufescens) are in clinical trials.8   
Most of the marine natural products are alkaloids and halogenated compounds.9 
Presence of bromine and chlorine is a most common scenario..10 Moreover, 
heterocyclic core structures such as indole are a common motif in many natural 
products. A few examples of bis-indole alkaloids11 include dendridine A, anti-
corrosive caulerpin, and hyrtiazepine whereas tris-indoles such as gelliusines12 also 
exist. 
Non-marine indole alkaloids functinalized with either prenyl and/or tert-prenyl groups 
are represented by amauromine (33),13 gypsetin (34),14 fumitremorgin B (35)15, and 
brevianamide, to name a few (Figure 1). 
N
H
N
N
H
N
HO
H
H
OH
O
O
gypsetin (
34
)
N
N
N
O
O
HO
O
HO
H
fumitremorgin B (
35
)
N
H
N
N
O
O
H
N
H
H
H
amauromine (
33
)
H
 
Figure 1: Structures of pyrrolo[2,3-b]indole natural products functionalized with 
prenyl and/or tert-prenyl groups. 
Marine natural products sharing similar structural features to 33, 34, and 35 are 
flustramines (see Section 2.2.1) which have been isolated from the marine bryozoan 
Flustra foliacea (see Section 2.2). 
                                            
8.  G. M. Cragg, D. J. Newmann, Pure Appl. Chem. 2005, 77, 1923–1942. 
9.   P. M. Pauletti, L. S. Cintra, C. G. Braguine, A. A. d-S. Filho, M. L. A. Silva, W. R. Cunha, A. H. 
Januário, Mar. Drugs 2010, 8, 1526–1549. 
10.  C. S. Neumann, D. G. Fujimori, C. T. Walsh, Chem. Biol. 2008, 15, 99–109. 
11.  (a) M. Tsuda, Y. Takahashi, J. Fromont, Y. Mikami, J. Kobayashi, J. Nat. Prod. 2005, 68, 1277–
1278. (b) C. Kamal, M. G. Sethuraman, Ind. Eng. Chem. Res. 2012, 51, 10399–10407. (c) P. 
Sauleau, M.-T. Martin, M.-E. T. H. Dau, D. T. A. Youssef, M.-L. Bourguet-Kondracki, J. Nat. 
Prod. 2006, 69, 1676–1679. 
12.  G. Bifulco, I. Bruno, L. Minale, R. Riccio, J. Nat. Prod. 1994, 57, 1294–1299. 
13.  S. Takase, M. Iwami, T. Ando, M. Okamoto, K. Yoshida, H. Horiai, M. Kohsaka, H. Aoki, H. 
Imanaka, J. Antibiotics 1984, 2, 1320–1323. 
14.  C. Shinohara, K. Hasumi, Y. Takei, A. Endo, J. Antibiot. 1994, 47, 163–167. 
15.  M. Yamazaki, S. Suzuki, K. Miyaki, Chem. Pharm. Bull. 1971, 19, 1739–1740. 
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2.2 Flustra foliacea 
Flustra foliacea is a cheilostome marine bryozoan (Figure 2) commonly found at a 
depth of 15-20 meters. The larvae of F. foliacea selectively settle at the initially 
explored site. The mucopolysaccharide secretion facilitates a temporary attachment 
onto the surface followed by the protein secretions from the internal sac of the 
bryozoan to make this attachment rigid and permanent.16  
 
Figure 2: Flustra foliacea.17 
F. foliacea has an annual growth season between March and November with 
exponential addition of zooids. The frontal buds have the capacity of giving rise to 
new branches of fronds. Thickening of the frontal fronds leads to strengthening of the 
holdfast.18 The slow growing F. foliacea can be cultivated in the laboratory under 
defined conditions.19 Recently, the mitochondrial genome of F. foliacea was 
sequenced.20 
Flustra foliacea is an abundant source for terpenes and heterocyclic natural products 
having an indole core decorated with prenyl and/or tert-prenyl groups at various 
positions. .  
 
                                            
16.  M. J. Loeb, G. Walker, Mar. Biol. 1977, 42, 37–46. 
17.  (a) Figure on Left: online at http://www.habitas.org.uk/marinelife/species.asp?item=Y6940, on 
11/11/2012. (b) Figure on right: with permission from Jason Gregory on 10/09/2009. 
18.  A. R. D. Stebbing, Mar. Ecol. 1971, 9, 267–273. 
19.  J. Kahle, G. Liebezeit, G. Gerdes, Hydrobiologia 2003, 503, 237–244. 
20.  M. P. Nesnidal, M. Helmkampf, I. Bruchhaus, B. Hausdorf, BMC Genomics 2011, 12, 572–591. 
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2.2.1 Isolation 
GC-MS analysis of the volatile constituents from Flustra foliacea by Christophersen 
and Carlé resulted in the identification of five known compounds, cis-citral (36), 
trans-citral (37), citronellol (38), nerol (39), and geraniol (40, Figure 3).21 
 
Figure 3: Volatile constituents isolated from Flustra foliacea 
Christophersen et al. continued the search and were able to isolate the first Flustra 
alkaloids, possessing a physostigmine skeleton, namely flustramine A (9) and 
flustramine B (41).22 Structural assignment was unambiguously done utilizing 
standard methods of mass spectrometry, MCD (Magnetic Circular Dichroism), UV, 
IR, and NMR spectroscopy. Flustramine A (9) bears an inverted prenyl (1,1-
dimethylallyl) group at C-3 of the indoline nucleus whereas flustramine B (41) 
exhibits a 3,3-dimethylallyl unit at C-3. Nuclear Overhauser enhanced 1H NMR 
experiments revealed that bromine was present at the 6-position and that the 
pyrrolidino ring was cis fused.23  
In 1981, Carlé and Christophersen isolated the oxidized versions of 9 and 41, 
namely flustraminol A (42) and flustraminol B (43) along with the identification of 
flustramine C (5). Extensive spectroscopic studies indicated the presence of bromine 
at C-6 and a fused pyrrolo[2,3-b]indole system in all of the new natural products. The 
position of the inverse prenyl group was at C-3a in flustramine C (5) and at C-8a in 
the case of flustraminol A (42). Flustraminol B (43) contained the regular prenyl (3,3-
dimethylallyl) group at N-8 of the cyclic system.24 They also reported the isolation 
and structure elucidation of flustrabromine (1), which occurs in the form of two 
                                            
21.  C. Christophersen, J. S. Carlé, Naturwissenschaften 1978, 65, 440–441. 
22.  S. Carlé, C. Christophersen, J. Am. Chem. Soc. 1979, 101, 4012–4013. 
23.  J. S. Carlé, C. Christophersen, J. Org. Chem. 1980, 45, 1586–1589. 
24.  J. S. Carlé, C. Christophersen, J. Org. Chem. 1981, 46, 3440–3443. 
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rotational isomers in the NMR (CDCl
3
, room temperature), of flustramide A (44) and 
of 6-bromo-N
b
-formyl-N
b
-methyltryptamine (45, Figure 4).25,26  
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Figure 4: Indole alkaloids isolated from F. foliacea by Christophersen et al.25,26 
Wright tested the crude dichloromethane extract from F. foliacea against B. subtilis 
and, utilizing assay guided fractionation, isolated the alkaloid dihydroflustramine C 
(7)27 as one of the major metabolites, along with dihydroflustramine C N-oxide (46), 
flustramine D (47), flustramine D N-oxide (48), and isoflustramine D (49, Figure 5).28 
The subsequent members to be isolated were flustramine E (50), and 
debromoflustramine B (51) from the Danish west coast waters of the North Sea.29 
Gas-phase extraction with diethyl ether led to the identification of a citral dimer 52, 
probably being a work-up artifact.30 
                                            
25.  P. Wulff, J. S. Carlé, C. Christophersen, J. Chem. Soc. Perkin Trans. 1 1981, 2895–2898. 
26.  P. Wulff, J. S. Carlé, C. Christophersen, Comp. Biochem. Physiol.–B: Biochem. Mol. Biol. 1982, 
71 (3), 523–524. 
27.  J. L. C. Wright, J. Nat. Prod. 1984, 47, 893–895. 
28.  M. V. Laycock, J. L. C. Wright, J. A. Findlay, A. D. Patil, Can. J. Chem. 1986, 64, 1312–1316.  
29.  P. B. Holst, U. Anthoni, C. Christophersen, P. H. Nielsen, J. Nat. Prod. 1994, 57, 997–1000. 
30.  P. B. Holst, U. Anthoni, C. Christophersen, P. H. Nielsen, K. Bock, Acta Chem. Scand. 1994, 48, 
765–768. 
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Figure 5: Natural products isolated from the bryozoan F. foliacea. 
Interestingly, under similar conditions, Peters, König, et al. re-isolated the citral dimer 
52, flustramine A (9), flustramine C (5), flustraminol A (42), flustrabromine (1), 
dihydroflustramine C (7), and flustramine D (47), along with five new bromo-indole 
alkaloids 53 – 56.31,32 Alkaloid 53 shows a physostigmine core decorated with a 
geranyl group at the bridgehead 3a-position, while the remaining three alkaloids 54, 
55, and deformylflustrabromine (3) contained an indole core substituted with a tert-
prenyl group at indole C-2 (Figure 6). Lysek, Lindel, et al. re-isolated the natural 
products flustramine A (9), dihydroflustramine C (7), flustramine D (47), and 
deformylflustrabromine (3).33 Peters, König, et al. reported the isolation of 
deformylflustrabromine B (56)34 and a study on the variation in concentrations of 
indole alkaloids from F. foliacea (Figure 5 andFigure 6).35 
                                            
31.  L. Peters, G. M. König, H. Terlau, A. D. Wright, J. Nat. Prod. 2002, 65, 1633–1637. 
32.  L. Peters, G. M. König, A. D. Wright, R. Pukall, E. Stackebrandt, L. Eberl, K. Riedel, Appl. 
Environ. Microbiol. 2003, 69, 3469–3475. 
33.  N. Lysek, E. Rachor, T. Lindel, Z. Naturforsch. 2002, 57c, 1056–1061.  
34.  L. Peters, A. D. Wright, S. Kehraus, D. Gündisch, M. C. Tilotta, G. M. König, Planta Med. 2004, 
70, 883–886.  
35.  L. Peters, A. D. Wright, A. Krick, G. M. König, J. Chem. Ecol. 2004, 30, 1165–1181. 
Introduction  12 
 
 
Figure 6: Natural products isolated from the bryozoan Flustra foliacea. 
Recently, Rochfort, Wright, et al. reported the isolation of new flustramines from 
Canadian waters36 possessing complex structures with varied functionalities and 
designated as flustramines F–P (59 – 70, Figure 7). Flustramine F (59) is an N
1
-
acetylated version while flustramine G (60 is a dibrominated analogue of 
dihydroflustramine C (7). Flustramine H (61) and debromoflustramine H (62) 
possessed a geranyl and a hydroxyl group whereas flustramine I (63) is prenylated. 
Flustramine J (64) and K (65) were the dibromo analogues of flustramines H (62) 
and I (63). Flustramine L (66) was a hydroxylated isomer of flustramine D (47) 
whereas flustramine M (67) contained an oxidized prenyl group at the benzene 
section of the molecule. Interestingly, flustramine N (68) exhibits a benzofuro[2,3-
b]pyrrole core structure functionalized with an amino-, a bromo-, and a prenyl group 
at the 4-, 5-, and 7- positions, respectively. Flustramine O (69) is a pseudodimer with 
two units of dihydroflustramine C (7) connected by a methylene bridge, whereas 
flustramine P (70) was also a pseudodimer comprising dihydroflustramine C (7) and 
                                            
36.  S. J. Rochfort, S. Moore, C. Craft, N. H. Martin, R. M. van Wagoner, J. L. C. Wright, J. Nat. 
Prod. 2009, 72, 1773–1781.  
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flustramine H (61) joined by a methylene bridge. The authors propose that 69 and 70 
might be isolation artifacts. 
flustramine F (
59
) flustramine G (
60
)
N
Br
N
X=Br, flustramine H (
61
)
X=H, debromo-
flustramine H (
62
)
O
N
H
Br
N
Br
N
H
N
OH
X
H
H H
flustramine I (
63
)
N
H
N
OH
Br
H
flustramine J (
64
)
N
H
N
OH
Br
Br
flustramine K (
65
)
N
H
N
OH
Br
Br
flustramine L (
66
)
N
H
N
OH
Br
H
H
H
flustramine M (
67
)
N
H
N
Br
H
O
HO
flustramine N (
68
)
O
N
NH
2
Br
H
flustramine O (
69
) flustramine P (
70
)
N
H
N
OH
H
Br
N
Br
N
H
N
Br
N
H
N
Br
N
H
 
Figure 7: Flustramines isolated by Rochfort, Wright, et al.  
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2.2.2 Synthesis of flustramines – a literature survey 
2.2.2.1 Total syntheses of flustramine A 
Morales-Ríos, Joseph-Nathan, et al. developed a facile method via addition of 
organomagnesium species to 2-hydroxy indolenines introducing an alkyl moiety at 
the 3-position of indole. This methodology was extended to advanced intermediates 
which, in turn, enabled the first total syntheses of flustramine A (9) and B (41), 
flustramide A (44) and B and debromoflustramine B (51).37 
The synthesis of flustramine A (9) started at an advanced intermediate 71 which was 
prepared from an appropriately substituted 3-acetonitrilindole.38 2-Hydroxyindolenine 
71 was stirred with 4 equivalents of prenylmagnesiumbromide in anhydrous 
THF/ether at –78 °C resulting in the formation of C-3 tert-prenylated endo isomer 72 
and the C-3 prenylated analogue (not shown in Scheme 7) in a combined yield of 
76% with a ratio of 53:47. The reason for the formation of two products was 
attributed to the formation of equilibrium between prenylmagnesiumbromide with its 
more stable 1,1-dimethylallyl isomer.  
In the presence of wet alumina, α-cyano-γ-lactone 72 was subjected to hydrolytic 
decyanation in refluxing THF. The electron-withdrawing N-CO
2
Me substituent of 73 
was cleaved-off by refluxing in methanolic NaOMe and immediate treatment with 
K
2
CO
3
/prenylbromide in boiling acetone to give the lactone 74 (68% over two steps). 
Lactamization of the lactone 74 to flustramide A (44) was achieved by treating it with 
methylamine in MeOH at room temperature in 98% yield. Finally, the reduction of 44 
using LiAlH
4
 at room temperature furnished the natural product flustramine A (9, 
96%) with an overall yield of 23% over six steps (Scheme 7). 
                                            
37.  M. S. Morales-Ríos, O. R. Suárez-Castillo, J. J. Trujillo-Serrato, P. Joseph-Nathan, J. Org. 
Chem. 2001, 66, 1186–1192. 
38.  M. S. Morales-Ríos, M. A. Bucio, P. Joseph-Nathan, J. Heterocycl. Chem. 1993, 30, 953–956. 
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Scheme 7: First synthesis of (±)-flustramine A (9) as reported by Morales-Ríos and 
Joseph-Nathan et al.37  
The second total synthesis of rac-flustramine A (9) was reported by Fuchs and Funk 
in 2005 (Scheme 8).39 Working on base-promoted reactions of 3-alkyl-3-bromo-
indoline-2-ones, they developed a facile method for introducing intra- and 
intermolecular nucleophiles/dienophiles into 3-bromo-indolin-2-ones. 
 
Scheme 8: Concise synthesis of (±)-flustramine A as shown by Fuchs and Funk.39  
                                            
39.  J. R. Fuchs, R. L. Funk, Org. Lett. 2005, 7, 677–680. 
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6-Bromoindole 75 afforded 3-alkyl-3-bromo-indolin-2-one 76 on reaction with NBS 
(N-bromosuccinimide). Reaction of compound 76 with caesium carbonate and 
prenyltributylstannane resulted in the introduction of the tert-prenyl unit at the indole 
C-3 (77, 74%). A second prenyl group was introduced by the standard procedure of 
treating the indol-2-one 77 with NaH/prenylbromide to give the doubly prenylated 
intermediate 78 in 83% yield. Deprotection of 78 using caesium carbonate, according 
to Fukuyama protocol,40 and subsequent reduction by treatment with 1.1 equivalents 
of alane in THF led to the formation of rac-flustramine A (9, 55%) with a yield of 21% 
over 6 steps. 
In 2006, Kawasaki et al. published the first enantioselective total synthesis of (–)-
flustramine A (9), (–)-flustramine B (41), (–)-flustramide A (44), and (–)-flustramide B 
via a domino olefination–isomerization–Claisen rearrangement and reductive 
cyclization (Scheme 9).41  
The synthesis started with the preparation of optically active (S)-methyldec-2-en-4-ol 
(99% ee) in moderate yield. Bromination of 79 and substitution with the synthetic (S)-
methyldec-2-en-4-ol gave indolin-3-one 80 in 64% yield. In the next step, the 
intermediate 80 was allowed to react with cyanomethylphosphonate in a Horner–
Wadsworth–Emmons olefination reaction. This resulted in consecutive isomerization, 
Claisen rearrangement of the prenyl group onto the indole C-3 followed by 
deacylation to provide the indolin-2-one intermediate (–)-81 (70%, 96% ee). 
Ozonolysis of (–)-81 resulted in an unstable aldehyde 82, which underwent N
a
-
prenylation and Wittig olefination to give the doubly prenylated advanced precursor 
(–)-83. Alkaline hydrolysis of the nitrile (–)-83 gave the free acid (–)-84 which upon 
condensation with methylamine via the pentafluorophenyl ester using EDAC (1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide) furnished N-methylamide (–)-85 (99% 
ee, 67% after recrystallisation). In the next key step of reductive cyclization, 
treatment of (–)-85 with alane complex (AlH
3
·EtNMe
2
) at –15 °C resulted in the 
smooth conversion to (–)-flustramide A ((–)-44, 92%) while further reduction with the 
alane complex at room temperature completed the first enantioselective synthesis of 
(–)-flustramine A ((–)-9, 90%) with an overall yield of 15% in 9 steps (Scheme 9). 
                                            
40.  T.Fukuyama, C.-K. Jow, M. Cheung, Tetrahedron Lett. 1995, 36, 6373–6374. 
41.  T. Kawasaki, M. Shinada, D. Kamimura, M. Ohzono, A. Ogawa, Chem. Commun. 2006, 420–
422. 
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Kawasaki et al. also presented the total syntheses of (±)-flustramines A (9) and C 
(5), (±)-flustramide A (44) and (–)-debromoflustramine A, and (+)-
debromoflustramine A.42 By coupling with (R)-4-phenyloxazolidine-2-one, the (–)- 
and (+)- enantiomers of a carboxylic acid intermediate 84 were separated and 
carried forward to complete the syntheses of (–)- and (+)-debromoflustramines A (not 
shown in Scheme 9). 
 
Scheme 9: Enantioselective synthesis of (–)-flustramine A (9) by Kawasaki et al.41  
                                            
42.  T. Kawasaki, M. Shinada, M. Ohzono, A. Ogawa, R. Terashima, M. Sakamoto, J. Org. Chem. 
2008, 73, 5959–5964. 
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Bromination of 6-bromoindolin-3-one 79 at C-2, followed by substitution with prenol 
in the presence of molecular sieves (4Å) at room temperature provided the key 
molecule 86. Compound 86 was exposed to cyanomethylphosphonate in the 
presence of tert-BuOK at –78 °C and allowed to warm to room temperature. This led 
to isomerization, Claisen rearrangement of the intermediate 86, and deacetylation in 
a single pot to afford the C-3 tert-prenylated indolin-2-one 88 (90%). N
a
-prenylation 
of 88 for the second time, followed by alkaline hydrolysis of the nitrile group and 
condensation with methylamine gave the amide 83. Chemoselective reduction of this 
amide 83 using alane, as demonstrated previously (Scheme 9), resulted in the 
formation of (±)-flustramine A (9) via (±)-flustramide A (44). Thus far, this is the best 
synthesis of (±)-flustramine A (9) with a yield of 54% over 8 steps (Scheme 10).42 
 
Scheme 10: Synthesis of (±)-flustramine A (9) by Kawasaki et al.42  
One of the recent enantioselective syntheses of (+)-flustramine A (9) was shown by 
Trost et al. who developed a general palladium catalyzed asymmetric prenylation 
and geranylation process with high regio- and enantioselectivity.43 After tuning the 
                                            
43.  B. M. Trost, S. Malhotra, W. H. Chan, J. Am. Chem. Soc. 2011, 133, 7328–7331. 
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selectivity toward tert-prenylation to optimal conditions with ligand 90 in DCM, N
a
-
prenylated precursor 89 was treated with 1.0 equivalent of the prenyl nucleophile, 
2.5 mol% palladium(0) source, 7.5 mol% of the ligand 90, and 30 mol% of the TBAT 
additive to furnish 85 with an excellent ee of 99%. Employing the conditions of 
Kawasaki et al., the doubly prenylated indole 85 was converted to (+)-flustramide A 
(44, 92%) and subsequently to (+)-flustramine A (9, 90%) with an overall yield of 
16% in 5 steps (Scheme 11). 
 
Scheme 11: Total synthesis of (+)-flustramine A by Trost et al.43  
 
2.2.2.2 Total syntheses of flustramine C, dihydroflustramine C, and 
deformylflustrabromine 
There are three total syntheses reported for flustramine C (5). Kawasaki et al. 
described the first synthesis of flustramine C (5). The synthesis commenced by 
exposure of the intermediate 88 to Red-Al to result in reductive cyclization to afford 
the tricyclic compound 91 (89%). Reaction of tricyclic compound 91 with 
methyliodide in the presence of sodium bicarbonate gave flustramine C (5, 38%) 
along with its regioisomer (92, 29%), completing the first total synthesis with an 
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overall yield of 9% in 8 steps (Scheme 12).44 Without any further modification, 
Kawasaki et al. reported the synthesis again and described the use of the common 
intermediate 88 for the construction of (±)-flustramine A (9).42  
 
Scheme 12: Total synthesis of (±)-flustramine C according to Kawasaki et al.44  
Similarly, starting from the advanced precursor 77, Fuchs and Funk showed the 
synthesis of rac-flustramine C (5). On reaction with the Meerwein salt 77 provided 
the imidate 93 (76%). Deprotection of the nosylamide functionality under Fukuyama 
conditions did not furnish rac-flustramine C (5). However, heating the crude 
deprotected amine mixture in toluene with one equivalent of acetic acid afforded rac-
flustramine C (5, 84%) with an overall yield of 39% over five steps, starting from 75 
(Scheme 13).39 
 
Scheme 13: Fuchs and Funk reported the total synthesis of (±)-flustramine C.39  
There exists only one total synthesis for dihydroflustramine C (7). Using the synthetic 
route as in the case of flustramine A (9,Scheme 7),37 Morales-Ríos, Joseph-Nathan, 
et al. synthesized dihydroflustramine C (7) and flustramine E (50) within five steps. 
The N-1 carboxylic ester was obtained within two steps from 71. Saponification of 94 
followed by reaction with methylamine, and reduction with alane complex furnished 
                                            
44.  T. Kawasaki, R. Terashima, K.-e. Sakaguchi, H. Sekiguchi, M. Sakamoto, Tetrahedron Lett. 
1996, 37, 7525–7528. 
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the natural product dihydroflustramine C (7) with an overall yield of 32% (Scheme 
14).45 
 
Scheme 14: Morales-Ríos, Joseph-Nathan, et al. reported the first synthesis of 
dihydroflustramine C (7).37  
Kim and co-workers explored the synthesis of the HCl salt of 3 from 6-bromoindole 
(95) with 16% overall yield in 7 steps (Scheme 15).46 Employing the Speeter/Anthony 
reaction on 6-bromoindole (95) and subsequent reduction and protection, the key 
compound 97 was obtained in 5 steps. Incorporation of 2-tert-prenyl group followed 
by deprotection and acidic treatment furnished the HCl salt of 
deformylflustrabromine. 
 
Scheme 15: The HCl salt of deformylflustrabromine (3) was reported by Kim et al.46  
 
                                            
45.  M. S. Morales-Ríos, O. R. Suárez-Castillo, P. Joseph-Nathan, Tetrahedron 2002, 58, 1479–
1484 
46.  J.-S. Kim, A. Padnya, M. Weltzin, B. W. Edmonds, M. K. Schulte, R. A. Glennon. Bioorg. Med. 
Chem. Lett. 2007, 17, 4855–4860. 
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2.2.2.3 Syntheses of other Flustra alkaloids and analogues 
Apart from the discussed syntheses of flustramine A (9), flustramine C (5), 
dihydroflustramine C (7), and deformylflustrabromine (3), there are several 
syntheses reported for the other members of the Flustra alkaloids. Table 1 highlights 
the syntheses of flustramine natural products while Table 2 summarizes the total 
syntheses of debrominated versions of the flustramines. 
The work of Morales-Ríos made it possible to synthesize natural products 
flustramide A (44), flustramide B, flustramine A (9), flustramine B (41), and 
flustramine E (50) in good overall yields whereas Kawasaki et al. achieved the total 
syntheses of (–)-flustramide A (44), (–)-flustramide B, and (–)-flustramine B ((–)-41). 
However, the most elegant synthesis was published by Trost et al. who were able to 
achieve the synthesis of (+)-flustramide A ((+)-44) and (+)-flustramide B in two steps 
with overall yields above 50%. There are three total syntheses reported for each of 
the rac-flustramine B (41) and (–)-flustramine B (41) with the best overall yields 
being 24% and 58%, respectively. There are two equally good syntheses for the 
construction of flustramine E (50) while only one synthesis exists for each of the 
natural products (+)-flustramine B (41), rac-flustraminol B (43), (–)-flustraminol B 
(43), deformylflustrabromine (3), and deformylflustrabromine B (56). Table 1 
provides an overview of the reported syntheses and compares each one of them in 
terms of number of steps and overall yield. As of today, there are no total syntheses 
published for the natural products flustramine D (47), as well as for the structurally 
challenging flustramines F–P (59–70). 
Table 1: Reported syntheses of flustramines. 
Flustramine Author 
∑ 
Steps 
Overall 
Yield 
(%) 
rac-flustramide A M. S. Morales-Ríos (2001)37  4 24 
(–)-flustramide A T. Kawasaki (2006)41  8 17 
(+)-flustramide A B. M. Trost (2011)43  2 53 
rac-flustramide B M. S. Morales-Ríos (2001)37  4 18 
 D. Aburano (2007)47 7 27 
(–)-flustramide B T. Kawasaki (2006)41  7 13 
                                            
47.  D. Aburano, T. Yoshida, N. Miyakoshi, C. Mukai, J. Org. Chem. 2007, 72, 6878–6884. 
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Flustramine Author 
∑ 
Steps 
Overall 
Yield 
(%) 
(+)-flustramide B B. M. Trost (2011)43  2 61 
rac-flustramine B T. Hino (1983)48 6 7 
 M. S. Morales-Ríos (2001)37  5 17 
 D. Aburano (2007)47  8 24 
(–)-flustramine B J. F. Austin (2004)49 7 58 
 T. Kawasaki (2006)41  8 12 
 S. Kobayashi (2009)50   
(+)-flustramine B B. M. Trost (2011)43  3 55 
rac-flustraminol B O. R. Suárez-Castillo (2007)51   
(–)-flustraminol B N. Hara (2011)52   
flustramine E M. S. Morales-Ríos (2002)53 5 27 
 D. Aburano (2007)47  7 28 
deformylflustrabromine B J.-S. Kim (2007)46 6 35 
 
The synthesis of debrominated Flustra alkaloids is an intensely studied area. 
Individual syntheses were described for (–)-debromoflustramine A, (+)-
debromoflustramine A, debromoflustraminol B, and debromoflustrabromine (2) with 
moderate yields. Morales-Ríos et al. and Aburano et al. described efficient routes for 
the construction of debromodihydroflustramine C (8) and debromoflustramide E with 
overall yields of 39% and 35%, respectively. Debromoflustramine E (32) was made 
via four different synthetic routes. The shortest route consisted of 3 steps (24% yield) 
whereas the longest synthetic sequence required 14 steps with 19% overall yield. 
Debromoflustramine B (51) is one of the most studied molecules from F. foliacea and 
there are 17 syntheses accounted altogether. Among the eight syntheses of rac-
debromoflustramine B (51), Morales-Ríos et al. prepared 51 on three occasions 
reaching the highest efficiency of 41% in 6 steps. The most recent synthesis was 
                                            
48.  T. Hino, T. Tanaka, K. Matsuki, M. Nakagawa, Chem. Pharm. Bull. 1983, 31, 1806–1807. 
49.  J. F. Austin, S.-G. Kim, C. J. Sinz, W.-J. Xiao, D. W. C. MacMillan, PNAS 2004, 101, 5482–
5487. 
50.  S. Kobayashi, T. Hirano, K. Iwakiri, H. Miyamoto, A. Nakazaki, Heterocycles 2009, 79, 805. 
51.  O. R. Suárez-Castillo, M. Sánchez-Zavala, M. Meléndez-Rodríguez, E. Aquino-Torres, M. S. 
Morales-Ríos, P. Joseph-Nathan, Heterocycles 2007, 71, 1539–1551. 
52.  N. Hara, S. Nakamura, Y. Funahashi, N. Shibata, Adv. Synth. Catal. 2011, 353, 2976–2980. 
53.  M. S. Morales-Ríos, O. R. Suárez-Castillo, P. Joseph-Nathan, Tetrahedron 2002, 58, 1479–
1484 
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reported by Zhou et al., who prepared the rac-debromoflustramine E (32) in 41% 
over 10 steps and thus far the best synthesis of 32. Although Cardoso et al. 
improved the synthesis of (+)-debromoflustramine B (51) from 12 to 10 steps, the 
best route to 51 in 8 steps and 18% overall yield was reported by Morales-Ríos. 
Enantiopure (–)-debromoflustramine B (51) also attracted much attention and there 
exist five synthetic routes to the molecule. Some of the best syntheses were 
developed by Trost et al. and Austin et al. providing (–)-debromoflustramine B (51) 
with isolated yields of 46% and 59%, respectively. Table 2 summarizes the total 
syntheses of individual debromoflustramines with emphasis on the number of steps 
and overall yield, placed in a chronological order. 
Table 2: Syntheses of debromoflustramines. 
Flustramine Author 
∑ 
Steps 
Overall 
Yield 
(%) 
(–)-debromoflustramine A T. Kawasaki (2008)42  9 11 
(+)-debromoflustramine A T. Kawasaki (2008)42  9 13 
rac-debromoflustramide B J. Jensen (1995)54 2 32 
 D. Aburano (2007)47  4 22 
 H. Miyamoto (2007)55 13 15 
(+)-debromoflustramide B A. S. Cardoso (2001)56 9 3 
 A. S. P. Cardoso (2007)57 7 4 
rac-debromoflustramine B J. Jensen (1995)54  3 25 
 M. S. Morales-Ríos (2001)37  5 16 
 G. H. Tan (2003)58 4 27 
 M. S. Morales-Ríos (2005)59 5, 6 38, 41 
 H. Miyamoto (2007)55  14 19 
 A. W. Schammel (2010)60 5 27 
 Y. Zhou (2012)61 10 29 
                                            
54.  J. Jensen, U. Anthoni, C. Christophersen, P. H. Nielsen, Acta Chem. Scand. 1995, 49, 68–71. 
55.  H. Miyamoto, Y. Okawa, A. Nakazaki, S. Kobayashi, Tetrahedron Lett. 2007, 48, 1805–1808. 
56.  A. S. Cardoso, N. Srinivasan, A. M. Lobo, S. Prabhakar, Tetrahedron Lett. 2001, 42, 6663–
6666. 
57.  A. S. P. Cardoso, M. M. B. Marques, N. Srinivasan, S. Prabhakar, A. M. Lobo, Tetrahedron 
2007, 63, 10211–10225. 
58.  G. H. Tan, X. Zhu, A. Ganesan, Org. Lett. 2003, 5, 1801–1803. 
59.  M. S. Morales-Ríos, E. Rivera-Becerril, P. Joseph-Nathan, Tetrahedron: Asymmetry 2005, 16, 
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Flustramine Author 
∑ 
Steps 
Overall 
Yield 
(%) 
(–)-debromoflustramine B A. S. Cardoso (2001)56  12 2 
 J. F. Austin (2004)49  6 59 
 M. S. Morales-Ríos (2005)59 8 18 
 A. S. P. Cardoso (2007)57 10 1 
 B. M. Trost (2011)43  4 46 
(+)-debromoflustramine B M. Bruncko (1984)62 12 5 
 A. S. Cardoso (2001)56  12 2 
 A. S. P. Cardoso (2007)57  10 2 
 M. S. Morales-Ríos (2005)59  8 18 
debromoflustraminol B O. R. Suárez-Castillo (2006)63 6, 7 32, 10 
debromodihydroflustramine C S.Takase (1986)64 9 2 
 M. S. Morales-Ríos (2002)53  5 39 
 A. Sabahi (2010)65 7 25 
rac-debromoflustramide E J. Jensen (1995)54  2 24 
 D. Aburano (2007)47 3 35 
rac-debromoflustramine E J. Jensen (1995)54  3 24 
 M. S. Morales-Ríos (2002)53  5 23 
 H. Miyamoto (2007)55  14 19 
 Y. Zhou (2012)61  10 41 
debromoflustrabromine I. V. Zhun (2004)66 3 34 
 
 
2.3 Biological evaluation of flustramines 
Even before the isolation of any alkaloids from the bryozoan F. foliacea, Al-Ogily and 
Knight-Jones reported, in 1977, that the larvae of F. foliacea readily settled at the 
distal growing edge of the other bryozoan Scrupocellaria reptans to colonize and that 
the older parts of the fronds showed higher antibacterial activity.67 They also 
indicated that the older parts of the fronds emitted the characteristic smell of lemon 
                                            
62.  M. Bruncko, D. Crich, R. Samy, J. Org. Chem. 1984, 59, 5543–5549. 
63.  O. R. Suárez-Castillo, M. Sánchez-Zavala, M. Meléndez-Rodríguez, L. E. Castelán-Duarte, M. 
S. Morales-Ríos, P. Joseph-Nathan, Tetrahedron 2006, 62, 3040–3051. 
64.  S. Takase, I. Uchida, H. Tanaka, H. Aoki, Tetrahedron 1986, 42, 5879–5886. 
65.  A. Sabahi, J. D. Rainier, Arkivoc 2010, 8, 116–125. 
66.  I. V. Zhun, A. V. Ignatenko, Russ. Chem. Bull.2004, 53, 2221–2223. 
67.  S. Al-Ogily, E. W. Knight-Jones, Nature 1977, 265, 728–729. 
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which is distinct from the growing edges of fronds. The muscle relaxation capability 
of the Flustra extract was partly attributed to flustramine A (9).68 
Later, Wright indicated strong activity of the crude extract of F. foliacea against B. 
subtilis although no exact quantification was mentioned.24 Similarly, the alkaloid 
fraction containing mainly dihydroflustramine C (7), and flustramine D (47) showed 
unspecific activity against Enterobacter cloacae, Escherichia coli, Klebsiella 
pneumoniae, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhimurium, 
Serratia marcescens, Staphylococcus aureus, and Staphylococcus epidermidis.69 
At a concentration of 1000 ppm in DMSO, flustramine E (50) was inactive against P. 
aeruginosa, Pythium ultimum, and Aspergillus niger. However, at the same dosage, 
a marginal activity was observed for B. subtilis, Fusarium oxysporum, and 
Saccharomyces cerevisiae with complete zones of inhibition in the range of 12, 10, 
and 14 mm, respectively. Further antimicrobial evaluation of flustramine E (50) was 
made at concentrations of 1000, 100, and 10 ppm, against Rhizotonia solani and 
Botrytis cinerea. The complete zones of inhibition for R. solani were 10, 9, and 9 mm 
whereas B. cinerea exhibited 27, 25, and 21 mm, respectively.29  
Other structurally related flustramines isolated from Canadian waters showed strong 
activity against B. subtilis while flustramine E (50) isolated from coastal Denmark 
showed only moderate activity. It could be speculated that the ecological 
environments in both these areas are substantially different resulting in differential 
response from the same bryozoan to produce different alkaloids with varied 
concentrations. This behavior supports the “theory of adaptive variance” as proposed 
by Christophersen.70 
Peters, Wright et al. extensively evaluated the 11 isolated secondary metabolites in 
an agar diffusion assay against marine and non-marine bacteria such as H. Marina, 
E. coli, B. megaterium, Roseobacter sp., Sulfitobacter sp., Pseudomonas pabuli, and 
Psychroserpens sp. The latter four bacterial strains were obtained from F. foliacea 
itself. Of the 11 tested compounds none was able to inhibit the growth of H. marina. 
The inhibition zones against E. coli, B. megaterium, and Roseobacter sp. were in the 
                                            
68.  T. Sjöblon, L. Bohlin, c. Christophersen, Acta Pharm. Suec. 1983, 20 (6), 415–418. 
69.  M. V. Laycock, J. L. C. Wright, J. A. Findlay, A. D. Patil, Can. J. Chem. 1986, 64, 1312–1316. 
70.  C. Christophersen, Comp. Biochem. Physiol. 1991, 98, 427–432. 
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range of 1 to 5 mm (1 mg/mL) while against P. pabuli the activities were in the range 
of 2 to 7 mm. With the exception of a 12 mm inhibition zone for compound 54, all 
other compounds showed inhibition zones ranging from 2 to 5 mm against 
Psychroserpens sp. However, moderate activity against Sulfitobacter sp. was 
observed with 2 to 7 mm for complete zones of inhibition for compounds 53, 54, 56, 
57, 3, and 41, respectively. 
Furthermore, the compounds 3, 53, 7, 41, and 47 were evaluated for AHL dependent 
quorum sensing activity. At a concentration of 20 µg/mL, dihydroflustramine C (7) 
caused a reduction in the fluorescent signal intensity of 50% against P. putida (pKR-
C12) and E. coli (pSB403) and of 30% against P. putida (pAS-C8). Similarly, 
flustramine D (47) caused reduction in the signal intensity by 50% against E. coli 
(pSB403) and by 20% against both P. putida (pKR-C12) and P. putida (pAS-C8). 
These results point at a specific inhibition of AHL-mediated cell-cell 
communication.32  
In 2011, Bunders, Melander, et al. synthesized deformylflustrabromine (3) and 
flustramine C (5) following the procedures reported by Lindel et al. and screened for 
a possible bacterial biofilm inhibition. When tested against three different strains of 
bacterial pathogens, Acetonetobacter baumannii, E. coli, and methicillin resistant 
Staphylococcus aureus (MRSA), flustramine C (5) showed moderate antibiofilm 
activity (30% at 100 µM).71 Deformylflustrabromine (3) inhibited E. coli and S. aureus 
biofilm formation with moderate activity as well (IC
50
 = 174 and 70 µM, 
respectively).72 Furthermore, synthetic derivatives of flustramines (Figure 8) were 
prepared and evaluated for antibiofilm activity resulting in enhanced activities.  
                                            
71.  C. Bunders, J. Cavanagh, C. Melander, Org. Biomol. Chem. 2011, 9, 5476–5481. 
72.  C. A. Bunders, M. J. Minvielle, R. J. Worthington, M. Ortiz, J. Cavanagh, C. Melander, J. Am. 
Chem. Soc. 2011, 133, 20160–20163. 
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Figure 8: Antibiofilm active analogues.71,72 
Lysek, Lindel, et al. reported the cytotoxicity of Flustra alkaloids for the first time. 
Deformylflustrabromine (3) showed the highest cytotoxicity against human colon 
cancer cell line HCT-116 with an IC
50
 value of 5.8 µM while flustramine A (9), 
flustramine D (47), and dihydroflustramine C (7) showed weak activity in the range of 
26 µM.33  
For concentrations up to 10 µM, deformylflustrabromine (3), flustramine A (9), 
flustramine C (5), and dihydroflustramine C (7) showed specific effects neither on 
evoked currents of the activated potassium channels (Kv1.1 and Kv1.4) nor on the 
rat brain Na
v
1.2 sodium channel.31  
Acetylcholine (ACh) is responsible for the opening of nicotinic acetylcholine 
receptors (nAChRs). Sala et al. reported that the natural product 
deformylflustrabromine (3) when co-applied with ACh, selectively caused 
potentiation in α4β2 human neuronal nicotinic acetylcholine receptors. This effect 
was fast, reversible, and concentration dependent although high concentrations were 
required.73 The same result was confirmed again, following experiments on human 
α7 and α4β2 nACh receptors expressed in Xenopus oocytes by Kim, Glennon, et al. 
They reported that deformylflustrabromine (3) and deformylflustrabromine B (56) 
were able to inhibit α7 nACh receptors with IC
50
 values of 44 µM and 14 µM, 
respectively.46 Continuing on the same topic, German, Glennon, et al. dis-assembled 
the natural product deformylflustrabromine (3) to prepare synthetic analogues, 
aiming at determining the structural components responsible for the action against 
                                            
73.  F. Sala, J. Mulet, K. P. Reddy, J. A. Bernal, P. Wikman, L. M. Valor, L. Peters, G. M. König, M. 
Criado, S. Sala, Neurosci. Lett. 2005, 373, 144–149. 
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α7 and α4β2 nACh receptors. Although the natural product 3 was moderately active 
against α4β2 nACh (EC
50
 = 0.32 µM) and α7 nACh receptors (pIC
50
 = 5.73), the 
molecule with a hydrogenated tert-prenyl group was more selective (pIC
50
 = 6.86).74 
Recently, Pérez, Gündisch, et al. prepared and tested a variety of indole derivatives, 
including deformylflustrabromine B (56) and deformylflustrabromine (3), for their 
affinity towards α4β2, α3β4, α7, and (α1)
2
β2 nicotinic acetylcholine receptors. The 
radioligand binding assays indicated that deformylflustrabromine B (56) did not 
increase responses when co-applied with ACh on α4β2 receptors. Instead, 56 
inhibited ACh-induced responses in α4β2 and α7 receptors.75 
Rivera-Becerril, Morales-Ríos, et al. synthesized and tested the analogues of 
debromoflustramine B (51) for in vitro cholinesterase inhibition.76 Against human 
butyrylcholinesterase (BChE), rac-debromoflustramine B (51) showed an inhibition 
with an IC
50
 of 2.6 µM, whereas (–)-debromoflustramine B (51) exhibited an 
elevation in activity (IC
50
 = 1.4 µM). The enantiopure (+)-debromoflustramine B was 
inactive, but other synthetic derivatives 99, 100, and 101 (Figure 9) were found to be 
more active than the natural products with IC
50
 values of 0.26, 1.72, and 4.59 µM, 
respectively. 
 
Figure 9: Synthetic analogues of 51 were active on human BChE.76 
 
                                            
74.  N. German, J.-S. Kim, A. Jain, M. Dukat, A. Pandya, Y. Ma, M. Weltzin, M. K. Schulte, R. A. 
Glennon, J. Med. Chem. 2011, 54, 7259–7267. 
75.  E. G. Pérez, B. K. Cassels, C. Eibl, D. Gündisch, Bioorg. Med. Chem. 2012, 20, 3719–3727. 
76.  E. Rivera-Becerril, P. Joseph-Nathan, V. M. Pérez-Álvarez, M. S. Morales-Ríos, J. Med. Chem. 
2008, 51, 5271–5284. 
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Flustra alkaloids possess complex structures having distinct functionalities at various 
positions. They exhibit a wide variety of selectivity against a range of biological 
targets. It is also very interesting to address the issue of “how nature makes these 
molecules effectively and converts one natural product into another?” The following 
section highlights some of the biomimetic postulations with respect to the formation 
of prenylated indole alkaloids, in general.  
 
2.4 Biomimetic syntheses of prenylated  indole alkaloids 
Biomimetic conversion of natural products is highly interesting. One of the earliest 
examples in the indole alkaloid field was given by Tillequin and Koch who chemically 
interconverted the natural product borrerine (102) to borreverine (103) and 
isoborreverine (104) by refluxing in TFA/benzene at 65 °C (Scheme 16).77  
 
Scheme 16: Biomimetic conversion of Borreria alkaloids.77  
 
                                            
77.  F. Tillequin, M. Koch, J.-L. Pousset, A. Cavé, J. Chem. Soc., Chem. Commun. 1978, 826–828. 
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The plausible biomimetic dimerization proceeds via protonation of borrerine (102) to 
result in two open analogous structures 105 and 106. The intermolecular 
cycloaddition via two cis-trans isomeric forms 107 and 108 would lead to the 
formation of these natural products (Scheme 17). 
 
Scheme 17: Postulated biomimetic conversion of borrerine (102) to borreverine (103) 
and isoborreverine (104).77  
The extract from aerial parts of the plant Borreria verticillata is externally applied for 
the treatment of skin diseases in West Africa. The indole alkaloids spermacoceine,78 
                                            
78.  A. M. Baldé, L. A. Pieters, A. Gergely, V. Wray, M. Claeys, A. J. Vlietinck, Phytochemistry 1991, 
30, 997–1000. 
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borrerine (102) 79 and its dimers borreverine (103)80 and isoborreverine (104) 81,82 co-
occurred in B. verticillata. 
With the aid of biotechnological techniques, Shu-Ming Li made significant 
contributions in developing biochemical prenylation methodologies. Aspergillus 
fumigatus is a fungal strain from which the prenylated diketopiperazine fumitremorgin 
B (113) was isolated. Grundmann and Li identified the prenyltransferase gene 
FtmPT1 (fumitremorgin prenyltransferase 1) and showed that this enzyme was able 
to catalyse the prenylation at indole 2-position of brevianamide F (109) to afford 
tryprostatin B (110) in a single biochemical transformation.83 Later, the N-
prenyltransferase enzyme FtmPT2 was found to catalyse the N-prenylation of indole 
nitrogen and thus demonstrating the feasibility of the last step in the biosynthesis of 
fumitremorgin B (113, Scheme 18).84  
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Scheme 18: Biosynthesis of tryprostatin B (110) and fumitremorgin C (113).83,84  
                                            
79.  J. L. Pousset, J. Kerharo, G. Maynart, X. Monseur, A. Cavé, R. Goutarel, Phytochemistry 1973, 
12, 2308–2310. 
80.  J. L. Pousset, A. Cavé, A. Chiaroni, C. Riche, J. Chem. Soc., Chem. Commun. 1977, 8, 261–
262. 
81.  F. Tillequin, M. Koch, A. Rabaron, J. Nat. Prod. 1985, 48, 120–123. 
82.  A. M. Baldé, A. Gergely, L. A. Pieters, M. Claeys, D. A. Vanden Berghe, A. J. Vlietinck, Planta 
Med. 1989, 55, 652. 
83.  A. Grundmann, S.-M. Li, Microbiology 2005, 151, 2199–2207. 
84.  A. Grundmann, T. Kuznetsova, S. S. Afiyatullov, S.-M. Li, ChemBioChem 2008, 9, 2059–2063. 
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Bhat and co-workers fed deuterium labeled L-[2,4,5,6,7-2H
5
]tryptophan to cultures of 
Penicillium roqueforti and Aspergillus zonatus and incorporated the entirely labeled 
tryptophan into roquefortine (115) and aszonalenin (116), respectively (Scheme 
19).85,86 The deuterium found at C-6 of the resulting natural products stemmed from 
the labeled L-tryptophan. It was also found that the tert-prenyl group in the final 
natural products had not been transferred via the C-2 of the indole precursor. This is 
in contrast to the proposal of Barrow et al. 87 and Gorst-Allmann et al.88 They 
postulated that the Claisen rearrangement of an N-prenyl group would result in a 2-
tert-prenyl group which in turn undergoes [1,2] rearrangement to provide the C-3 tert-
prenylated natural products. 
 
Scheme 19: Incorporation of deuterated tryptophan into roquefortine (115) and 
aszonalenin (116).85,86  
Geneserine and geneseroline were shown to participate in an acid/base catalyzed 
equilibrium to form physostigmine N-1 oxide and geneseroline N-1 oxide respectively 
(not shown in Scheme 20).89 Similarly, Hoist and co-workers reported a reversible 
facile conversion of flustrarine B (117) into flustramine B N-1 oxide hydrochloride 
                                            
85.  B. Bhat, D. M. Harrison, H. M. Lamont, J. Chem. Soc., Chem. Commun. 1990, 1518–1519. 
86.  B. Bhat, D. M. Harrison, H. M. Lamont, Tetrahedron 1993, 49, 10663–10668. 
87.  K. D. Barrow, P. W. Colley, D. E. Tribe, J. Chem. Soc., Chem. Commun. 1979, 225–226. 
88.  C. P.Gorst-Allman, P. S. Steyn, R. Vleggaar, J. Chem. Soc., Chem. Commun. 1982, 652–653. 
89.  Q.-S. Yu, H. J. C. Yeh, A. Brossi, J. L. Flippen-Anderson, J. Nat. Prod. 1989, 52, 332–336. 
Introduction  34 
 
(118) in a quantitative manner.90 On treatment of flustrarine B (117) with ethanolic 
hydrogen chloride, isomeric flustramine B N-1 oxide (118) was formed by means of 
ring contraction. This reaction proved to be reversible under alkaline conditions 
resulting in the formation of indole 117. Based on these results, it was proposed that 
dihydroflustramine C N-oxide (46) and flustramine D N-oxide (48) isolated from the 
Canadian collection of F. foliacea could exist as hexahydro-1,2-oxazino[5,6-b]indole 
regioisomers 119 and 120 (Scheme 20). 
 
 
Scheme 20: Interconversion of flustrarines and flustramines.90  
Recently, Finefield et al. and Li et al. reported the in vitro characterization of a FAD 
dependent monooxygenase NotB (notoamide B prenyltransferase). NotB was 
utilized for the biomimetic conversion of notoamide E (121) into notoamide C (122) 
and notoamide D (123), in a ratio of 1:16 (Scheme 21).91 
                                            
90.  P. B. Holst, U. Anthoni, C. Christophersen, P. H. Nielsen, J. Nat. Prod. 1994, 57, 1310–1312. 
91.  (a) J. M. Finefield, T. J. Greshock, D. H. Sherman, S. Tsukamoto, R. M. Williams, Tetrahedron 
Lett. 2011, 52, 1987–1989. (b) S. Li, J. M. Finefield, J. D. Sunderhaus, T. J. McAfoos, R. M. 
Williams, D. H. Sherman, J. Am. Chem. Soc. 2012, 134, 788–791. 
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Scheme 21: Notoamide E (121) can be enzymatically converted to notoamide C 
(122) and D (123).91 
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3 Results and discussion 
The chemical synthesis of the natural products N
b
-formyl-N
b
-methyltryptamine (131), 
flustrabromine (1), deformylflustrabromine (3), flustramine A (9), flustramine C (5), 
dihydroflustramine C (7), and flustramine E (50) and the enantioselective synthesis 
of flustramine C (5) was undertaken in this thesis work. Subsequently, the biological 
activity of the synthesized natural products and their derivatives was assessed 
against different biological targets. 
3.1 Synthesis of flustrabromine 
Flustrabromine (1) is an important intermediate towards the total synthesis of 
pyrrolo[2,3-b]indole alkaloids such as flustramine A (9), flustramine C (5), and 
dihydroflustramine C (7). Retrosynthetic analysis of this natural product would result 
in known indole alkaloids such as N
b
-formyl-N
b
-methyltryptamine (131) N
b
-
methyltryptamine (126) and commercially available tryptamine (124). A stepwise 
introduction of the structural features is crucial for the total synthesis of this natural 
product. For the synthesis of flustrabromine (1), an efficient methodology was 
adopted that has been developed by Bräuchle.92. 
3.1.1 Synthesis of N
b
-formyl-N
b
-methyltryptamine (131) 
The initial target was to introduce a methyl group onto the amino group of the 
aliphatic side chain of tryptamine (124). This methyl group can serve as a protecting 
group at the initial stages as well as a methyl substituent of the pyrrolo[2,3-b]indole 
natural products 5, 7, 9, and 32 at the later stages. Efficient methylation can be 
achieved by formylation of the primary amino group, followed by reduction with 
DIBAL-H. 
For the formylation of tryptamine (124), the protocol by Bosch was used.93 A mixture 
of Ac
2
O and HCO
2
H was stirred at 60 °C for 1 h. A solution of tryptamine (124) in 
DCM was added to this acid mixture and stirred for 2 h at room temperature 
affording the formamide 125 in an excellent yield of 94%. Without any further 
                                            
92.  L. Bräuchle, Dissertation 2005, Ludwig-Maximilians-Universität München. 
93.  J. Bosch, T. Roca, M. Armengol, D. Fernandez-Forner, Tetrahedron 2001, 57, 1041–1048. 
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purification, the formamide 125 was reduced with DIBAL-H (4.4 equivalents) to form 
the natural product N
b
-methyltryptamine (126, 74% in two steps (Scheme 22). 
 
Scheme 22: Two step synthesis of N
b
-methyltryptamine (126) 
N
b
-Methyltryptamine (126) is also a natural product isolated from a wide variety of 
Amazonian plants. The flowering shoots and barks of Virola theiodora, as well as the 
leaves of V. rufula and V. calophylla yielded natural product 126.94  
The plant bark of Virola sebifera is extensively used for the preparation of 
hallucinogenic snuffs and drinks in Venezuela. The major chemical components 
identified from the roots and bark of the plant V. sebifera were N,N-
dimethyltryptamine (127), 5-methoxy-N,N-dimethyltryptamine (128), 5-methoxy-N-
methoxytryptamine (129), 2-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 
(130),94,95 along with N
b
-formyl-N
b
-methyltryptamine (131) and N
b
-acetyl-N
b
-
methyltryptamine (132, Figure 10).96 The latter two natural products are present in 
the form of E and Z rotamers in NMR spectroscopy (either in CDCl
3
 or C
6
D
6
).  
 
Figure 10: Chemical components isolated from Virola sebifera 
                                            
94.  S. Agurell, B. Holmstedt, J. E. Lindgren, R. E. Schultes, Acta. Chem. Scand., 1969, 23, 903–
916. 
95.  E. Corothie, T. Nakano, Planta Medica, 1969, 17, 184–188. 
96.  K. Kawanishi, Y. Uhara, Y. Hashimoto, Phytochemistry 1985, 24, 1373–1375. 
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Following Bosch93 conditions for the second time, 126 was exposed to the pre-
heated acidic mixture of Ac
2
O and HCO
2
H (1:1) to result in smooth transformation of 
the natural product 131 with a yield ranging between 84-92% (Scheme 23). 
 
Scheme 23: One pot conversion of 126 to N
b
-formyl-N
b
-methyltryptamine (131). 
The hindered rotation around the C-N bond of the amide functional group makes the 
natural product to exist as two rotational isomers (Figure 11). These two rotamers 
are present in Z and E forms, the latter form being the major contributor. In the 1H 
NMR and 13C NMR spectra (CDCl
3
), all signals are duplicated.  
 
Figure 11: N
b
-formyl-N
b
-methyltryptamine (131) exists as two rotational isomers at 
room temperature (either in CDCl
3
 or C
6
D
6
). 
The structurally related natural product 6-bromo-N
b
-formyl-N
b
-methyltryptamine (45), 
isolated from F. foliacea, could also serve as a possible precursor for the natural 
product flustrabromine (1).26 Tert-prenylation at the indole C-2 of 45 may result in 
flustrabromine (1) in one step. However, the preparation of the 6-brominated natural 
product might require a longer sequence. Therefore, 2-tert-prenylation followed by 
bromination on N
b
-formyl-N
b
-methyltryptamine (131) was chosen for further 
transformations. 
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3.1.2 Tert-Prenylation at the indole C-2 
Danishefsky et al. discovered a one step procedure for introducing the entire 1,1-
dimethylallyl group.97 Reaction of 3-substituted indole 132 with tert-BuOCl at –78 °C, 
in presence of Et
3
N, generates a transient chloroindolenine species 133. This 
chloroindolenine 133 is highly electrophilic at the indole 2-position and, hence, 
readily attacked by an incoming nucleophile. With a suitable nucleophile it is a 
straight forward approach for the functionalization of indole 2-position with a tert-
prenyl group (Scheme 24). 
 
Scheme 24: Mechanism of Danishefsky’s tert-prenylation of the indole 2-position.97  
To apply Danishefsky’s protocol, the reagents tert-BuOCl (137) and prenyl-9-BBN 
(142) were prepared according to the literature procedures. Reaction of tert-Butanol 
(136) with commercially available NaOCl and AcOH at room temperature for 5-10 
min furnished the tert-BuOCl (137) as light sensitive yellow oil (56%, Scheme 25).98  
 
Scheme 25: Synthesis of tert-butylhypochlorite (137).98  
The prenyl moiety of the prenyl-9-BBN (142) arose from 3-methyl-1,2-butadiene 
(140) which was prepared in two steps. The reaction of propargylalcohol 138 with 
concentrated HCl in presence of CaCl
2
 resulted in propargylchloride (139). The 
                                            
97.  J. M. Schkeryantz, J. C. G. Woo, S. J. Danishefsky, J. Am. Chem. Soc. 1995, 117, 7025–7026. 
98.  M. J. Mintz, C. Walling, Org. Synth. 1969, 49, 9. 
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propargylchloride (139) in butanol gave the low boiling colorless allene 140 on 
reaction with metallic Zn powder (19% over two steps (Scheme 26). 99,100 
 
Scheme 26: Allene 140 was synthesized in two steps.99,100  
9-BBN-H (9-borabicyclo[3.3.1]nonane, 141) is an unusually stable hydroboration 
reagent and was discovered by Brown et al.101,102,103 Following anti-Markovnikov’s 
rule, 9-BBN-H boronates the least hindered site of the diene system.104 As a result, 
reaction of 9-BBN-H (141) with 3-methyl-1,2-butadiene (140) at room temperature 
and inert atmosphere gave almost exclusively 3,3-dimethylallyl-9-BBN (142, Scheme 
27).  
 
Scheme 27: In situ preparation of prenyl-9-BBN (142).  
Another synthetic route to prepare alkylated boranes was presented by Soderquist et 
al.105 Organolithium or organomagnesium reagents were added to (TIPS)S-9-BBN 
(143) to form “ate” complexes 144 which thermally collapsed to form organoboranes 
(145) in yields above 85% after distillation (Scheme 28). 
                                            
99.  H. Mayr, I. K. Halberstadt-Kausch, Chem. Ber. 1982, 115, 3479–3515. 
100.  J. Chengebroyen, M. Linke, M. Robitzer, C. Sirlin, M. Pfeffer, J. Organomet. Chem. 2003, 
687,313-321. 
101.  E. F. Knights, H. C. Brown, J. Am. Chem. Soc. 1968, 90, 5280–5281. 
102.  E. F. Knights, H. C. Brown, J. Am. Chem. Soc. 1968, 90, 5281–5283. 
103.  H. C. Brown, A. K. Mandal, J. Org. Chem. 1992, 57, 4976–4986. 
104.  G. W. Kramer, H. C. Brown, J. Organomet. Chem. 1977, 132, 9–27. 
105.  J. A. Soderquist, J. C. J. de Pomar, Tetrahedron Lett. 2000, 41, 3537–3539. 
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Scheme 28: Soderquist et al. showed an alternative preparation of alkylboranes.105 
N
b
-Formyl-N
b
-methyltryptamine (131) in THF was reacted with tert-BuOCl at –78 °C, 
in presence of Et
3
N, for 45 min to generate the chloroindolenine in situ. The 
chloroindolenine was treated with prenyl-9-BBN to affect the 2-tert-prenylation. Along 
with the desired product debromoflustrabromine (2, 80%), N-prenylated product 146 
(9%), and acetylated indole 147 (2%) were also found in minor amounts (Scheme 
29). Formation of 147 was attributed to the presence of trace amounts of N
b
-acetyl-
N
b
-methyltryptamine (132) from the previous step. 
 
Scheme 29: Tert-prenylation on N
b
-formyl-N
b
-methyltryptamine (131). 
X-ray crystallography unambiguously proved the structure of the major compound 2. 
Interestingly, compound 2 occurred in two independent forms in a single crystal 
(Figure 12).  
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Figure 12: ORTEP drawings of two independent forms of debromoflustrabromine (2); 
hydrogen’s are omitted for clarity; displacement parameters drawn at 50% 
probability.  
Alternative to Danishefsky’s procedure of introducing nucleophiles at the indole 2-
position, Gribble et al.106 and Fukuyama et al.107 reported alkylation of the indole 2-
position. Suitably N-1 protected indoles dissolved in THF were reacted with LDA at –
100 °C to generate 2-lithiated indoles which were quenched with alkylhalides to 
result in selective alkylation at the indole C-2 with moderate yields. 
 
3.1.3 Completion of flustrabromine (1) synthesis 
To determine the existence of rotamers, a variable-temperature NMR experiment at 
35 °C and 50 °C was carried out. Coalescence of the signals began to occur at 50 
°C despite compound 1 being unstable at higher temperatures.25  
The isolation of debromoflustramine B (51) and flustramine B (41) from the same 
extract of F. foliacea suggested that bromination might be the last step in the 
                                            
106.  (a) M. G. Saulnier, G. W. Gribble, J. Org. Chem. 1982, 47, 757–761. (b). Y. Liu, G. W. Gribble, 
Tetrahedron Lett. 2001, 42, 2949–2951. 
107.  T. Fukuyama, X. Chen, G. Peng, J. Am. Chem. Soc. 1994, 116, 3127–3128. 
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biosynthesis of flustramine B (41).29 Keeping this in mind, bromination was 
performed as the last step of the synthesis. 
Table 3 highlights a few examples on the bromination/chlorination patterns of indoles 
with emphasis on halogenating agents, solvents, and selectivities. In most cases, 
monobromination on indole was achieved using 1 equivalent of the bromine source. 
In acidic media, indoles prefer bromination at 2-position while the 3, 5, and 6 
positions were preferred under slightly basic or neutral conditions. Among the 5 and 
6-positions the 5-position is favored. Excess of brominating reagent always resulted 
in multi bromination (Table 3). 
Table 3: Regioselective halogenation on indole.  
 
Halogen 
Source 
Solvent 
Starting 
Material 
Product Priority Ref.  
NCS (1 eq.) 
acetic acid + 
formic acid 
R
3
= aminoethyl R
2
 = Cl (70%) 2 
108
 
NBS (1 eq.) 
DCM + Silica / 
CCl
4
 
R
3
 = CH
2
CN / 
Me 
R
2
 = Br (90% / 86%) 2 
109
 
NBS (2 eq.) aq. t-BuOH R
3
 = CHO 
R
3,3
 = Br, R
2
 = oxo 
(43%) 
3 
110 
Br
2
 Et
3
N R
2,3
 = Me R
3
 = Br 3 
111 
NBS (1 eq.) 
aq. t-BuOH + 
H
2
O (5%) 
R
3
 = alkyl R
5 
= Br, oxindole 5 
112 
NBS (1 eq.) aq. t-BuOH R
2
=Br, R
3
= Me R
2,6
 = Br, R
3
= Me 6 
112 
NBS (2 eq.) DCM + Silica R
3
 = CH
2
CN R
2,6
 = Br (95%) 2,6 
109 
NBS (2 eq.) DCM + Silica R
2
 = Me R
3,6
 = Br (95%) 3,6 
109 
NBS (3 eq.) aq. t-BuOH R
4,7
 = OMe R
3,3,5
 = Br 3,3,5 
110 
Br
2
 (1 eq.) 
acetic 
anhydride 
R
1 
= Me, R
3
 = 
glyoxylate 
R
5
 = Br & R
6
 = Br 
(7:3) 
5 > 6 
113f 
Br
2
 (1.5 eq.) acetic acid 
R
1 
= Me, R
3
 = 
CHO 
R
5
 = Br (17%) & 
R
3,3,5
 = Br (7%) 
5 > 3,3,5 
113 
NBS (2 eq.) acetic acid + R
3
= aminoethyl R
2,5
 = Br & R
2,6
 = Br 2,5 > 2,6 
114 
                                            
108.  F. Y. Miyake, K. Yukushijin, D. A. Horne, Org. Lett. 2004, 6, 711–713. 
109.  A. G. Mistry, K. Smith, M. R. Bye, Tetrahedron Lett. 1986, 27, 1051–1054. 
110.  J. Parrick, A. Yahya, A. S. Ijaz, J. Yizun, J. Chem. Soc., Perkin Trans. 1, 1989, 2009–2015. 
111.  E. A. Gross, S. F. Vice, G. I. Dmitrienko, Can. J. Chem. 1981, 59, 635–640. 
112.  R. L. Hinman, C. P. Bauman, J. Org. Chem. 1960, 29, 1206–1215. 
113.  A. D. Settimo, E. Nannipieri, J. Org. Chem. 1970, 35, 2546–2551. 
114.  F. Y. Miyake, K. Yakushijin, D. A. Horne, Org. Lett. 2004, 6, 4249–4251. 
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Halogen 
Source 
Solvent 
Starting 
Material 
Product Priority Ref.  
formic acid (4:3) 
Br
2
 (5 eq.) acetic acid R
1 
= Me 
R
2,3,5,6
 = Br (major) & 
R
3,3,5,6
= Br (minor) 
2,3,5,6 > 
3,3,5,6 
113 
 
Horne et al.114 showed that 2 equivalents of NBS in presence of AcOH and HCO
2
H 
react with indole to furnish dibrominated compounds in a ratio of 4:3 with a priority of 
2,5-dibrominated compounds over 2,6-dibrominated adducts. Under similar 
conditions, debromoflustrabromine (2) was reacted in a mixture of AcOH and HCO
2
H 
with 1.1 equivalents of NBS at room temperature. 6-Bromination dominated 1 (53%) 
over formation of the 4-bromo regioisomer 148 (20%, Scheme 30). Probably, the 
indole 3-position is protonated115 in AcOH-HCO
2
H (3:1) affording the indoleninium 
ion. S
E
Ar reaction will be favored at the indole 4- and 6-positions which are located 
at the meta-positions with respect to the iminium nitrogen and in the ortho- and para-
positions of the indole-3-positon. 
There are distinct differences between both regioisomers. In the 1H NMR spectrum 
of 1 (CDCl
3
) a doublet with a large coupling constant (J = 8.4 Hz) was observed for 
each of the rotamers (δ = 7.29, 7.49 ppm, respectively). This doublet coupled with C-
3 (δ = 107.1, 108.0, respectively) in the HMBC experiment whereas the doublets with 
small coupling constant (J = 1.6 Hz, 7-H) did not couple with C-3. A melting point of 
218 °C was observed for flustrabromine (1) whereas isoflustrabromine (148) 
degraded above 155 °C.  
 
Scheme 30: Regioselective bromination afforded flustrabromine (1). 
Until now, no bromination of the benzene part of indole was reported in THF. When 
the bromination reaction was performed in THF, flustrabromine (1) precipitated in the 
                                            
115.  V. A. Budylin, L. G. Yudin, A. N. Kost. Khim. Geterotsikl. Soedin. 1980, 1181–1199. 
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reaction flask in low yield (32%), although other compounds formed in this reaction 
were not characterized. X-ray crystallography confirmed the presence of bromine at 
6-position of flustrabromine (1, Figure 13). All the other analytical data were in full 
agreement with the published information. 
 
Figure 13: ORTEP drawing of flustrabromine (1); hydrogen’s are omitted for clarity; 
displacement parameters drawn at 50% probability. 
 
3.2 Synthesis of flustramine C 
The pyrrolo[2,3-b]indole flustramine C (5) was isolated by Carlé and Christophersen. 
For the chemical synthesis of flustramine C (5), the synthetic route developed by 
Lindel et al. was adopted. 116 
 
3.2.1 Synthesis of deformylflustrabromine (3)  
The name was derived from flustrabromine (1) as the isolated 3 is lacking the formyl 
group.33 Peters et al. independently described the isolation of deformylflustrabromine 
(3).31  
                                            
116.  T. Lindel, L. Bräuchle, G. Golz, P. Böhrer. Org. Lett. 2007, 9, 283–286. 
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Lysek et al. proposed that the deformylflustrabromine (3) represents the missing link 
between other isolated members of F. foliacea such as flustrabromine (1) and 
flustraminol A (42).33 Flustraminol A (42) with its tricyclic pyrrolo[2,3-b]indole core 
may serve as a starting point for flustramine C (5) and dihydroflustramine C (7) 
derivatives as well (Scheme 31). To prove the above hypothesis, the conversion of 
the natural product flustrabromine (1) to deformylflustrabromine (3) was attempted. 
Flustrabromine (1) was dissolved in EtOH and refluxed in presence of 32% aqueous 
NaOH for two days to undergo deformylation. The natural product 3 was obtained in 
almost quantitative yield (Scheme 32). 
 
Scheme 31: Deformylflustrabromine (3) as the missing link between 
flustramines.33,116 
Thus far, this was the best chemical route to obtain 3 from the commercially 
available tryptamine (124) in 6 steps with an overall yield of 27%. 
 
Scheme 32: Conversion of flustrabromine (1) to deformylflustrabromine (3). 
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3.2.2 Biomimetic preparation of flustramine C (5) 
Lindel et al. discovered the key biomimetic transformation of deformylflustrabromine 
(3) to flustramine C (5).116 Exposure of the natural product 3 to tert-BuOCl (137) in 
presence of NEt
3
 at –78 °C induced ring closure and sigmatropic [1,5] 
rearrangement of the 2-tert-prenyl group affording flustramine C (5) in an isolated 
yield of 60% in six days. A mechanistic rationale was presented on the basis of 
1H,15N HMBC experiments. It was confirmed that the treatment of 3 with tert-BuOCl 
(137) resulted in the chlorination of the aliphatic side chain amino group. Upon 
standing in CDCl
3
 for one week, this halogenated intermediate 149 lost the side 
chain chloride ion and formed protonated flustramine C (5), presumably via 
transferring the side chain chlorine to form chloroindolenine 150 followed by ring 
closure to form 151 and [1,5] sigmatropic rearrangement of the 2-tert-prenyl group. 
Treatment of 152 with 2 M NaOH gave rac-flustramine C (5, Scheme 33). 
 
Scheme 33: 1H 15N HMBC studies shed light on the formation of flustramine C (5).116  
Although the formation of flustramine C (5) was efficient using tert-BuOCl, a 
remarkable improvement of this step was observed using NBS.116 
Deformylflustrabromine (3) dissolved in THF was reacted with 1 equivalent of NBS at 
0 °C to afford rac-flustramine C (5) in an isolated yield of 71% within 2 h (Scheme 
34). 
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Scheme 34: NBS-induced [1,5] prenyl shift to form flustramine C (5).116,121 
 
3.3 Studies towards enantioselective synthesis of flustramine C 
For the enantioselective synthesis of the natural product rac-flustramine C (5), it was 
necessary to reveal the optical rotation of the individual enantiomers. Until now, the 
optical activity for none of the individual enantiomers was reported. 
 
3.3.1 Separation of (+)- and (–)-flustramine C 
Deformylflustrabromine (3) and flustramine C (5) can be conveniently separated by 
reversed phase HPLC (Figure 14). When co-injected and eluted on a C-18 reversed-
phase analytical column (LichroCART
®
, RP-18, particle size 5 µm, flow rate=0.9 
mL/min) with MeOH/H
2
O (85:15), flustramine C (5) appeared at a retention time of 
8.2 min whereas deformylflustrabromine (3) was eluted at 11.4 min. 
 
Figure 14: Rac-flustramine C (5) and deformylflustrabromine (3) were conveniently 
separated by reversed phase HPLC.  
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The individual enantiomers from synthetic rac-flustramine C (5) were conveniently 
separated on a chiral analytical column (Chiralcel OD, normal phase, particle size 10 
µm).The solvent system was optimized to hexane–isopropanol in a ratio of 15:1 with 
a flow rate of 1.2 mL/min (Figure 15). 
The enantiomer with the lower retention time (6.2 min) showed an optical rotational 
value of [α]
D
21.6 = +153 ° (c = 0.79, CHCl
3
) whereas the peak with delayed retention 
time (8.1 min) showed an optical rotation of [α]
D
21.8 = –155 ° (c = 0.81, CHCl
3
). Carlé 
and Christophersen did not report any optical activity for the isolated flustramine C 
(5).24 However, Peters and co-workers re-isolated flustramine C (5) and determined 
the optical activity as [α]
D
22 = –10.1 ° (c = 0.1, CHCl
3
).31 This implies that the isolated 
natural product flustramine C (5) is mostly racemic and the (–)-enantiomer with 
higher optical activity is responsible for the measured optical activity by Peters et al. 
 
Figure 15: The individual enantiomers of rac-flustramine C (5) showed opposite 
values of optical rotation.  
 
3.3.2 Use of hypervalent iodine reagents to form ent-flustramine C 
Treatment of deformylflustrabromine (3) with NBS, NCS (N-chlorosuccinimide), and 
NIS (N-iodosuccinimide) resulted in rac-flustramine C (5) on every occasion. At the 
same time, there was a distinct difference in reaction times. With 1.0 equivalent of 
NBS, the reaction was complete in 1 h while 2.4 equivalents of NIS reacted slowly to 
complete the reaction in 3 hours. In the case of NCS, the reaction was even slower 
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and after 48 h of reaction time, there was plenty of unreacted starting material 3 
(Scheme 35). 
 
Scheme 35: Rac-flustramine C (5) was accessible by NBS, NIS, and NCS. 
It was envisaged that the oxidative cyclization/rearrangement using a more 
electrophilic chiral halide reagent to form 5 was a direct way to get ent-flustramine C 
(5). As the reaction times were either faster with NBS or slower with NCS, NIS was 
chosen as potential parent compound of a enantioselective reagent. PIDA 
(Phenyliodo(III)diacetate) and PIFA (phenyliodo(III)bis(trifluoroacetate, shown in 
Scheme 36) were purchased from commercial suppliers, whereas the chiral reagent 
155 was synthesized.  
The synthesis of chiral reagent (R)-methyl-2-(2-(diacetoxyiodo)phenoxy)propanoate 
(155) commenced from 2-iodophenol (153).117 Mitsunobu reaction of 153 with 
optically active methyl lactate inverted the stereogenic center of lactate to yield 
phenolether 154 in 81% yield. Oxidation of 154 with sodium perborate in acetic acid 
did not work. Alternatively, when 154 was reacted with in situ generated AcOOH in 
AcOH at 45 °C for 24 hours,118 the desired chiral reagent 155 was isolated in 43% 
over two steps (Scheme 36). 
                                            
117.  M. Fujita, S. Okuno, H. J. Lee, T. Sugimura, T. Okuyama, Tetrahedron Lett. 2007, 48, 8691–
8694. 
118.  A. Yoshimura, V. N. Nemykin, V. V. Zhdankin, Chem. Eur. J. 2011, 17, 10538–10541. 
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Scheme 36: Hypervalent iodine reagents used as an alternative to NIS. 
With the hypervalent iodine reagents in hand, deformylflustrabromine (3) was 
reacted with PIDA, PIFA, and chiral reagent 155. In the first attempt, 3.0 equivalents 
of PIDA were reacted with 3, but analysis by HPLC did not indicate any formation of 
flustramine C (5). Compound 5 was not detected either, when the reagent was 
changed to 3.0 equivalents of more electrophilic PIFA. However, increasing the 
amounts of PIFA to 9.0 equivalents formed rac-flustramine C (5) in low yield (5%). 
The majority of reagent PIFA remained in the reaction mixture and purification of 3 
and 5 proved to be difficult. With the synthesized chiral reagent 155 (1.2 or 4.5 
equivalents) no flustramine C (5) was formed (Scheme 37). 
No further attempts were made on the synthesis of rac-flustramine C (5) using 
hypervalent iodine reagents. Apart from the evaluation of different hypervalent iodine 
reagents, fine tuning of solvent systems and additives might be alternative 
parameters to induce the formation of flustramine C (5).  
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Scheme 37: Hypervalent iodine reagents were not helpful to form flustramine C (5). 
Kajiyama and co-workers studied the oxidation of tryptamines using hypervalent 
iodine reagents.119 Treatment of N
b
-substituted tryptamines with PIDA resulted in 
formation of pyrrolo[2,3-b]indoles and 2-acetoxylated tryptamines with the highest 
yields of 38%. A mechanistic rationale for the formation of products of type 161 and 
162 was described (Scheme 38). Moreover, the purification of the resulting products 
proved to be difficult due to fast degradation. 
Recently, a variation of the method to synthesize functionalized pyrrolo[2,3-b]indoles 
was reported by Tu et al.120 Tryptamines suitably protected at indole N-1 and at the 
aliphatic amine side-chain readily underwent intramolecular annulations to form 
pyrrolo[2,3-b]indoles (not shown in Scheme 38) by treatment with hypervalent 
reagents in presence of metalhalides in MeCN. Most of the transformations furnished 
the tricyclic products with yields up to 99%. 
                                            
119.  D. Kajiyama, T. Saitoh, S. Yamaguchi, S. Nishiyama, Synthesis 2012, 1667–1671. 
120.  D. Tu, L. Ma, X. Tong, X. Deng, C. Xia, Org. Lett. 2012, 14, 4830–4833. 
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Scheme 38: Formation of pyrrolo[2,3-b]indoles (161) and acetoylindoles (162) in low 
yields (3-38%) by hypervalent iodine reagents.119  
 
3.4 Synthesis of dihydroflustramine C 
Another natural product isolated from F. foliacea is dihydroflustramine C (7). 
Reduction of the imine bond of 5 may furnish 7. 
The first attempt to effect this was made by Carlé and Christophersen. Flustramine C 
(5) reacted with 4.1 equivalents of LiAlH
4
 to provide debromoflustramine C (6) in 
88% yield (Scheme 39), but no reduction of the amidine moiety.24 
N
Br
N
H
H
rac-dihydro-
flustramine C (
7
)
rac-flustramine C (
5
)
N
Br
N
DIBAL-H,
THF, rt, 26 h
93%
rac-debromo-
flustramine C (
6
)
N
H
N
LiAlH
4,
Et
2
O, rt, 1 h
88%
 
Scheme 39: Rac-flustramine C (5) was reduced to rac-dihydroflustramine C (7). 
The direct conversion of flustramine C (5) to rac-dihydroflustramine C (7) was 
achieved when 5 was treated with 1.8 equivalents of DIBAL-H at room temperature. 
Results and discussion  54 
 
The imine bond of 5 was diastereoselectively reduced to form 7 in an isolated yield 
of 93% (Scheme 39) without debromination. 
 
3.5 Scope of NBS-induced tert-prenyl rearrangements  
NBS induced cyclization and rearrangement of a 2-tert-prenyl group to the indole 3-
position occurred in a single pot transformation. The scope of this reaction was 
interesting. It was unclear whether the cyclization and rearrangement sequence 
reaction would work if: 
(a) the indole nitrogen in deformylflustrabromine (3) was protected with an alkyl 
group 
(b) the bromine at the benzene section of the molecule was absent 
(c) the starting material was methylated at N-1  
(d) the methyl group at the aliphatic side chain was replaced by hydrogen  
(e) the proton at the aliphatic secondary amine was replaced by a methyl group 
(f) the aliphatic side chain carried a formyl group 
To address all the above issues, a systematic study was carried out.121 
 
3.5.1 Rearrangement of N
a
-methyl-deformylflustrabromine (10) 
Flustrabromine (1) was the optimal starting material to introduce the methyl group at 
the indole nitrogen. Following the standard conditions of treating indole 1 with NaH at 
0 °C for 20 min and reaction with MeI provided the N
a
-methyl-flustrabromine (163) in 
moderate yield of 72%. Deformylation was achieved upon refluxing 163 in aqueous 
ethanolic NaOH for 48 h to afford the key compound N
a
-methyl-
deformylflustrabromine (10) in 96%. Compound 10 was reacted with 1 equivalent of 
NBS which, as expected, induced the cyclization and 2,3-prenyl shift to form the 
N,N’-dimethylamidinium salt 12 (Scheme 40). The reaction was complete within 1 h 
and the product 12 precipitated as a colourless amorphous solid (62%). 
                                            
121.  S. K. Adla, G. Golz, P. G. Jones, T. Lindel, Synthesis 2010, 13, 2161–2170. 
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Scheme 40: N
a
-methyl-deformylflustrabromine (10) underwent cyclization and prenyl 
shift.  
 
3.5.2 Rearrangement to form debromoflustramine C (6)  
A starting material devoid of bromine on the benzene part of indole was desired for 
the preparation of debromoflustramine C (6). Debromoflustrabromine (2) was 
deformylated using the alkaline conditions as in the earlier cases to furnish 
debromodeformylflustrabromine (4) in 97%. NBS induced the cyclization and 
sigmatropic [1,5] shift of the 2-tert-prenyl group gave debromoflustramine C (6, 71% 
within 1 h, Scheme 41). Thus, the reaction was equally good even in the absence of 
the bromine substituent. No side products were isolated, as in the other examples. 
This synthetic route provided debromoflustramine C (6), for the first time, with an 
overall yield of 36% in 6 steps.  
 
Scheme 41: 2-Tert-prenyl shift occurred on debromodeformylflustrabromine (4). 
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3.5.3 Rearrangement of debromo-N
a
-methyl-deformylflustrabromine (11) 
The scope of the sigmatropic [1,5] prenyl shift reaction was thus evaluated with two 
parameters changed. The bromine was absent on the benzene section of the 
precursor and the indole NH was protected by a methyl group. Methylation of the 
indole nitrogen was achieved in excellent yield of 99% to result in 164. Compound 
164 was deformylated and reacted with 1 equivalent of NBS. Stretching the scope of 
oxidative cyclization and rearrangement by NBS, compound 164 was oxidized to 
result in N,N’-dimethylamidinium salt 13 (63%, Scheme 42).  
The precipitate formed in the flask was washed with EtOAc to result in clean 13. The 
amidinium salt 13 showed a characteristic imine resonance at δ = 180.9 ppm in the 
13C NMR spectrum. X-ray crystallography of 13 confirmed the presence of bromide 
as counter ion (Figure 16). 
 
 
Scheme 42: Formation of N,N’-dimethylamidinium salt 13 via cyclization and 
rearrangement.  
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Figure 16: ORTEP drawing of N,N’-dimethylamidinium salt 164; hydrogen’s are 
omitted for clarity; displacement parameters drawn at 50% probability. 
 
3.5.4 Rearrangement on 2-tert-prenyltryptamine (16) 
Oxidative rearrangement of 2-tert-prenyl-methyltryptamine analogues 4, 10, and 12 
also worked well. From these experiments it was concluded that neither the 
presence of bromine nor the presence of an indole proton was necessary. Now, 2-
tert-prenyltryptamine (16) was prepared with an absent side-chain methyl group. 
Tryptamine (124) was reacted, in presence of Et
3
N, with phthalic anhydride in boiling 
toluene for 8 hours. The precipitate formed was recrystallized from MeOH to obtain 
the pure compound 165 (86%) as fine needles for which an X-ray crystal structure 
was established (Figure 17). There exist slight variations in phthalimide protection 
methodologies.122,123,124  
                                            
122.  Q. Zeng, Z. Liu, B. Li, F. Wang, Amino Acids 2004, 27, 183–186. 
123.  B. S. Jursic, P. K. Patel, Carbohydr. Res. 2006, 341, 2858–2866. 
124.  Y. Liu, S. Luo, X. Fu, Fang, Z. Zhuang, W. Xiong, X. Jia, H. Zhai, Org. Lett. 2006, 8, 115–118. 
Results and discussion  58 
 
 
Figure 17; ORTEP drawings of phthalimide protected tryptamine 165; hydrogen’s are 
omitted for clarity; displacement parameters drawn at 50% probability. 
Phthalimide protected tryptamine 165 was subjected to Danishefsky’s tert-
prenylation at the indole 2-position. Reaction of 165 with tert-BuOCl at –78 °C in THF 
generated the transient chloroindolenine which was treated with prenyl-9-BBN (142). 
Addition of 3 M NaOH and H
2
O
2
 to the reaction mixture afforded the 2-tert-prenylated 
indole 166. Recrystallisation from CHCl
3
/hexane (1:5) afforded the product 166 
(51%). After successful introduction of the tert-prenyl group, the compound 166 was 
subjected to hydrazinolysis. The compound 166 was dissolved in a mixture of 
MeOH/DCM (1:1) and reacted with 2.8 equivalents of hydrazine monohydrate at 
ambient temperature for 48 h to provide 16. The free amine 16 was reacted with 
NBS at 0 °C for 35 min. NBS-induced cyclization/2-tert-prenyl shift occurred, albeit in 
a lower yield (55%, Scheme 43).  
This experiment confirmed that the aliphatic side-chain methyl group was not 
necessary for the ring closure and 2-tert-prenyl rearrangement sequence. 
Regular prenylation at N-8 position of the tricycle 17 followed by introduction of a 
methyl substituent, as shown by Kawasaki et al. for the synthesis of rac-flustramine 
C (5),44 may furnish rac-debromoflustramine A. 
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Scheme 43: Cyclization/rearrangement of 2-tert-prenyltryptamine (16).  
 
3.5.5 Rearrangement of 2-tert-prenylformamide 18 
When the free amine 16 was treated with a mixture of Ac
2
O/HCO
2
H for 2 h, 2-tert-
prenylated formyltryptamine 18 was formed in an excellent yield of 97%. However, 
reaction of the formamide 18 with NBS did not induce oxidative rearrangement to 
afford pyrrolo[2,3-b]indole 19. The starting material was recovered in good quantity 
(70%, Scheme 44). 
 
Scheme 44: 2-Tert-prenylformyltryptamine (18) was reluctant to undergo oxidation. 
It was confirmed that the aliphatic side-chain should not bear an amide group to 
undergo oxidation/rearrangement to form formylated pyrrolo[2,3-b]indoles. 
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3.5.6 Rearrangement of N
b
,N
b
-dimethyl-2-tert-prenyltryptamine (20) 
The synthesis commenced at debromoflustrabromine (2). Reduction of the formyl 
group of 2 with 4.2 equivalents of DIBAL-H proceeded smoothly to result in 
dimethylated compound 20. No chromatography was needed (86%). Compound 20 
was dissolved in acetone for solubility reasons and reacted with NBS. Surprisingly, 
after the work-up with 2 M NaOH, 3-bromo-2-tert-prenylindole (22) was obtained as a 
minor product (21%) and as the least polar component from the reaction. Analysis of 
the NMR spectrum of the major product showed that all signals of the product 23 had 
very similar chemical shifts as the starting material apart from the aliphatic side-chain 
signals shifted to up-field region. Elemental analysis and X-ray crystallography 
(Figure 18) confirmed this major product as the hydrobromide salt of the starting 
material 20 (58%, Scheme 45). 
 
Figure 18: ORTEP drawing of HBr salt of N
b
,N
b
-dimethyl-2-tert-prenyltryptamine (20); 
hydrogen’s are omitted for clarity; displacement parameters drawn at 50% 
probability.  
Neither prenyl rearrangement nor bromination at the benzene part occurred when N-
prenylated 2-unsubstituted indole 146 was treated with NBS in an acidic mixture of 
AcOH and HCO
2
H (3:1). Unstable, yet isolable, 2-brominated prenylindole 167 was 
isolated as black oil which degraded readily at room temperature (23%, Scheme 46). 
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Scheme 45: Unexpected outcome of the treatment of 20 with NBS. 
 
Scheme 46: 2-Unsubstituted N-prenylindole 146 preferred bromination at C-2 over 
prenyl shift.  
 
3.6 Synthesis of rac-flustramine A 
Rac-dihydroflustramine C (7) was synthesized from flustrabromine (1) in 3 steps 
(65%). Prenylation at N-8 of 7 would afford the natural product rac-flustramine A (9).  
In the earlier experiments, reaction of 7 with either NaH or K
2
CO
3 
followed by 
prenylbromide did not result in rac-flustramine A (9). Analysis by GC-MS (EI) 
indicated that compound 7 had degraded and resulted only in peaks below m/z 220 
compared to 320/388 for dihydroflustramine C (7)/flustramine A (9). 
Treatment of 7 with DIBAL-H for four days did not lead to reduction of the amidinium 
salt. Meanwhile, reduction of the N,N’-dimethylamidinium salts with NaBH
4
 had been 
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published.57 Indeed, replacement of DIBAL-H with NaBH
4
 afforded the product (14) 
with the newly introduced hydrogen placed at C-8a of 14 albeit in moderate yield 
(40%). The reduction procedure was also performed on the structurally similar 
compound 13, affording the reduced product 15 (55%, Scheme 47). 
N
H
Br
N
rac-dihydro-
flustramine C (
7
)
H
N
Br
N
H
base,
prenylchloride
rac-flustramine A (
9
)
N
N
12
: X = H
13
: X = Br
Br
X
NaBH
4,
MeOH,
rt, 5 - 9 h
N
N
14
: X = H (40%)
15
: X = Br (55%)
X
H
 
Scheme 47: NaBH
4
 reduced the N,N’-dimethylamidinium salts effectively. 
For compound 14, in the 1H NMR spectrum, a sharp singlet at δ = 4.20 ppm (Figure 
19) and in the 13C NMR spectrum a signal at δ = 91.4 ppm (Figure 20) confirmed the 
introduction of the new proton at the bridgehead 8a position. 
 
Figure 19: 1H NMR spectrum (400 MHz, CDCl
3
) of compound 14. 
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Figure 20: 13C NMR spectrum (100 MHz, CDCl
3
) of compound 14. 
Encouraged by this result, an alternative strategy for proton replacement at N-1 in 
flustrabromine (1) with a prenyl group, followed by oxidation with NBS to the 
amidinium salt and successive reduction to rac-flustramine A (9) was envisaged. 
However, new questions arose: (a) how to introduce the prenyl group 
regioselectively? (b) would the oxidative rearrangement reaction work on a doubly 
prenylated precursor? (c) if the cyclization and prenyl shift work, what will be the 
priority of prenyl migration?  
 
3.6.1 Unexpected prenylation on 2-tert-prenylated phthalimide 166 
Indole prenylation is an important step in natural product synthesis and biosynthesis. 
The biosynthesis of prenylated tryptophan alkaloids was investigated by Williams et 
al.125,126 whereas Li published the chemoenzymatic synthesis of prenylated indole 
alkaloids of fungal origin.127 Recently, Lindel et al. reviewed the strategies and 
technologies available for prenylation towards the total synthesis of indole alkaloids. 
                                            
125.  R. M. Williams, E. M. Stocking, J. F. Sanz-Cervera, Top. Curr. Chem. 2000, 209, 97–173. 
126.  Y. Ding, J. R. de Wet, J. Cavalcoli, S. Li, T. J. Greshock, K. A. Miller, J. M. Finefield, J. D. 
Sunderhaus, T. McAfoos, S. Tsukamoto, R. M. Williams, D. H. Sherman, J. Am. Chem. Soc. 
2010, 132, 12733–12740. 
127.  S.-M. Li, Nat. Prod. Rep. 2010, 27, 57–78. 
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With a few exceptions for tert-prenylation at indole 4-, 5-, and 6-positions, it is 
possible either to tert-prenylate or regularly prenylate all positions of indole.128 
Prenylation was attempted of the phthalimide protected tert-prenylindole 166 to 
preserve valuable amounts of natural product 1. A solution of 166 in DMF was added 
to NaH at –20 °C followed by 1.5 equivalents of prenylbromide. After two days of 
reaction, there were substantial amounts of unreacted starting material (61%) along 
with the desired product 168 in low yield (22%). The reaction temperature was 
increased from –20 °C to 0 °C and loading of base/prenyl source was changed from 
1.5/1.5 to 1.8/1.8 equivalents. However, a marginal increase in the yield (29%) of the 
desired product 168 along with the recovery of starting material (45%) was observed. 
Finally, increasing the amounts of NaH to 5.0 equivalents and prenylchloride to 4.0 
equivalents showed an unexpected prenylation pattern. In a ratio of 1:4, the desired 
N-prenylated indole 168 was formed in the lowest yield of 16% whereas the C-3 
prenylated regioisomer 169 resulted as the major product with 62% yield (Table 4). 
Further attempts towards selective C-3 prenylation or N-prenylation of 166 were not 
undertaken. 
 
Table 4: Prenylation on 166 gave unexpected non-regioselectivity. 
Base/prenyl-X 
(eq.) 
Conditions 168 169 
SM 
recovered 
1.5/1.5 
i. NaH, DMF, –20 °C, 90 min 
ii. prenylbromide, –20 °C, 12 h, then rt, 2 d 
22% - 61% 
1.8/1.8 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, 0 °C, 2 d, then rt, 4 d 
29% - 45% 
5.0/4.0 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, rt, 6 h 
16% 62% - 
                                            
128.  T. Lindel, N. Marsch, S. K. Adla, Top. Curr. Chem. 2012, 309, 67–129. 
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Towards the first total synthesis of (–)-debromoflustramine B (51), Cardoso and co-
workers encountered a similar situation. On reaction with NaH and prenylbromide in 
DMF at 0 °C compound 170 underwent predominant C-3 prenylation (58%) 
compared to formation of the N-prenylindole (11%, Scheme 48).56,57  
 
Scheme 48: Predominant C-3 prenylation as reported by Cardoso et al.56,57 
 
3.6.2 Non-regioselective prenylation on 2 and flustrabromine (1) 
Reaction of debromoflustrabromine (2) with 1.8 equivalents of NaH and then 1.8 
equivalents of prenylchloride at 0 °C for 24 h resulted in the desired N-prenylated 
indole 27 (33%). As in the case of 166, unreacted starting material 2 was recovered 
(22%). However, by increasing the equivalents of base and prenylchloride to 5.0 and 
4.0, respectively, a combined yield of 89% was achieved of doubly prenylated 
regioisomers 27 (37%) and 174 (52%, Table 5).  
Using silica gel column chromatography with EtOAc-petrolether as solvent system, 
separation of doubly prenylated indoles 27 and 174 was accomplished. 
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Table 5: Optimization of prenylation on debromoflustrabromine (2). 
Base/prenyl-X (eq.) Conditions 27 174 SM recovered 
1.8/1.8 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, rt, 1 d 
33%  22 
5.0/4.0 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, rt, 6 h 
37% 52% - 
 
Upon reaction of 1 with 1.5 equivalents of both NaH and prenylbromide at –20 °C for 
2 days, flustrabromine (1) failed to react. Even by altering the reaction temperature 
from –20 °C to 0 °C and the prenyl source from prenylbromide to prenylchloride, no 
prenylation of flustrabromine (1) took place. However, performing the reaction at 
room temperature for two days furnished the desired N-prenyl-flustrabromine (175) 
as a minor product (10-14%). The major product isolated was C-3-prenylated 
flustrabromine (176) in a yield of 60%.  
By increasing the amounts of NaH and prenylchloride to 1.8 equivalents, a balanced 
formation of each regioisomer was observed (28% for 175 and 176). In the last 
attempt, 5.0 equivalents of NaH and 4.0 equivalents of prenylchloride were used to 
generate the desired N-prenylated indole 175 in the highest isolated yield of 41% 
while the C-3 prenylated regioisomer 176 was the major product with a yield of 50%. 
Table 6 highlights the optimization results regarding prenylation of flustrabromine (1).  
Purification of doubly prenylated products 175 and 176 by normal phase silica gel 
column chromatography proved difficult as both regioisomers exhibited very close 
retention factors in different solvent systems. However, reversed phase (C-18) 
column chromatography with MeOH/H
2
O (5:1) resulted in a facile separation of 
regioisomers 175 and 176. 
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Table 6: Prenylation on 1 gave N-1 and C-3 prenylated regioisomers 175 and 176. 
Base/prenyl-X (eq.) Conditions 175 176 Comment 
1.5/1.5 
i. NaH, DMF, –20 °C, 90 min 
ii. prenylbromide, –20 °C, 2 d 
- - No reaction 
1.5/1.5 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, 0 °C, 2 d 
- - No reaction 
1.5/1.5 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, rt, 2 d 
10-14% 40% - 
1.8/1.8 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, rt, 2 d 
28% 28% - 
5.0/4.0 
i. NaH, DMF, 0 °C, 2 h 
ii. prenylchloride, rt, 1 d 
41% 50% - 
 
The doubly prenylated indoles were smoothly deformylated in excellent yields. In a 
general procedure, prenylated indoles were refluxed in 32% aqueous NaOH in 
ethanol for 48 h resulting in N
a
-prenylated and C-3 prenylated secondary amines 
with yields above 83%. The products were obtained in high purity without further 
purification (Scheme 49). 
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Scheme 49: Deformylation resulted in secondary amines in high yields. 
3.6.3 Completion of the synthesis of rac-flustramine A  
N
a
-prenyl-flustrabromine (175) was dissolved in EtOH and refluxed in 32% aqueous 
NaOH for two days to afford N
a
-prenyl-deformylflustrabromine (24) in an excellent 
yield of 92%. The doubly prenylated indole 24 was reacted with NBS at 0 °C. Once 
again, NBS-induced oxidative ring closure and sigmatropic [1,5] prenyl group 
rearrangement took place to form amidinium salt 25.  
Unlike other NBS-induced oxidations, the reaction of 24 with NBS was slow and took 
5 h for completion. The salt 25 was soluble in organic solvents such as CHCl
3
, DCM, 
and MeOH and purification of 25 by reversed phase HPLC using MeOH/H
2
O (80:20) 
as mobile phase resulted in the isolation of pure 25 (26%) with loss of substantial 
amounts of product. When 25 was reacted with 0.8 equivalents of NaBH
4
 at room 
temperature for 24 h rac-flustramine A (9) was obtained in 54% yield.  
N
a
-prenyl-deformylflustrabromine (24) in THF was treated with NBS to result in N-
prenyl-N’-methyl amidinium salt 25. The crude concentrate was dissolved in MeOH 
and was treated under inert atmosphere with NaBH
4
. Purification by reversed phase 
HPLC resulted in rac-flustramine A (9) in 28% over two steps (Scheme 50). 
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Scheme 50: Lindel’s oxidative 2-tert-prenyl shift resulted in rac-flustramine A (9). 
A tert-prenyl group, a regular prenyl group, indole protons, and diastereotopic 
protons had remained intact. The new proton at C-8a appeared as a sharp singlet at 
δ = 4.36 ppm in the 1H NMR spectrum (Figure 21) whereas δ = 89.4 ppm was 
observed for the C-8a in the 13C NMR spectrum (Figure 22). All other analytical data 
were in good agreement with those published in the literature. 
 
Figure 21: 1H NMR spectrum (400 MHz, CDCl
3
) of rac-flustramine A (9). 
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Figure 22: 13C NMR spectrum (100 MHz, CDCl
3
) of rac-flustramine A (9). 
Debromo-N
a
-prenyl-flustrabromine (27) was deformylated by boiling in ethanolic 32% 
aqueous NaOH to furnish the doubly prenylated precursor 26. It might be possible to 
cyclize and rearrange the compound 26 to rac-debromoflustramine A. 
 
3.6.4 Possible biosynthesis of flustramine C, dihydroflustramine C, and 
flustramine A 
The biomimetic synthesis of flustramine C (5) and dihydroflustramine C (7) was 
addressed by Lindel et al (Scheme 51).116 The biosynthesis of the natural product 
dihydroflustramine C (7) could proceed via three major pathways. Starting at natural 
product 45, regioselective N-prenylation could result in 179. Aza-Claisen 
rearrangement of the prenyl group from N-1 to the 3-position of the indole and 
deformylation of the C-3 tert-prenylindole followed by cyclization would furnish the 
natural product 7 (path A, Scheme 51). Alternatively, starting at the same natural 
product 45, inverse prenylation by S
N
2’ reaction at C-3 and deformylation followed by 
ring closure would result in dihydroflustramine C (7, path B, Scheme 51). A similar 
strategy was proposed by Bhat and co-workers for the biosynthesis of 
roquefortine.85,86  
In contrast to pathways A and B, a direct 2-tert-prenylation could occur resulting in 
the known Flustra alkaloid flustrabromine (1). Deformylation of 1 would result in 
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Flustra secondary metabolite deformylflustrabromine (3). Successful oxidative 
cyclization followed by 2-tert-prenyl migration would furnish the pyrrolo[2,3-b]indole 
5. The rearrangement may proceed in any of the two s of the molecule. Any 
enantiocontrol of the rearrangement step would result in exclusive enantiomers with 
defined optical rotations. Diastereoselective reduction of the imine 7 may lead to 
dihydroflustramine C (7, path C, Scheme 51). The proposed pathway C was proven 
by chemical synthesis of dihydroflustramine C (7).116,121 
 
Scheme 51: Possible biosynthesis of dihydroflustramine C (7) via 
deformylflustrabromine (3).116 
Addressing the biosynthesis of roquefortine, Barrow et al.87 and Gorst-Allmann et 
al.88 proposed that the aza-Claisen rearrangement of a N-prenyl group results in the 
C-2 tert-prenyl intermediate which subsequently undergoes sigmatropic [1,5] 
rearrangement to furnish the C-3 tert-prenylindoles. Recently, Li et al. and Williams 
et al. showed the biochemical transformation of 2-tert-prenylated precursor 
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notoamide E (121) into 3-tert-prenylated notoamide C (122) using the prenyl 
transferase NotB.91 A similar pathway of 2-tert-prenyl migration was proposed by 
Stocking et al. regarding the biosynthesis of paraherquamide A.129 
Further support to the proposal by Lindel et al. regarding the biomimetic synthesis of 
flustramines was demonstrated by the successful construction of rac-flustramine A 
(9). Wulff et al. isolated the natural products flustrabromine (1) and flustramide A 
(44). Considering the fact that both 1 and 44 were isolated from the same extract of 
Flustra foliacea, it is possible that flustrabromine (1) is a biomimetic precursor for 
flustramide A (44) which in turn may be converted to flustramine A (9, Scheme 52). 
 
Scheme 52: Biomimetic rac-flustramine A (9) synthesis from flustrabromine (1).  
Starting at the natural product flustrabromine (1) and 180, selective N-prenylation 
and deformylation would result in the formation of N
a
-prenyl-deformylflustrabromine 
                                            
129.  (a) E. M. Stocking, J. F. Sanz-Cervera, R. M. Williams, Angew. Chem. Int. Ed. 1999, 38, 786–
789. (b) E. M. Stocking, R. M. Williams, J. F. Sanz-Cervera, J. Am. Chem. Soc. 2000, 122, 
9089–9098. 
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(24) and 181. Upon oxidative ring closure and 2-tert-prenyl shift compounds 24 and 
181 would furnish the amidinium salts 25 and 182. Upon reduction at the 8a-position 
salt 182 would furnish the natural product flustramide A (44). Morales-Ríos et al.,37 
Kawasaki et al.41,42, and Trost et al.43 had shown the successful conversion of 
flustramide A (44) to flustramine A (9). Therefore, flustramide A (44) could be the 
biomimetic precursor to flustramine A (9).  
It could be also possible that N
a
-prenyl-deformylflustrabromine (24) is a natural 
product yet to be isolated. 
 
3.7 Behavior of prenylindoles under acidic and non-oxidative conditions 
Regular prenyl groups are often sensitive to acids and high temperatures. Apart from 
the NBS-induced oxidative tert-prenyl rearrangements, attempts to shift the prenyl 
groups under acidic and microwave conditions were made. 
The rearrangement of N-prenylindoles to 2-prenylindoles is well studied. In early 
publications, Casnati et al. studied echinulin-type compounds and reported the 
conversion of an N-prenylated compound to a mixture of C-2 tert-prenylated and C-2 
regularly prenylated compounds. When 3-methyl-N-prenylindole (183) was refluxed 
in TFA for 1 hour, unequal amounts (70:30) of 184 and 185 were formed. However, 
when the reaction was carried out at 0 °C for 7 days, a shift in the amounts (35:65) of 
184 and 185 was observed (Scheme 53).130,131  
 
Scheme 53: TFA induced N-prenyl migration on 2-unsubstituted indoles.130,131  
Nakagawa showed that 3a-prenylated pyrrolo[2,3-b]indole 186 reacted with TFA in 
DCM, as a shift of the 3a-prenyl group occurred to form 2-prenylindole 187 with 
                                            
130.  G. Casnati, A. Pochini, J. Chem. Soc. 1970, 1328–1329. 
131.  G. Casnati, A. Pochini, J. Chem. Soc. Perkin Trans. 1 1974, 754–757.  
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simultaneous opening of the pyrrolidine ring (89%).132 In a similar attempt, Plate et 
al. published the reaction of 3a-prenylindole 188 with 5.0 equivalents of TFA in DCM 
at room temperature, which furnished the 2-prenylindole 190 and C-2 tert-
prenylindole 189 in a 9:1 ratio within 1 h. It was found that when two regular prenyl 
groups at N-1 and C-3a are available, the N-prenyl group did not undergo 
rearrangement. Only the C-3a prenyl group was shifted to the indole 2-position 
(Scheme 54).133 
 
Scheme 54: TFA-mediated rearrangements of regular prenylindoles.132,133  
Acid-mediated reactions of 2-tert-prenylindoles were interesting. In one experiment, 
debromoflustrabromine (2) was allowed to react with 5.0 equivalents of TFA. 
Unfortunately, no reaction had taken place after 2 h and 87% of the starting material 
                                            
132.  M. Nakagawa, K. Matsuki, T. Hino, Tetrahedron Lett. 1983, 24, 2171–2174.  
133.  R. Plate, H. C. J. Ottenheijm, Tetrahedron Lett. 1986, 27, 3755–3758. 
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was recovered. In same conditions, 192a gave 192b. However, when 
deformylflustrabromine (3) was exposed to 5.0 equivalents of TFA in DCM for 24 
hours, the TFA salt 193 was formed (Scheme 55). Due to disorder in the olefinic 
bond of the tert-prenyl group, the X-ray crystal structure of 193 is not presented.  
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Scheme 55: 2-tert-prenylindoles were stable to TFA and higher temperatures  
Next, flustrabromine (1) and deformylflustrabromine (3) were heated to 180 °C for 8 
h in N,N-dimethylaniline. The solvent was UV-absorbent at 254 nm and 
overshadowed the TLC control and thus purification of the reaction mixture was not 
possible. Only in the case of flustrabromine (1), the starting material was 
recrystallized (31%). N,N-Dimethylaniline was replaced with PhOH as another high 
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boiling solvent and deformylflustrabromine (3) was refluxed again at 180 °C for 8 
hours. Unfortunately, no thermal rearrangement of the 2-tert-prenyl group took place 
and starting material was recovered (80%, Scheme 55). 
Furthermore, the thermal stability was evaluated by heating the doubly prenylated 
secondary amine 26 which was obtained from the deformylation of 27. In an early 
experiment, compound 26 in H
2
O, although not soluble, was packed in a sealed tube 
and irradiated under microwave conditions at 120 °C for 1 h with a power of 500 W. 
No reaction took place and starting material was recovered (82%). The temperature 
and the solvent were changed in the next experiment. Compound 26 was dissolved 
in toluene and 0.5 equivalents of TFA and irradiated at 150 °C for 1 h to afford the 
TFA salt 194 (67%). When 26 in DMF was irradiated at 180 °C, the formyl group of 
the solvent DMF was incorporated in the aliphatic secondary amine side-chain of 26 
to form 27 (80%, Scheme 56). When the reaction was done at 210 °C in NMP, even 
the pyrrolidine ring of NMP was cleaved and was added to the secondary amine 
nitrogen (not shown in Scheme 56). 
 
Scheme 56: Doubly prenylated indole 26 did not undergo any prenyl shift under 
microwave irradiation.  
No clean products were formed under microwave conditions when the structural 
isomer 177 was exposed to 0.5 equivalents of TFA in toluene at 150 °C for 15 min 
(Scheme 57). Some of the isolated fractions showed 3 fold excess signals in the 13C 
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NMR spectrum with very broad signals in the 1H NMR spectrum, probably being 
polymerized. 
 
Scheme 57: Indole 177 formed unseparable complex mixtures under microwave 
conditions.  
3.8 Studies towards the total synthesis of debromoflustramine E 
Based on the experimental experience with NBS-induced rearrangements on 2-tert-
prenyltryptamines, it is speculated that a regularly prenylated derivative 31 may 
furnish the oxidized version of debromoflustramine E (195) which upon reduction of 
the imine bond of tricyclic compound 195 would result in the synthesis of 
debromoflustramine E (32). Additional prenylation at the indolic nitrogen may afford 
debromoflustramine B (51, Scheme 58). 
 
Scheme 58: Possible synthetic route to debromoflustramine E (32) and B (51). 
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Once more, N
b
-formyl-N
b
-methyltryptamine (131) served as starting material towards 
the synthesis of directly prenylated natural product analogues. The initial target was 
to introduce a regular prenyl group at the indole 2-position of 131. 
 
3.8.1 Installation of a regular prenyl group at the indole 2-position 
The N-prenylation of N
b
-formyl-N
b
-methyltryptamine (131) led to 1-(3,3-dimethylallyl)-
N
b
-formyl-N
b
-methyltryptamine (146). However, the attempted rearrangement of 146 
using BF
3
·Et
2
O in DCM did not result in the 2-prenylated product 196. Although the 
TLC showed several spots, efforts to obtain any of the pure compounds were not 
fruitful. Compound 196 was unstable at room temperature and degradation of 196 
was observed (Scheme 59).25  
N
N
146
O
N
H
N
131
i. NaH, DMF.
0 °C, 1 h
ii. prenylbromide,
rt, 4 h
84%
O
N
H
N
O
BF
3
·Et
2
O, DCM,
0 °C to rt, 42 h
196
 
Scheme 59: BF
3
·Et
2
O did not induce rearrangement of the N-prenyl group.  
Similar attempts were made on the structurally related, phthalimide-protected 
compound 165. Treatment of 165 with NaH and prenylbromide resulted in the 
conversion to N
a
-prenylated phthalimide protected indole 208 in good yields. For 
compound 208 an X-ray crystal structure was also obtained (Figure 23).  
When 208 was treated with BF
3
·Et
2
O at –4 °C or 0 °C, rearrangement failed to occur 
even after 24 hours. The sharp singlet at δ = 6.87 ppm corresponding to 2-H was 
intact in the 1H NMR spectrum and confirmed that rearrangement had not taken 
place. The starting material 208 was recovered in good amounts (up to 80%, 
Scheme 62).  
 
Results and discussion  79 
 
 
Figure 23: ORTEP drawing of N
a
-prenyl-phthaloyltryptamine (208); hydrogen’s are 
omitted for clarity; displacement parameters drawn at 50% probability.  
On the other hand, Cardoso et al. reported this desired rearrangement on a 
structurally similar molecule, using BF
3
·Et
2
O. Under optimized conditions, the yield of 
the product 198 reached up to 61%.134 Danishefsky and co-workers have reported 
the total synthesis of tryprostatin B (199) starting from this advanced intermediate 
198 (Scheme 60).135 
 
Scheme 60: Prenyl rearrangement is important for the synthesis of 
tryprostatin B.134,135  
As an alternative to the oxidative rearrangements of N-prenylated indoles to 2-
prenylindoles, direct introduction of a regular prenyl group was necessary. To install 
                                            
134.  A. S. P. Cardoso, M. M. B. Marques, N. Srinivasan, S. Prabhakar, A. M. Lobo, H. S. Rzepa, 
Org. Biomol. Chem. 2006, 4, 3966. 
135.  J. M. Schkeryantz, J. C. G. Woo, P. Siliphaivanh, K. M. Depew, S. J. Danishefsky, J. Am. Chem. 
Soc. 1999, 121, 11964–11975. 
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a regular prenyl group in a single pot process, the protocol developed by 
Danishefsky et al. was adopted. Towards the total synthesis of tryprostatin B (199), 
Danishefsky et al. designed a new methodology for introducing regular prenyl group 
at the indole 2-position. In the presence of NEt
3
, the suitably protected L-tryptophan 
derivative 200 was reacted with tert-BuOCl at –78 °C to generate a chloroindolenine 
201. It was speculated that exposure of prenyl(tri-n-butyl)stannane to BCl
3
 would 
result in the intermediates 204 and/or 205. Any of these intermediates 204 and/or 
205, upon reaction with the chloroindolenine 201, would provide 206. This advanced 
chloroindolenine 206, finally underwent allyl rearrangement furnishing the 2-
prenylated indole 202 in good yield (Scheme 61).135  
 
Scheme 61: Danishefsky’s prenyl group installation at the indole 2-position.135  
Phthalimide protected tryptamine (165) was reacted with tert-BuOCl (137) in 
presence of NEt
3 
at –78 °C for 45 min to produce the chloroindolenine. Addition of 
prenyl(tri-n-butyl)stannane followed by rapid addition of BCl
3
 within 2 min and stirring 
further for 45 min gave the desired prenylated indole 29 (Figure 24 and Figure 25) 
with yields ranging from 23 to 31% (Scheme 62).  
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Scheme 62: Synthesis of an indole derivative functionalized with a direct prenyl 
moiety at indole C-2.  
 
Figure 24: 1H NMR spectrum (400 MHz, CDCl
3
) of compound 29. 
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Figure 25: 13C NMR spectrum (100 MHz, CDCl
3
) of compound 29. 
Optimization of this step by varying the temperature, reaction time, addition rates of 
reagents, and number of equivalents of BCl
3
 and prenylstannane did not improve the 
yield. Although the TLC indicated a good conversion, the efforts to isolate the 
desired compound 29 were unsuccessful. Removal of excess amounts of prenyl(tri-
n-butyl)stannane reagent proved to be difficult and substantial amounts of product 
were lost during chromatography even on a silica gel column loaded with 10% KF 
(w/w). The directly prenylated compound 29 was stable indefinitely as an orange 
amorphous solid whereas it degraded to a mixture of unknown compounds in 
solution state.  
Cardoso and co-workers mentioned in their publication that the N-prenyl group 
underwent migration to 2-prenylindole 210 which reacted further with BF
3
·Et
2
O to 
afford 211 and 212 (Scheme 63).136 
                                            
136.  A. S. Cardoso, A. M. Lobo, S. Prabhakar, Tetrahedron Lett. 2000, 41, 3611–3613. 
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Scheme 63: 2-Prenylindole 210 reacted further to afford 211 and 212.136  
Regularly prenylated at C-2, compound 29 could be envisaged as starting material 
towards the synthesis of advanced precursors for flustramine E (50) and flustramine 
B (41). The focus was turned onto the conversion of the phthalimide protected 
ethylamine side chain of 29 to a methyl substituted secondary amine. 
 
3.8.2 Synthesis of 2-prenyl-methyltryptamine 
Removal of the phthalimide group was effected by treating indole 29 with excess 
hydrazine monohydrate in MeOH/DCM (1:1) at room temperature. After two days, 
the desired amine 213 was obtained in moderate yield (46%). Changing the solvent 
system to EtOH and by refluxing for 9 h124 afforded negligible improvement (49%). 
However, refluxing for 24 h in the presence of 12.0 equivalents of hydrazine 
monohydrate gave the desired product 213 in the best yield of 82%.  
Application of Bosch conditions on the amine 213 afforded the 2-prenyl-N
b
-
formyltryptamine (30). A mixture of Ac
2
O and HCO
2
H was stirred at 60 °C for 1 h. A 
solution of 213 in DCM was added to the acidic mixture at room temperature and 
stirred for 90 min to furnish the formylindole 30 in an excellent yield of 99% (Scheme 
64) requiring no further purification (Figure 26 and Figure 27). 
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Scheme 64: Synthesis of 2-prenyl-N
b
-formyltryptamine (30). 
 
Figure 26: 1H NMR spectrum (400 MHz, CDCl
3
) of compound 30. 
 
Figure 27: 13C NMR spectrum (100 MHz, CDCl
3
) of compound 30. 
Compound 30 was reacted with 4.2 equivalents of DIBAL-H at room temperature for 
24 hours. Column chromatography of the resulting crude reaction mixture led to the 
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isolation of the desired product, but the NMR spectrum of 31 showed impurities. The 
low resolution GC-EI-MS analysis indicated a molecular ion peak at 240 confirming 
the presence of the desired 31 as a major product. Repeated column 
chromatography including reversed phase HPLC did not afford the pure compound, 
either. The TLC of the isolated spots was neither stable nor reproducible. 
Compound 29 was prenylated for the second time to obtain 214. The doubly 
prenylated 214 is also a potential structural phthalimide isomer to Li-0097 and Li-
0098 for evaluation of biological activity. Behaving in similar manner as in the case of 
prenylation on 166 and 2, compound 29 afforded the doubly prenylated indole 214 in 
an isolated yield of 32% (Scheme 65). Under standard GC conditions (see Section 
4.1) 214 did not elute from the GC column. 
 
Scheme 65. Synthesis of doubly prenylated indole 214. 
 
3.9 Biological activity  
Flustra alkaloids and synthetic derivatives were tested against microorganisms, 
quorum sensing, bacterial biofilm, ion channels, acetylcholine receptors and 
cholinesterase targets (see Section 2.3). They showed activity against a wide range 
of biological targets indicating that these natural products and analogues have great 
potential towards medicinal applications. Extensive screening of prenylated indole 
alkaloids and derivatives was not investigated before. A thorough biological 
evaluation with respect to cytotoxicity, specific antimicrobial activities and biofilm 
formation inhibitions was needed.  
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Given the broad extent of biological activities, evaluation of 30 indole derivatives 
(Figure 28 and Figure 29) including natural products N
b
-methyltryptamine (Li-78), N
b
-
formyl-N
b
-methyltryptamine (Li-21), and Flustra alkaloids flustrabromine (Li-23), 
deformylflustrabromine (Li-67), flustramine C (Li-68), and dihydroflustramine C (Li-
69) was performed. Most of the synthetic derivatives and intermediates were Flustra 
analogues with varying substitution patterns, functionalized with one or two prenyl or 
tert-prenyl groups. Figure 28 and Figure 29 give the structures of the indole 
derivatives tested for cytotoxicity, antimicrobial activity, and inhibition of biofilm 
formation. Figure 29 depicts the structures of phthalimide protected tryptamines 
functionalized with mono- and/or double prenyl groups at the pyrrole section.  
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Figure 28: Structures of biologically evaluated flustramine-type compounds (The 
numbers are adapted from the compound library maintained at Lindel group). 
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Figure 29: Mono- and doubly prenylated phthalimides were evaluated for biological 
activity (The numbers are adapted from the compound library maintained at Lindel 
group). 
 
3.9.1 Cytotoxicity 
 
3.9.1.1 In vitro evaluation against human cancer cell lines  
The cytotoxicity evaluation was performed by Prof. Dr. Fiebig and co-workers at 
Oncotest GmbH, Freiburg (Germany). The cancer cell lines were derived from 
tumors of stomach, lung, breast, melanoma, ovary, pancreas, prostate, 
mesothelioma, kidney, and uterus. The preliminary in vitro cytotoxicity evaluation 
was carried out against twelve cell lines of ten different cancer types.  
During the preliminary examination, a total of 30 molecules were tested at five 
different concentrations. The compounds exhibiting cytotoxicity under 25 µM were 
screened thoroughly against a panel of 42 different human cancer cell lines (Table 7, 
Table 8 and Table 9). In the tables, compounds exhibiting IC
50
 values ranging 
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between 0–25 µM are colored in green, 25–50 µM in yellow and 50–99 µM in blue 
whereas 100–above µM cytotoxicity values are not colored. 
N
b
-formyl-N
b
-methyltryptamine (Li-21), N
b
-formyltryptamine (Li-77), N
b
-
methyltryptamine (Li-78), and phthaloyltryptamine (Li-93) showed no cytotoxicity. 
Deformylflustrabromine (Li-67) was cytotoxic against the colon cancer cell line CXF-
HT29 (IC
50
=12.3 µM) and lung cancer cell lines LXFA–629 and LXFL–529 (IC
50
=12.9 
and 12.8 µM, respectively). Flustramine C (Li-68) showed a geometric mean IC
50 
value of 37.3 µM with sensitivity only against the lung cancer cell line LXFL–529 
(IC
50
=21 µM). Dihydroflustramine C (Li-69) showed much better activity than Li-68 
with good selectivity against colon cancer cell line CXF–HT29 and lung cancer cell 
line LXFA–629 with IC
50
 values of 8.8 and 12.9 µM, respectively. N-prenylated 
secondary amine Li-74 showed good sensitivity to colon cancer cell line CXF–HT29 
(IC
50
=9.1 µM) whereas flustrabromine (Li-23) was only cytotoxic to lung cancer cell 
line LXFL–529 (IC
50
=12.1 µM). Very weak cytotoxicity was observed for synthetic 
indoles Li-70, Li-71, debromoflustramine C (Li-72), N-prenylated Li-73, and 
debromoflustrabromine (Li-22).  
The best cytotoxicity was exhibited by the doubly prenylated N
a
-prenyl-
flustrabromine (Li-75) and N
a
-prenyl-deformylflustrabromine (Li-76) with geometric 
mean IC
50
 values of 12.4 and 3.8 µM, respectively. Presence of a second prenyl 
group in the case of Li-76 increased the cytotoxicity by a factor of six, when 
compared to Li-67. Debromo analogues Li-100 and Li-101 also showed good 
cytotoxicity (geometricmean IC
50
 values of 22.6 and 3.76 µM, respectively). 
Weak activity was recorded for 2-prenyl-N
b
-formyltryptamine (Li-92), and C-3 
prenylated Li-102 and Li-104. Replacement of a formyl group by a hydrogen caused 
a two-fold increment in activity in case of Li-103 compared to Li-102. Structural 
isomers Li-90 and Li-91 possessed similar cytotoxicity.  
An interesting trend was observed for phthalimide protected tryptamines (Li-93 – Li-
99). Li-93 did not show any activity. 2-Tert-prenylindole Li-94 possessed good 
activity (geometric mean IC
50
=25.4 µM) whereas N-prenylated structural isomer Li-
95 was weakly active (geometric mean IC
50
= 53.9 µM). 2-Prenylindole Li-96 was 
more active against stomach GXF–251(IC
50
=8.3 µM) and showed better activity than 
Li-94 and Li-95. Interestingly, 1,2-diprenylated indoles Li-97 and Li-99 showed no 
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significant cytotoxicity (geometric mean IC
50
=45.9 and 62.8 µM, respectively) than 
2,3-diprenylated indole Li-98 (geometric mean IC
50
 = 16.7 µM). 
Table 7: Proliferation inhibition of human cancer cell lines by indole derivatives. 
Cancer 
type 
type name 
Li- 
67 
Li- 
68 
Li- 
69 
Li- 
70 
Li- 
71 
Li- 
72 
Li- 
73 
Li- 
74 
Li- 
75 
Li- 
76 
Li- 
22 
Li- 
23 
Stomach 
CXF HT29 12.3 34 8.76 49.8 42.4 48.1 42.5 9.1 11.7 2.43 100 100 
Stomach 
GXF 251 31.7 39.6 32.6 38.1 80 100 80 34.5 12.9 4.15 80 100 
Lung 
LXFA 629 12.9 41.2 12.9 52.3 100 87.1 80 13.8 12.8 3.12 100 100 
Lung 
LXFL 529 12.8 21 18.7 49 46.9 59.4 51.6 14.5 9.83 3.41 58.6 12.1 
Melanoma 
MEXF 462 41.5 40.5 75.5 47.6 41.7 100 68.5 78.2 14.6 12.4 100 100 
Ovary 
OVXF 899 16 45 29.2 68.8 100 97.3 100 17 13.2 3.66 100 100 
Pancreas 
PAXF 1657 29.4 58.7 44.8 91.9 87.9 100 87.6 41.1 16 3.55 100 100 
Prostate 
PRXF 22R
V
1 21.1 30.8 16.7 44.6 27.7 37.3 57 23.1 8.49 2.99 50.6 100 
Mesothe- 
lioma 
PXF 1752 18.3 36 15.7 38 59.7 87.4 62 17.1 16.4 3.33 100 100 
Kidney 
RXF 486 22.8 49.8 38.4 100 100 100 100 42.6 11.8 3.73 100 100 
Uterus 
UXF 1138 19.7 28.2 37.2 41.8 43.7 100 80 47.7 10.9 3.71 80 100 
Geometric mean IC
50
 = 
20.1 37.3 25.1 53.6 60.8 79.4 71.2 25.3 12.4 3.8 86 82.6 
 
Table 8: Proliferation inhibition of human cancer cell lines by indole derivatives. 
Cancer 
type 
type name 
Li- 
90 
Li- 
91 
Li- 
92 
Li- 
94 
Li- 
95 
Li- 
96 
Li- 
97 
Li- 
98 
Li- 
99 
Li-
100 
Li-
101 
Li-
102 
Li-
103 
Li-
104 
Stomach CXF HT29 37.2 32 82.1 23.3 28.9 15.1 42.7 16.2 65.1 17.1 2.95 64.8 13.9 71.9 
Stomach GXF 251 
n.e. 27.4 44.2 16.1 24.4 8.3 24.1 16.1 36.1 21 3.96 69.4 29 55.3 
Lung LXFA 629 
n.e. 43.8 73.6 40.2 87.8 22.2 100 28.8 100 37.9 3.64 96.7 20 51.5 
Lung LXFL 529 
39.1 49.4 81.2 21.9 34.5 13.7 36.6 15.1 44.1 29.6 4.68 51.7 38 37.7 
Breast MAXF 401 
n.e. 39.4 86.4 19.9 47.1 17.8 38 14.2 100 22.6 3.20 48.4 23.9 40.8 
Melanoma MEXF 462 
83.4 77.2 100 45.5 100 48.5 52.4 15.4 100 16.7 5.01 60.2 37.8 50.3 
Ovary OVXF 899 
49.4 75.7 100 30.2 100 27 31.8 19.5 100 22.1 4.26 59.5 20.5 42 
Pancreas PAXF 1657 
67.8 60.3 100 32 100 23.7 100 33.3 100 37.8 4.46 100 41.6 70 
Prostate PRXF 22Rv1 
40.9 44.4 100 16.7 34.8 17.9 32.1 11.2 39.2 15.6 3.59 42.6 30.8 45.7 
Mesothe- 
lioma 
PXF 1752 
54.8 46.7 100 36.4 43.6 28.7 46.4 15.3 62.6 29.5 3.94 66.7 23.9 70 
Kidney RXF 486 
61.4 50.1 100 29.8 78.8 32.9 25.2 15.4 41.1 20.2 3.17 41.2 15.1 32.7 
Uterus UXF 1138 
41.7 77.1 100 14 49.9 19.8 98.3 10.8 36 14.6 2.90 39.8 23.7 33.6 
Geometric mean IC
50
 =  51 49.4 87 25.4 53.9 20.9 45.9 16.7 62.8 22.6 3.76 59.1 25.1 48.3 
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Among the 30 tested compounds, Li-67, Li-68, N
a
-prenyl-2-H indole Li-74, doubly 
prenylated Li-75 and Li-76 were evaluated for cytotoxicity against a panel of 42 
human cancer cell lines (Table 9). 
Deformylflustrabromine (Li-67) showed good cytotoxicity against colon cancer cell 
lines CXF–DIFI (IC
50
 = 12.6 µM) and CXF–RKO (IC
50
 = 13.8 µM). Compound Li-67 
also showed activity on lung tumor cell line LXFA–629L (IC
50
 = 13.4 µM), breast 
cancer cell line MAXF–401NL (IC
50
 = 12.1 µM), and melanoma tumor cell line 
MEXF–1341L (IC
50
 =13.7 µM), respectively. Flustramine C (Li-68) was cytotoxic to 
only prostate cancer cell line PRXF–LNCAP (IC
50
= 13.6 µM). Slightly more active 
than Li-68 was the N-1-prenyl-2-H indole Li-74 with IC
50
 values of 10.6 and 13.7 µM 
against colon cancer cell line CXF–HT29 and lung cancer cell line LXFA-629L, 
respectively. 
Doubly prenylated Li-75 showed excellent cytotoxicity towards colon cancer cell line 
CXF–HT29, lung cancer cell line LIXF–575L, breast cancer cell line MAXF–401NL, 
and prostate cancer cell line PRXF–LNCAP with IC
50 
values of 14.9, 12.8, 12.8, and 
4.14 µM, respectively). However, N
a
-prenyl-deformylflustrabromine (Li-76) was more 
active (geometric mean IC
50 
= 5.1 µM) than any other indole tested from the series. 
Against 28 different cancer cell lines, Li-76 showed IC
50
 values below 4.8 µM. The 
best IC
50
 values of 1.88 and 2.41 µM were recorded against lung cancer cell line 
LXFA–629L and breast cancer cell line MAXF-401NL, respectively. 
Table 9: Antitumor activity of Li-67, Li-68, Li-74, Li-75, and Li-76 against 42 human 
cancer cell lines. 
Cancer type type name Li-67 Li-68 Li-74 Li-75 Li-76 
Bladder BXF 1218L 39.9 48 n.e. 21.3 3.7 
 
BXF 1352L 33.6 47.8 47.3 33 9.51 
 
BXF T24 58.7 83 82.3 22.3 9.64 
Colon CXF 269L 21 38.7 n.e. 22 3.89 
 
CXF DIFI 12.6 40.5 30.2 16.4 3.78 
 
CXF HCT116 27.5 46.2 39.6 15.8 3.92 
 
CXF HT29 16.4 46.6 10.6 14.9 3.55 
 
CXF RKO 13.8 42.1 18.5 15.5 3.98 
Stomach GXF 251L 31.4 39.1 29.9 19.6 3.23 
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Cancer type type name Li-67 Li-68 Li-74 Li-75 Li-76 
 
GXF MKN45 48.4 36.3 40.5 31.6 4.83 
Throat-head HNXF CAL27 41.8 42.3 49.1 25.5 3.76 
Lung LXF 575L n.e. 23.2 n.e. 12.8 n.e. 
 
LXF H460 36 49.9 35.4 29.1 12.9 
 
LXFA 289L 18.1 38.4 n.e. 23 10.7 
 
LXFA 526L 35.7 39.7 38.8 29.7 3.74 
 
LXFA 629L 13.4 37 13.7 15.2 1.88 
 
LXFL 1121L 30.5 40.2 n.e. 18.4 12.1 
 
LXFL 529L 27 32.2 31.7 19.7 3.75 
Breast MAXF 401NL 12.1 29.5 22.9 12.8 2.41 
 
MAXF MCF7 21.5 38.5 20.8 15.8 14.5 
 
MAXF MDA231 36.7 56.2 41.7 32 12.8 
Melanoma MEXF 1341L 13.7 36.6 n.e. 17.2 3.88 
 
MEXF 276L 41.2 51.3 46.3 22.9 8.99 
 
MEXF 462NL 56.7 62.7 48.8 25.5 8.09 
Ovary OVXF 899L 28.3 47.2 39.6 15.9 10.3 
 
OVXF OVCAR3 47.9 77 77 28.5 10.8 
Pancreas PAXF 1657L 57.8 88.9 51.4 48.9 6.88 
 
PAXF 546L 30.2 37.3 40.7 32.4 11.3 
 
PAXF PANC1 40.9 59.6 49.8 21.4 3.79 
Prostate PRXF 22RV1 46.3 51 51.8 17.2 3.66 
 
PRXF DU145 39.9 47.3 42.5 24.5 3.88 
 
PRXF LNCAP 31.5 13.6 21.7 4.14 5.82 
 
PRXF PC3M 29.7 41.2 43.1 18.2 4.01 
Mesothelioma PXF 1118L 28.3 51.6 45.9 48.1 3.91 
 
PXF 1752L 44 39.7 39.1 29.2 3.81 
 
PXF 698L 42.6 50.6 37.9 46 3.84 
Kidney RXF 1781L 30.9 46.5 37.1 15.5 3.4 
 
RXF 393NL 44.6 37.9 45.4 21.7 3.71 
 
RXF 486L 23.9 50.1 31.5 21.2 3.72 
Sarcoma SXF SAOS2 47.3 63.5 48 23.5 4 
 
SXF TE671 51.3 38 51.9 22.6 4.02 
Uterus UXF 1138L 16.6 27.7 24.5 15.7 3.38 
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Cancer type type name Li-67 Li-68 Li-74 Li-75 Li-76 
Geometric mean 
IC
50
 =
 
   
30.5 43.4 36.7 21.2 5.14 
 
In summary, open chain prenylindoles appear to be more cytotoxic than pyrrolo[2,3-
b]indoles. Doubly prenylated indoles showed higher cytotoxicity than the 
corresponding mono prenyl indoles which, in turn, are more cytotoxic than non-
prenylated indoles. The effect of presence/absence of bromine for cytotoxicity is 
unclear whereas the formyl group diminished cytotoxicity.  
 
Figure 30: SAR summary of prenylated indoles. 
 
3.9.1.2 MTT assay with mouse cell line L-929 
Further cytotoxicity evaluation was performed on the mouse fibroblast connective 
tissue cell line L-929 by Dr. Florenz Sasse and co-workers at the Helmholtz Centre 
for Infection Research, Braunschweig (Germany).  
Among the 30 indole derivatives evaluated, the compounds Li-67, Li-75, Li-76, and 
Li-101 exhibited highest cytotoxicity once again. N
a
-prenyl-deformylflustrabromine 
(Li-76) exhibited an IC
50
 and IC
90
 values of 2.4 and 4 µg/mL, respectively. The 
debromo analogue Li-101 showed similar cytotoxicity IC
50
 and IC
90
 values of 2.2, 3.2 
µg/mL, respectively (Table 10). 
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Table 10: Cytotoxicity of 30 indole derivatives was determined in a MTT assay with 
mouse cell line L-929. 
µg/mL 
Li-
77 
Li-
78 
Li-
21 
Li-
22 
Li-
23 
Li-
67 
Li-
68 
Li-
69 
Li-
70 
Li-
71 
Li-
72 
Li-
73 
Li-
74 
Li-
75 
Li-
76 
IC
50
 
24 16 14 10 16 8 15 15 16 14 15 15 12 9 2.4 
IC
90
 
>40 >40 38 38 >40 23 >>40 33 39 39 >40 >40 32 32 4 
                
µg/mL 
Li-
90 
Li-
91 
Li-
92 
Li-
93 
Li-
94 
Li-
95 
Li-
96 
Li-
97 
Li-
98 
Li-
99 
Li-
100 
Li-
101 
Li-
102 
Li-
103 
Li-
104 
IC
50
 
12 12 20 20 12 23 15 20 18 18 14 2.2 18 20 17 
IC
90
 
40 31 >40 >40 30 >40 30 36 30 40 30 3.2 >40 32 32 
 
3.9.2 Antimicrobial activity 
Collaborative work with Dr. Florenz Sasse and co-workers from the Helmholtz 
Centre for Infection Research, Braunschweig (Germany) also allowed the 
determination of antimicrobial activities.  
Using agar diffusion assays, the 30 indole derivatives were evaluated for 
antimicrobial activity against gram positive bacteria Micrococcus luteus, 
Mycobacterium phlei, gram negative bacterium Escherichia coli-3949, yeast species 
Hansenula anomela and Saccharomyces cerevisiae and fungi Botrytis cinerea, 
Pythium debaryanum. The test compounds dissolved in methanol were applied onto 
6 mm cellulose discs and were allowed to diffuse into the inoculated agar medium. 
The zones of complete inhibition were determined in mm. Larger zones of complete 
inhibition correspond to greater antimicrobial activity. Serial dilution assays with 
bacteria resulted in growth curves from which IC
50
 values of selected compounds 
were determined. 
None of the compounds were antifungal. Only five of the compounds, amidinium salt 
Li-71, N
a
-prenyl-2-H indole Li-74, doubly prenylated N
a
-prenyl-
deformylflustrabromine Li-76, debromo analogues Li-100 and Li-101 showed 
greater complete zones of inhibition. Li-71 and Li-74 exhibited inhibition zones of 10 
mm and 11 mm, respectively against M. phlei. Li-76 showed 13 mm zones of 
inhibition against each of the M. luteus, M. phlei and S. cerevisiae with 
corresponding IC
50
 values of 5.9, 7.7, and 17.9 µM, respectively. Li-100 showed an 
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8 mm inhibition zone and an IC
50
 value of 23.6 µM against M. luteus. The best 
antimicrobial candidate was debromo-N
a
-prenyl-deformylflustrabromine (Li-101). The 
zones of inhibitions against M. luteus, M. phlei, E. coli, H. anomela, and S. cerevisiae 
were 20, 15, 8, 12, and 12 mm, respectively. An IC
50
 value of 7.7 µM was recorded 
for Li-101 against M. phlei (Table 11). 
Table 11: Antimicrobial evaluation of indoles. 
Microorganism 
Li-71 Li-74 Li-76 Li-100 Li-101 
IZ IC
50
 IZ IC
50
 IZ IC
50
 IZ IC
50
 IZ IC
50
 
Gram(+)ve Bacteria 
Micrococcus luteus 
- - - - 13 5.9 8 23.6 20 22.6 
Mycobacterium phlei 
10 >110 11 95 13 7.7 - - 15 7.7 
Gram(-)ve Bacteria 
E. Coli 3949 
- - - - - - - - 8 29 
Yeast 
Hansenula anomela 
- - - - - - - - 12 >119 
Saccharomyces 
cerevisiae 
- - - - 13 17.9 - - 12 77 
Fungi 
Botrytis cinerea 
- - - - - - - - - - 
Pythium debaryanum 
- - - - - - - - - - 
 
3.9.3 Inhibition of bacterial biofilm formation 
Dr. Werner Tegge and co-workers from the Helmholtz Centre for Infection Research, 
Braunschweig (Germany) evaluated the Flustra alkaloids and their derivatives for 
possible inhibition of bacterial biofilm formation. 
All of the 30 indole derivatives were evaluated against S. aureus and methicillin 
resistant S. aureus (MRSA) in three different concentrations of 1, 5, and 25 µM, 
respectively. Among the tested compounds, three indole derivatives showed 
inhibition of biofilm formation within these dosages. N
a
-prenyl-flustrabromine (Li-75) 
was active only at a concentration of 25 µM whereas 2-tert-prenyl-
phthaloyltryptamine (Li-94) showed activity at 30 µM concentration. Interestingly, 2-
prenyl-phthaloyltryptamine (Li-96), a structural isomer to Li-94, is the most active 
among the tested compounds: It inhibited the bacterial biofilm formation at  
concentrations of 1, 5, and 25 µM, respectively.  
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4 Experimental Section 
4.1 General Materials and Methods 
Chemicals and Synthesis: All non-aqueous reactions were conducted in dried 
glassware under nitrogen or argon atmosphere. The chemicals were purchased in 
high quality from the commercial suppliers Aldrich, Acros, Fluka, ABCR, TCI, and 
Merck and used without further purification unless noted otherwise. All solvents were 
purified by standard methods and distilled prior to use. All yields refer to isolated 
yields of compounds after the final purification process, unless otherwise stated. 
NMR spectra were recorded with instruments Bruker DPX-Bruker 200 (200.1 MHz 
for 1H NMR, 13C NMR with 50.3 MHz, T=300 K), AV II-300 (300.1 MHz for 1H NMR, 
13C NMR with 75.5 MHz, T=296 K), AV III-400 (400.1 MHz for 1H NMR, 13C NMR 
with 100.6 MHz, T=296 K), Bruker DRX-400 (400.1 MHz for 1H NMR, 13C NMR with 
100.6 MHz, T=300 K), and Bruker AV II-600 (600.1 MHz for 1H NMR; 13C NMR with 
150.3 MHz). The chemical shifts δ are given in ppm and referenced to the external 
standard TMS or internal solvent standard. The connectivity was determined by 
1H,1H-COSY, 1H,13C-HSQC, and 1H,13C-HMBC experiments. Multiplicities of NMR 
signals are indicated as follows: s (singlet), d (doublet), t (triplet), m (multiplet), dd 
(doublet of doublets), dt (doublet of triplets). 
Mass spectra were obtained with instruments Thermofinnigan MAT95, 
Thermofinnigan MAT95XLT, Thermofinnigan MAT95XL, and ThermoFisher Scientific 
LTQ-Orbitrap Velos. For low resolution EI measurements (Thermofinnigan 
MAT95XL) the lower limit was set to 2000 and the high resolution was set to 10000 
(10% valley definition). Depending on the method, the mass ranges were selected 
between 40 – 1000 amu. Measurements were performed at an ionization energy of 
70 eV with the source temperature set to 180 °C. For ESI measurements (LTQ-
Orbitrap Velos) the low resolution was set to 3000 and high resolution to 100000 
FWHM at (m/z = 400 amu). Depending on method, mass ranges between 50-2000 
amu were acquired. 
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Typical spray voltages were 2.3–2.8 kV (positive mode) and 1.7–2.5 kV (negative 
mode). A sample concentration of 50 µg/mL in MeOH (spiked with 0.1 mg/mL 
tetradecyltrimethylammonium bromide) with a flow rate of 1 µL/min was used. 
For GC–MS, an Agilent 6890 gas chromatograph (analytical column: Phenomenex 
ZB5-MS, 30m x 0.25 mm I.D, thickness=0.25 µm) and a JMS-T100GC 
(GCAccuTOF, JEOL, Japan) time of flight mass spectrometer in EI mode at 70eV 
were used. A split injection port at 250 °C was used for sample introduction and the 
split ratio was set to 10:1. The helium carrier gas was set to 1.0 ml/min flow rate and 
the transfer line was kept at 270°C. An oven-temperature programme of starting 
initially at 70 °C, 3 min isothermal conditions and 10 °C/min until 300 °C was utilized 
for measurements 
IR spectra were recorded with a Bruker Tensor 27 spectrometer. The wave number 
is given in cm-1. The signal intensities are given in parentheses as “s” (strong), “m” 
(medium), “w” (weak), and “br” (broad). 
UV/Vis spectra were measured with a Varian Cary 100 Bio UV/Vis-spectrometer. 
The wavelength of absorption maxima (λ
max
) is given in nm and the extinction 
coefficient was given as logarithmic value in brackets. 
Melting points were identified with a Büchi 530 melting point apparatus and are 
uncorrected. 
X-ray crystallography was performed at the Institute of Inorganic and Analytical 
Chemistry of TU Braunschweig with an Oxford Diffraction Nova O instrument. 
Complete crystallographic data of the measured compounds are presented in 
Section 5 
Optical rotations were measured on a Dr. Kernchen Propol Automatic Polarimeter 
at ambient temperature, using a 1 mL capacity cell with 1 dm path length. 
Chromatography 
Thin layer chromatography was performed on pre-coated plastic sheets, 
POLIGRAM® SIL G/UV
254
 purchased from Merck (0.20 mm silica gel with fluorescent 
indicator UV
254
). Zones were detected by fluorescence irradiation at 254 nm and/or 
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staining using a solution of Vaughn’s reagent (9.6 g (NH
4
)
6
Mo
7
O
24
·4 H
2
O and 0.4 g 
Ce(SO
4
)
2
·4 H
2
O in 200 mL 7 M H
2
SO
4
) followed by heating. 
Column chromatography/flash chromatography was done using Geduran® Silica 
gel (Merck) having pore size 40-63 µm (without pressure) or 63-200 µm (with 
pressure) . For reversed-phase chromatography LiChroprep RP-18 (40-63 µm, 94 g, 
Merck) was used in a column with 3 cm diameter, which was regenerated by 
washing with MeOH. 
HPLC was performed using a system consisting L-6200 intelligent pump (Merck 
Hitachi), a diode array detector DDT-3200 USB (Duratec) and the computer 
programme Clarity Data Apex. The enantiomers were separated on a chiral 
analytical column (Chiralcel OD, normal phase, particle size 10 µM). For reversed 
phase separations, analytical (LichroCART
®
, RP-18, particle size 5 µm) and semi-
preparative columns (Hibar
®
, RP-18, particle size 7 µm and Phenomenex, RP-18, 
particle size 5 µm) were used. The HPLC grade solvents were purchased from 
Fisher Scientific, Honeywell, and Chromanorm  
Microwave reactions were performed in a sealed reaction vessel ofan MLS START 
1500 microwave synthesizer with an output power of 500 W.  
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4.2 Experimental Procedures 
N-(2-(1H-indol-3-yl)ethyl)formamide (125)93 
To tryptamine (124, 10.2 g, 62.4 mmol, 1.0 eq.) in DCM (100 mL) 
was added a mixture (1:1) of Ac
2
O (29.6 mL, 312.0 mmol, 5.0 eq.) 
and HCO
2
H (11.9 mL, 312.0 mmol, 5.0 eq.) which were stirred at 
60 °C for 1 h and allowed to cool to rt. After having added a few 
drops of acidic mixture, the tryptamine dissolved completely. The 
reaction mixture was stirred for 90 min at rt. 12 M NaOH (75 mL) 
was added at 0 °C and the alkaline mixture was diluted with DCM (600 mL), washed 
with H
2
O (3x 100 mL), dried over MgSO
4
, and concentrated in vacuum. The resulting 
bright orange oil was further dried by heating at 70 °C under HV to give 125 (11.0 g, 
58.6 mmol, 94%) as a bright orange oil. 
TLC [silica gel, EtOAc]: R
f
 = 0.42. 
Ratio of rotamers in CDCl
3
: 1.0:0.2. 
Major rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.58 (s, br, 1H, NH), 7.97 (s, br, 1H, CHO), 7.55 (d, 
3J = 7.8 Hz, 1H, o-CHCHCNH), 7.31 (dd, 4J = 0.9 Hz, 3J = 8.0 Hz, 1H, o-
CHCHCCNH), 7.20-7.06 (m, 2H, CCHCHCHCHCNH), 6.93 (d, 3J = 2.3 Hz, 1H, 
CNHCHC), 5.83 (s, br, 1H, CNHCH), 3.57 (t, 3J = 6.6 Hz, 2H, NHCH
2
CH
2
), 2.93 (t, 3J 
= 6.8 Hz, 2H, NHCH
2
CH
2
C).  
13C NMR (100 MHz, CDCl
3
): δ = 161.3 (CHO), 136.3 (CHCNH), 127.1 ( (NHC)CC), 
122.2 (NHCHC), 121.9 (m-CHCHCHCNH), 119.2 (m-CHCHCHCHCNH), 118.4 (o-
CHCHCCNH), 112.1 (NHCHCCH
2
), 111.3 (CHCHCCNH), 38.2 (CCH
2
CH
2
NHCHO), 
25.0 (CCH
2
CH
2
NHCHO).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.58 (s, br, 1H, NH), 7.97 (s, br, 1H, CHO), 7.77 (d, 
3J = 12.4 Hz, 1H, o-CHCHCN), 7.51 (dd, 4J = 3.0 Hz, 3J = 5.0 Hz, 1H, o-CHCHCCN), 
7.20-7.06 (m, 2H, CCHCHCHCHCN), 6.89 (d, 3J = 2.4 Hz, 1H, NHCHC), 5.83 (s, br, 
125
N
H
HN
O
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1H, CNHCH), 3.53 (t, 3J = 3.6 Hz, 2H, NHCH
2
CH
2
), 2.88 (t, 3J = 6.4 Hz, 2H, 
NHCH
2
CH
2
C).  
13C NMR (100 MHz, CDCl
3
): δ = 164.6 (CHO), 136.4 (CHCNH), 127.2 ((NHC)CC), 
122.1 (NHCHC), 121.9 (m-CHCHCHCNH), 119.2 (m-CHCHCHCHCNH), 118.2 (o-
CHCHCCNH), 112.5 (NHCHCCH
2
), 111.4 (CHCHCCNH), 39.8 (CH
2
CH
2
NHCHO), 
25.1 (CCH
2
CH
2
NHCHO).  
IR (Diamond-ATR): ν~  = 3389 cm-1 (br, w), 3276 (br, m), 3054 (br, w), 2926 (br, w), 
2872 (br, w), 1654 (s), 1516 (m), 1455 (m), 1434 (m), 1383 (m), 1339 (m), 1226 (m), 
1096 (m), 1009 (w), 810 (w), 740 (br, s), 608 (m), 583 (m), 559 (m).  
UV (CH
2
Cl
2
): λ
max
 (log ε) = = 290 nm (3.66), 280 (3.76), 274 (3.75), 229 (4.17). 
MS (EI, 70 eV): m/z (%) = 189 (2), 188 (12), 144 (8), 143 (58), 131 (14), 130 (100), 
128 (8), 115 (10), 103 (15), 102 (8), 89 (6), 84 (6), 77 (21), 76 (6), 75 (5), 63 (5), 51 
(10), 50 (8), 44 (7). 
 
2-(1H-Indol-3-yl)-N-methylethanamine (126)92 
N
b
-Formyltryptamine 125 (11.0 g, 58.4 mmol, 1.0 eq.) in THF (165 
mL) was stirred at rt. To this mixture DIBAL-H (17% in toluene – 
261.2 mL, 267.9 mmol, 4.6 eq.) was added drop wise. The reaction 
mixture was stirred at rt for 24 h and afterwards added in portions to 
200 g of ice and 50 mL H
2
O at 0 °C. 75 mL of 12 M HCl was added 
at 0 °C (pH 2) and the organic layer was extracted with Et
2
O (2x 100 mL). The 
aqueous layer was made strongly alkaline with NaOH (12 M, 120 mL, pH 11) and 
was extracted with Et
2
O (3x 150 mL). The resultant organic layer was washed with 
H
2
O (3x 150 mL) and all combined organic layers were dried over MgSO
4 
and 
concentrated in vacuum to afford N
b
-methyltryptamine (126, 8.0 g, 45.9 mmol, 79%) 
which solidified after drying in a desiccator over KOH. 
TLC [silica gel, CHCl
3
/MeOH/NH
4
OH (9:1:0.1)]: R
f
 = 0.07. 
Mp: 88–91 °C. 
126
N
H
NH
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1H NMR (400 MHz, CDCl
3
): δ = 8.53 (s, br, 1H, NH), 7.63 (dd, 4J = 1.5 Hz, 3J = 7.1 
Hz, 1H, o-CHCHCNH), 7.33 (dd, 4J = 1.2 Hz, 3J = 7.0 Hz, 1H, o-CHCHCCNH), 7.20 
(dd, 4J = 1.4 Hz, 3J = 7.0 Hz, 1H, m-CHCHCHCNH), 7.12 (dd, 4J = 1.6 Hz, 3J = 8.3 
Hz, 1H, m-CHCHCHCCNH), 6.99 (d, 3J = 1.7 Hz, 1H, NHCHC), 3.03-2.87 (m, 4H, 
NHCH
2
CH
2
C), 2.44 (s, 3H, NHCH
3
), 1.89 (s, br, 1H, CH
2
NHCH
3
).  
13C NMR (100 MHz, CDCl
3
): δ = 136.4 (CHCNH), 127.4 ((NHC)CC), 122.0 
(NHCHC), 121.8 (m-CHCHCHCNH), 119.1 (m-CHCHCHCHCNH), 113.7 (o-
CHCHCCNH), 111.1 (CH
2
CCHNHC), 52.0 (CH
2
CH
2
NHCH
3
), 36.3 (CH
3
), 25.6 
(CCH
2
CH
2
NHCH
3
). 
IR (Diamond-ATR): ν~  = 3407 cm-1 (w, br), 3300 (w), 3137 (w, br), 3080 (w), 2966 
(w), 2930 (w), 2853 (m), 2830 (m), 2789 (m, br), 2754 (m), 2713 (w, br), 2606 (w, br), 
1623 (w), 1508 (w), 1472 (w), 1452 (m), 1379 (w), 1341 (m), 1220 (m), 1160 (w), 
1125 (w), 1101 (m), 1074 (w), 1011 (m), 968 (w), 894 (w), 791 (m), 769 (w), 736 (s, 
br), 615 (w), 587 (w), 560 (w).  
UV (CH
2
Cl
2
): λ
max
 (log ε) =  290 nm (3.67), 281 (3.75), 229 (4.23).  
MS (EI, 70 eV): m/z (%) = 175 (8), 174 (44), 172 (14), 158 (6), 157 (6), 155 (5), 144 
(28), 142 (18), 132 (10), 131 (100), 130 (84), 128 (8), 115 (6), 103 (12), 102 (8), 77 
(22), 76 (6), 75 (5), 74 (5), 65 (6), 63 (5), 58 (12), 51 (12). 
 
N-(2-(1H-indol-3-yl)ethyl)-N-methylformamide (131) and N-(2-(1H-indol-3-
yl)ethyl)-N-methylacetamide 
131
N
H
N
O
131b
N
H
N
O
 
A mixture (1:1) of Ac
2
O (9.0 mL, 94.5 mmol, 2.5 eq.) and HCO
2
H (3.6 mL, 94.5 
mmol, 2.5 eq.) was stirred at 60 °C for 1 h. After cooling to rt, a solution of N
b
-
methyltryptamine 15 (6.6 g, 37.8 mmol, 1.0 eq.) in DCM (100 mL) was added drop 
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wise. The reaction mixture was stirred at rt for 90 min. Upon completion, the reaction 
mixture was added to NaOH (12 M, 110 mL, pH 11) and ice (100 g). The alkaline 
mixture was diluted with DCM (300 mL) and the aqueous layer was extracted twice 
with DCM (100 mL). The combined organic layers were washed with 2 M HCl (3x 75 
mL), with H
2
O (3x 150 mL), dried over MgSO
4
, filtered and concentrated in vacuum. 
The resulting viscous oil was dried further by stirring at 70 °C under vacuum. Et
2
O 
was added and concentrated in vacuum, affording N
b
-formyl-N
b
-methyltryptamine 
(131, 10.4 g, 51.7 mmol, 90%) as a brownish, semi crystalline oil which could be 
recrystallized using EtOAc/hexane (1:1) as needle shaped yellow crystals. 
Acetylated compound 131b was also isolated as a minor product (163 mg, 0.76 
mmol, 2%) as a brown oil. 
Compound 131: 
TLC [silica gel, EtOAc]: R
f 
= 0.3. 
Ratio of rotamer in CDCl
3
: 1.6:1.  
Major rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.59 (s, br, 1H, NH), 7.73 (s, 1H, CHO), 7.53 (d, 3J = 
7.8 Hz, 1H, o-CHCHCNH), 7.32 (d, 3J = 8.0 Hz, 1H, o-CHCHCCNH), 7.17 (dd, 4J = 
1.1Hz, 3J = 8.0 Hz, 1H, m-CHCHCHCNH), 7.12 (dd, 4J = 1.1 Hz, 3J = 7.7 Hz, 1H, m-
CHCHCHCCNH), 6.88 (d, 3J = 2.2 Hz, 1H, NHCHC), 3.50 (t, 3J =6.8 Hz, 2H, 
NCH
2
CH
2
C), 3.02-2.96 (m, 2H, NCH
2
CH
2
C), 2.91 (s, 3H, CH
2
NCH
3
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.9 (CHO), 136.3 (CHCNH), 126.7 ((NHC)CC), 
122.5 (NHCHC), 121.9 (m-CHCHCHCNH), 119.3 (m-CHCHCHCCNH), 118.0 (o-
CHCHCNH), 111.4 (CH
2
CCHNH), 111.1 (o-CHCHCCNH), 50.0 (CH
2
CH
2
NCH
3
), 29.6 
(NCH
3
), 24.2 (CCH
2
CH
2
NCH
3
).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.52 (s, br, 1 H, NH), 8.04 (s, 1 H, CHO), 7.65 (d, 3J 
= 7.8 Hz, 1H, o-CHCHCNH), 7.32 (d, 3J = 8.0 Hz, 1H, o-CHCHCCNH), 7.19 (dd, 4J = 
1.1 Hz, 3J = 8.9 Hz, 1H, m-CHCHCHCNH), 7.11 (dd, 4J = 1.1 Hz, 3J = 7.7 Hz, 1H, m-
CHCHCHCCNH), 6.97 (d, 3J = 2.1 Hz,1H, NHCHC), 3.65 (t, 3J = 7.3 Hz, 2H, 
NCH
2
CH
2
C), 3.02-2.96 (m, 2H, NCH
2
CH
2
C), 2.85 (s, 3H, CH
2
NCH
3
).  
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13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 136.2 (CHCNH), 127.2 ((NHC)CC), 
122.0 (NHCHC), 121.8 (m-CHCHCHCNH), 119.1 (m-CHCHCHCCNH), 118.4 (o-
CHCHCNH), 112.2 (CH
2
CCHNH), 111.2 (o-CHCHCCNH), 44.8 (CH
2
CH
2
NCH
3
), 34.9 
(NCH
3
), 22.6 (CCH
2
CH
2
NCH
3
).  
IR (Diamond-ATR): ν~  = 3405 cm-1, 3270 (w, br), 3055 (w), 2924 (w), 2862 (w), 1649 
(s, br), 1488 (w), 1454 (m), 1433 (m), 1392 (m), 1339 (m), 1229 (m), 1176 (w), 1073 
(m, br), 1011 (w), 739 (s), 687 (m, br), 657 (m), 621 (w), 584 (w), 560 (w).  
UV (CH
2
Cl
2
): λ
max
 (log ε) = 290 nm (3.68), 280 (3.77), 274 (3.76), 229 (4.22).  
MS (EI, 70 eV): m/z (%) = 203 (2), 202 (14) [M+], 144 (10), 143 (80), 131 (8),130 
(100), 128 (5),115 (8), 103 (10), 102 (6), 77 (12), 44 (6).  
Compound 131b: 
TLC [silica gel, EtOAc]: R
f 
= 0.45. 
Ratio of rotamer in CDCl
3
: 1.4:1.  
Major rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.53 (s, br, 1H, NH), 7.56 (d, 3J = 7.6 Hz, 1H, o-
CHCHCNH), 7.46 (d, 3J = 7.2 Hz, 1H, o-CHCHCCNH), 7.26-7.00 (m, 2H, m-
CHCHCHCNH), 6.95 (s, 1H, NHCHC), 3.57 (t, 3J = 7.1 Hz, 2H, NCH
2
CH
2
C), 3.01 (t, 
3J = 6.7 Hz, 2H, NCH
2
CH
2
C), 2.98 (s, 3H, CH
2
N(CH
3
)COCH
3
), 2.08 (s, 3H, 
CH
2
N(CH
3
)COCH
3
). 
13C NMR (100 MHz, CDCl
3
): δ = 170.9 (COCH
3
), 136.4 (CHCNH), 127.0 ((NHC)CC), 
122.1 (NHCHC), 122.0 (m-CHCHCHCNH), 119.4 (m-CHCHCHCCNH), 118.5 (o-
CHCHCNH), 113.0 (o-CHCHCCNH), 111.5 (CH
2
CCHNH), 51.4 (CH
2
CH
2
NCH
3
), 33.3 
(NCH
3
), 24.1 (CCH
2
CH
2
NCH
3
), 21.0 (CH
2
N(CH
3
)COCH
3
).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.40 (s, br, 1H, NH), 7.64 (d, 3J = 7.7 Hz, 1H, o-
CHCHCNH), 7.34 (d, 3J = 7.1 Hz, 1H, o-CHCHCCNH), 7.26-7.00 (m, 2H, m-
CHCHCHCNH), 7.01 (s, 1H, NHCHC), 3.68 (t, 3J = 7.1 Hz, 2H, NCH
2
CH
2
C), 3.01 (t, 
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3J = 6.7 Hz, 2H, NCH
2
CH
2
C), 2.90 (s, 3H, CH
2
N(CH
3
)COCH
3
), 1.84 (s, 3H, 
CH
2
N(CH
3
)COCH
3
). 
13C NMR (100 MHz, CDCl
3
): δ = 170.9 (COCH
3
), 136.3 (CHCNH), 127.5 ((NHC)CC), 
122.4 (NHCHC), 121.8 (m-CHCHCHCNH), 119.2 (m-CHCHCHCCNH), 118.6 (o-
CHCHCNH), 111.8 (CH
2
CCHNH), 111.1 (o-CHCHCCNH), 48.7 (CH
2
CH
2
NCH
3
), 36.7 
(NCH
3
), 23.2 (CCH
2
CH
2
NCH
3
), 22.0 (CH
2
N(CH
3
)COCH
3
).  
 
N-Methyl-N-(2-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethyl)-formamide (2)  
To a solution of N
b
-Formyl-N
b
-methyltryptamine (131, 0.5 g, 2.5 
mmol, 1.0 eq.) in THF (18 mL) and Et
3
N (0.4 mL, 3.0 mmol, 1.2 
eq.) was added tert-BuOCl (137, 0.3 mL, 3.0 mmol, 1.2 eq.) at –78 
°C. The colourless solution was stirred for 30 min at –78 °C, before 
a freshly prepared solution of prenyl-9-BBN (142, 0.5 M, 10.4 mL, 
4.9 mmol, 2.0 eq.) in THF was added drop wise. It proved to be 
beneficial, if 1,1- dimethylallene and 9-BBN-H were allowed to react for 18 h at rt 
before use. After 30 min the yellow solution was allowed to warm to rt and was 
stirred for 1 h. Aqueous NaOH (3 M, 4 mL) and H
2
O
2
 (30%, 4 mL) were added drop 
wise. The mixture was stirred at rt for 1 h and diluted in Et
2
O (400 mL). The organic 
layer was washed three times with semi saturated solution of NaCl, dried over 
MgSO
4
, filtered, and concentrated in vacuum. The residual oil was washed twice 
with Et
2
O (10 mL) affording 2 (2.2 g, 8.0 mmol, 80%) as colourless solid. Further 
purification was possible by recrystallisation in n-heptane/toluene (5:1). 
TLC [silica gel, EtOAc/petrolether (1:1)]: R
f 
= 0.4.  
Mp: 146-147 °C. 
Ratio of rotamer in CDCl
3
: 1.6:1.  
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.10 (s, br, 1H, NH), 8.03 (s, 1H, CHO), 7.44 (d, 3J = 
7.7 Hz, 1H, o-CHCHCNH), 7.31 (d, 3J = 7.7 Hz, 1H, o-CHCHCCNH), 7.17-7.07 (m, 
2H, m-CHCHCHCHCNH), 6.12 (dd, 3J = 10.5, 17.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.20-
2
N
H
N
O
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5.14 (m, 2H, C(CH
3
)
2
CH=CH
2
), 3.55-3.42 (m, 2H, CH
3
NCH
2
CH
2
C), 3.07-3.03 (m, 
2H, CH
3
NCH
2
CH
2
C), 2.97 (s, 3H, CH
2
NCH
3
), 1.52 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 145.8 (, C(CH
3
)
2
CH=CH
2
), 140.1 
(NHCC(CH
3
)
2
CH), 134.2 ((NHC)CC), 129.0 (CHCNH), 121.6 (m-CHCHCHCNH), 
119.5 (o-CHCHCNH), 117.4 (o-CHCHCCNH), 111.9 (C(CH
3
)
2
CH=CH
2
), 110.7 (m-
CHCHCHCCNH), 106.7 (NHCCCH
2
), 50.1 (CH
2
CH
2
NCH
3
), 38.8 (NHCC(CH
3
)
2
), 29.9 
(NCH
3
), 27.6 (2C, C(CH
3
)
2
CH=CH
2
) 24.9 (CCH
2
CH
2
NCH
3
).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.07 (s, 1H, CHO), 8.00 (s, br, 1H, NH), 7.63 (d, 3J = 
7.5 Hz, 1H, o-CHCHCNH), 7.28 (d, 3J = 7.3 Hz, 1H, o-CHCHCCNH), 7.17-7.07 (m, 
2H, m-CHCHCHCHCNH), 6.13 (dd, 3J = 10.5, 17.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.20- 
5.14 (m, 2H, C(CH
3
)
2
CH=CH
2
), 3.55-3.42 (m, 2H, CH
3
NCH
2
CH
2
C), 3.07-3.03 (m, 
2H, CH
3
NCH
2
CH
2
C), 2.95 (s, 3H, CH
2
NCH
3
), 1.56 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.3 (CHO), 145.7 (C(CH
3
)
2
CH=CH
2
), 139.8 
(NHCC(CH
3
)
2
CH), 134.1 ((NHC)CC), 129.5 (CHCNH), 121.4 (m-CHCHCHCNH), 
119.3 (o-CHCHCNH), 118.1 (o-CHCHCCNH), 111.9 (C(CH
3
)
2
CH=CH
2
), 110.4 (m-
CHCHCHCCNH), 107.5 (NHCCCH
2
), 45.3 (CH
2
CH
2
NCH
3
), 38.9 (NHCC(CH
3
)
2
), 34.9 
(NCH
3
), 27.6 (2C, C(CH
3
)
2
CH=CH
2
), 22.6 (CCH
2
CH
2
NCH
3
).  
IR (Diamond-ATR): ν~  = 3297 cm-1 (m, br), 3051 (w), 2967 (w), 2928 (w), 2873 (w), 
1651 (s), 1457 (m), 1433 (m), 1391 (m), 1359 (m), 1340 (m), 1297 (m), 1242 (m), 
1167 (m), 1044 (m), 1002 (m), 913 (s), 786 (w), 758 (w), 740 (s), 723 (s), 688 (s), 
657 (m), 582 (w), 532 (w). 
UV (CH
3
CN): λ
max
 (log ε) = 290 nm (3.76), 283 (3.80), 226 (4.47), 195 (4.39), 192 
(4.38). 
MS (EI, 70 eV): m/z (%) = 271 (4), 270 (24) [M+], 212 (5), 211 (24), 199 (14), 198 
(100), 197 (6), 196 (24), 184 (8), 183 (51), 182 (36), 181 (12), 180 (11), 170 (8), 169 
(14), 168 (50), 167 (30), 166 (6), 156 (8), 154 (10), 143 (6), 130 (8), 128 (6), 115 (6), 
84 (6), 82 (6), 77 (7), 67 (5), 55 (5), 44 (5). 
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N-(2-(6-Bromo-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethyl)-N-
methylformamide (1) and N-(2-(4-bromo-2-(2-methylbut-3-en-2-yl)-1H-indol-3-
yl)ethyl)-N-methylformamide (148) 
 
To a stirred solution of debromoflustrabromine (2, 0.8 g, 2.98 mmol, 1.0 eq.) in 
HOAc-HCO
2
H (24.1 mL, 3:1) was added a solution of NBS (0.6 g, 3.1 mmol, 1.0 eq.) 
in HOAc-HCO
2
H (15 mL, 3:1). The solution was stirred at rt for 30 min, before the 
solution was added to a mixture of Et
2
O (50 mL) and ice (50 g) and again diluted 
with Et
2
O (100 mL). The organic layer was washed with H
2
O (3 x 50 mL) and with 
aqueous NaOH (1 M, 50 mL). The organic layer was washed again with H
2
O (2 x 50 
mL), dried over MgSO
4
, filtered, and concentrated in vacuum. The crude solid was 
washed thrice with MeOH (3 x 4 mL). Remaining solvent was removed under 
reduced pressure, affording flustrabromine (1, 0.55 g, 1.57 mmol, 53%) and 4-
brominated side product 148 (0.21 g, 0.60 mmol, 20%) as a colourless solids, which 
were separated by column chromatography (silica gel, EtOAc/petrolether (1:1)).  
6-Bromoindole 1: 
TLC [silica gel, EtOAc/petrolether (1:1)]: R
f 
= 0.43.  
Mp: 218-220 °C.  
Ratio of rotamers in CDCl
3
: 1:0.8. 
Major rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.21 (s, br, 1H, indole NH), 7.99 (s, 1H, CHO), 7.49 
(d, 3J = 8.4 Hz, 1H, indole 4-H), 7.46 (d, 4J = 1.7 Hz, 1H, indole 7-H), 7.20 (dd, 4J = 
1.7 Hz, 3J = 8.4 Hz, 1H, indole 5-H), 6.10 (dd, 3J = 17.5, 10.4 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
), 5.21-5.15 (dd, 3J = 17.5 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
E
), 5.21-5.15 (dd, 3J = 10.4 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 3.53-3.38 (m, 
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2H, CCH
2
CH
2
N(CH
3
)CHO), 3.06-2.99 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.96 (s, 3H, 
CCH
2
CH
2
N(CH
3
)CHO), 1.52 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 145.5 (C(CH
3
)
2
CH=CH
2
), 140.9 
(indole C-2), 135.0 (indole C-7a), 128.1 (indole C-3a), 122.9 (indole C-5), 119.9 
(indole C-4), 115.0 (indole C-6), 113.7 (indole C-7), 112.4 (C(CH
3
)
2
CH=CH
2
), 107.1 
(indole C-3), 50.2 (CCH
2
CH
2
N(CH
3
)CHO), 38.9 (NHCC(CH
3
)
2
CH=CH
2
), 30.1 
(CCH
2
CH
2
N(CH
3
)CHO), 27.6 (2C, C(CH
3
)
2
CH=CH
2
), 24.9 (CCH
2
CH
2
N(CH
3
)CHO).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.07 (s, br, 1H, indole NH), 8.00 (s, 1H, CHO), 7.43 
(d, 4J = 1.3 Hz, 1H, indole 7-H), 7.29 (d, 3J = 8.4 Hz, 1H, indole 4-H), 7.19 (dd, 4J = 
1.7 Hz, 3J = 8.4 Hz, 1H, indole 5-H), 6.13-6.08 (dd, 3J = 17.6, 10.4 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
), 5.21-5.15 (dd, 3J = 17.6 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
E
), 5.21-5.15 (dd, 3J = 10.4 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 3.53-3.38 (m, 
2H, CCH
2
CH
2
N(CH
3
)CHO), 3.06-2.99 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.95 (s, 3H, 
CCH
2
CH
2
N(CH
3
)CHO), 1.55 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 145.5 (C(CH
3
)
2
CH=CH
2
), 140.5 
(indole C-2), 134.9 (indole C-7a), 128.5 (indole C-3a), 122.7 (indole C-5), 119.5 
(indole C-4), 114.9 (indole C-6), 113.4 (indole C-7), 112.3 (C(CH
3
)
2
CH=CH
2
), 108.0 
(indole C-3), 45.5 (CCH
2
CH
2
N(CH
3
)CHO), 39.0 (NHCC(CH
3
)
2
CH=CH
2
), 35.1 
(CCH
2
CH
2
N(CH
3
)CHO), 27.6 (2C, C(CH
3
)
2
CH=CH
2
), 22.6 (CCH
2
CH
2
N(CH
3
)CHO).  
IR (ATR): ν~  = 3435 cm-1 (m, br), 3087 (w), 3054 (w), 2972 (w), 2929 (w), 2872 (w), 
1653 (s, br), 1463 (m, br), 1392 (m), 1334 (w), 1222 (m), 1164 (m), 1067 (w), 1043 
(w), 995 (w), 909 (m), 863 (m), 804 (m), 784 (m), 728 (m), 695 (m), 661 (m), 633 (w), 
620 (w), 590 (m), 539 (w).  
UV (CH
3
CN): λ
max
 (log ε) = 288 nm (3.85), 232 (4.58), 200 (4.40).  
MS (ESI): m/z (%) = 348 [M]+ (25), 289 [M-C
5
H
9
]+ (33), 276 [M-C
3
H
6
NO]+ (100). 
HRMS (ESI):  calcd. for C
17
H
21
79BrN
2
O [M]+  348.0837, 
found      348.0838.  
4-Bromoindole 148: 
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TLC [silica gel, EtOAc/Petrolether (1:1)]: R
f 
= 0.58.  
Mp: Degrades after 155 °C.  
Ratio of rotamer in CDCl
3
: 1:0.8. 
Major rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.21 (s, br, 1H, indole NH), 8.06 (s, 1H, CHO), 7.44 
(dd, 4J = 1.3 Hz, 3J = 10.7 Hz, 1H, indole 6-H), 7.29-7.23 (m, 2H, indole 5-H, indole 
7-H), 6.09 (dd, 3J = 10.3, 6.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.22 (dd, 3J = 14.7 Hz, 2J = 
0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.18 (dd, 3J = 1.4 Hz, 2J = 2.2 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 3.53-3.40 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.08-2.99 (m, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.99 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.51 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CHO), 145.4 (C(CH
3
)
2
CH=CH
2
), 140.9 
(indole C-2), 135.0 (indole C-7a), 128.0 (indole C-3a), 122.7 (indole C-5), 118.7 
(indole C-6), 114.9 (indole C-4), 113.7 (indole C-7), 112.1 (C(CH
3
)
2
CH=CH
2
), 106.9 
(indole C-3), 50.1 (CCH
2
CH
2
N(CH
3
)CHO), 38.8 (NHCC(CH
3
)
2
CH=CH
2
), 30.0 
(CCH
2
CH
2
N(CH
3
)CHO), 27.6 (2C, C(CH
3
)
2
CH=CH
2
), 24.8 (CCH
2
CH
2
N(CH
3
)CHO).  
Minor Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.09 (s, br, 1H, indole NH), 7.98 (s, 1H, CHO), 7.21-
7.15 (m, 2H, indole 5-H, indole 7-H), 6.94 (dd, 4J = 1.3 Hz, 3J = 8.4 Hz, 1H, indole 6-
H), 6.12 (dd, 3J = 10.3, 6.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.19 (dd, 3J = 2.6 Hz, 2J = 0.8 
Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.15 (dd, 3J = 3.2 Hz, 2J = 2.2 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 3.53-3.40 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.08-2.99 (m, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.99 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.54 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.9 (CHO), 145.5 (C(CH
3
)
2
CH=CH
2
), 140.5 
(indole C-2), 134.9 (indole C-7a), 128.4 (indole C-3a), 122.6 (indole C-5), 119.4 
(indole C-6), 114.7 (indole C-4), 113.3 (indole C-7), 112.2 (C(CH
3
)
2
CH=CH
2
), 107.8 
(indole C-3), 45.3 (CCH
2
CH
2
N(CH
3
)CHO), 35.0 (NHCC(CH
3
)
2
CH=CH
2
), 29.7 
(CCH
2
CH
2
N(CH
3
)CHO), 27.5 (2C, C(CH
3
)
2
CH=CH
2
), 22.4 (CCH
2
CH
2
N(CH
3
)CHO).  
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IR (ATR): ν~  = 3295 cm-1 (m, br), 3081 (w), 3055 (w), 2970 (w), 2930 (w), 2872 (w), 
1655 (s, br), 1463 (m, br), 1390 (m), 1333 (w), 1246 (w), 1223 (w), 1160 (m), 1067 
(w), 1044 (w), 997 (w), 909 (m), 862 (w), 803 (m), 728 (m), 694 (m), 659 (w), 590 
(w).  
UV (CH
3
CN): λ
max
 (log ε) = 289 nm (3.86), 232 (4.56), 200 (4.41).  
MS (EI, 70 eV): m/z (%) = 348 [M]+ (18), 289 [M-C
5
H
9
]+ (9), 276 [M-C
3
H
6
NO]+ (100). 
GC-HRMS (EI):  calcd. for C
17
H
21
79BrN
2
O [M]+  348.0832, 
found     348.0826.  
calcd. for C
17
H
21
81BrN
2
O [M]+  350.0811, 
found      350.0809.  
 
(R)-Methyl 2-(2-iodophenoxy)propanoate (154)117  
A solution of diisopropylazodicarboxylate (DIAD, 16.83 mL, 0.08 
mmol, 1.51 eq.) in toluene (35 mL) was added drop wise to a solution 
of Ph
3
P (21.28 g, 0.08 mmol, 1.51 eq.), (S)-methyllactate (8.07 mL, 
0.08 mmol, 1.51 eq.), and 2-iodophenol (153, 11.94 g, 0.053 mmol, 
1.0 eq.) in THF (240 mL) at rt. The reaction mixture was stirred at rt 
for 4.5 h and concentrated in vacuum. The resulting yellow residue was purified by 
chromatography (silica gel, Petrolether/EtOAc (15:1 to 1:1) to obtain the title 
compound 154 (13.2 g, 0.043 mmol, 81%) as a yellow oil. 
TLC [silica gel, EtOAc/Petrolether (4:1)]: R
f 
= 0.62. 
1H NMR (400 MHz, CDCl
3
): δ = 7.79 (dd, 4J = 1.6 Hz, 3J = 7.8 Hz, 1H, 3-H), 7.27-
7.22 (m, 1H, 5-H), 6.74 (dd, 4J = 1.4 Hz, 3J = 7.5 Hz, 1H, 4-H), 6.71 (dd, 4J = 1.4 Hz, 
3J = 8.0 Hz, 1H, 6-H), 4.76 (q, 3J = 6.8 Hz, 1H, OCH(CH
3
)COOCH
3
), 3.76 (s, 3H, 
OCH(CH
3
)COOCH
3
), 1.70 (d, 3J = 6.8 Hz, 3H, OCH(CH
3
)COOCH
3
). 
13C NMR (100 MHz, CDCl
3
): δ = 172.1 (OCH(CH
3
)COOCH
3
), 156.6 (C-1), 139.8 (C-
3), 129.3 (C-5), 123.5 (C-4), 113.4 (C-6), 87.3 (C-2), 74.1 (OCH(CH
3
)COOCH
3
), 52.3 
(OCH(CH
3
)COOCH
3
), 18.6 (OCH(CH
3
)COOCH
3
). 
154
I
O
O
O
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IR (ATR): ν~ = 3062 cm-1 (w), 2992 (w), 2951 (w), 1754 (s), 1736 (s), 1580 (w), 1469 
(s), 1438 (m), 1375 (w), 1277 (m), 1240 (m), 1203 (s), 1133 (s), 1094 (s), 1050 (m), 
1017 (s), 973 (m), 933 (w), 844 (w), 806 (w), 745 (s), 648 (m), 599 (w).  
UV (DMSO): λ
max
 (log ε) = 333 nm (1.65), 285 (3.40), 278 (3.44), 254 (3.18), 252 
(3.16). 
GCMS (EI, 70 eV): m/z (%) = 307 (8), 306 (61), 248 (8), 247 (83), 221 (8), 220 (91), 
219 (5), 203 (26), 191 (6), 180 (13), 179 (100), 148 (9), 146 (7), 121 (18), 120 (40), 
105 (7), 104 (9), 94 (9), 93 (21), 92 (22), 91 (10), 87 (5), 77 (13), 76 (32), 65 (25), 64 
(18), 63 (16), 59 (12), 55 (12), 50 (14), 44 (14). 
 
(R)-Methyl-2-(2-(diacetoxyiodo)phenoxy)propanoate (155)118 
The mixture of Ac
2
O (60 mL, 634.7 mmol, 63.47 eq.) and H
2
O
2
 
(30%, 14 mL, 137.04 mmol, 13.704 eq.) was stirred at 40 °C for 16 
h. To the in situ generated Acetoxyperacid, 2-
iodophenoxypropanoate methyl ester (154, 3.06 g, 10.0 mmol, 1.0 
eq.) was added drop wise and stirred further at 45 °C for 24 h. The 
reaction mixture was diluted with DCM (200 mL) and H
2
O (100 mL). 
The aqueous layer was extracted with DCM (2 x 100 mL) and the 
combined organic layers were dried over Na
2
SO
4
 and concentrated. The crude 
reaction mixture was repeatedly washed with pentane (8 x 5 mL) to obtain the title 
compound 155 (2.26 g, 5.33 mmol, 53%) as an amorphous white solid. (The reaction 
was performed with caution as the in-situ generated Acetoxyperacids are explosive). 
Mp: 124-126 °C [132 °C]. 
1H NMR (400 MHz, CDCl
3
): δ = 8.15 (dd, 4J = 1.6 Hz, 3J = 7.9 Hz, 1H, 3-H), 7.53 
(ddd, 4J = 1.6 Hz, 3J = 8.4, 7.4 Hz, 1H, 5-H), 7.07 (ddd, 4J = 1.3 Hz, 3J = 7.8, 7.5 Hz, 
1H, 4-H), 7.00 (dd, 4J = 1.2 Hz, 3J = 8.4 Hz, 1H, 6-H), 4.90 (q, 3J = 6.8 Hz, 1H, 
OCH(CH
3
)COOCH
3
), 3.77 (s, 3H, OCH(CH
3
)COOCH
3
), 1.98 (s, 6H, I(OCOCH
3
)
2
), 
1.70 (d, 3J = 6.8 Hz, 3H, OCH(CH
3
)COOCH
3
). 
13C NMR (100 MHz, CDCl
3
): δ = 176.6 (2C, I(OCOCH
3
)
2
), 171.2 
(OCH(CH
3
)COOCH
3
), 154.6 (C-1), 137.8 (C-3), 134.2 (C-5), 123.6 (C-4), 114.2 (C-
155
I
O
O
O
O
O
O
O
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2), 113.3 (C-6), 74.4 (OCH(CH
3
)COOCH
3
), 52.5 (OCH(CH
3
)COOCH
3
), 20.3 (2C, 
I(OCOCH
3
)
2
), 18.3 (OCH(CH
3
)COOCH
3
). 
IR (ATR): ν~ = 3090 cm-1 (w), 3020 (w), 2987 (w), 2957 (w), 1740 (s), 1647 (s), 1587 
(m), 1570 (w), 1474 (m), 1444 (m), 1364 (m), 1270 (s, br), 1244 (s, br), 1165 (w), 
1134 (m), 1090 (s), 1052 (m), 1011 (m), 975 (m), 923 (m), 842 (m), 802 (m), 765 (s), 
612 (m), 566 (w). 
UV (MeOH): λ
max
 (log ε) = 284 nm (3.59), 204 (4.42). 
MS (ESI): m/z (%) = 361 (8), 347 (11), 345 (100), 339 (4), 329 (32), 325 (10), 323 
(94), 301 (6). 
HRMS (ESI): calcd. for C
10
H
11
INaO
5
 [M+H+Na-(C
4
H
7
O
2
)]+  360.9549, 
found        360.9543. 
 
6-Bromo-1-methyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a,8,8a-hexahydropyrrolo 
[2,3-b]indole (rac-dihydroflustramine C, 7) 
At rt, DIBAL-H (20% in toluene, 0.48 mL, 0.57 mmol, 1.8 eq.) 
was added drop wise to a solution of rac-flustramine C116 (5, 
100 mg, 0.31 mmol, 1.0 eq.) in THF (10 mL). The reaction 
mixture was stirred at rt for 26 h and added drop wise to ice 
water (250 mL). The reaction mixture was diluted with Et
2
O (75 
mL) and made strongly alkaline with aqueous NaOH (12 M 35 
mL). The aqueous layer was extracted with Et
2
O (3 x 50 mL), washed with H
2
O (3 x 
50 mL), dried over Na
2
SO
4
, filtered, and concentrated in vacuum to afford rac-
dihydroflustramine C (7, 94 mg, 0.293 mmol, 93%) as a yellow oil.  
TLC [silica gel, EtOAc/petrolether (1:1)]: R
f 
= 0.2 
1H NMR (300 MHz, CDCl
3
): δ = 6.95 (d, 3J = 7.0 Hz, 1H, 4-H), 6.77 (dd, 4J = 1.7 Hz, 
3J = 8.0 Hz, 1H, 5-H), 6.67 (d, 4J = 1.7 Hz, 1H, 7-H), 5.96 (dd, 3J = 17.4 Hz, 10.8 Hz, 
1H, C(CH
3
)
2
CH=CH
2
), 5.07 (dd, 3J = 10.8 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
5.01 (dd, 3J = 17.4 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.39 (s, 1H, 8a-H), 
4.26 (s, br, 1H, 8-H), 2.59 (ddd, 3J = 6.9, 4.2, 2.1Hz, 2J = 11.7 Hz, 1H, 
7
N
H
Br
N
H
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CH
2
CH
2
N(CH
3
)), 2.52 (ddd, 3J = 6.1, 4.9, 3.7 Hz, 2J = 1.2 Hz, 1H, CH
2
CH
2
N(CH
3
)), 
2.37 (s, 3H, NCH
3
), 2.27 (ddd, , 3J = 9.7, 7.1, 2.0 Hz, 2J = 12.2 Hz, 1H, 
CH
2
CH
2
N(CH
3
)), 1.79 (ddd, 3J = 5.5, 5.0 Hz, 2J = 12.0 Hz, 1H, CH
2
CH
2
N(CH
3
)), 1.03 
(s, 3H, C(CH
3
)
2
CH=CH
2
), 0.99 (s, 3H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (75.5 MHz, CDCl
3
): δ = 152.0 (C-7a), 144.6 (C(CH
3
)
2
CH=CH
2
), 132.6 (C-
3b), 126.2 (C-4), 121.2 (C-6), 120.6 (C-5), 113.1 (C(CH
3
)
2
CH=CH
2
), 111.5 (C-7), 
84.4 (C-8a), 63.9 (C-3a), 53.0 (C-2), 41.2 (HNCHCC(CH
3
)
2
), 36.8 (NCH
3
), 34.7 (C-
3), 23.1 (C(CH
3
)
2
CH=CH
2
), 22.3 (C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~  = 3413 cm-1 (w, br), 3260 (w, br), 3081 (w), 3033 (w), 2965 (m), 2935 
(m), 2870 (w), 2843 (w), 2790 (w), 1595 (s), 1481 (s), 1446 (s), 1414 (m), 1380 (w), 
1365 (m), 1349 (m), 1310 (m), 1249 (m, br), 1155 (m), 1120 (m), 1097 (w), 1072 (m), 
1048 (m), 1004 (s), 942 (w), 910 (s), 886 (m), 834 (m), 789 (s), 687 (m), 605 (m).  
UV (MeOH): λ
max
 (log ε) = 356 nm (2.17), 350 (2.20), 308 (3.58), 251 (3.75), 228 
(3.90).  
MS (EI, 70 eV): m/z (%) = 320 [M]+ (22), 249 [M-C
5
H
9
]+ (100), 207 (32), 172 (43).  
GC-HRMS (EI):  calcd. for C
16
H
21
79N
2
Br [M]+  320.0883, 
found      320.0883  
calcd. for C
16
H
21
81N
2
Br [M]+  322.0862, 
found      322.0864.  
 
N-(2-(6-bromo-1-methyl-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethyl)-N-
methylformamide (163) 
NaH (60% suspension in mineral oil, 232 mg, 5.80 mmol, 1.5 
eq.) was washed with pentane (2 mL) and dried in HV. At 0 °C, 
a solution of flustrabromine (1, 1.35 g, 3.87 mmol, 1.0 eq.) in 
DMF (32 mL) was added drop wise. After 1 h at 0 °C, a 
solution of MeI (610 mg, 4.25 mmol, 1.1 eq.) in DMF (10 mL) 
was added drop wise, and the reaction mixture was stirred at rt 
for 2 h. H
2
O (50 mL) was added cautiously and the reaction mixture was extracted 
163
N
N
O
Br
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with TBME (3 x 100 mL). The combined organic layers were washed with H
2
O (3 x 
100 mL) and brine (1 x 100 mL), dried over Na
2
SO
4
, filtered, and concentrated in 
vacuum. The residue obtained was purified by column chromatography (silica gel, 
EtOAc/petrolether (1:1)) to obtain the title compound 163 (1.01 g, 2.77 mmol, 72%) 
as a yellow oil.  
TLC [silica gel, EtOAc/petrolether (1:1)]: R
f 
= 0.42. 
Ratio of rotamers in CDCl
3
: 1:0.8.  
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 7.98 (s, 1H, CHO), 7.39 (d, 4J = 1.6 Hz, 1H, indole 7-
H), 7.31 (d, 3J = 8.4 Hz, 1H, indole 4-H), 7.22 (dd, 4J = 1.7 Hz, 1H, 3J = 3.0 Hz, 1H, 
indole 5-H), 6.15 (dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.12 (dd, 3J = 10.6 
Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.97 (t, 2J = 0.7 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
E
), 3.68 (s, 3H, CN(CH
3
)C), 3.42-3.38 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.20-3.15 
(m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.96 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.61 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 147.0 (C(CH
3
)
2
CH=CH
2
), 141.4 
(indole C-2), 138.6 (indole C-7a), 127.0 (indole C-3a), 122.4 (indole C-5), 118.7 
(indole C-4), 115.5 (indole C-6), 112.4 (C(CH
3
)
2
CH=CH
2
), 112.0 (indole C-7), 107.9 
(indole C-3), 51.3 (CCH
2
CH
2
N(CH
3
)CHO), 40.7 (CN(CH
3
)CC(CH
3
)
2
CH=CH
2
), 33.4 
(CHCN(CH
3
)CC(CH
3
)
2
), 30.1 (CCH
2
CH
2
N(CH
3
)CHO), 29.4 (2C, C(CH
3
)
2
CH=CH
2
) 
25.4 (CCH
2
CH
2
N(CH
3
)CHO).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.05 (s, 1H, CHO), 7.50 (d, 3J = 8.4 Hz, 1H, indole 4-
H), 7.37 (d, 4J = 1.7 Hz, 1H, indole 7-H), 7.19 (dd, 4J = 1.7 Hz, 1H, 3J = 3.0 Hz, 1H, 
indole 5-H), 6.16 (dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.10 (dd, 3J = 10.6 
Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.93 (t, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
E
), 3.67 (s, 3H, CN(CH
3
)C), 3.48-3.44 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.20-3.15 
(m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.93 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.65 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
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13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CHO), 147.3 (C(CH
3
)
2
CH=CH
2
), 141.2 
(indole C-2), 138.5 (indole C-7a), 127.5 (indole C-3a), 122.3 (indole C-5), 119.3 
(indole C-4), 115.3 (indole C-6), 112.2 (C(CH
3
)
2
CH=CH
2
), 111.7 (indole C-7), 108.8 
(indole C-3), 46.6 (CCH
2
CH
2
N(CH
3
)CHO), 40.8 (CN(CH
3
)CC(CH
3
)
2
CH=CH
2
), 35.1 
(CCH
2
CH
2
N(CH
3
)CHO), 33.3 (CHCN(CH
3
)CC(CH
3
)
2
), 29.4 (2C, C(CH
3
)
2
CH=CH
2
), 
23.0 (CCH
2
CH
2
N(CH
3
)CHO).  
IR (ATR): ν~ = 3078 cm-1 (w), 2969 (w), 2927 (w), 2871 (w), 1668 (s), 1601 (w), 1473 
(m), 1387 (m), 1355 (w), 1331 (w), 1298 (w), 1229 (m), 1177 (w), 1138 (w), 1080 
(m), 995 (w), 915 (m), 845 (m), 802 (m),.745 (m), 655 (w),.593 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 301 nm (3.89), 294 (3.90), 241 (4.39), 231 (3.89).  
MS (EI, 70 eV): m/z (%) = 365 [M+H]+ (4), 364 [M]+ (19), 363 [M+H]+ (4), 362 [M]+ 
(21), 293 (21), 292 (98), 291 (19), 290 (100), 278 (7), 277 (50), 276 (25), 275 (50), 
274 (21), 264 (6), 263 (11), 262 (24), 261 (16), 260 (25), 259 (6), 258 (6), 249 (5), 
248 (5), 247 (10), 246 (8), 245 (7), 223 (6), 221 (8), 211 (23), 210 (10), 209 (16), 208 
(5), 197 (9), 196 (58),.195 (65),.194 (40),.193 (7),.183 (7),.182 (28),.181 (93),.180 
(46),.179 (9),.178 (7),.169 (14),.168 (32),.167 (28),.166 (14),.165 (5),.156 (13),.155 
(8),.154 (7),.128 (9),.127 (8),.115 (14),.72 (32). 
GC-HRMS (EI):  calcd. for C
18
H
23
BrN
2
O [M]+  362.0988, 
found      362.0983.  
 
2-(6-Bromo-1-methyl-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)-N-
methylethanamine (10) 
To a solution of N
a
-methylflustrabromine (163, 881 mg, 2.42 
mmol, 1.0 eq.) in EtOH (100 mL) was added aqueous NaOH 
(32%, 12 mL). The reaction mixture was refluxed for 60 h and 
cooled to rt. H
2
O (50 mL) was added and the reaction mixture 
was extracted with EtOAc (3 x 100 mL), washed with H
2
O (4 x 
100 mL), brine (100 mL), dried over Na
2
SO
4
, and filtered. The solvent was removed 
under reduced pressure affording the pure title compound 10 (779 mg, 2.32 mmol, 
96%) as a slight yellow oil.  
10
N
NH
Br
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TLC [silica gel, CHCl
3
/MeOH (9:1)]: R
f 
= 0.07. 
1H NMR (400 MHz, CDCl
3
): δ = 7.44 (d, 3J = 8.4 Hz, 1H, indole 4-H), 7.36 (d, 4J = 1.6 
Hz, 1H, indole 7-H), 7.17 (dd, 4J = 1.7 Hz, 3J = 8.4 Hz, 1H, indole 5-H), 6.14 (dd, 3J = 
17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.09 (dd, 3J = 10.6 Hz, 2J = 0.9 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 4.93 (dd, 3J = 17.5 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 
3.65 (s, 3H, CN(CH
3
)C), 3.18-3.14 (m, 2H, CCH
2
CH
2
NHCH
3
), 2.83-2.79 (m, 2H, 
CCH
2
CH
2
NHCH
3
), 2.47 (s, 3H, CCH
2
CH
2
NHCH
3
), 1.89 (s, br, 1H, CCH
2
CH
2
NHCH
3
), 
1.62 (s, 6H, C(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 147.5 (C(CH
3
)
2
CH=CH
2
), 140.9 (indole C-2), 138.5 
(indole C-7a), 127.7 (indole C-3a), 122.0 (indole C-5), 119.5 (indole C-4), 115.5 
(indole C-6), 112.1 (C(CH
3
)
2
CH=CH
2
), 111.6 (indole C-7), 110.0 (indole C-3), 54.1 
(CCH
2
CH
2
NHCH
3
), 40.8 (N(CH
3
)CC(CH
3
)
2
CH=CH
2
), 36.4 (CCH
2
CH
2
NHCH
3
), 33.3 
(CHCN(CH
3
)CC), 29.5 (2C, C(CH
3
)
2
CH=CH
2
), 25.7 (CCH
2
CH
2
NHCH
3
). 
IR (ATR): ν~ = 3318 cm-1 (w), 3078 (w), 2968 (m), 2933 (m), 2879 (m), 2790 (w), 
1633 (w), 1600 (w), 1472 (s), 1448 (m), 1383 (w), 1353 (m), 1330 (m), 1295 (w), 
1229 (m), 1137 (m), 1110 (m), 1085 (w), 1058 (m), 992 (m), 914 (m), 846 (), 800 (s), 
750 (s), 686 (w), 563 (w), 592 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 301 nm (3.84), 294 (3.85), 241 (4.35), 231 (3.89).  
MS (EI, 70 eV): m/z (%) = 337 [M+H]+ (2), 336 [M]+ (5), 335 [M+H]+ (2), 334 [M]+ (6), 
294 (26), 293 (98), 292 (76), 291 (100), 290 (62), 279 (14), 278 (65), 277 (62), 276 
(75), 275 (58), 274 (21), 266 (9), 265 (14), 264 (22), 263 (16), 262 (21), 261 (6), 249 
(8), 248 (7), 247 (13), 236 (8), 224 (9), 222 (10), 212 (7), 211 (13), 210 (9), 209 (7), 
197 (16),196 (53), 195 (48), 194 (24), 183 (9), 182 (39), 181 (53), 180 (27), 186 (6), 
169 (9), 168 (18), 167 (16), 166 (8), 154 (8), 155 (6), 154 (7), 143 (7), 128 (7), 127 
(6), 115 (8), 102 (5).  
GC-HRMS (EI):  calcd. for C
17
H
23
BrN
2
 [M]+   334.1039, 
found      334.1040. 
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6-Bromo-1,8-dimethyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a-tetrahydropyrrolo[2,3-
b]indol-8-ium bromide (12) 
To a solution of N
a
-methyldeformylflustrabromine (10, 715 
mg, 2.13 mmol, 1.0 eq.) in THF (20 mL) at 0 °C was added 
NBS (426 mg, 2.345 mmol, 1.1 eq.). After 1 h, the 
precipitate was washed with EtOAc (3 x 5 mL) and dried in 
vacuum to afford compound 12 (549 mg, 1.33 mmol, 62%) 
as a colourless amorphous solid.  
Mp: 165-166 °C.  
1H NMR (400 MHz, D
2
O): δ = 7.40-7.37 (m, 2H, 5-H, 7-H), 7.28 (d, 3J = 8.4 Hz, 1H, 
4-H), 5.93 (dd, 3J = 17.4, 10.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.17 (dd, 3J = 10.8 Hz, 2J = 
0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 5.12 (dd, 3J = 17.4 Hz, 2J = 0.9 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 4.46 (ddd, 3J = 9.5, 6.3 Hz, 2J = 11.9 Hz, 1H, 
=CN(CH
3
)CH
2
CH
2
C), 4.00 (dd, 3J = 11.7, 10.0 Hz, 1H, =CN(CH
3
)CH
2
CH
2
C), 3.67 (s, 
3H, CN+(CH
3
)=CN(CH
3
)CH
2
CH
2
C), 3.55 (s, 3H, CN+(CH
3
)=CN(CH
3
)CH
2
CH
2
C), 2.70 
(dd, 3J = 5.9 Hz, 2J = 13.5, 1H, N(CH
3
)CH
2
CH
2
C), 2.43 (td, 3J = 9.8 Hz, 2J = 13.4 Hz, 
1H, N(CH
3
)CH
2
CH
2
C), 1.09 (s, 3H, C(CH
3
)
2
CH=CH
2
), 0.93 (s, 3H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, D
2
O): δ = 181.1 (C-8a), 152.7 (C-7a), 144.2 (C(CH
3
)
2
CH=CH
2
), 
133.3 (C-3b), 129.5 (C-5), 128.9 (C-4), 124.9 (C-6), 116.5 (C-7), 118.4 
(C(CH
3
)
2
CH=CH
2
), 71.5 (C-3a), 67.9 (C-2), 48.6 (N+(CH
3
)=CCC(CH
3
)
2
CH=CH
2
), 
37.4 (N+(CH
3
)=CN(CH
3
)CH
2
CH
2
C), 33.6 (N+(CH
3
)=CN(CH
3
)CH
2
CH
2
C), 29.5 
(CCH
2
CH
2
N(CH
3
)C), 25.8 (C(CH
3
)
2
CH=CH
2
), 24.7 (C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~ = 2966 cm-1 (w), 2922 (w), 2852 (w), 1698 (s), 1603 (m), 1493 (m), 1451 
(w), 1413 (m), 1395 (m), 1372 (w), 1318 (w), 1288 (w), 1254 (w), 1153 (w), 1108 (m), 
1060 (w), 1013 (w), 981 (w), 928 (m), 878 (w), 836 (s), 765 (w), 734 (w), 712 (w), 
662 (w), 609 (m), 585 (w), 563 (w), 540 (w). 
UV (DMSO): λ
max
 (log ε) = 283 nm (3.82), 253 (3.60). 
MS (ESI): m/z (%) = 336 [M+H]+ (18), 335 [M]+ (96), 334 [M+H]+ (17), 333 [M]+ (100), 
267 (6), 266 (49), 265 (12), 264 (49), 263 (12), 254 (10). 
HRMS (ESI):  calcd. for C
17
H
22
BrN
2
+ [M]+  333.0961, 
12
N
N
Br
Br
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found      333.0965. 
 
(3a,8a)-6-Bromo-1,8-dimethyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a,8,8a-
hexahydropyrrolo[2,3-b]indole (15) 
Indole derivative 12 (459 mg, 1.11 mmol, 1.0 eq.) in MeOH (10 
mL) was added to NaBH
4
 (30 mg, 0.78 mmol, 0.7 eq.) under Ar, 
at rt. The reaction mixture was stirred further for 24 h at rt and 
diluted cautiously with H
2
O (10 mL), followed by 2 N NaOH (50 
mL). The aqueous phase was extracted with TBME (3 x 100 
mL). The combined organic layers were washed with H
2
O (3 x 100 mL), brine (50 
mL), dried over Na
2
SO
4
; filtered, and concentrated in vacuum. The crude residue 
was purified by column chromatography (silica gel, CHCl
3
/MeOH/NH
4
OH (9:1:0 to 
9:1:0.1) to obtain the title compound 15 (204 mg, 0.61 mmol, 55%) as a colorless oil. 
TLC [silica gel, CHCl
3
/MeOH/NH
4
OH (9:1:0.1)]: R
f 
= 0.91. 
1H NMR (400 MHz, CDCl
3
): δ = 6.90 (d, 3J = 7.9 Hz, 1H, 4-H), 6.70 (d, 4J = 1.8 Hz, 3J 
= 7.9 Hz, 1H, 5-H), 6.46 (d, 4J = 1.8 Hz, 1H, 7-H), 5.91 (dd, 3J = 17.4, 10.8 Hz, 1H, 
(C(CH
3
)
2
CH=CH
2
), 5.06 (dd, 3J = 10.8 Hz, 2J = 1.3 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.99 (dd, 3J = 17.4 Hz, 2J = 1.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.20 (s, 1H, 8a-H), 
2.92 (s, 3H, CN(CH
3
)CHN(CH
3
)CH
2
), 2.66 (ddd, 3J = 6.6, 2.9 Hz, 2J = 9.4, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 2.47-2.41 (m, 1H, CHN(CH
3
)CH
2
CH
2
C), 2.43 (s, 3H, 
CN(CH
3
)CHN(CH
3
)CH
2
), 2.24 (ddd, 3J = 9.4, 6.7 Hz, 2J = 11.9, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 1.76 (ddd, 3J = 5.5, 2.9 Hz, 2J = 11.9 Hz, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 1.00 (s, 3H, C(CH
3
)
2
CH=CH
2
), 0.94 (s, 3H, C(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 154.2 (C-7a), 144.8 (C(CH
3
)
2
CH=CH
2
), 132.3 (C-
3b), 125.7 (C-4), 121.8 (C-6), 119.2 (C-5), 113.1 (C(CH
3
)
2
CH=CH
2
), 108.9 (C-7), 
91.4 (C-8a), 63.6 (C-3a), 53.4 (C-2), 41.0 (NCHCC(CH
3
)
2
CH=CH
2
), 37.7 
(CN(CH
3
)CHN(CH
3
)CH
2
), 35.1 (CN(CH
3
)CHN(CH
3
)CH
2
), 34.3 (C-3), 23.4 
(C(CH
3
)
2
CH=CH
2
), 22.4 (C(CH
3
)
2
CH=CH
2
). 
IR (ATR): ν
~
 = 3080 cm-1 (w), 2964 (m), 2930 (m), 2870 (w), 2792 (w), 1724 (w), 1635 
(s), 1593 (s), 1493 (s), 1443 (m), 1410 (m), 1367 (w), 1346 (w), 1315 (w), 1257 (m), 
15
N
N
H
Br
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1207 (w), 1158 (m), 1116 (m), 1069 (w), 1044 (m), 974 (m), 914 (s), 823 (s), 798 
(m), 781 (m), 753 (w), 692 (w), 661 (w), 623 (w), 609 (m), 577 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 319 nm (3.63), 264 (3.91), 236 (3.75), 231 (3.74). 
MS (ESI): m/z (%) = 357 [M+Na]+ (7), 336 [M+H]+ (19), 335 [M]+ (100), 334 (18), 333 
(99), 307 (9), 306 (51), 305 (9), 304 (56), 294 (8), 292 (8), 255 (12), 238 (35), 236 
(35), 226 (5), 224 (5), 186 (5). 
HRMS (ESI):  calcd. for C
17
H
24
BrN
2
+ [M+H]+  335.1117, 
found      335.1122. 
 
N-Methyl-N-(2-(1-methyl-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethyl) 
formamide (164) 
NaH (60% suspension in mineral oil, 222 mg, 5.552 mmol, 1.5 eq.) 
was washed with pentane (5 mL) and dried in HV. At 0 °C, a 
solution of debromoflustrabromine (2, 1.0 g, 3.701 mmol, 1.0 eq.) 
in DMF (30 mL) was added. After 30 min at 0 °C, a solution of MeI 
(580 mg, 4.072 mmol, 1.1 eq.) in DMF (10 mL) was added drop 
wise, and the reaction mixture was stirred at rt for 45 min. H
2
O (40 
mL) was added cautiously and the reaction mixture was extracted with EtOAc (3 x 
100 mL). The combined organic layers were washed with H
2
O (3 x 100 mL) and 
brine (1 x 100 mL), dried over Na
2
SO
4
, filtered, and concentrated in vacuum to afford 
the pure title compound 164 (1.04 g, 3.66 mmol, 99%) as a yellow oil.  
Ratio of rotamers in CDCl
3
: 1.7:1.  
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.02 (s, 1H, CHO), 7.47 (d, 3J = 7.0 Hz, 1H, indole 4-
H), 7.26-7:18 (m, 2H, indole 6-H, indole 7-H), 7.14-7.01 (m, 1H, indole 5-H), 6.17 
(dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.10 (dd, 3J = 10.6 Hz, 2J = 0.9 Hz, 
1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.99 (t, 3J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 3.72 (s, 3H, 
CN(CH
3
)C), 3.45-3.41 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.24-3.19 (m, 2H, 
164
N
N
O
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CCH
2
CH
2
N(CH
3
)CHO), 2.98 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.62 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 147.4 (C(CH
3
)
2
CH=CH
2
), 140.7 
(indole C-2), 137.7 (indole C-7a), 128.1 (indole C-3a), 121.8 (indole C-6), 119.3 
(indole C-5), 117.4 (indole C-4), 112.1 (C(CH
3
)
2
CH=CH
2
), 108.9 (indole C-7), 107.6 
(indole C-3), 51.3 (CCH
2
CH
2
N(CH
3
)CHO), 40.7 (CN(CH
3
)CC(CH
3
)
2
CH), 33.2 
(CHCN(CH
3
)C), 30.1 (CCH
2
CH
2
N(CH
3
)CHO), 29.4 (2C, C(CH
3
)
2
CH=CH
2
) 25.5 
(CCH
2
CH
2
N(CH
3
)CHO).  
Minor rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.06 (s, 1H, CHO), 7.64 (d, 3J = 7.0 Hz, 1H, indole 4-
H), 7.26-7.18 (m, 2H, indole 6-H, indole 7-H), 7.14-7.01 (m, 1H, indole 5-H), 6.18 
(dd, 3J = 17.5, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.09 (dd, 3J = 10.6 Hz, 2J = 1.0 Hz, 
1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.94 (t, 3J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 3.71 (s, 3H, 
CN(CH
3
)C), 3.52-3.48 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.24-3.19 (m, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.96 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.66 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CHO), 147.7 (C(CH
3
)
2
CH=CH
2
), 140.6 
(indole C-2), 137.6 (indole C-7a), 128.5 (indole C-3a), 121.6 (indole C-6), 119.1 
(indole C-5), 118.0 (indole C-4), 111.9 (C(CH
3
)
2
CH=CH
2
), 108.6 (indole C-7), 108.4 
(indole C-3), 46.6 (CCH
2
CH
2
N(CH
3
)CHO), 40.8 (CN(CH
3
)CC(CH
3
)
2
CH), 35.1 
(CCH
2
CH
2
N(CH
3
)CHO), 33.2 (CHCN(CH
3
)C), 29.5 (2C, C(CH
3
)
2
CH=CH
2
), 23.1 
(CCH
2
CH
2
N(CH
3
)CHO).  
IR (ATR): ν~  = 3050 cm-1 (w), 2970 (w), 2930 (w), 2873 (w), 1669 (s), 1474 (m), 
1383 (m), 1355 (m), 1320 (w), 1232 (w), 1177 (w), 1148 (w), 1081 (m), 1015 (w), 995 
(w), 913 (m), 741 (s), 562 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 290 nm (3.84), 240 (4.09).  
MS (EI, 70 eV): m/z (%) = 284 [M]+ (20), 212 [M-C
3
H
6
NO]+ (100), 198 [M-C
4
H
8
NO]+ 
(10), 182 (55).  
GC-HRMS (EI):  calcd. for C
18
H
24
N
2
O [M]+   284.1883, 
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found      284.1859.  
 
N-Methyl-2-(1-methyl-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethanamine (11) 
To a solution of N
a
-methyldebromoflustrabromine (164, 600 mg, 
2.11 mmol, 1.0 eq.) in EtOH (80 mL) was added aqueous NaOH 
(32%, 8 mL). The reaction mixture was refluxed for 48 h and cooled 
to rt. H
2
O (50 mL) was added and the reaction mixture was 
extracted with EtOAc (3 x 100 mL), washed with H
2
O (4 x 100 mL), 
dried over Na
2
SO
4
, and filtered. The solvent was removed under reduced pressure 
affording the pure title compound 11 (436 mg, 1.702 mmol, 81%) as a yellow oil.  
1H NMR (400 MHz, CDCl
3
): δ = 7.60 (dt, 4J = 0.8 Hz, 3J = 7.8 Hz, 1H, indole 4-H), 
7.23-7.17 (m, 2H, indole 6-H, indole 7-H), 7.09 (dd, 4J = 1.6 Hz, 3J = 6.4 Hz, 1H, 
indole 5-H), 6.17 (dd, 3J = 17.5, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.07 (dd, 3J = 10.6 
Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.95 (dd, 3J = 17.5 Hz, 2J = 1.0 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 3.70 (s, 3H, CN(CH
3
)C), 3.19 (t, 3J = 7.7 Hz, 2H, 
CH
3
NHCH
2
CH
2
C), 2.83 (t, 3J = 7.7 Hz, 2H, CH
3
NHCH
2
CH
2
C), 2.47 (s, 3H, 
CH
2
CH
2
NHCH
3
), 1.70 (s, br, 1H, CH
2
CH
2
NHCH
3
), 1.63 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 147.9 (C(CH
3
)
2
CH=CH
2
), 140.2 (indole C-2), 137.6 
(indole C-7a), 128.8 (indole C-3a), 121.5 (indole C-6), 118.9 (indole C-5), 118.2 
(indole C-4), 111.8 (C(CH
3
)
2
CH=CH
2
), 109.8 (indole C-3), 108.5 (indole C-7), 54.3 
(CH
2
CH
2
NHCH
3
), 40.8 (N(CH
3
)CC(CH
3
)
2
CH), 36.5 (CH
2
CH
2
NHCH
3
), 33.2 
(CHCN(CH
3
)CC), 29.6 (2C, C(CH
3
)
2
CH=CH
2
), 25.9 (CCH
2
CH
2
NHCH
3
).  
IR (ATR): ν~  = 3314 cm-1 (w, br), 3050 (w), 2968 (w), 2933 (w), 2880 (w), 2791 (w), 
1472 (s), 1355 (m), 1319 (m), 1233 (m), 1131 (w), 1109 (w), 1085 (w), 1015 (w), 995 
(w), 912 (m), 739 (s), 707 (m), 686 (w), 562 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 290 nm (3.84), 240 (4.10), 232 (3.75).  
MS (EI, 70 eV): m/z (%) = 256 [M]+ (6), 213 [M-(C
2
H
5
N)+H]+ (100), 212 [M-C
2
H
5
N]+ 
(64), 199 (10), 198 [M-C
3
H
8
N]+ (70), 182 (35).  
GC-HRMS (EI):  calcd. for C
17
H
24
N
2
 [M]+   256.1934, 
11
N
NH
Experimental Section  120 
 
found      256.1961.  
 
1,8-Dimethyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a-tetrahydropyrrolo[2,3-b] 
indolium bromide (13) 
To a solution of N
a
-methyldebromodeformylflustrabromine (11, 
233 mg, 0.91 mmol, 1.0 eq.) in THF (16 mL) at 0 °C was added 
NBS (165 mg, 0.91 mmol, 1.0 eq.). After 20 min, the precipitate 
was washed with EtOAc (20 mL) and dried in vacuum to afford 
compound 13 (192 mg, 0.57 mmol, 63%) as a colourless 
amorphous solid.  
Mp: 166 °C.  
1H NMR (400 MHz, D
2
O): δ = 7.58 (dt, 4J = 1.3 Hz, 3J = 7.9 Hz, 1H, 6-H), 7.42 (dd, 4J 
= 1.2 Hz, 3J = 7.6 Hz, 1H, 4-H), 7.32-7.27 (m, 2H, 5-H, 7-H), 6.03 (dd, 3J = 17.4, 10.8 
Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.26 (dd, 3J = 10.8 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
Z
), 5.21 (dd, 3J = 17.4 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.56 (ddd, 3J = 
9.5, 6.3 Hz, 2J = 11.7 Hz, 1H, =CN(CH
3
)NCH
2
CH
2
C), 4.16 (ddd, 3J = 11.5, 10.1 Hz, 
1H, =CN(CH
3
)CH
2
CH
2
C), 3.83 (s, 3H, CN+(CH
3
)=CN(CH
3
)), 3.72 (s, 3H, 
CN+(CH
3
)=CN(CH
3
)), 2.79 (dd, 3J = 6.0 Hz, 2J = 13.4, 1H, N(CH
3
)CH
2
CH
2
C), 2.49 
(dt, 3J = 9.7, 3.6 Hz, 2J = 13.3 Hz, 1H, N(CH
3
)CH
2
CH
2
C), 1.14 (s, 3H, 
C(CH
3
)
2
CH=CH
2
), 0.96 (s, 3H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, D
2
O): δ = 180.9 (C-8a), 152.0 (C-7a), 144.6 (C(CH
3
)
2
CH=CH
2
), 
134.4 (C-3b), 132.5 (C-6), 127.9 (C-4), 126.8 (C-7), 118.7 (C(CH
3
)
2
CH=CH
2
), 113.3 
(C-5), 71.8 (C-3a), 68.0 (C-2), 48.8 (N+(CH
3
)=CCC(CH
3
)
2
CH=CH
2
), 38.0 
(N+(CH
3
)=CN(CH
3
)CH
2
), 34.0 (N+(CH
3
)=CN(CH
3
)CH
2
), 30.0 (CCH
2
CH
2
N(CH
3
)C), 
25.8 (C(CH
3
)
2
CH=CH
2
), 24.7 (C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~  = 3403 cm-1 (w, br), 3328 (w), 3157 (w), 3080 (w), 3030 (w), 3006 (w), 
2960 (w), 2895 (w), 2797 (w), 1772 (w), 1691 (s), 1608 (m), 1456 (m), 1433 (m), 
1402 (m), 1373 (m), 1348 (w), 1329 (m), 1294 (m), 1178 (m), 1151 (m), 1105 (m), 
1005 (w), 933 (m), 811 (m), 775 (s), 709 (w), 639 (m).  
UV (DMSO): λ
max
 (log ε) = 296 nm (3.39), 275 (3.55), 253 (3.51).  
13
N
N
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MS (ESI): m/z (%) = 255 [M]+ (100), 186 [M-C
5
H
9
]+ (16), 185 (5).  
HRMS (ESI):  calcd. for C
17
H
23
N
2
+ [M]+   255.1856, 
found      255.1855. 
EA:    calcd. for C
17
H
23
BrN
2
  C = 60.90, H = 6.91, N = 8.36 
found     C = 60.59, H = 6.87, N = 8.34 
 
1,8-Dimethyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-
b]indole (14) 
To the indole derivative 13 (40 mg, 0.12 mmol, 1.0 eq.) in MeOH (4 
mL) was added NaBH
4
 (3.2 mg, 0.08 mmol, 0.7 eq.) at rt. The 
reaction mixture was stirred under Ar for 7 h at rt and diluted 
cautiously with H
2
O (4 mL), followed by 2 N NaOH (50 mL). The 
aqueous phase was extracted with EtOAc (3 x 50 mL). The 
combined organic layers were washed with H
2
O (3 x 50 mL), brine (50 mL), dried 
over Na
2
SO
4
, filtered, and concentrated in vacuum. The resulting crude was purified 
by HPLC (RP-silica gel, MeOH/H
2
O (5:1)) to obtain the title compound 14 (11.3 mg, 
0.04 mmol, 40%) as an oil. 
1H NMR (400 MHz, CDCl
3
): δ = 7.10-7.06 (m, 2H, 4-H, 6-H), 6.61 (dt, 4J = 1.0 Hz, 3J 
= 7.3 Hz, 1H, 5-H), 6.37 (d, 3J = 7.5 Hz, 1H, 7-H), 5.96 (dd, 3J = 17.6, 10.8 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
), 5.06 (dd, 3J = 10.8 Hz, 2J = 1.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 5.00 
(dd, 3J = 17.4 Hz, 2J = 1.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.18 (s, 1H, 8a-H), 2.94 (s, 
3H, CN(CH
3
)CHN(CH
3
)CH
2
), 2.66 (ddd, 3J = 4.7, 2.5 Hz, 2J = 9.3, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 2.47-2.40 (m, 1H, CHN(CH
3
)CH
2
CH
2
C), 2.44 (s, 3H, 
CN(CH
3
)CHN(CH
3
)CH
2
), 2.26 (ddd, 3J = 9.5, 6.6 Hz, 2J = 11.9, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 1.81 (ddd, 3J = 5.5, 2.9 Hz, 2J = 11.9 Hz, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 1.02 (s, 3H, C(CH
3
)
2
CH=CH
2
), 0.91 (s, 3H, C(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 153.2 (C-7a), 145.3 (C(CH
3
)
2
CH=CH
2
), 133.2 (C-
3b), 127.9 (C-6), 124.7 (C-4), 116.7 (C-5), 112.7 (C(CH
3
)
2
CH=CH
2
), 106.1 (C-7), 
91.2 (C-8a), 63.9 (C-3a), 53.4 (C-2), 41.1 (NCHCC(CH
3
)
2
CH=CH
2
), 37.5 
(CN(CH
3
)CHN(CH
3
)CH
2
), 35.7 (CN(CH
3
)CHN(CH
3
)CH
2
), 34.5 (C-3), 23.6 
(C(CH
3
)
2
CH=CH
2
), 22.6 (C(CH
3
)
2
CH=CH
2
). 
14
N
N
H
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IR (ATR): ν
~
 = 3299 cm-1 (w, br), 3131 (w), 2967 (m), 2724 (w), 1771 (w), 1697 (s), 
1608 (m), 1456 (m), 1407 (m), 1370 (w), 1350 (m), 1331 (w), 1293 (w), 1240 (w), 
1180 (m), 1150 (m), 1106 (m), 1010 (w), 936 (m), 914 (m), 851 (w), 815 (m), 762 (s), 
710 (w), 691 (w), 635 (m), 605 (w), 540 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 296 nm (3.47), 276 (3.56), 239 (3.72), 233 (3.43). 
MS (ESI): m/z (%) = 257 [M+H]+ (2), 256 [M]+ (19), 255 [M-H]+ (100), 200 (5), 187 
(7), 186 (52), 185 (25), 144 (4). 
HRMS (ESI):  calcd. for C
17
H
24
N
2
+ [M-H]+  255.1856, 
found      255.1857. 
 
N-Methyl-2-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethanamine (4) 
To a solution of debromoflustrabromine (2, 1 g, 3.70 mmol, 1.0 eq.) 
in EtOH (150 mL) was added aqueous NaOH (32%, 11 mL). The 
reaction mixture was refluxed for 48 h and cooled to rt. H
2
O (100 
mL) was added and the reaction mixture was extracted with EtOAc 
(3 x 100 mL). The combined organic phases were washed with H
2
O 
(4x 100 mL) and dried over Na
2
SO
4
. The solvent was removed under reduced 
pressure affording 4 (870 mg, 3.59 mmol, 97%) as an orange oil.  
1H NMR (400 MHz, CDCl
3
): δ = 7.89 (s, br, 1H, indole NH), 7.56 (dd, 4J = 2.0 Hz, 3J 
= 6.4 Hz, 1H, indole 4-H), 7.30 (dd, 4J = 2.2 Hz, 3J = 6.6 Hz, 1H, indole 7-H), 7.16-
7.02 (m, 2H, indole 5-H, 6-H), 6.13 (dd, 3J = 17.4, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 
5.20-5.11 (m, 2H, C(CH
3
)
2
CH=CH
2
), 3.09-2.98 (m, 2H, CH
3
NHCH
2
CH
2
C), 2.89-2.81 
(m, 2H, CH
3
NHCH
2
CH
2
C), 2.48 (s, 3H, CH
2
CH
2
NHCH
3
), 1.54 (s, 6H, 
C(CH
3
)
2
CH=CH
2
), 1.50 (s, br, 1H, CCH
2
CH
2
NH CH
3
).  
13C NMR (100 MHz, CDCl
3
): δ = 146.0 (C(CH
3
)
2
CH=CH
2
), 139.5 (indole C-2), 134.1 
(indole C-7a), 129.8 (indole C-3a), 121.3 (indole C-6), 119.1 (indole C-5), 118.3 
(indole C-4), 111.9 (C(CH
3
)
2
CH=CH
2
), 110.3 (indole C-7), 109.0 (indole C-3), 53.1 
(CH
2
CH
2
NHCH
3
), 39.0 (NHCC(CH
3
)
2
CH), 36.5 (CH
2
CH
2
NHCH
3
), 27.7 (2C, 
C(CH
3
)
2
CH=CH
2
), 25.6 (CCH
2
CH
2
NHCH
3
).  
4
N
H
NH
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IR (ATR): ν~  = 3434 cm-1 (w), 3298 (w, br), 3185 (w, br), 3080 (w), 3056 (w), 2967 
(m), 2932 (w), 2870 (w), 2798 (w), 1632 (w), 1460 (m), 1360 (w), 1339 (w), 1303 (w), 
1232 (w), 1129 (w), 1103 (w), 1008 (m), 914 (m), 738 (s), 597 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 283 nm (3.86), 239 (3.98), 233 (3.79).  
MS (EI, 70 eV): m/z (%) = 242 [M]+ (5), 199 (100), 184 [M-C
3
H
8
N]+ (83), 172 [M-
C
5
H
9
]+ (7), 168 (44.  
GC-HRMS (EI):  calcd. for C
16
H
22
N
2
 [M]+   242.1778,, 
found      242.1758.  
 
1-Methyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 
(rac-Debromoflustramine C, 6) 
To a solution of debromodeformylflustrabromine (4, 200 mg, 0.83 
mmol, 1.0 eq.) in THF (20 mL) was added NBS (147 mg, 0.83 mmol, 
1.0 eq.). The reaction mixture was stirred at 0 °C for 1 h and diluted 
with Et
2
O (50 mL). The organic layer was washed with 2 N NaOH (3x 
50 mL) and with H
2
O (3x 50 mL), dried over Na
2
SO
4
, filtered, and 
concentrated in vacuum. The residue was purified by column chromatography (silica 
gel, EtOAc) affording rac-debromoflustramine C (6, 156 mg, 0.61 mmol, 71%) as a 
colourless oil.  
TLC [silica gel, EtOAc]: R
f 
= 0.23.  
1H NMR (400 MHz, CDCl
3
): δ = 7.17 (dt, 4J = 1.3 Hz, 3J = 7.6 Hz, 1H, 6-H), 7.11 (dd, 
4J = 0.8 Hz, 3J = 7.8 Hz, 1H, 5-H), 7.09-7.07 (m, 1H, 4-H), 6.80 (dt, 4J = 1.2 Hz, 3J = 
7.4 Hz, 1H, 7-H), 6.08-6.01 (m, 1H, C(CH
3
)
2
CH=CH
2
), 5.07 (s, 1H, C(CH
3
)
2
CH=CH
2
-
H
Z
), 5.04 (dd, 3J = 7.0 Hz, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 3.95 (ddd, 3J = 6.3, 
3.9 Hz, 2J = 12.7 Hz, 1H, (CH
3
)NCH
2
CH
2
C), 3.40 (dt, 3J = 10.1, 1.0 Hz, 1H, 
(CH
3
)NCH
2
CH
2
C), 3.05 (s, 3H, NCH
3
), 2.39 (ddd, 3J = 6.1, 0.7 Hz, 2J = 13.1 Hz, 1H, 
(CH
3
)NCH
2
CH
2
C), 2.11 (ddd, 3J = 7.7, 5.8 Hz, 2J = 16.0 Hz, 1H, (CH
3
)NCH
2
CH
2
C), 
1.01 (s, 3H, C(CH
3
)
2
CH=CH
2
), 0.87 (s, 3H, C(CH
3
)
2
CH=CH
2
).  
6
N
N
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13C NMR (100 MHz, CDCl
3
): δ = 187.0 (C-8a), 160.8 (C-7a), 143.7 
(C(CH
3
)
2
CH=CH
2
), 138.2 (C-3b), 128.5 (C-6), 123.5 (C-4), 119.6 (C-7), 115.7 (C-5), 
113.3 (C(CH
3
)
2
CH=CH
2
), 66.1 (C-3a), 59.9 (C-2), 43.1 (N=CCC(CH
3
)
2
CH=CH
2
), 
33.4 (NCH
3
), 27.9 (C-3), 22.8 (C(CH
3
)
2
CH=CH
2
), 21.6 (C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~  = 3059 cm-1 (w), 2969 (w), 2930 (w), 2877 (w), 2796 (w), 1633 (s), 1576 
(s), 1446 (m), 1412 (m), 1380 (w), 1364 (w), 1307 (w), 1278 (m), 1216 (m), 1181 (m), 
1154 (w), 1103 (w), 1007 (w), 987 (w), 915 (m), 848 (w), 818 (w), 765 (s), 747 (s), 
685 (w), 656 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 283 nm (3.83), 239 (3.62), 231 (3.55).  
MS (EI, 70 eV): m/z (%) = 240 [M]+ (15), 172 [M-(C
5
H
9
)+H]+ (30), 171 [M-C
5
H
9
]+ 
(100), 130 (30).  
GC-HRMS (EI):  calcd. for C
16
H
20
N
2
 [M]+   240.1621,  
found      240.1638.  
 
1-Methyl-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b] 
indole (rac-Debromodihydroflustramine C, 8) 
At rt, DIBAL-H (1.0 M in toluene, 0.61 mL, 0.61 mmol, 1.85 eq.) was 
added drop wise to a solution of rac-debromoflustramine C (6, 80 
mg, 0.33 mmol, 1.0 eq.) in THF (5 mL) under Ar. The reaction 
mixture was stirred at rt for 24 h and added drop wise to ice water 
(60 mL). Et
2
O (30 mL) was added, followed by aqueous NaOH (12 
M, 20 mL). After extraction with Et
2
O (3 x 20 mL), the combined ethereal layers were 
washed with H
2
O (3 x 30 mL) and brine (20 mL), and dried over Na
2
SO
4
. 
Concentration in vacuum and column chromatography (silica gel, CHCl
3
/MeOH (5:1)) 
afforded rac-debromodihydroflustramine C (8, 58 mg, 0.24 mmol, 73%) as a yellow 
oil.  
TLC [silica gel, CHCl
3
/MeOH (5:1)]: R
f 
= 0.2.  
1H NMR (400 MHz, CDCl
3
): δ = 7.13 (ddd, 4J = 0.4, 1.2 Hz, 3J = 7.5 Hz, 1H, 4-H), 
7.08 (dt, 4J = 1.2 Hz, 3J = 7.6 Hz, 1H, 6-H), 6.74 (dt, 4J = 1.0 Hz, 3J = 7.5 Hz, 1H, 5-
8
N
H
N
H
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H), 6.65 (d, 3J = 7.8 Hz, 1H, 7-H), 5.99 (dd, 3J = 17.4, 10.8 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
), 5.10 (dd, 3J = 1.3 Hz, 2J = 10.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 5.03 
(dd, 3J = 1.3 Hz, 2J = 17.3 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.82 (s, br, 1H, 8a-H), 
2.993-2.92 (m, 1H, (CH
3
)NCH
2
CH
2
C), 2.59-2.51 (m, 1H, (CH
3
)NCH
2
CH
2
C), 2.54 (s, 
3H, NCH
3
), 2.45 (ddd, 3J = 9.5, 6.5 Hz, 2J = 12.2, 1H, (CH
3
)NCH
2
CH
2
C), 1.98 (ddd, 
3J = 5.7, 3.2 Hz, 2J = 12.4 Hz, 1H, (CH
3
)NCH
2
CH
2
C), 1.08 (s, 3H, C(CH
3
)
2
CH=CH
2
), 
1.03 (s, 3H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 150.0 (C-7a), 144.3 (C(CH
3
)
2
CH=CH
2
), 132.2 (C-
3b), 128.3 (C-6), 125.0 (C-4), 118.9 (C-5), 113.7 (C(CH
3
)
2
CH=CH
2
), 109.4 (C-7), 
88.4 (C-8a), 64.5 (C-3a), 53.2 (C-2), 41.3 (NHCHCC(CH
3
)
2
CH=CH
2
), 36.3 (NCH
3
), 
33.9 (C-3), 23.2 (C(CH
3
)
2
CH=CH
2
), 22.5 (C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~  = 3259 cm-1 (w, br), 3082 (w), 2964 (m), 2932 (m), 2872 (w), 2790 (w), 
2659 (w), 2469 (w), 1669 (w), 1604 (m), 1483 (m), 1467 (s), 1414 (w), 1381 (w), 
1365 (w), 1350 (w), 1316 (w), 1257 (w), 1153 (m), 1077 (w), 1004 (m), 913 (m), 740 
(s), 689 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 294 nm (3.37), 243 (3.75).  
MS (EI, 70 eV): m/z (%) = 242 [M]+ (22), 174 [M-(C
5
H
9
)+H]+ (24), 173 [M-C
5
H
9
]+ 
(100), 130 (42).  
GC-HRMS (EI):  calcd. for C
16
H
22
N
2
 [M]+   242.1778, 
found      242.1762.  
 
2-(2-(1H-Indol-3-yl)ethyl)isoindoline-1,3-dione (165) 
Phthalic anhydride (4.03 g, 27.0 mmol, 1.1 eq.) was added to a 
solution of tryptamine (124, 3.9 g, 24.33 mmol, 1.0 eq.) in toluene 
(50 mL), followed by addition of Et
3
N (3.75 mL, 27.0 mmol, 1.1 
eq.). The reaction mixture was refluxed at 125 °C for 8 h, cooled 
to rt and added to ice water (100 mL). The yellow precipitate was 
recrystallized from MeOH (5 mL of MeOH/g) to obtain compound 
165 (5.52 g, 19.01 mmol, 77%) as a brown solid.  165
N
H
N
O
O
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Mp: 164-166 °C.  
1H NMR (400 MHz, CDCl
3
): δ = 8.01 (s, br, 1H, indole NH), 7.82 (dd, 3J = 5.8, 3.2 
Hz, 2H, N(C(=O)CCHCH)
2
), 7.73 (d, 3J = 8.32 Hz, 1H, indole 4-H), 7.69 (dd, 3J = 5.8, 
3.1 Hz, 2H, N(C(=O)CCHCH)
2
), 7.34 (d, 3J = 7.8 Hz, 1H, indole 7-H), 7.17 (ddd, 3J = 
13.7, 6.1 Hz, 2J = 1.3 Hz, 1H, indole 6-H), 7.10 (dd, 3J = 7.0 Hz, 4J = 1.2 Hz, 1H, 
indole 5-H), 7.08 (s, 1H, indole 2-H), 4.00 (t, 3J = 7.8 Hz, 2H, CCH
2
CH
2
N), 3.15 (t, 3J 
= 7.8 Hz, 2H, CCH
2
CH
2
N).  
13C NMR (100 MHz, CDCl
3
): δ = 168.4 (2C, N(C(=O)CCHCH)
2
), 136.2 (indole C-7a), 
133.8 (2C, N(C(=O)CCHCH)
2
), 132.2 (2C, N(C(=O)CCHCH)
2
), 127.4 (indole C-3a), 
123.2 (2C, N(C(=O)CCHCH)
2
), 122.1 (indole C-6), 122.0 (indole C-2), 119.5 (indole 
C-5), 118.9 (indole C-4), 112.5 (indole C-3), 111.1 (indole C-7), 38.5 
(CNHCHCCH
2
CH
2
N), 24.5 (CNHCHCCH
2
CH
2
N).  
IR (ATR): ν~  = 3379 cm-1 (m), 3352 (br, m), 3043 (w), 2979 (w), 2861 (w), 1767 (m), 
1696 (s, br), 1617 (m), 1460 (m), 1430 (m), 1395 (s), 1355 (m), 1327 (m), 1230 (m), 
1186 (w), 1169 (w), 1097 (m), 1058 (m), 1011 (w), 985 (m), 867 (m), 821 (w), 741 
(s), 707 (s), 654 (m), 632 (m), 586 (m), 529 (s).  
UV (CH
3
CN): λ
max
 (log ε) = 354 nm (2.28), 289 (3.80), 281 (3.84), 240 (4.10), 220 
(4.84), 194 (4.49).  
MS (EI, 70 eV): m/z (%) = 290 [M]+ (29), 143 (36), 130 [M-C
9
H
6
NO
2
]+ (100), 77 (11).  
GC-HRMS (EI):  calcd. for C
18
H
14
N
2
O
2
 [M]+  290.1050, 
found      290.1071.  
2-(2-(2-(2-Methylbut-3-en-2-yl)-1H-indol-3-yl)ethyl)isoindoline-1,3-dione (166) 
To a solution of 165 (2.2 g, 7.58 mmol, 1.0 eq.) in THF (45 mL) 
and Et
3
N (1.4 mL, 10.34 mmol, 1.2 eq.) was added tert-BuOCl 
(1.17 mL, 10.34 mmol, 1.2 eq.) at –78 °C. The reaction mixture 
was stirred for 30 min at –78 °C, before a freshly prepared 
solution of prenyl-9-BBN (142, 0.5 M, 34.5 mL, 17.24 mmol, 2.0 
eq.) in THF was added drop wise. After 30 min the reaction 
mixture was allowed to warm to rt and was stirred for 1 h. 
Aqueous NaOH (3 M, 18 mL) and H
2
O
2
 (30%, 18 mL) were added drop wise. The 
166
N
H
N
O
O
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reaction mixture was stirred at rt for 1 h and diluted in Et
2
O (200 mL). The organic 
layer was washed three times with brine-water (1:1, 150 mL) , dried over MgSO
4
, 
filtered, and concentrated in vacuum. The residual yellow oil was recrystallized from 
CHCl
3
/hexane (1:5, 30 mL) to afford compound 166 (1.37 g, 3.83 mmol, 50%) as a 
yellow amorphous solid.  
Mp: 143-146 °C.  
1H NMR (400 MHz, CDCl
3
): δ = 7.91 (s, br, 1H, indole NH), 7.88-7.83 (m, 2H, 
N(C(=O)CCHCH)
2
), 7.79-7.77 (m, 1H, indole 4-H), 7.73-7.68 (m, 2H, 
N(C(=O)CCHCH)
2
), 7.32-7.27 (m, 1H, indole 7-H), 7.16-7.10 (m, 2H, indole 5-H, 
indole 6-H), 6.17 (dd, 3J = 17.4, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.22 (dd, 3J = 10.4 
Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 5.19 (dd, 3J = 3.5 Hz, 2J = 1.0 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 3.93-3.89 (m, 2H, CCH
2
CH
2
N), 3.20-3.15 (m, 2H, CCH
2
CH
2
N), 
1.62 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 168.3 (2C, N(C(=O)CCHCH)
2
), 145.6 
(C(CH
3
)
2
CH=CH
2
), 140.1 (indole C-2), 134.1 (indole C-7a), 133.8 (2C, 
N(C(=O)CCHCH)
2
), 132.3 (2C, N(C(=O)CCHCH)
2
), 129.6 (indole C-3a), 123.1 (2C, 
N(C(=O)CCHCH)
2
), 121.5 (indole C-6), 119.6 (indole C-5), 118.3 (indole C-4), 112.3 
(C(CH
3
)
2
CH=CH
2
), 110.4 (indole C-7), 107.1 (indole C-3), 38.9 (CNHCC(CH
3
)
2
CH), 
38.4 (CNHCCCH
2
CH
2
N), 27.7 (2C, C(CH
3
)
2
CH=CH
2
), 24.6 (CNHCCCH
2
CH
2
N).  
IR (ATR): ν~  = 3355 cm-1 (m), 3084 (w), 3031 (w), 2970 (w), 2936 (w), 2867 (w), 
1766 (w), 1696 (s), 1463 (m), 1430 (w), 1394 (s), 1354 (m), 1336 (m), 1245 (w), 
1170 (w), 1103 (m), 1017 (m), 920 (m), 898 (w), 871 (m), 747 (s), 714 (s, br), 608 
(m), 566 (w).  
UV (CHCl
3
): λ
max
 (lg ε) = 283 nm (3.97), 242 (4.21).  
MS (EI, 70 eV): m/z (%) = 358 [M]+ (100), 290 [M-(C
5
H
9
)+H]+ (12), 289 [M-C
5
H
9
]+ 
(25), 210 (32).  
HRMS (EI):  calcd. for C
23
H
22
N
2
O
2
 [M]+   358.1676, 
found       358.1676.  
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2-(2-(2-Methylbut-3-en-2-yl)-1H-indol-3-yl)ethanamine (16) 
To a solution of N
b
-phthaloyl-2-tert.-prenyl-tryptamine (166, 1.0 g, 
2.79 mmol, 1.0 eq.) in DCM/MeOH (1:1, 30 mL) was added 
NH
2
NH
2
-H
2
O (0.38 mL, 7.82 mmol, 2.8 eq.) at rt. The reaction 
mixture was stirred for 48 h and poured into H
2
O (60 mL). After 
extraction with Et
2
O (4 x 100 mL), the organic extract was washed 
with HCl (1 N, 50 mL) and brine (50 mL), dried over MgSO
4
, filtered, and 
concentrated in vacuum. Chromatography of the residual oil (silica gel, CHCl
3
/MeOH 
(6:1)) afforded compound 166 (0.43 g, 1.61 mmol, 58%) as a colourless oil.  
TLC [silica gel, CHCl
3
/MeOH (6:1)]: R
f 
= 0.23.  
1H NMR (400 MHz, CDCl
3
): δ = 7.90 (s, br, 1H, indole NH), 7.55 (d, 3J = 7.8 Hz, 1H, 
indole 4-H), 7.28 (dt, 4J = 0.9 Hz, 3J = 7.8 Hz, 1H, indole 7-H), 7.12 (dt, 4J = 1.3 Hz, 
3J = 7.5 Hz, 1H, indole 6-H), 7.07 (dt, 4J = 1.2 Hz, 3J = 7.4 Hz, 1H, indole 5-H), 6.13 
(dd, 3J = 17.4, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.17 (dd, 3J = 9.4 Hz, 2J = 1.0 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 5.14 (dd, 3J = 2.5 Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 
3.02 (s, br, 4H, CCH
2
CH
2
NH
3
+Cl), 2.34 (s, br, 3H, CCH
2
CH
2
NH
3
+Cl), 1.54 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 146.0 (C(CH
3
)
2
CH=CH
2
), 139.7 (indole C-2), 134.1 
(indole C-7a), 129.8 (indole C-3a), 121.4 (indole C-6), 119.2 (indole C-5), 118.3 
(indole C-4), 112.0 (C(CH
3
)
2
CH=CH
2
), 110.4 (indole C-7), 108.4 (indole C-3), 43.0 
(2C, CNHCCCH
2
CH
2
N), 39.0 (CNHCC(CH
3
)
2
CH), 27.8 (2C, C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~  = 3432 cm-1 (w), 3140 (w), 3057 (w), 2965 (m), 2928 (m), 2871 (m), 
1585 (m), 1460 (m), 1360 (w), 1340 (w), 1306 (m), 1228 (w), 1031 (w), 1009 (m), 
905 (s, br), 734 (s, br).  
UV (CHCl
3
): λ
max
 (log ε) = 283 nm (3.83), 240 (3.92).  
MS (EI, 70 eV): m/z (%) = 229 [M+H]+ (4), 228 [M]+ (23), 198 (100), 183 (56), 168 
(41).  
GC-HRMS (EI):  calcd. for C
15
H
20
N
2
 [M]+   228.1621, 
found      228.1630.  
16
N
H
NH
2
Experimental Section  129 
 
 
3a-(2-Methylbut-3-en-2-yl)-2,3,3a,8-tetrahydropyrrolo[2,3-b]indole (17) 
To a solution of 2-tert-prenyl-tryptamine (16, 100 mg, 0.38 mmol, 1.0 
eq.) in THF (15 mL) was added NBS (79 mg, 0.44 mmol, 1.16 eq.) at 
rt. The reaction mixture was stirred at 0 °C for 35 min, before CHCl
3
 
(50 mL) was added. The organic layer was washed with 2 N NaOH (3 
x 40 mL) and H
2
O (3 x 40 mL), dried over Na
2
SO
4
, filtered, and 
concentrated in vacuum. The residual green solid was purified by column 
chromatography (silica gel, CHCl
3
/MeOH (7:1 to 5:1)) to afford compound 17 (47 mg, 
0.21 mmol, 55%) as a green amorphous solid.  
TLC [silica gel, CHCl
3
/MeOH (5:1)]: R
f 
= 0.45.  
Mp: 160 °C.  
1H NMR (400 MHz, CDCl
3
): δ = 7.28 (s, br, 8-H), 7.17 (dt, 4J = 1.3 Hz, 3J = 7.7 Hz, 
1H, 6-H), 7.11 (dd, 4J = 0.8 Hz, 3J = 7.4 Hz, 1H, 4-H), 6.89 (dd, 4J = 1.1 Hz, 3J = 8.3 
Hz, 1H, 5-H), 6.86 (dd, 4J = 1.0 Hz, 3J = 7.5 Hz, 1H, 7-H), 6.03 (dd, 3J = 17.1, 11.0 
Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.05 (s, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 5.01 (dd, 3J = 8.0 Hz, 
2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 3.93 (ddd, 3J = 9.3, 5.8 Hz, 2J = 12.4 Hz, 1H, 
CNHC=NCH
2
CH
2
C), 3.82 (dd, 3J = 9.0 Hz, 2J = 12.4 Hz, 1H, CNHC=NCH
2
CH
2
C), 
2.43 (dd, 3J = 5.2 Hz, 2J = 13.0 Hz, 1H, CNHC=NCH
2
CH
2
C), 2.13 (dt, 3J = 6.4 Hz, 2J 
= 16.7 Hz, 1H, CNHC=NCH
2
CH
2
C), 1.03 (s, 3H, C(CH
3
)
2
CH=CH
2
), 0.95 (s, 3H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 183.1 (C-8a), 152.5 (C-7a), 143.6 
(C(CH
3
)
2
CH=CH
2
), 134.4 (C-3b), 128.3 (C-6), 124.7 (C-4), 120.4 (C-7), 113.2 
(C(CH
3
)
2
CH=CH
2
), 112.0 (C-5), 65.5 (C-3a), 57.5 (C-2), 43.4 
(CNHC(=N)CC(CH
3
)
2
CH), 32.1 (C-3), 22.9 (C(CH
3
)
2
CH=CH
2
), 21.9 
(C(CH
3
)
2
CH=CH
2
).  
IR (ATR): ν~  = 3053 cm-1 (w), 2968 (m), 2929 (m), 2874 (m), 2819 (m), 2738 (w), 
1672 (s), 1638 (w), 1608 (m), 1455 (s), 1419 (m), 1380 (w), 1331 (m), 1233 (m), 
1196 (m), 1153 (m), 1106 (m), 999 (m), 921 (s), 816 (m), 798 (w), 741 (s), 708 (s), 
654 (m), 610 (m), 539 (m).  
17
N
H
N
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UV (CHCl
3
): λ
max
 (log ε) = 258 nm (3.73).  
MS (EI, 70 eV): m/z (%) = 226 [M]+ (20), 157 [M-C
5
H
9
]+ (100), 156 (30), 130 (32).  
HRMS (EI):  calcd. for C
15
H
18
N
2
 [M]+    226.1465, 
found       226.1464.  
 
N,N-Dimethyl-2-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)ethanamine (20) 
At rt, DIBAL-H (17% in toluene, 6.22 mL, 6.218 mmol, 4.2 eq.) was 
added drop wise to a solution of debromoflustrabromine (2, 400 mg, 
1.48 mmol, 1.0 eq.) in THF (10 mL) under Ar. After 24 h, the 
reaction mixture was added in portions to ice water (150 mL). 
Aqueous HCl (12 M, 10 mL) was added at 0 °C (pH 2) and the 
organic layer was extracted with Et
2
O (3x 30 mL). The aqueous layer was brought to 
pH 11 by addition of aqueous NaOH (12 M, 20 mL) and was extracted with Et
2
O (3 x 
50 mL). The combined organic layers were washed with H
2
O (3 x 100 mL), dried 
over Na
2
SO
4
, and concentrated in vacuum to afford compound 20 (325 mg, 1.27 
mmol, 86%) as a colourless oil.  
1H NMR (400 MHz, CDCl
3
): δ = 7.83 (s, br, 1H, indole NH), 7.53 (d, 3J = 7.5 Hz, 1H, 
indole 4-H), 7.27 (dd, 4J = 1.2 Hz, 3J = 7.6 Hz, 1H, indole 7-H), 7.12 (dt, 4J = 1.4 Hz, 
3J = 7.5 Hz, 1H, indole 6-H), 7.07 (dt, 4J = 1.2 Hz, 3J = 7.4 Hz, 1H, indole 5-H), 6.13 
(dd, 3J = 17.4, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.17 (dd, 3J = 17.4 Hz, 2J = 1.0 Hz, 
1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.15 (dd, 3J = 10.5 Hz, 2J = 1.1 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
Z
), 3.04-3.00 (m, 2H, CCH
2
CH
2
N(CH
3
)
2
), 2.56-2.47 (m, 2H, CCH
2
CH
2
N(CH
3
)
2
), 
2.35 (s, 6H, CCH
2
CH
2
N(CH
3
)
2
), 1.54 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 145.9 (C(CH
3
)
2
CH=CH
2
), 139.3 (indole C-2), 134.2 
(indole C-7a), 129.7 (indole C-3a), 121.3 (indole C-6), 119.2 (indole C-5), 118.1 
(indole C-4), 112.0 (C(CH
3
)
2
CH=CH
2
), 110.4 (indole C-7), 108.9 (indole C-3), 60.4 
(CCH
2
CH
2
N(CH
3
)
2
), 45.5 (2C, CCH
2
CH
2
N(CH
3
)
2
), 38.9 (NHCC(CH
3
)
2
CH), 27.7 (2C, 
C(CH
3
)
2
CH=CH
2
), 23.4 (CCH
2
CH
2
N(CH
3
)
2
).  
20
N
H
N
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IR (ATR): ν~  = 3434 cm-1 (w), 3255 (w, br), 3055 (w), 2968 (m), 2936 (m), 2867 (w), 
2828 (w), 2789 (w), 1638 (w), 1459 (s), 1360 (w), 1341 (w), 1302 (w), 1247 (w), 1229 
(w), 1137 (w), 1098 (w), 1029 (m), 1008 (m), 736 (s), 597 (m).  
UV (CHCl
3
): λ
max
 (log ε) = 284 nm (3.87), 240 (3.98).  
MS (EI, 70 eV): m/z (%) = 256 [M]+ (7), 198 [M-C
3
H
8
N]+ (10), 183 [M-(C
4
H
10
N)+H]+ 
(10), 58 (100).  
GC-HRMS (EI):  calcd. for C
17
H
24
N
2
 [M]+   256.1934, 
found      256.1944.  
 
2-(3-Bromo-2-(2-methylbut-3-en-2-yl)-3H-indol-3-yl)-N,N-dimethylethanamine 
(21, NMR experiment)  
To a solution of N
b
,N
b
-dimethyl-2-tert.-prenyl-tryptamine (20, 60 mg, 
0.23 mmol, 1.0 eq.) in acetone-d
6
 (0.6 mL, NMR tube) was added 
NBS (42 mg, 0.23 mmol, 1.0 eq.) at rt. The NMR tube was shaken 
for 5 min and after 25 min the NMR spectrum was recorded.  
1H NMR (400 MHz, acetone-d
6
): δ = 7.53 (d, 3J = 7.4 Hz, 1H, indole 
4-H), 7.47 (d, 3J = 6.7 Hz, 1H, indole 7-H), 7.38 (dt, 4J = 1.2 Hz, 3J = 7.6 Hz, 1H, 
indole 6-H), 7.30 (dt, 4J = 1.1 Hz, 3J = 7.4 Hz, 1H, indole 5-H), 6.55 (dd, 3J = 17.5, 
10.7 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.30 (d, 3J = 17.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.19 
(d, 3J = 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 2.88-2.75 (m, 2H, CCH
2
CH
2
N(CH
3
)
2
), 
2.68 (s, 4H, (CH
2
CO)
2
NH), 2.01 (s, 6H, CCH
2
CH
2
N(CH
3
)
2
), 1.97-1.88 (m, 1H, 
CCH
2
CH
2
N(CH
3
)
2
), 1.71-1.65 (m, 1H, CCH
2
CH
2
N(CH
3
)
2
), 1.67 (s, 3H, 
C(CH
3
)
2
CH=CH
2
), 1.62 (s, 3H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, acetone-d
6
): δ = 186.6 (indole C-2), 179.0 (2C, (CH
2
CO)
2
NH), 
151.9 (indole C-7a), 145.0 (C(CH
3
)
2
CH=CH
2
), 141.2 (indole C-3a), 130.5 (indole C-
6), 127.6 (indole C-5), 123.3 (indole C-4), 121.3 (indole C-7), 113.5 
(C(CH
3
)
2
CH=CH
2
), 63.9 (indole C-3), 54.9 (CCH
2
CH
2
N(CH
3
)
2
), 45.1 (2C, 
CCH
2
CH
2
N(CH
3
)
2
), 44.3 (N=CC(CH
3
)
2
CH=CH
2
), 37.8 (CCH
2
CH
2
N(CH
3
)
2
), 30.2 (2C, 
CH
2
CO)
2
NH), 29.6 (C(CH
3
)
2
CH=CH
2
), 27.7 (C(CH
3
)
2
CH=CH
2
). 
21
N
N
Br
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3-Bromo-2-(2-methylbut-3-en-2-yl)-1H-indole (22) and N,N-dimethyl-2-(2-(2-
methylbut-3-en-2-yl)-1H-indol-3-yl)ethanamine hydrobromide (23) 
 
To a solution of N
b
,N
b
-dimethyl-2-tert.-prenyl-tryptamine (20, 400 mg, 1.56 mmol, 1.0 
eq.) in acetone (20 mL) was added NBS (308 mg, 1.72 mmol, 1.1 eq.) at 0 °C. The 
reaction mixture was stirred at 0 °C for 50 min and diluted with Et
2
O (100 mL). The 
reaction mixture was washed twice with 2N NaOH (2 x 50 mL), followed by 
extraction with H
2
O (3 x 50 mL). The organic layer was dried over Na
2
SO
4
 and 
concentrated in vacuum. The residue was purified by column chromatography (silica 
gel, CHCl
3
/MeOH (9:1)) to afford compound 22 (88 mg, 0.33 mmol, 21%) as a dark 
green oil and compound 23 (305 mg, 0.91 mmol, 58%) as a yellow oil. 
3-Bromoindole 22 
TLC [silica gel, acetone/petrolether (1:2)]: R
f 
= 0.73.  
1H NMR (400 MHz, CDCl
3
): δ = 8.07 (s, br, 1H, indole NH), 7.55-7.50 (m, 1H, indole 
4-H), 7.30-7.26 (m, 1H, indole 7-H), 7.20-7.13 (m, 2H, indole 5-H, indole 6-H), 6.17 
(dd, 3J = 17.4, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.24 (dd, 3J = 7.0 Hz, 2J = 1.0 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 5.21 (dd, 3J = 13.4 Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 
1.63 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 144.3 (C(CH
3
)
2
CH=CH
2
), 139.5 (indole C-2), 133.3 
(indole C-7a), 129.0 (indole C-3a), 122.5 (indole C-6), 120.4 (indole C-5), 118.6 
(indole C-4), 113.5 (C(CH
3
)
2
CH=CH
2
), 110.7 (indole C-7), 87.9 (indole C-3), 39.0 
(NHCC(CH
3
)
2
CH), 26.4 (2C, C(CH
3
)
2
CH=CH
2
).  
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IR (ATR): ν~  = 3151 cm-1 (w, br), 3059 (w, br), 2964 (m), 2925 (m), 1704 (w), 1641 
(w), 1617 (m), 1455 (m), 1385 (w), 1363 (w), 1259 (w), 1211 (w), 1101 (m), 1011 
(m), 913 (w), 802 (m), 746 (s).  
UV (CHCl
3
): λ
max
 (log ε) = 557 nm (3.02), 428 (3.16), 354 (3.25), 279 (3.86), 272 
(3.87), 240 (3.99).  
MS (EI, 70 eV): m/z (%) = 263 [M]+ (24), 169 (100), 167 (18), 127 (31).  
GC-HRMS (EI):  calcd. for C
13
H
14
N
2
Br79 [M]+  263.0304, 
found      263.0295.  
 
Hydrobromide 23  
TLC [silica gel, acetone/petrolether (1:2)]: R
f 
= 0.49.  
1H NMR (400 MHz, CDCl
3
): δ = 8.15 (s, br, 1H, indole NH), 7.57 (d, 3J = 7.6 Hz, 1H, 
indole 4-H), 7.35 (dd, 4J = 1.3 Hz, 3J = 7.5 Hz, 1H, indole 7-H), 7.14 (dt, 4J = 1.4 Hz, 
3J = 7.5 Hz, 1H, indole 6-H), 7.09 (dt, 4J = 1.2 Hz, 3J = 7.4 Hz, 1H, indole 5-H), 6.10 
(dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.17 (dd, 3J = 14.4 Hz, 2J = 0.9 Hz, 
1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.15 (dd, 3J = 7.4 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
Z
), 3.32-3.28 (m, 2H, CCH
2
CH
2
N(CH
3
)
2
), 3.00-2.96 (m, 2H, CCH
2
CH
2
N(CH
3
)
2
), 
2.72 (s, 6H, CCH
2
CH
2
N(CH
3
)
2
), 1.54 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 145.6 (C(CH
3
)
2
CH=CH
2
), 140.3 (indole C-2), 134.2 
(indole C-7a), 128.8 (indole C-3a), 121.7 (indole C-6), 119.7 (indole C-5), 117.7 
(indole C-4), 112.2 (C(CH
3
)
2
CH=CH
2
), 110.8 (indole C-7), 105.2 (indole C-3), 58.2 
(CCH
2
CH
2
N(CH
3
)
2
), 43.3 (2C, CCH
2
CH
2
N(CH
3
)
2
), 38.8 (NHCC(CH
3
)
2
CH), 27.7 (2C, 
C(CH
3
)
2
CH=CH
2
), 20.9 (CCH
2
CH
2
N(CH
3
)
2
).  
IR (ATR): ν~  = IR (ATR): ν~  = 3270 cm-1 (w, br), 2966 (w, br), 2666 (w, br), 2462 (w), 
1469 (s), 1342 (w), 1307 (w), 1236 (w), 1008 (m), 956 (m), 918 (m), 744 (s), 716 (m).  
UV (CH
2
Cl
2
): λ
max
 (log ε) = 282 nm (3.86), 239 (3.91), 233 (3.68).  
MS (ESI): m/z (%) = 257 [M]+ (67), 212 [M-C
2
H
7
N]+ (100).  
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HRMS (ESI):  calcd. for C
17
H
25
N
2
 [M]+   257.2012, 
found      257.2011. 
 
N-(2-(2-(2-Methylbut-3-en-2-yl)-1H-indol-3-yl)ethyl)formamide (18) 
A mixture of Ac
2
O (0.23 mL, 2.42 mmol, 2.5 eq.) and HCO
2
H (0.1 
mL, 2.42 mmol, 2.5 eq.) was stirred at 60 °C for 1 h. After cooling 
to rt, a solution of 2-tert-prenyltryptamine (16, 221 mg, 0.97 mmol, 
1.0 eq.) in DCM (10 mL) was added drop wise. The reaction 
mixture was stirred at rt for 2 h. Upon completion, the reaction 
mixture was added to aqueous NaOH (12 M, 14 mL) and ice (15 
g). The alkaline mixture was diluted with DCM (50 mL) and the aqueous layer was 
extracted with DCM (3 x 30 mL). The combined organic layers were washed with 
HCl (2M, 2 x 30 mL), H
2
O (3 x 50 mL), dried over Na
2
SO
4
, filtered, and concentrated 
in vacuum to afford compound 18 (240 mg, 0.94 mmol, 97%) as an oil.  
Ratio of rotamers in CDCl
3
: 1:0.2. 
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.12 (s, 1H, CHO), 8.02 (s, br, 1H, indole NH), 7.55 
(dt, 4J = 0.5 Hz, 3J = 7.7 Hz, 1H, indole 4-H), 7.30 (dt, 4J = 0.9 Hz, 3J = 8.0 Hz, 1H, 
indole 7-H), 7.14 (td, 4J = 1.3 Hz, 3J = 7.4 Hz, 1H, indole 6-H), 7.09 (td, 4J = 1.2 Hz, 
3J = 7.4 Hz, 1H, indole 5-H), 6.12 (dd, 3J = 17.7, 10.3 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.67 
(s, br, 1H, CH
2
NHCHO), 5.17 (dd, 3J = 6.2 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
5.14 (d, 2J = 1.2 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 3.58 (q, 3J = 13.8, 6.9 Hz, 2H, 
CCH
2
CH
2
NHCHO), 3.08 (t, 3J = 7.3 Hz, 2H, CCH
2
CH
2
NHCHO), 1.54 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 161.2 (CHO), 145.8 (C(CH
3
)
2
CH=CH
2
), 140.2 
(indole C-2), 134.2 (indole C-7a), 129.6 (indole C-3a), 121.5 (indole C-6), 119.6 
(indole C-5), 118.1 (indole C-4), 112.1 (C(CH
3
)
2
CH=CH
2
), 110.5 (indole C-7), 107.4 
(indole C-3), 39.0 (NHCC(CH
3
)
2
CH), 38.8 (CCH
2
CH
2
NHCHO), 27.8 (2C, 
C(CH
3
)
2
CH=CH
2
), 24.9 (CCH
2
CH
2
NHCHO).  
Minor Rotamer:  
18
N
H
HN
O
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1H NMR (400 MHz, CDCl
3
): δ = 7.97 (s, 1H, CHO), 7.94 (s, br, 1H, indole NH), 7.45 
(dt, 4J = 0.6 Hz, 3J = 7.8 Hz, 1H, indole 4-H), 7.31 (dt, 4J = 0.9 Hz, 3J = 7.9 Hz, 1H, 
indole 7-H), 7.15 (td, 4J = 1.4 Hz, 3J = 6.7 Hz, 1H, indole 6-H), 7.15-7.06 (m, 1H, 
indole 5-H), 6.12 (dd, 3J = 17.7, 10.3 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.67 (s, br, 1H, 
CH
2
NHCHO), 5.18 (dd, 3J = 6.7 Hz, 2J = 1.2 Hz, 1H, : C(CH
3
)
2
CH=CH
2
-H
Z
), 5.14 (s, 
1H, C(CH
3
)
2
CH=CH
2
-H
E
), 3.54-3.46 (m, 2H, CCH
2
CH
2
NHCHO), 3.13-3.04 (m, 2H, 
CCH
2
CH
2
NHCHO), 1.53 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 164.3 (CHO), 145.9 (C(CH
3
)
2
CH=CH
2
), 140.2 
(indole C-2), 134.2 (indole C-7a), 129.6 (indole C-3a), 121.7 (indole C-6), 119.4 
(indole C-5), 117.8 (indole C-4), 112.0 (C(CH
3
)
2
CH=CH
2
), 110.7 (indole C-7), 106.6 
(indole C-3), 42.1 (CCH
2
CH
2
NHCHO), 39.0 (NHCC(CH
3
)
2
CH), 28.1 (2C, 
C(CH
3
)
2
CH=CH
2
), 25.3 (CCH
2
CH
2
NHCHO).  
IR (ATR): ν~  = 3299 cm-1 (w, br), 3056 (w), 2968 (w), 2868 (w), 1660 (s, br), 1517 
(w), 1460 (m), 1435 (m), 1383 (m), 1338 (w), 1304 (w), 1238 (m, br), 1173 (w), 1006 
(w), 915 (m), 741 (s, br).  
UV (CHCl
3
): λ
max
 (log ε) = 283 nm (3.79), 240 (3.88), 232 (3.69).  
MS (EI, 70 eV): m/z (%) = 256 [M]+ (27), 198 [M-C
2
H
4
NO]+ (100), 184 [M-C
3
H
6
NO]+ 
(9), 168 (48).  
GC-HRMS (EI):  calcd. for C
15
H
20
N
2
 [M]+   256.1576, 
found      256.1572.  
 
N-Methyl-N-(2-(1-(3-methylbut-2-enyl)-1H-indol-3-yl)ethyl)formamide (146) 
To NaH (60% in mineral oil, 713 mg, 17.81 mmol, 1.2 eq.) was 
added N
b
-formyl-N
b
-methyltryptamine (131, 3.0 g, 14.84 mmol, 1.0 
eq.) dissolved in DMF (60 mL) at 0 °C. The reaction mixture was 
stirred at 0 °C for 1 h. Prenylbromide (2.1 mL, 17.81 mmol, 1.2 eq.) 
was added drop wise at 0 °C and the reaction mixture was allowed 
to warm to rt, stirred further for 3 h. H
2
O (25 mL) was cautiously 
added and the aqueous phase was extracted with Et
2
O (3 x 100 
146
N
N
O
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mL). The combined ethereal phases were washed with H
2
O (3 x 100 mL), brine (1 x 
100 mL), dried over Na
2
SO
4
, filtered, and concentrated in vacuum. The residue 
obtained was purified by column chromatography (silica gel, EtOAc) to afford 
compound 146 (3.36 g, 12.14 mmol, 84%) as a red oil.  
TLC [silica gel, EtOAc]: R
f 
= 0.54.  
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 7.82 (s, 1H, CHO), 7.53 (d, 3J = 7.9 Hz, 1 H, indole 
7-H), 7.29 (d, 3J = 8.2 Hz, 1 H, indole 4-H), 7.13-7.08 (m, 2H, indole 5-H, indole 6-H), 
6.87 (s, 1H, indole 2-H), 5.36-5.31 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 4.63 (d, 3J = 6.9 
 Hz, 2H, NCH
2
CH=C(Me)
2
), 3.51 (t, 3J = 7.0 Hz, 2H, CCH
2
CH
2
N(CH
3
)CHO), 
2.98 (t, 3J = 7.0 Hz, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.91 (s, NCH
3
), 1.81 (s, 6H, 
NCH
2
CH=C(CH
3
)
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CHO), 136.5 (NCH
2
CH=C(CH
3
)
2
), 136.1 
(indole C-7a), 127.6 (indole C-3a), 125.2 (indole C-2), 119.9 (NCH
2
CH=C(CH
3
)
2
), 
119.1, 118.9 (indole C-6, indole C-5), 118.4 (indole C-7), 110.3 (indole C-3), 109.8 
(indole C-4), 50.3 (CCH
2
CH
2
N(CH
3
)CHO), 44.0 (NCH
2
CH=C(CH
3
)
2
), 29.7 
(N(CH
3
)CHO), 25.7 (2C, NCH
2
CH=C(CH
3
)
2
), 24.6 (CCH
2
CH
2
N(CH
3
)CHO).  
Minor Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.05 (s, 1H, CHO), 7.63 (d, 3J = 7.9 Hz, 1 H, indole 
7-H), 7.30 (d, 3J = 8.2 Hz, 1 H, indole 4-H), 7.23-7.19 (m, 2H, indole 5-H, indole 6-H), 
6.96 (s, 1H, indole 2-H), 5.36-5.31 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 4.63 (d, 3J = 6.9 
 Hz, 2H, NCH
2
CH=C(Me)
2
), 3.63 (t, 3J = 7.0 Hz, 2H, CCH
2
CH
2
N(CH
3
)CHO), 
2.99 (t, 3J = 7.0 Hz, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.88 (s, NCH
3
), 1.76 (s, 6H, 
NCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 162.7 (CHO), 136.5 (NCH
2
CH=C(CH
3
)
2
), 136.3 
(CH=C(CH
3
)
2
),136.2 (indole C-7a), 128.0 (indole C-3a), 125.3 (indole C-2), 120.0 
(NCH
2
CH=C(CH
3
)
2
), 121.7, 121.5 (indole C-6, indole C-5), 118.8 (indole C-7), 111.3 
(indole C-3), 119.6 (indole C-4), 45.2 (CCH
2
CH
2
N(CH
3
)CHO), 43.9 
(NCH
2
CH=C(CH
3
)
2
), 35.0 (N(CH
3
)CHO), 22.8 (CCH
2
CH
2
N(CH
3
)CHO), 18.0 (2C, 
NCH
2
CH=C(CH
3
)
2
).  
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IR (ATR): ν~ = 3051 cm-1 (w), 2967 (w), 2918 (w), 2858 (w), 1665 (s), 1465 (m), 1393 
(m), 1333 (w), 1164 (w), 1069 (m), 1014 (w), 844 (w), 737 (s), 654 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 292 nm (3.75), 240 (3.99).  
MS (EI, 70 eV): m/z (%) = 270 [M]+ (23), 211 [M-C
2
H
4
NO]+ (50), 198 [M-C
3
H
6
NO]+ 
(33), 143 (33), 130 [C
9
H
9
N]+ (100), 69 (26).  
HRMS (EI):  calcd. for C
17
H
22
N
2
O [M]+    270.1727, 
found       270.1733.  
 
N-(2-(2-Bromo-1-(3-methylbut-2-enyl)-1H-indol-3-yl)ethyl)-N-methylformamide 
(167) 
To a stirred solution of N
a
-prenyl-N
b
-formyl-N
b
-methyltryptamine 
(146, 500 mg, 1.85 mmol, 1.0 eq.) in HOAc-HCO
2
H (16 mL, 3:1) 
was added a solution of NBS (336 mg, 1.89 mmol, 1.02 eq.) in 
HOAc-HCO
2
H (8 mL, 3:1). The solution was stirred at rt for 3 h, 
before the solution was added to a mixture of Et
2
O (70 mL) and ice 
(70 g) and was diluted with Et
2
O (100 mL). The organic layer was 
washed with H
2
O (3 x 50 mL) and with aqueous NaOH (1 M, 50 
mL). The organic layer was washed again with H
2
O (2 x 50 mL), 
dried over MgSO
4
, filtered, and concentrated in vacuum. The residue obtained was 
purified by column chromatography (silica gel, EtOAc/Hexane (1:1)) to afford the title 
compound 167 (148 mg, 0.43 mmol, 23%) as a black oil which degrades over time. 
TLC [silica gel, EtOAc/Hexane (1:1)]: R
f 
= 0.42. 
Ratio of rotamers in CDCl
3
: 1.0:0.5. 
Major Rotamer: 
1H NMR (400 MHz, CDCl
3
): δ = 7.76 (s, 1H, CHO), 7.46 (d, 3J = 7.5 Hz, 1H, indole 7-
H), 7.246 (d, 3J = 4.3 Hz, 1H, indole 4-H), 7.21-7.16 (m, 1H, indole 5-H), 7.12 (dd, 3J 
= 7.0 Hz, 4J = 1.0 Hz, 1H, indole 6-H), 5.17-5.12 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 4.76 (d, 
3J = 6.5 Hz, 2H, NCH
2
CH=C(Me)
2
), 3.48 (t, 3J = 6.9 Hz, 2H, CCH
2
CH
2
N(CH
3
)CHO), 
167
N
N
O
Br
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3.02-2.96 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.94 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.86 
(s, 3H, NCH
2
CH=C(CH
3
)
2
), 1.70 (d, 4J = 1.3 Hz, 3H, NCH
2
CH=C(CH
3
)
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CHO), 136.2 (indole C-7a), 135.1 
(NCH
2
CH=C(CH
3
)
2
), 126.9 (indole C-3a), 122.0 (indole C-5), 119.8, (indole C-6), 
117.5 (indole C-7), 119.6 (NCH
2
CH=C(CH
3
)
2
), 113.2 (indole C-2), 110.3 (indole C-3), 
109.9 (indole C-4), 49.2 (CCH
2
CH
2
N(CH
3
)CHO), 43.3 (NCH
2
CH=C(CH
3
)
2
), 30.0 
(CCH
2
CH
2
N(CH
3
)CHO), 25.5 (2C, NCH
2
CH=C(CH
3
)
2
), 24.8 (CCH
2
CH
2
N(CH
3
)CHO).  
Minor Rotamer: 
1H NMR (400 MHz, CDCl
3
): δ = 8.03 (s, 1H, CHO), 7.62 (d, 3J = 7.8 Hz, 1H, indole 7-
H), 7.253 (d, 3J = 4.3 Hz, 1H, indole 4-H), 7.21-7.16 (m, 1H, indole 5-H), 7.10 (dd, 3J 
= 7.0 Hz, 4J = 1.0 Hz, indole 6-H), 5.17-5.12 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 4.76 (d, 3J 
= 6.5  Hz, 2H, NCH
2
CH=C(Me)
2
), 3.55 (dd, 3J = 6.8, 8.2 Hz, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 3.02-2.96 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 2.84 (s, 3H, 
CCH
2
CH
2
N(CH
3
)CHO), 1.86 (s, 3H, NCH
2
CH=C(CH
3
)
2
), 1.70 (d, 4J = 1.3 Hz, 3H, 
NCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CHO), 136.1 (indole C-7a), 135.0 
(NCH
2
CH=C(CH
3
)
2
), 127.3 (indole C-3a), 122.0 (indole C-5), 119.7 (indole C-6), 
118.2 (indole C-7), 119.6 (NCH
2
CH=C(CH
3
)
2
), 112.7 (indole C-2), 111.5 (indole C-3), 
109.6 (indole C-4), 44.5 (CCH
2
CH
2
N(CH
3
)CHO), 43.2 (NCH
2
CH=C(CH
3
)
2
), 35.2 
(CCH
2
CH
2
N(CH
3
)CHO), 23.1 (CCH
2
CH
2
N(CH
3
)CHO), 18.2 (2C, NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3053 cm-1 (w), 2968 (w), 2924 (w), 2857 (w), 1668 (s), 1453 (s), 1383 
(m), 1352 (m), 1333 (m), 1311 (m), 1217 (w), 1179 (m), 1155 (w), 1069 (m), 1041 
(w), 1014 (w), 843 (w), 738 (s), 567 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 354 nm (1.72), 286 (3.93), 240 (4.03), 231 (3.71).  
MS (EI, 70 eV): m/z (%) = 351 (3), 350 (15), 349 (3), 348 (16), 292 (5), 291 (26), 290 
(5), 289 (27), 269 (21), 223 (5), 222 (31), 221 (5), 220 (32), 211 (11), 210 (99), 209 
(12), 208 (100), 181 (5), 130 (9), 129 (15), 128 (17), 101 (9), 77 (6), 69 (44). 
HRMS (EI):  calcd. for C
17
H
22
BrN
2
O [M]+   348.0832, 
found       348.0827. 
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2-(2-(1-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-1H-indol-3-
yl)ethyl)isoindoline-1,3-dione (168) and 2-(2-(3-(3-methylbut-2-enyl)-2-(2-
methylbut-3-en-2-yl)-3H-indol-3-yl)ethyl)isoindoline-1,3-dione (169) 
 
To NaH (60% in mineral oil, 292 mg, 7.31 mmol, 5.0 eq.) was added pentane (4 mL) 
at rt and stirred for 2 min. Pentane was removed via syringe. The reaction flask was 
cooled on an ice bath and 2-tert-prenyl-phthaloyltryptamine (166, 524 mg, 1.46 
mmol, 1.0 eq.) in DMF (30 mL) was added drop wise at 0 °C and the reaction 
mixture was stirred for 2 h at 0 °C. To the red colored reaction mixture, 
prenylchloride (0.72 mL, 5.84 mmol, 4.0 eq.) in DMF (2 mL) was added drop wise 
and stirred at rt for 24 h. H
2
O (50 mL) was cautiously added and the reaction mixture 
was extracted with TBME (4 x 70 mL). The combined etherial layers were washed 
with H
2
O (3 x 70 mL), brine (1 x 70 mL), dried over Na
2
SO
4
, and concentrated in 
vacuum. The residual oil was purified by column chromatography (silica gel, 
EtOAc/petrolether (4:1 to 1:1)) to obtain the title compounds 169 (383 mg, 0.9 mmol, 
61%) and 168 (98 mg, 0.23 mmol, 16%) as pale yellow solids. 
TLC [silica gel, EtOAc/petrolether (4:1)]: R
f 
= 0.63. 
Mp: 161-162 °C.  
1H NMR (400 MHz, CDCl
3
): δ = 7.85 (dd, 3J = 5.4, 3.1 Hz, 2H, N(C(=O)CCHCH)
2
), 
7.83-7.80 (m, 1H, indole 4-H), 7.71 (dd, 3J = 5.4, 3.0 Hz, 2H, N(C(=O)CCHCH)
2
), 
7.15-7.10 (m, 3H, indole 5-H, indole 6-H, indole 7-H), 6.23 (dd, 3J = 17.5, 10.6 Hz, 
1H, C(CH
3
)
2
CH=CH
2
), 5.15-5.12 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 5.09 (dd, 3J = 10.6 Hz, 
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2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 5.01 (dd, 3J = 17.5 Hz, 2J = 0.9 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 4.80 (d, 3J = 5.5 Hz, 2H, NCH
2
CH=C(CH
3
)
2
), 3.91-3.87 (m, 2H, 
CCH
2
CH
2
N(phthaloyl)), 3.35-3.31 (m, 2H, CCH
2
CH
2
N(phthaloyl)), 1.78 (d, 4J = 0.9 
Hz, 3H, NCH
2
CH=C(CH
3
)
2
), 1.70 (s, 9H, C(CH
3
)
2
CH=CH
2
,
 
NCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 168.4 (2C, N(C(=O)CCHCH)
2
), 145.6 
(C(CH
3
)
2
CH=CH
2
), 140.6 (indole C-2), 136.9 (indole C-7a), 133.8 (2C, 
N(C(=O)CCHCH)
2
), 133.0 (2C, N(C(=O)CCHCH)
2
), 132.3 (NCH
2
CH=C(CH
3
)
2
), 128.9 
(indole C-3a), 123.1 (2C, N(C(=O)CCHCH)
2
), 122.2 (NCH
2
CH=C(CH
3
)
2
), 121.5 
(indole C-6), 119.2 (indole C-5), 118.2 (indole C-4), 111.8 (C(CH
3
)
2
CH=CH
2
), 109.6 
(indole C-7), 107.7 (indole C-3), 44.1 (NCH
2
CH=C(CH
3
)
2
), 40.8 
(NCC(CH
3
)
2
CH=CH
3
), 39.4 (CCH
2
CH
2
N(phthaloyl)), 29.7 (2C, NCC(CH
3
)
2
CH=CH
2
), 
25.4 (NCH
2
CH=C(CH
3
)
2
), 25.1 (CCH
2
CH
2
N(phthaloyl)), 18.3 (NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3050 cm-1 (w), 2919 (w), 2867 (w), 1771 (w), 1703 (s), 1467 (w), 1429 
(w), 1394 (m), 1352 (m), 1329 (w), 1255 (w), 1188 (w), 1103 (m), 1018 (m), 995 (w), 
910 (w), 876 (w), 793 (w), 733 (s), 716 (s), 625 (w), 592 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 292 nm (3.94), 241 (4.27). 
MS (EI, 70 eV): m/z (%) = 449 [M+Na]+ (100), 427 [M+H]+ (11). 
HRMS (ESI): calcd. for C
28
H
30
NaN
2
O
2
 [M+Na]+  449.2199, 
found       449.2203. 
 
Compound 169 
TLC [silica gel, EtOAc/petrolether (4:1)]: R
f 
= 0.42. 
Mp: 143-146 °C.  
1H NMR (400 MHz, CDCl
3
): δ = 7.76 (dd, 3J = 5.5, 3.0 Hz, 2H, N(C(=O)CCHCH)
2
), 
7.67 (dd, 3J = 5.5, 3.0 Hz, 2H, N(C(=O)CCHCH)
2
), 7.57 (dd, 4J = 1.3 Hz, 3J = 7.3 Hz, 
1H, indole 7-H), 7.27-7.25 (m, 2H, indole 6-H, indole 4-H), 7.20-7.17 (m, 1H, indole 
5-H), 6.40 (dd, 3J = 17.4, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.32 (dd, 3J = 17.5 Hz, 2J = 
1.1 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.22 (dd, 3J = 10.7 Hz, 2J = 1.1 Hz, 1H, 
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C(CH
3
)
2
CH=CH
2
-H
Z
), 4.46-4.44 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 3.18 (ddd, 3J = 
11.8, 4.5 Hz, 2J = 13.7 Hz, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.92 (ddd, 3J = 11.3, 5.6 Hz, 
2J = 13.7 Hz, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.69 (dd, 3J = 6.2 Hz, 2J = 15.0 Hz, 1H, 
CCH
2
CH
2
N(phthaloyl)), 2.57 (dd, 3J = 5.8 Hz, 2J = 14.6 Hz, 1H, 
CCH
2
CH
2
N(phthaloyl)), 2.53 (ddd, 3J = 11.3, 4.5 Hz, 2J = 13.4 Hz, 1H, 
CCH
2
CH
2
N(phthaloyl)), 2.35 (ddd, 3J = 11.8, 5.6 Hz, 2J = 13.4 Hz, 1H, 
CCH
2
CH
2
N(phthaloyl)), 1.68 (s, 3H, N=CC(CH
3
)
2
CH=CH
2
), 1.56 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.51 (d, 4J = 1.1 Hz, 3H, N=CCCH
2
CH=C(CH
3
)
2
), 1.46 (s, 3H, 
N=CCCH
2
CH=C(CH
3
)
2
. 
13C NMR (100 MHz, CDCl
3
): δ = 190.7 (indole C-2), 167.9 (2C, N(C(=O)CCHCH)
2
), 
153.7 (indole C-7a), 144.5 (C(CH
3
)
2
CH=CH
2
), 141.6 (indole C-3a), 134.3 
(N=CCCH
2
CH=C(CH
3
)
2
), 133.8 (2C, N(C(=O)CCHCH)
2
), 132.0 (2C, 
N(C(=O)CCHCH)
2
), 127.8 (indole C-6), 125.7 (indole C-5), 123.0 (2C, 
N(C(=O)CCHCH)
2
), 121.5 (indole C-4), 120.1 (indole C-7), 118.2 
(N=CCCH
2
CH=C(CH
3
)
2
), 113.1 (C(CH
3
)
2
CH=CH
2
), 62.8 (indole C-3), 43.7 
(N=CC(CH
3
)
2
CH=CH
2
), 35.3 (CCH
2
CH
2
N(phthaloyl)), 34.1 (CCH
2
CH
2
N(phthaloyl)), 
34.0 (N=CCCH
2
CH=C(CH
3
)
2
), 27.6 (N=CC(CH
3
)
2
CH=CH
2
), 27.5 
(N=CC(CH
3
)
2
CH=CH
2
), 25.6 (N=CCCH
2
CH=C(CH
3
)
2
), 18.2 
(N=CCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 2970 cm-1 (w), 2929 (w), 2877 (w), 1717 (s), 1636 (s), 1540 (w), 1491 
(w), 1451 (m), 1376 (m), 1261 (s), 1123 (m), 1075 (m), 1039 (w), 917 (w), 840 (w), 
749 (s), 708 (m), 678 (w), 645 (w), 577 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 240 nm (3.93). 
MS (EI, 70 eV): m/z (%) = 449 [M+Na]+ (5). 
HRMS (ESI): calcd. for C
28
H
30
NaN
2
O
2
 [M+Na]+  449.2199, 
found       449.2201. 
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N-Methyl-N-(2-(1-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-1H-indol-3-
yl)ethyl)formamide (27) and N-methyl-N-(2-(3-(3-methylbut-2-enyl)-2-(2-
methylbut-3-en-2-yl)-3H-indol-3-yl)ethyl)formamide (174): 
 
To NaH (60% in mineral oil, 740 mg, 18.51 mmol, 5.0 eq.) was added pentane (3 
mL) at rt and stirred for 2 min. Pentane was removed via syringe. The reaction 
mixture was cooled on an ice bath and debromoflustrabromine (2, 1.0 g, 3.70 mmol, 
1.0 eq.) in DMF (23 mL) was added drop wise and stirred for 2 h at 0 °C. 
Prenylchloride (1.73 mL, 14.81 mmol, 4.0 eq.) in DMF (2 mL) was added drop wise 
to the reaction mixture and stirred at 0 °C for 6 h. H
2
O (50 mL) was cautiously added 
and the reaction mixture was extracted with TBME (4 x 150 mL). The combined 
etherial layers were washed with H
2
O (3 x 150 mL), brine (150 mL), dried over 
Na
2
SO
4
, and concentrated in vacuum. The residue obtained was purified by column 
chromatography (silica gel, EtOAc/petrolether (4:1 to 1:1)) to obtain the title 
compounds 27 (467 mg, 1.41 mmol, 37%) and 174 (648 mg, 1.96 mmol, 52%) as 
pale yellow oils. 
TLC [silica gel, EtOAc/petrolether (4:1)]: R
f 
= 0.41. 
Ratio of rotamers in CDCl
3
: 1:0.7. 
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.04 (s, CCH
2
CH
2
N(CH
3
)CHO), 7.47 (d, 4J = 1.0 Hz, 
3J = 7.7 Hz, 1H, indole 4-H), 7.20-7.14 (m, 2H, indole 5-H, indole 6-H), 7.13-7.09 (m, 
1H, indole 7-H), 6.18 (dd, 3J = 17.5, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.13-5.11 (m, 
1H, NCH
2
CH=C(CH
3
)
2
), 5.09 (d, 3J = 10.6 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.97 (dt, 3J = 17.5 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.80-4.78 (m, 2H, 
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NCH
2
CH=C(CH
3
)
2
), 3.45-3.41 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.24-3.19 (m, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.99 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 1.70 (d, 4J = 1.3 Hz, 6H, 
NCH
2
CH=C(CH
3
)
2
), 1.60 (s, 6H, NCC(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 162.5 (CH
2
CH
2
N(CH
3
)CHO), 147.6 
(C(CH
3
)
2
CH=CH
2
), 140.5 (indole C-2), 137.0 (indole C-7a), 133.3 
(NCH
2
CH=C(CH
3
)
2
), 128.4 (indole C-3a), 121.9 (NCH
2
CH=C(CH
3
)
2
), 121.5 (indole 
C-5), 119.2 (indole C-7), 117.4 (indole C-4), 111.7 (C(CH
3
)
2
CH=CH
2
), 109.9 (indole 
C-5), 107.4 (indole C-3), 51.3 (CCH
2
CH
2
N(CH
3
)CHO), 44.2 (NCH
2
CH=C(CH
3
)
2
), 
40.8 (NCC(CH
3
)
2
CH=CH
2
), 30.0 (CCH
2
CH
2
N(CH
3
)CHO), 29.7 (2C, 
CC(CH
3
)
2
CH=CH
2
), 25.6 (CCH
2
CH
2
N(CH
3
)CHO), 25.4 (2C, NCH
2
CH=C(CH
3
)
2
). 
Minor Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.06 (s, CCH
2
CH
2
N(CH
3
)CHO), 7.64 (dt, 3J = 7.5, 
4.1 Hz, 1H, indole 4-H), 7.20-7.14 (m, 2H, indole 5-H, indole 6-H), 7.13-7.09 (m, 1H, 
indole 7-H), 6.19 (dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.13-5.11 (m, 1H, 
NCH
2
CH=C(CH
3
)
2
), 5.07 (d, 3J = 10.6 Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.97 (dt, 3J = 17.5 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.80-4.78 (m, 2H, 
NCH
2
CH=C(CH
3
)
2
), 3.53-3.49 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.24-3.19 (m, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.96 (s, 3H, CH
2
CH
2
N(CH
3
)CHO), 1.78 (s, 6H, 
NCH
2
CH=C(CH
3
)
2
), 1.65 (s, 6H, NCC(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CH
2
CH
2
N(CH
3
)CHO), 147.9 
(C(CH
3
)
2
CH=CH
2
), 140.4 (indole C-2), 136.9 (indole C-7a), 133.1 
(NCH
2
CH=C(CH
3
)
2
), 128.8 (indole C-3a), 122.1 (NCH
2
CH=C(CH
3
)
2
), 121.7 (indole 
C-5), 119.1 (indole C-7), 117.9 (indole C-4), 112.0 (C(CH
3
)
2
CH=CH
2
), 109.6 (indole 
C-5), 108.2 (indole C-3), 46.6 (CCH
2
CH
2
N(CH
3
)CHO), 44.1 (NCH
2
CH=C(CH
3
)
2
), 
40.8 (NCC(CH
3
)
2
CH=CH
2
), 35.1 (CCH
2
CH
2
N(CH
3
)CHO), 29.7 (2C, 
CC(CH
3
)
2
CH=CH
2
), 23.1 (CCH
2
CH
2
N(CH
3
)CHO), 18.3 (2C, NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 2968 cm-1 (w), 2927 (m), 2866 (w), 1668 (s), 1470 (m), 1451 (m), 1396 
(w), 1350 (w), 1312 (w), 1241 (w), 1177 (m), 1066 (m), 1040 (w), 1006 (w), 910 (m), 
840 (w), 744 (s), 697 (w), 578 (m). 
UV (CHCl
3
): λ
max
 (log ε) = 290 nm (3.84), 240 (4.09). 
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MS (ESI): m/z (%) = 361 [M+Na]+ (100), 339 [M+H]+ (6). 
HRMS (ESI):   calcd. for C
22
H
31
N
2
O [M+H]+  339.2431, 
found      339.2433. 
 
Compound 174: 
TLC [silica gel, EtOAc/petrolether (2:1)]: R
f 
= 0.22. 
Ratio of rotamers in CDCl
3
: 1:0.6. 
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 7.64(s, CCH
2
CH
2
N(CH
3
)CHO), 7.59 (d, 3J = 7.0 Hz, 
1H, indole 7-H), 7.33 (dt, 4J = 1.2 Hz, 3J = 7.3 Hz, 1H, indole 6-H), 7.20 (dd, 4J = 1.0 
Hz, 3J = 6.2 Hz, 1H, indole 5-H), 7.14 (d, 3J = 7.4 Hz, 1 H, indole 4-H), 6.25 (dd, 3J = 
17.5, 10.6 Hz, 1H, N=CC(CH
3
)
2
CH=CH
2
), 5.27 (dd, 3J = 17.5 Hz, 2J = 0.9 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 5.20 (dd, 3J = 10.6 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.43-4.37 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.75-2.71 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 
2.70 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 2.69-2.65 (m, 2H, N=CCCH
2
CH=C(CH
3
)
2
), 2.42 
(ddd, 3J = 12.9, 4.6 Hz, 2J = 11.3 Hz, 1H, CCH
2
CH
2
N(CH
3
)CHO), 2.32-2.20 (m, 1H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.14-2.06 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 1.55 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.53 (s, 6H, N=CCCH
2
CH=C(CH
3
)
2
,
 
N=CC(CH
3
)
2
CH=CH
2
), 
1.50 (s, 3H, N=CCCH
2
CH=C(CH
3
)
2
. 
13C NMR (100 MHz, CDCl
3
): δ = 190.1 (indole C-2), 162.2 (CH
2
CH
2
N(CH
3
)CHO), 
153.7 (indole C-7a), 144.6 (C(CH
3
)
2
CH=CH
2
), 141.7 (indole C-3a), 134.6 
(N=CCCH
2
CH=C(CH
3
)
2
), 128.1 (indole C-6), 125.8 (indole C-5), 120.9 (indole C-4), 
120.4 (indole C-7), 117.8 (CCH
2
CH=C(CH
3
)
2
), 113.0 (C(CH
3
)
2
CH=CH
2
), 62.6 (indole 
C-3), 45.0 (CCH
2
CH
2
N(CH
3
)CHO), 43.7 (N=CC(CH
3
)
2
CH=CH
2
), 35.5 
(N=CCCH
2
CH=C(CH
3
)
2
), 35.0 (CCH
2
CH
2
N(CH
3
)CHO), 34.5 (CCH
2
CH
2
N(CH
3
)CHO), 
27.9 (N=CC(CH
3
)
2
CH=CH
2
), 26.9 (N=CC(CH
3
)
2
CH=CH
2
), 25.5 
(N=CCCH
2
CH=C(CH
3
)
2
), 18.2 (N=CCCH
2
CH=C(CH
3
)
2
). 
Minor Rotamer:  
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1H NMR (400 MHz, CDCl
3
): δ = 7.87 (s, CCH
2
CH
2
N(CH
3
)CHO), 7.58 (d, 3J = 6.2 Hz, 
1H, indole 7-H), 7.32-7.29 (m, 1H, indole 6-H), 7.23 (dd, 4J = 1.1 Hz, 3J = 7.4 Hz, 1H, 
indole 5-H), 7.22 (dd, 4J = 1.0 Hz, 3J = 4.3 Hz, 1H, indole 4-H), 6.34 (dd, 3J = 17.4, 
10.6 Hz, 1H, N=CC(CH
3
)
2
CH=CH
2
), 5.27 (dd, 3J = 17.5 Hz, 2J = 1.3 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 5.19 (dd, 3J = 10.6 Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.43-4.37 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 3.00 (ddd, 3J = 13.0, 4.9 Hz, 2J = 11.8 Hz, 
1H, CCH
2
CH
2
N(CH
3
)CHO), 2.67 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 2.64-2.58 (m, 2H, 
N=CCCH
2
CH=C(CH
3
)
2
), 2.41 (ddd, 3J = 12.9, 4.8 Hz, 2J = 11.5 Hz, 1H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.32-2.20 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 2.14-2.06 (m, 1H, 
CCH
2
CH
2
N(CH
3
)CHO), 1.60 (s, 3H, N=CC(CH
3
)
2
CH=CH
2
), 1.51 (s, 6H, 
N=CCCH
2
CH=C(CH
3
)
2
,
 
N=CC(CH
3
)
2
CH=CH
2
), 1.48 (s, 3H, N=CCCH
2
CH=C(CH
3
)
2
). 
 13C NMR (100 MHz, CDCl
3
): δ = 190.1 (indole C-2), 162.2 (CH
2
CH
2
N(CH
3
)CHO), 
153.7 (indole C-7a), 144.6 (C(CH
3
)
2
CH=CH
2
), 142.0 (indole C-3a), 134.2 
(N=CCCH
2
CH=C(CH
3
)
2
), 127.8 (indole C-6), 125.6 (indole C-5), 121.2 (indole C-4), 
120.1 (indole C-7), 118.2 (CCH
2
CH=C(CH
3
)
2
), 112.8 (C(CH
3
)
2
CH=CH
2
), 62.8 (indole 
C-3), 43.7 (N=CC(CH
3
)
2
CH=CH
2
), 40.6 (CCH
2
CH
2
N(CH
3
)CHO), 35.2 
(N=CCCH
2
CH=C(CH
3
)
2
), 34.5 (CCH
2
CH
2
N(CH
3
)CHO), 32.8 (CCH
2
CH
2
N(CH
3
)CHO), 
27.8 (N=CC(CH
3
)
2
CH=CH
2
), 27.2 (N=CC(CH
3
)
2
CH=CH
2
), 25.5 
(N=CCCH
2
CH=C(CH
3
)
2
), 18.2 (N=CCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 2968 cm-1 (w), 2925 (w), 2863 (w), 1674 (s), 1540 (w), 1455 (m), 1381 
(m), 1298 (w), 1240 (w), 1118 (w), 1075 (w), 1011 (w), 918 (w), 835 (w), 762 (m), 
739 (w), 685 (w), 586 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 264 nm (3.83), 238 (3.75). 
MS (ESI): m/z (%) = 361 [M+Na]+ (100), 339 [M+H]+ (15). 
HRMS (ESI):   calcd. for C
22
H
31
N
2
O [M+H]+  339.2431, 
found      339.2433. 
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N-(2-(6-Bromo-1-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl) 
ethyl)-N-methylformamide (175)  and N-(2-(6-bromo-3-(3-methylbut-2-enyl)-2-(2-
methylbut-3-en-2-yl)-3H-indol-3-yl)ethyl)-N-methylformamide (176): 
 
To NaH (60% in mineral oil, 574 mg, 14.36 mmol, 5.0 eq.) was added pentane (3 
mL) at rt and stirred for 2 min. Pentane was removed via syringe. The reaction 
mixture was cooled on an ice bath and flustrabromine (1, 1.0 g, 2.87 mmol, 1.0 eq.) 
in DMF (30 mL) was added drop wise and stirred for 2 h at 0 °C. Prenylchloride (1.35 
mL, 11.49 mmol, 4.0 eq.) in DMF (2 mL) was added drop wise to the reaction 
mixture and stirred for 24 h. H
2
O (50 mL) was cautiously added and the reaction 
mixture was extracted with TBME (4 x 150 mL). The combined ethereal layers were 
washed with H
2
O (3 x 150 mL), brine (150 mL), dried over Na
2
SO
4
 and concentrated 
in vacuum. The crude residue was chromatographed over RP-18 silica gel 
(MeOH/H
2
O (5:1)) to obtain the title compounds 175 (488 mg, 1.17 mmol, 41%) and 
176 (592 mg, 1.43 mmol, 50%) as pale yellow oils. 
TLC [RP-18 silica gel, MeOH/H
2
O (10:1)]: R
f 
= 0.26. 
Ratio of rotamers in CDCl
3
: 1:0.9.  
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.00 (s, CCH
2
CH
2
N(CH
3
)CHO), 7.31 (d, 3J = 8.4 Hz, 
1H, indole 4-H), 7.29 (d, 4J = 1.5 Hz, 1 H, indole 7-H), 7.20 (dd, 4J = 1.7 Hz, 3J = 8.3 
Hz, 1H, indole 5-H), 6.16 (dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.11 (d, 3J = 
0.7 Hz, 1H, NCH
2
CH=C(CH
3
)
2
), 5.07 (d, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.96 
(dd, 3J = 17.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.74 (d, 3J = 4.2 Hz, 2H, 
NCH
2
CH=C(CH
3
)
2
), 3.42-3.38 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.20-3.15 (m, 2H, 
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CCH
2
CH
2
N(CH
3
)CHO), 2.96 (s, 3H, CH
2
CH
2
N(CH
3
)CHO), 1.77 (s, 6H, 
NCH
2
CH=C(CH
3
)
2
), 1.59 (s, 6H, NCC(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CH
2
CH
2
N(CH
3
)CHO), 147.3 
(C(CH
3
)
2
CH=CH
2
), 141.3 (indole C-2), 137.9 (indole C-7a), 134.0 
(NCH
2
CH=C(CH
3
)
2
), 127.3 (indole C-3a), 122.4 (indole C-5), 121.2 
(NCH
2
CH=C(CH
3
)
2
), 118.6 (indole C-4), 115.4 (indole C-6), 112.9 (indole C-7), 112.2 
(C(CH
3
)
2
CH=CH
2
), 107.8 (indole C-3), 51.3 (CCH
2
CH
2
N(CH
3
)CHO), 44.3 
(NCH
2
CH=C(CH
3
)
2
), 40.78 (NCC(CH
3
)
2
CH=CH
2
), 30.1 (CCH
2
CH
2
N(CH
3
)CHO), 29.6 
(2C, CC(CH
3
)
2
CH=CH
2
), 25.4 (2C, NCH
2
CH=C(CH
3
)
2
), 25.4 (CCH
2
CH
2
N(CH
3
)CHO). 
Minor Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 8.05 (s, CCH
2
CH
2
N(CH
3
)CHO), 7.50 (d, 3J = 8.4 Hz, 
1H, indole 4-H), 7.27 (d, 4J = 1.6 Hz, 1 H, indole 7-H), 7.19 (dd, 4J = 1.7 Hz, 3J = 8.4 
Hz, 1H, indole 5-H), 6.17 (dd, 3J = 17.5, 10.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.09 (d, 3J = 
0.9 Hz, 1H, NCH
2
CH=C(CH
3
)
2
), 5.085 (d, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.93 
(dd, 3J = 17.5 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.74 (d, 3J = 4.2 Hz, 2H, 
NCH
2
CH=C(CH
3
)
2
), 3.49-3.45 (m, 2H, CCH
2
CH
2
N(CH
3
)CHO), 3.20-3.15 (m, 2H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.93 (s, 3H, CH
2
CH
2
N(CH
3
)CHO), 1.72 (d, 4J = 1.2 Hz, 6H, 
NCH
2
CH=C(CH
3
)
2
), 1.64 (s, 6H, NCC(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 162.4 (CH
2
CH
2
N(CH
3
)CHO), 147.6 
(C(CH
3
)
2
CH=CH
2
), 140.1 (indole C-2), 137.8 (indole C-7a), 133.8 
(NCH
2
CH=C(CH
3
)
2
), 127.7 (indole C-3a), 122.2 (indole C-5), 121.4 
(NCH
2
CH=C(CH
3
)
2
), 119.3 (indole C-4), 115.2 (indole C-6), 112.6 (indole C-7), 112.0 
(C(CH
3
)
2
CH=CH
2
), 108.6 (indole C-3), 46.6 (CCH
2
CH
2
N(CH
3
)CHO), 44.2 
(NCH
2
CH=C(CH
3
)
2
), 40.83 (NCC(CH
3
)
2
CH=CH
2
), 35.1 (CCH
2
CH
2
N(CH
3
)CHO), 29.6 
(2C, CC(CH
3
)
2
CH=CH
2
), 23.1 (CCH
2
CH
2
N(CH
3
)CHO), 18.3 (2C, NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 2971 cm-1 (w), 2927 (w), 2871 (w), 1726 (w), 1672 (s), 1600 (w), 1469 
(m), 1384 (m), 1311 (w), 1244 (m), 1175 (w), 1061 (w), 998 (w), 914 (m), 850 (m), 
802 (m), 597 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 302 nm (3.87), 394 (3.88), 242 (4.37). 
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MS (EI, 70 eV): m/z (%) = 421 (8), 420 (22), 419 (7), 418 (20), 346 (50), 344 (53), 
279 (18), 278 (93), 277 (17), 276 (100), 263 (19), 261 (19), 167 (15), 69 (100). 
GC-HRMS (EI):   calcd. for C
22
H
29
BrN
2
O [M]+  416.1458, 
found      416.1426. 
 
Compound 176 
TLC [RP-18 silica gel, MeOH/H
2
O (5:1)]: R
f 
= 0.23. 
Ratio of rotamers in CDCl
3
: 1:0.8. 
Major Rotamer:  
1H NMR (400 MHz, CDCl
3
): δ = 7.74 (d, 4J = 1.8 Hz, 1H, indole 7-H), 7.70(s, 
CCH
2
CH
2
N(CH
3
)CHO), 7.36 (dd, 4J = 1.8 Hz, 3J = 6.1 Hz, 1H, indole 5-H), 7.01 (d, 
3J = 7.9 Hz, 1 H, indole 4-H), 6.22 (dd, 3J = 17.5, 10.6 Hz, 1H, 
N=CC(CH
3
)
2
CH=CH
2
), 5.27 (dd, 3J = 17.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.21 (dd, 3J 
= 10.6 Hz, 2J = 0.6 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.42-4.36 (m, 1H, 
N=CCCH
2
CH=C(CH
3
)
2
), 2.98-2.91 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.70 (s, 3H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.67 (d, 3J = 4.7 Hz, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.601 (d, 
3J = 7.2 Hz, 1H, CCH
2
CH
2
N(CH
3
)CHO), 2.45-2.36 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 
2.33.2.25 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 2.11-2.03 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 
1.53 (s, 6H, N=CCCH
2
CH=C(CH
3
)
2
,
 
N=CC(CH
3
)
2
CH=CH
2
), 1.51 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.49 (s, 3H, N=CCCH
2
CH=C(CH
3
)
2
. 
13C NMR (100 MHz, CDCl
3
): δ = 192.1 (indole C-2), 162.1 (CH
2
CH
2
N(CH
3
)CHO), 
155.1 (indole C-7a), 144.2 (C(CH
3
)
2
CH=CH
2
), 140.7 (indole C-3a), 135.2 
(N=CCCH
2
CH=C(CH
3
)
2
), 128.6 (indole C-5), 124.0 (indole C-7), 122.1 (indole C-4), 
121.4 (indole C-6), 117.4 (CCH
2
CH=C(CH
3
)
2
), 113.4 (C(CH
3
)
2
CH=CH
2
), 62.6 (indole 
C-3), 44.9 (CCH
2
CH
2
N(CH
3
)CHO), 43.9 (N=CC(CH
3
)
2
CH=CH
2
), 35.3 
(N=CCCH
2
CH=C(CH
3
)
2
), 34.9 (CCH
2
CH
2
N(CH
3
)CHO), 34.6 (CCH
2
CH
2
N(CH
3
)CHO), 
27.9 (N=CC(CH
3
)
2
CH=CH
2
), 27.2 (N=CC(CH
3
)
2
CH=CH
2
), 25.6 
(N=CCCH
2
CH=C(CH
3
)
2
), 18.3 (N=CCCH
2
CH=C(CH
3
)
2
). 
Minor Rotamer:  
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1H NMR (400 MHz, CDCl
3
): δ = 7.89 (s, CCH
2
CH
2
N(CH
3
)CHO), 7.72 (d, 4J = 1.4 Hz, 
1H, indole 7-H), 7.34 (dd, 4J = 1.4 Hz, 3J = 5.8 Hz, 1H, indole 5-H), 7.07 (d, 3J = 7.8 
Hz, 1 H, indole 4-H), 6.31 (dd, 3J = 17.4, 10.6 Hz, 1H, N=CC(CH
3
)
2
CH=CH
2
), 5.27 
(dd, 3J = 17.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.20 (dd, 3J = 10.7 Hz, 2J = 0.8 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 4.42-4.36 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.76-2.73 (m, 1H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.71 (s, 3H, CCH
2
CH
2
N(CH
3
)CHO), 2.64 (d, 3J = 7.2 Hz, 2H, 
N=CCCH
2
CH=C(CH
3
)
2
), 2.45-2.36 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 2.33-2.25 (m, 1H, 
CCH
2
CH
2
N(CH
3
)CHO), 2.11-2.03 (m, 1H, CCH
2
CH
2
N(CH
3
)CHO), 1.58 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.54 (d, 4J = 1.4 Hz, 3H, N=CCCH
2
CH=C(CH
3
)
2
), 1.49 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.47 (s, 3H, N=CCCH
2
CH=C(CH
3
)
2
). 
 13C NMR (100 MHz, CDCl
3
): δ = 192.9 (indole C-2), 162.2 (CH
2
CH
2
N(CH
3
)CHO), 
155.2 (indole C-7a), 144.3 (C(CH
3
)
2
CH=CH
2
), 141.0 (indole C-3a), 134.8 
(N=CCCH
2
CH=C(CH
3
)
2
), 128.4 (indole C-5), 123.7 (indole C-7), 122.4 (indole C-4), 
121.1 (indole C-6), 117.8 (CCH
2
CH=C(CH
3
)
2
), 113.1 (C(CH
3
)
2
CH=CH
2
), 62.9 (indole 
C-3), 43.9 (N=CC(CH
3
)
2
CH=CH
2
), 40.5 (CCH
2
CH
2
N(CH
3
)CHO), 35.1 
(N=CCCH
2
CH=C(CH
3
)
2
), 32.5 (CCH
2
CH
2
N(CH
3
)CHO), 29.6 (CCH
2
CH
2
N(CH
3
)CHO), 
27.7 (N=CC(CH
3
)
2
CH=CH
2
), 26.9 (N=CC(CH
3
)
2
CH=CH
2
), 25.6 
(N=CCCH
2
CH=C(CH
3
)
2
), 18.2 (N=CCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 2969 (w), 2926 (w), 2862 (w), 1672 (s), 1599 (w), 1538 (w), 1453 (m), 
1380 (m), 1250 (w), 1106 (w), 1075 (m), 1009 (w), 919 (m), 894 (w), 873 (w), 817 
(w), 754 (w), 691 (w), 596 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 267 nm (3.79), 240 (4.06).  
MS (EI, 70 eV): m/z (%) = 442 (21), 441 (90), 440 (21), 439 (93), 419 (26), 417 (27), 
351 (10), 349 (11), 257 (26)  
HRMS (EI):    calcd. for C
22
H
30
BrN
2
O [M+H]+  417.1536, 
found      417.1538. 
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2-(6-Bromo-1-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)-N-
methylethanamine (24) 
To a solution of N
a
-prenylflustrabromine (175, 150 mg, 0.36 
mmol, 1.0 eq.) in EtOH (20 mL) was added 32% aq. NaOH (2 
mL) at rt. The reaction mixture was refluxed for 48 h and cooled 
to rt. H
2
O (50 mL) was added and the reaction mixture was 
extracted with Et
2
O (3 x 80 mL), washed with H
2
O (4 x 50 mL), 
brine (50 mL), dried over Na
2
SO
4
 and filtered. The solvent was 
removed under reduced pressure affording the title compound 
24 (128 mg, 0.33 mmol, 92 %) as a slight yellow oil. 
1H NMR (400 MHz, CDCl
3
): δ = 7.43 (d, 3J = 8.4 Hz, 1H, indole 4-H), 7.26 (d, 4J = 2.2 
Hz, 1 H, indole 7-H), 7.16 (dd, 4J = 1.7 Hz, 3J = 8.4 Hz, 1H, indole 5-H), 6.15 (dd, 3J 
= 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.07 (d, 3J = 0.9 Hz, 1H, NCH
2
CH=C(CH
3
)
2
), 
5.03 (d, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.93 (dd, 3J = 17.5 Hz, 2J = 0.8 Hz, 
1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.72 (d, 3J = 5.4 Hz, 2H, NCH
2
CH=C(CH
3
)
2
), 3.14 (t, 3J = 
8.2 Hz, 2H, CCH
2
CH
2
NHCH
3
), 2.79 (t, 3J = 8.2 Hz, 2H, CCH
2
CH
2
NHCH
3
), 2.46 (s, 
3H, CH
2
CH
2
NHCH
3
), 1.76 (d, 4J = 0.9 Hz, 3H, NCH
2
CH=C(CH
3
)
2
), 1.71 (d, 4J = 1.4 
Hz, 3H, NCH
2
CH=C(CH
3
)
2
), 1.60 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 147.7 (C(CH
3
)
2
CH=CH
2
), 140.7 (indole C-2), 137.7 
(indole C-7a), 133.6 (NCH
2
CH=C(CH
3
)
2
), 127.9 (indole C-3a), 121.9 (indole C-5), 
121.6 (NCH
2
CH=C(CH
3
)
2
), 119.4 (indole C-4), 115.0 (indole C-6), 112.5 (indole C-7), 
111.9 (C(CH
3
)
2
CH=CH
2
), 109.8 (indole C-3), 54.2 (CCH
2
CH
2
NHCH
3
), 44.2 
(NCH
2
CH=C(CH
3
)
2
), 40.8 (NCC(CH
3
)
2
CH=CH
2
), 36.5 (CCH
2
CH
2
NHCH
3
)), 29.7 (2C, 
NCC(CH
3
)
2
CH=CH
2
), 25.8 (CCH
2
CH
2
NHCH
3
), 25.4 (NCH
2
CH=C(CH
3
)
2
), 18.3 
(NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3402 cm-1 (w), 3310 (w), 3079 (w), 2969 (m), 2929 (m), 2875 (m), 
2791 (w), 1598 (m), 1469 (s), 1447 (s), 1377 (m), 1311 (m), 1243 (w), 1117 (m), 
1054 (m), 1037 (m), 1008 (m), 912 (s), 838 (m), 799 (s), 779 (m), 686 (w), 628 (w), 
595 (m). 
UV (CH
3
CN): λ
max
 (log ε) = 351 nm (2.32), 300 (3.72), 293 (3.72), 234 (4.37), 191 
(4.47). 
24
N
NH
Br
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MS (EI, 70 eV): m/z (%) = 391 (3), 390 (14), 389 (4), 388 (15), 348 (16), 348 (100), 
346 (29), 345 (94), 344 (16), 279 (75), 278 (88), 277 (78), 276 (82), 264 (25), 262 
(38), 69 (94).  
HRMS (EI):   calcd. for C
21
H
29
BrN
2
 [M]+   388.1509, 
found      388.1504. 
 
6-Bromo-1-methyl-8-(3-methylbut-2-enyl)-3a-(2-methylbut-3-en-2-yl)-1,2,3,3a-
tetrahydropyrrolo[2,3-b]indol-8-ium bromide (25) 
To a solution of N
a
-prenyl-deformylflustrabromine (24, 46 
mg, 0.12 mmol, 1.0 eq.) in THF (10 mL) was added NBS 
(24 mg, 0.13 eq. 1.1 eq.) at 0 °C. The reaction mixture was 
stirred at 0 °C for 12 h and concentrated in vacuum. The 
crude residue was purified by HPLC (RP-silica gel, 
MeOH/H
2
O (5:1)) to afford the title compound 25 (14 mg, 
0.03 mmol, 26%) as a yellow oil. 
1H NMR (400 MHz, D
2
O): δ = 7.29 (dd, 4J = 1.6 Hz, 3J = 8.0 Hz, 1H, 5-H), 7.09 (d, 3J 
= 8.0 Hz, 1H, 4-H), 7.03 (d, 4J = 1.6 Hz, 1H, 7-H), 6.02 (dd, 3J = 17.4, 10.7 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
), 5.23-5.21 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 5.20 (d, 3J = 10.7 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
Z
), 5.14 (d, 3J = 17.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.11-5.051 (m, 
1H, NCH
2
CH=C(CH
3
)
2
), 4.78 (dd, 3J = 5.5 Hz, 2J = 16.9 Hz, 1H, NCH
2
CH=C(CH
3
)
2
), 
4.45-4.38 (m, 1H, =CN(CH
3
)NCH
2
CH
2
C), 4.33 (t, 2J = 10.5, 1H, 
=CN(CH
3
)CH
2
CH
2
C), 3.77 (s, 3H, N+=CN(CH
3
)CH
2
CH
2
C), 2.69-2.61 (m, 1H, 
=CN(CH
3
)CH
2
CH
2
C), 2.55 (dd, 3J = 5.9 Hz, 2J = 13.1 Hz, 1H, =CN(CH
3
)CH
2
CH
2
C), 
1.86 (s, 3H, NCH
2
CH=C(CH
3
)
2
), 1.80 (s, 3H, NCH
2
CH=C(CH
3
)
2
), 1.11 (s, 3H, 
N=CCC(CH
3
)
2
CH=CH
2
), 1.0 (s, 3H, N=CCC(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, D
2
O): δ = 180.0 (C-8a), 149.2 (C-7a), 141.1 (C(CH
3
)
2
CH=CH
2
), 
139.4 (N+CH
2
CH=C(CH
3
)
2
), 130.1 (C-3b), 126.9 (C-5), 125.9 (C-4), 122.9 (C-6), 
116.9 (N+CH
2
CH=C(CH
3
)
2
), 116.2 (C(CH
3
)
2
CH=CH
2
), 114.0 (C-7), 68.8 (C-3a), 65.7 
(C-2), 46.2 (N+=CCC(CH
3
)
2
CH=CH
2
), 44.3 (N+CH
2
CH=C(CH
3
)
2
), 36.8 
(N+=CN(CH
3
)CH
2
CH
2
C), 27.2 (N+=CN(CH
3
)CH
2
CH
2
C), 25.7 (N+CH
2
CH=C(CH
3
)
2
), 
22.7 (C(CH
3
)
2
CH=CH
2
), 21.9 (C(CH
3
)
2
CH=CH
2
), 18.9 (N+CH
2
CH=C(CH
3
)
2
). 
25
N
N
Br
Br
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IR (ATR): ν~ = 3366 cm-1 (w, br), 2969 (m), 2927 (m), 2727 (w), 1693 (s), 1602 (s), 
1414 (s), 1370 (m), 1318 (w), 1150 (w), 1109 (w), 1066 (w), 1012 (w), 921 (w), 839 
(m), 814 (m), 775 (w), 734 (w), 664 (w), 607 (m), 583 (m). 
UV (MeOH): λ
max
 (log ε) = 460 nm (1.67), 286 (3.61), 223 (4.27), 202 (4.34). 
MS (ESI): m/z (%) = 390 (22), 389 (98), 388 (22), 387 (100), 321 (6), 320 (35), 319 
(6), 318 (38), 251(8), 249 (9). 
HRMS (ESI):  calcd. for C
21
H
28
BrN
2
+ [M]+  387.1430, 
found      387.1433. 
 
6-Bromo-1-methyl-8-(3-methylbut-2-en-1-yl)-3a-(2-methylbut-3-en-2-yl)-
1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole, rac-flustramine A (9) 
Indole derivative 25 (13 mg, 0.027 mmol, 1.0 eq.) in MeOH (6 
mL) was added to NaBH
4
 (0.86 mg, 0.22 mmol, 0.8 eq.) under 
Ar, at rt. The reaction mixture was stirred further for 24 h at rt 
and diluted cautiously with H
2
O (10 mL), followed by 2 N NaOH 
(20 mL). The aqueous phase was extracted with TBME (3 x 30 
mL). The combined organic layers were washed with H
2
O (3 x 
30 mL), brine (30 mL), dried over Na
2
SO
4
; filtered, and 
concentrated in vacuum. The residual crude was purified by chromatography (silica 
gel, EtOAc/petrolether (1:8 to 1:2) to obtain the title compound 9 (5.8 mg, 0.015 
mmol, 54%) as a colorless oil. 
TLC [silica gel, EtOAc/petrolether (1:4)]: R
f 
= 0.20. 
1H NMR (400 MHz, CDCl
3
): δ = 6.90 (d, 3J = 7.9 Hz, 1H, 4-H), 6.70 (dd, 4J = 1.8 Hz, 
3J = 7.9 Hz, 1H, 5-H), 6.48 (d, 4J = 1.8 Hz, 1H, 7-H), 5.94 (dd, 3J = 17.4, 10.8 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
), 5.22 (tq, 4J = 1.3 Hz, 3J = 8.7, 5.8 Hz, 1H, NCH
2
CH=C(CH
3
)
2
), 
5.07 (dd, 3J = 10.8 Hz, 2J = 1.3 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 4.99 (dd, 3J = 17.4 Hz, 
2J = 1.4 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.36 (s, 1H, NCHN(CH
3
)CH
2
CH
2
), 3.84 (d, 3J 
= 5.9 Hz, 2H, NCH
2
CH=C(CH
3
)
2
), 2.67 (ddd, 3J = 6.7, 2.3 Hz, 2J = 9.0 Hz, 1H, 
CHN(CH
3
)CH
2
CH
2
C), 2.47-2.38 (m, 1H, CHN(CH
3
)CH
2
CH
2
C), 2.43 (s, 3H, 
CHN(CH
3
)CH
2
CH
2
C), 2.24 (ddd, 3J = 6.7 Hz, 2J = 11.9, 9.9 Hz, 1H, 
9
N
N
Me
Br
H
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CHN(CH
3
)CH
2
CH
2
C), 1.76-1.72 (m, 1H, CHN(CH
3
)CH
2
CH
2
C), 1.73 (s, 6H, 
NCH
2
CH=C(CH
3
)
2
), 1.01 (s, 3H, CHCC(CH
3
)
2
CH=CH
2
), 0.95 (s, 3H, 
CHCC(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 153.5 (C-7a), 144.9 (C(CH
3
)
2
CH=CH
2
), 134.7 
(NCH
2
CH=C(CH
3
)
2
), 132.5 (C-3b), 125.8 (C-4), 121.8 (C-6), 120.9 
(NCH
2
CH=C(CH
3
)
2
), 119.2 (C-5), 113.1 (C(CH
3
)
2
CH=CH
2
), 109.4 (C-7), 89.4 (C-8a), 
63.4 (C-3a), 53.2 (C-2), 45.9 (NCH
2
CH=C(CH
3
)
2
), 41.4 (CHCC(CH
3
)
2
CH=CH
2
), 37.8 
(CHN(CH
3
)CH
2
CH
2
C), 34.5 (C-3), 25.6 (NCH
2
CH=C(CH
3
)
2
), 23.5 (C(CH
3
)
2
CH=CH
2
), 
22.5 (C(CH
3
)
2
CH=CH
2
), 18.1 (NCH
2
CH=C(CH
3
)
2
).  
IR (ATR): ν~ = 3081 cm-1 (w), 2964 (m), 2925 (m), 2853 (m), 2793 (w), 1674 (w), 
1592 (s), 1487 (s), 1445 (m), 1374 (m), 1347 (w), 1314 (m), 1253 (m), 1158 (m), 
1115 (w), 1091 (w), 1064 (w), 1044 (m), 1003 (m), 911 (s), 823 (m), 798 (m), 780 
(m), 692 (w), 639 (w), 607 (w), 578 (w). 
UV (MeOH): λ
max
 (log ε) = 317 nm (3.56), 262 (3.95), 214 (4.39). 
MS (ESI): m/z (%) = 392 (21), 391 (97), 390 (21), 389 (100), 360 (12), 358 (13), 323 
(11), 321 (11), 309 (13), 292 (23), 290 (23), 245 (11), 180(13), 167 (14). 
HRMS (ESI):  calcd. for C
21
H
30
79BrN
2
+ [M+H]+  389.1592,  
found      389.1592. 
 
2-(6-Bromo-3-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-3H-indol-3-yl)-N-
methylethanamine (178) 
To a solution of 3-prenyl-flustrabromine (176, 140 mg, 0.34 
mmol, 1.0 eq.) in EtOH (40 mL) was added 32% aq. NaOH (4 
mL) at rt. The reaction mixture was refluxed for 3 d and 
cooled to rt. H
2
O (100 mL) was added and the reaction 
mixture was extracted with Et
2
O (4 x 100 mL), washed with 
H
2
O (3 x 100 mL), brine (100 mL), dried over Na
2
SO
4
, and 
filtered and concentrated in vacuum. The residue obtained was purified by column 
chromatography (silica gel, CHCl
3
/MeOH/NH
4
OH (9:1:0.1)) to afford the title 
compound 178 (110 mg, 0.28 mmol, 83%) as a slight yellow oil. 
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TLC [silica gel, CHCl
3
/MeOH/NH
4
OH (9:1:0.1)]: R
f 
= 0.63. 
1H NMR (400 MHz, CDCl
3
): δ = 7.70 (d, 4J = 1.7 Hz, 1H, indole 7-H), 7.30 (dd, 4J = 
1.8 Hz, 3J = 7.9 Hz, 1H, indole 5-H), 7.01 (d, 3J = 7.9 Hz, 1 H, indole 4-H), 6.20 (dd, 
3J = 17.5, 10.6 Hz, 1H, N=CC(CH
3
)
2
CH=CH
2
), 5.24 (dd, 3J = 17.4 Hz, 2J = 0.7 Hz, 
1H, C(CH
3
)
2
CH=CH
2
-H
E
), 5.16 (dd, 3J = 10.6 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-
H
Z
), 4.43-4.39 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.62 (dd, 3J = 6.6 Hz, 2J = 15.0 Hz, 
2H, N=CCCH
2
CH=C(CH
3
)
2
), 2.31 (ddd, 3J = 10.0, 4.0 Hz, 2J = 14.4 Hz, 1H, 
CCH
2
CH
2
NHCH
3
), 2.24 (s, 3H, CCH
2
CH
2
NHCH
3
), 2.13 (dd, 3J = 4.7 Hz, 2J = 11.5 
Hz, 1H, CCH
2
CH
2
NHCH
3
), 2.09-2.01 (m, 1H, CCH
2
CH
2
NHCH
3
), 1.84-1.77 (m, 1H, 
CCH
2
CH
2
NHCH
3
), 1.52 (d, 4J = 0.8 Hz, 3H, N=CCCH
2
CH=C(CH
3
)
2
), 1.51 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.48 (s, 6H, N=CCCH
2
CH=C(CH
3
)
2
,
 
=CC(CH
3
)
2
CH=CH
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 193.2 (indole C-2), 155.2 (indole C-7a), 144.4 
(C(CH
3
)
2
CH=CH
2
), 141.7 (indole C-3a), 134.5 (N=CCCH
2
CH=C(CH
3
)
2
), 128.1 
(indole C-5), 123.5 (indole C-7), 122.5 (indole C-4), 120.8 (indole C-6), 118.1 
(CCH
2
CH=C(CH
3
)
2
), 112.8 (C(CH
3
)
2
CH=CH
2
), 63.2 (indole C-3), 47.0 
(CCH
2
CH
2
NHCH
3
), 43.8 (N=CC(CH
3
)
2
CH=CH
2
), 36.2 (CCH
2
CH
2
NHCH
3
)), 35.9 
(CCH
2
CH
2
NHCH
3
), 35.3 (N=CCCH
2
CH=C(CH
3
)
2
), 27.7 (N=CC(CH
3
)
2
CH=CH
2
), 27.0 
(N=CC(CH
3
)
2
CH=CH
2
), 25.6 (N=CCCH
2
CH=C(CH
3
)
2
), 18.2 
(N=CCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3411 cm-1 (w), 3309 (w), 3080 (w), 2964 (s), 2928 (s), 2876 (m), 2789 
(w), 1710 (w), 1598 (s), 1538 (m), 1477 (s), 1451 (s), 1413 (m), 1376 (m), 1320 (w), 
1242 (w), 1218 (w), 1165 (w), 1119 (m), 1036 (s), 1012 (m), 913 (s), 897 (s), 873 
(w), 838 (w), 812 (m), 797 (m), 726 (w), 689 (w), 661 (w), 597 (m), 539 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 239 nm (4.00). 
MS (EI, 70 eV): m/z (%) = 391 (2), 390 (8), 389 (3), 388 (8), 322 (10), 321 (68), 320 
(18), 319 (100), 317 (23), 279 (15), 278 (52), 277 (18), 276 (55), 252 (39), 250 (43), 
69 (40), 44 (87). 
HRMS (EI):   calcd. for C
21
H
29
BrN
2
 [M]+   388.1509, 
found      388.1497. 
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N-Methyl-2-(1-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-1H-indol-3-
yl)ethanamine (26) 
To a solution of N
a
-prenyl-debromoflustrabromine (27, 790 mg, 2.35 
mmol, 1.0 eq.) in EtOH (30 mL) was added 32% aq. NaOH (9 mL) at 
rt. The reaction mixture was refluxed for 60 h and cooled to rt. H
2
O 
(50 mL) was added and the reaction mixture was extracted with 
EtOAc (4 x 150 mL). The combined organic layers were washed 
with H
2
O (3 x 150 mL), brine (150 mL), dried over Na
2
SO
4
 and 
filtered. The solvent was removed under reduced pressure affording 
the title compound 26 (728 mg, 2.19 mmol, 93 %) as a dark red oil with the smell of 
mint. 
1H NMR (400 MHz, CDCl
3
): δ = 7.59 (d, 3J = 7.8 Hz, 1H, indole 4-H), 7.17-7.12 (m, 
2H, indole 6-H, indole 7-H), 7.08 (ddd, 4J = 2.4 Hz, 3J = 5.7, 7.9 Hz, 1H, indole 5-H), 
6.18 (dd, 3J = 17.5, 10.5 Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.15-5.11 (m, 1H, 
NCH
2
CH=C(CH
3
)
2
), 5.06 (dd, 3J = 10.6 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.95 (dd, 3J = 17.5 Hz, 2J = 0.9 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.77 (d, 3J = 5.5 Hz, 
2H, NCH
2
CH=C(CH
3
)
2
), 3.19 (t, 3J = 7.8 Hz, 2H, CCH
2
CH
2
NHCH
3
), 2.84 (t, 3J = 7.7 
Hz, 2H, CCH
2
CH
2
NHCH
3
), 2.48 (s, 3H, CCH
2
CH
2
NHCH
3
), 1.87 (s, br, 1H, 
CCH
2
CH
2
NHCH
3
), 1.77 (s, 3H, NCH
2
CH=C(CH
3
)
2
), 1.69 (d, 4J = 1.3 Hz, 3H, 
NCH
2
CH=C(CH
3
)
2
), 1.62 (s, 6H, C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 148.1 (C(CH
3
)
2
CH=CH
2
), 140.0 (indole C-2), 136.9 
(indole C-7a), 132.9 (NCH
2
CH=C(CH
3
)
2
), 129.0 (indole C-3a), 122.2 
(NCH
2
CH=C(CH
3
)
2
), 121.3 (indole C-7), 118.8 (indole C-5), 118.2 (indole C-4), 111.6 
(C(CH
3
)
2
CH=CH
2
), 109.6 (indole C-6), 109.5 (indole C-3), 54.2 (CCH
2
CH
2
NHCH
3
), 
44.1 (NCH
2
CH=C(CH
3
)
2
), 40.8 (NCC(CH
3
)
2
CH=CH
2
), 36.4 (CCH
2
CH
2
NHCH
3
)), 29.9 
(2C, NCC(CH
3
)
2
CH=CH
2
), 25.9 (CCH
2
CH
2
NHCH
3
), 25.4 (NCH
2
CH=C(CH
3
)
2
), 18.3 
(NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3049 cm-1 (w), 2969 (w), 2928 (w), 2873 (w), 2790 (w), 1632 (w), 1469 
(m), 1447 (m), 1378 (w), 1350 (w), 1327 (w), 1309 (m), 1258 (w), 1178 (w), 1113 (w), 
1018 (w), 997 (w), 912 (m), 837 (w), 738 (s), 709 (m), 597 (w), 532 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 290 nm (3.83), 240 (4.11), 231 (3.70). 
26
N
NH
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MS (EI, 70 eV): m/z (%) = 310 (3), 268 (18), 267 (84), 266 (23), 252 (5), 200 (5), 199 
(43), 198 (100), 196 (11), 185 (5), 184 (34), 183 (33), 182 (26), 181 (8), 180 (9), 169 
(6), 168 (16), 167 (19), 154 (5), 130 (5), 69 (37).  
GC-HRMS (EI):  calcd. for C
21
H
30
N
2
 [M]+   310.2409, 
found      310.2421. 
 
N-Methyl-2-(3-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-3H-indol-3-
yl)ethanamine (177) 
To a solution of 3-prenyl-debromo-flustrabromine (174, 590 mg, 
1.74 mmol, 1.0 eq.) in EtOH (30 mL) was added 32% aq. NaOH 
(7 mL) at rt. The reaction mixture was refluxed for 60 h and 
cooled to rt. H
2
O (50 mL) was added and the reaction mixture 
was extracted with EtOAc (4 x 100 mL). The combined organic 
layers were washed with H
2
O (3 x 100 mL), brine (100 mL), dried 
over Na
2
SO
4
 and filtered. The solvent was removed under reduced pressure 
affording the title compound 177 (463 mg, 1.49 mmol, 86 %) as a dark red oil with 
smell of mint. 
TLC [silica gel, CHCl
3
/MeOH/NH
4
OH (9:1:0.1)]: R
f 
= 0.38. 
1H NMR (400 MHz, CDCl
3
): δ = 7.49 (d, 3J = 7.7 Hz, 1H, indole 7-H), 7.24-7.20 (m, 
1H, indole 6-H), 7.12-7.06 (m, 2H, indole 4-H, indole 5-H), 6.16 (dd, 3J = 17.5, 10.6 
Hz, 1H, N=CC(CH
3
)
2
CH=CH
2
), 5.16 (dd, 3J = 17.5 Hz, 2J = 0.9 Hz, 1H, 
C(CH
3
)
2
CH=CH
2
-H
E
), 5.08 (dd, 3J = 10.6 Hz, 2J = 1.0 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.35-4.31 (m, 1H, N=CCCH
2
CH=C(CH
3
)
2
), 2.61 (dd, 3J = 6.2 Hz, 2J = 15.0 Hz, 1H, 
N=CCCH
2
CH=C(CH
3
)
2
), 2.52 (dd, 3J = 7.1 Hz, 2J = 15.0 Hz, 1H, 
N=CCCH
2
CH=C(CH
3
)
2
), 2.27-2.19 (m, 1H, CCH
2
CH
2
NHCH
3
), 2.14 (s, 3H, 
CCH
2
CH
2
NHCH
3
), 2.08-2.01 (m, 1H, CCH
2
CH
2
NHCH
3
), 1.96 (dt, 3J = 4.0 Hz, 2J = 
11.0 Hz, 1H, CCH
2
CH
2
NHCH
3
), 1.74-1.67 (m, 1H, CCH
2
CH
2
NHCH
3
), 1.46 (s, 3H, 
N=CC(CH
3
)
2
CH=CH
2
), 1.43 (d, 4J = 1.1 Hz, 3H, N=CC(CH
3
)
2
CH=CH
2
), 1.42 (s, 3H, 
N=CCCH
2
CH=C(CH
3
)
2
), 1.42 (s, 3H, N=CCCH
2
CH=C(CH
3
)
2
).
 
 
177
N
NH
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13C NMR (100 MHz, CDCl
3
): δ = 191.3 (indole C-2), 153.8 (indole C-7a), 144.8 
(C(CH
3
)
2
CH=CH
2
), 142.7 (indole C-3a), 133.9 (N=CCCH
2
CH=C(CH
3
)
2
), 127.5 
(indole C-6), 125.3 (indole C-5), 121.3 (indole C-4), 120.0 (indole C-7), 118.5 
(CCH
2
CH=C(CH
3
)
2
), 112.3 (C(CH
3
)
2
CH=CH
2
), 63.2 (indole C-3), 47.2 
(CCH
2
CH
2
NHCH
3
), 43.6 (N=CC(CH
3
)
2
CH=CH
2
), 36.3 (CCH
2
CH
2
NHCH
3
)), 36.3 
(CCH
2
CH
2
NHCH
3
), 35.4 (N=CCCH
2
CH=C(CH
3
)
2
), 27.7 (N=CC(CH
3
)
2
CH=CH
2
), 27.0 
(N=CCCH
2
CH=C(CH
3
)
2
), 25.5 (N=CC(CH
3
)
2
CH=CH
2
), 18.2 
(N=CCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3305 cm-1 (w), 3079 (w), 2966 (m), 2927 (m), 2875 (m), 2790 (w), 
1634 (w), 1607 (w), 1541 (m), 1455 (s), 1413 (w), 1376 (m), 1320 (w), 1240 (w), 
1218 (w), 1112 (m), 1034 (m), 1012 (m), 914 (m), 838 (w), 759 (s), 740 (s), 684 (w), 
624 (w), 590 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 263 nm (3.82), 239 (3.74). 
MS (EI, 70 eV): m/z (%) = 310 (4), 266 (13), 253 (8), 252 (15), 242 (12), 241 (62), 
240 (8), 239 (28), 310 (11), 199 (24), 198 (100), 197 (5), 196 (15), 194 (5), 185 (14), 
184 (37), 183 (28), 182 (32), 181 (8), 180 (12), 173 (8), 172 (22), 171 (9), 170 (10), 
169 (9), 168 (22), 167 (19), 156 (5), 154 (7), 130 (8), 115 (6), 69 (22), 44 (39). 
GC-HRMS (EI):  calcd. for C
21
H
30
N
2
 [M]+   310.2409, 
found      310.2398. [deviation?]  
 
N-Methyl-2-(1-(3-methylbut-2-enyl)-1H-indol-3-yl)ethanamine (192a) 
To a solution of N
a
-prenyl-N
b
-formyl-N
b
-methyltryptamine (146, 1.43 
g, 5.29 mmol, 1.0 eq.) in EtOH (120 mL) was added 32% aq. NaOH 
(25 mL) at rt. The reaction mixture was refluxed for 48 h and cooled 
to rt and concentrated to volume of 40 mL. H
2
O (150 mL) was added 
and the reaction mixture was extracted with EtOAc (3 x 100 mL), 
washed with H
2
O (4 x 100 mL), brine (100 mL), dried over Na
2
SO
4
, 
and filtered. The solvent was removed under reduced pressure 
affording the title compound 192a (1.20 g, 4.96 mmol, 94 %) as a orange oil. 
192a
N
NH
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1H NMR (400 MHz, CDCl
3
): δ = 7.61 (d, 3J = 7.9 Hz, 1H, indole 4-H), 7.29 (d, 3J = 8.2 
Hz, 1H, indole 7-H), 7.19 (ddd, 4J = 1.1 Hz, 3J = 8.1, 7.1 Hz, 1H, indole 6-H), 7.09 
(ddd, 4J = 0.9 Hz, 3J = 7.8, 7.0 Hz, 1H, indole 5-H), 6.93 (s, 1H, indole 2-H), 5.40-
5.32 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 4.64 (d, 3J = 6.9 Hz, 2H, NCH
2
CH=C(Me)
2
), 3.01-
2.85 (m, 4H, CCH
2
CH
2
NHCH
3
), 2.43 (s, 3H, CCH
2
CH
2
NHCH
3
), 1.81 (s, 3H, 
NCH
2
CH=C(CH
3
)
2
), 1.81 (s, 1H, CCH
2
CH
2
NHCH
3
), 1.75 (d, 4J = 0.9 Hz, 3H, 
NCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 136.4 (indole C-7a), 136.0 (NCH
2
CH=C(CH
3
)
2
), 
128.1 (indole C-3a), 125.3 (indole C-2), 121.4 (indole C-6), 120.1 
(NCH
2
CH=C(CH
3
)
2
), 119.0 (indole C-4), 118.7 indole C-5), 112.4 (indole C-3), 109.5 
(indole C-7), 52.1 (CCH
2
CH
2
NHCH
3
), 43.9 (NCH
2
CH=C(CH
3
)
2
), 36.3 
(CCH
2
CH
2
NHCH
3
), 25.62 (NCH
2
CH=C(CH
3
)
2
), 25.55 (CCH
2
CH
2
NHCH
3
), 18.0 
(NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3317 cm-1 (w), 3051 (w), 2968 (w), 2913 (w), 2848 (w), 2791 (w), 1468 
(m), 1443 (m), 1374 (w), 1332 (w), 1311 (w), 1172 (w), 1109 (w), 1013 (w), 846 (w), 
734 (s). 
UV (CHCl
3
): λ
max
 (log ε) = 293 nm (3.73), 240 (3.98), 232 (3.68).  
MS (EI, 70 eV): m/z (%) = 242 (4), 200 (12), 199 (84), 198 (10), 132 (5), 131 (54), 
130 (100), 129 (12), 102 (8), 77 (5), 69 (22), 44 (30). 
HRMS (EI):  calcd. for C
16
H
22
N
2
 [M]+    242.1778, 
found       242.1716. 
3-(2-(Methylamino)ethyl)-1-(3-methylbut-2-enyl)-1H-indolium 2,2,2-trifluoroace-
tate (192b) 
To a solution of N
a
-prenyl-N
b
-methyltryptamine (192a, 300 
mg, 1.24 mmol, 1.0 eq.) in DCM (20 mL) was added TFA 
(0.46 mL, 6.19 mmol, 5.0 eq.) at rt over 5 min. The reaction 
mixture was stirred at rt for 1 h diluted with DCM (100 mL). 
The organic layer was washed with H
2
O (3 x 100 mL), brine 
(100 mL), dried over Na
2
SO
4
, and filtered. The solvent was 
removed under reduced pressure and the residue obtained 192b
N
NH
CF
3
CO
2
H
Experimental Section  159 
 
was purified by column chromatography (silica gel, CHCl3/MeOH (5:1)) to obtain the 
title compound 192b (46 mg, 0.24 mmol, 19%) as an orange oil. 
TLC [silica gel, CHCl
3
/MeOH (5:1)]: R
f 
= 0.48. 
1H NMR (400 MHz, CDCl
3
): δ = 7.55 (dd, 4J = 0.9 Hz, 3J = 7.9 Hz, 1H, indole 4-H), 
7.28 (d, 3J = 8.2 Hz, 1H, indole 7-H), 7.19 (ddd, 4J = 1.1 Hz, 3J = 8.2, 7.0 Hz, 1H, 
indole 6-H), 7.12 (s, br, 1H, CHCNH+CH), 7.09 (ddd, 4J = 1.0 Hz, 3J = 8.0, 7.0 Hz, 
1H, indole 5-H), 6.95 (s, 1H, indole 2-H), 5.30-5.35 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 4.61 
(d, 3J = 6.9 Hz, 2H, NCH
2
CH=C(Me)
2
), 3.11 (s, 4H, CCH
2
CH
2
NHCH
3
), 2.56 (s, 3H, 
CCH
2
CH
2
NHCH
3
), 1.80 (d, 4J = 0.5 Hz, 3H, NCH
2
CH=C(CH
3
)
2
), 1.75 (d, 4J = 1.1 Hz, 
3H, NCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 136.4 (indole C-7a), 136.3 (NCH
2
CH=C(CH
3
)
2
), 
127.6 (indole C-3a), 125.7 (indole C-2), 121.7 (indole C-6), 119.8 
(NCH
2
CH=C(CH
3
)
2
), 119.1 (indole C-5), 118.6 indole C-4), 109.7 (indole C-7), 109.5 
(indole C-3), 50.6 (CCH
2
CH
2
NHCH
3
), 44.0 (NCH
2
CH=C(CH
3
)
2
), 36.9 
(CCH
2
CH
2
NHCH
3
), 25.6 (NCH
2
CH=C(CH
3
)
2
), 23.1 (CCH
2
CH
2
NHCH
3
), 18.0 
(NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3050 cm-1 (w), 2970 (w), 2916 (w), 2858 (w), 2482 (w), 1673 (s), 1466 
(m), 1378 (w), 1334 (w), 1199 (s), 1173 (s), 1128 (s), 1014 (w), 831 (m), 798 (m), 
739 (s), 720 (s). 
UV (CHCl
3
): λ
max
 (log ε) = 290 nm (3.62), 240 (3.76).  
MS (EI, 70 eV): m/z (%) = 242 (4), 240 (4), 200 (10), 199 (64), 198 (10), 143 (5), 132 
(5), 131 (49), 130 (100), 129 (7), 102 (5), 69 (20): 
HRMS (ESI):  calcd. for C
16
H
23
N
2
 [M]+    243.1856, 
found       243.1857. 
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N-Methyl-2-(1-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-1H-indol-3-
yl)ethanaminium 2,2,2-trifluoroacetate (193) 
To a solution of N
a
-prenyl-debromodeformylflustrabromine 
(26, 98 mg, 0.32 mmol, 1.0 eq.) in toluene (6 mL) was 
added TFA (18 mg, 0.15 mmol, 1 eq.) at rt. The reaction 
mixture and a magnet stir bar were sealed in the reaction 
vessel of an MLS START 1500 microwave synthesizer and 
irradiated at 150 °C for 1 h. To the cooled reaction mixture, 
EtOAc (200 mL) was added. The reaction mixture was 
washed with H
2
O (4 x 100 mL), dried over Na
2
SO
4
, filtered, and concentrated in 
vacuum. The residual oil was purified by column chromatography (silica gel, 
CHCl
3
/MeOH (9:1 to 4:1)) to obtain the title compound 193 (90 mg, 0.21 mmol, 67%) 
as a red oil. 
TLC [silica gel, CHCl
3
/MeOH (9:1)]: R
f 
= 0.38. 
1H NMR (400 MHz, CDCl
3
): δ = 7.66 (d, 3J = 7.7 Hz, 1H, indole 4-H), 7.17-7.11 (m, 
2H, indole 6-H, indole 7-H), 7.11-7.07 (m, 1H, indole 5-H), 6.17 (dd, 3J = 17.5, 10.5 
Hz, 1H, C(CH
3
)
2
CH=CH
2
), 5.15 (s, br, 2H, CCH
2
CH
2
NH
2
+CH
3
), 5.13-5.10 (m, 1H, 
NCH
2
CH=C(CH
3
)
2
), 5.06 (dd, 3J = 10.6 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
Z
), 
4.94 (dd, 3J = 17.5 Hz, 2J = 0.8 Hz, 1H, C(CH
3
)
2
CH=CH
2
-H
E
), 4.77 (d, 3J = 5.4 Hz, 
2H, NCH
2
CH=C(CH
3
)
2
), 3.39-3.35 (m, 2H, CCH
2
CH
2
NH
2
+CH
3
), 2.97-2.93 (m, 2H, 
CCH
2
CH
2
NH
2
+CH
3
), 2.58 (s, 3H, CCH
2
CH
2
NH
2
+CH
3
), 1.77 (s, 3H, 
NCH
2
CH=C(CH
3
)
2
), 1.69 (d, 4J = 1.2 Hz, 3H, NCH
2
CH=C(CH
3
)
2
), 1.61 (s, 6H, 
C(CH
3
)
2
CH=CH
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 147.8 (C(CH
3
)
2
CH=CH
2
), 140.3 (indole C-2), 136.9 
(indole C-7a), 133.1 (NCH
2
CH=C(CH
3
)
2
), 128.7 (indole C-3a), 122.1 
(NCH
2
CH=C(CH
3
)
2
), 121.5 (indole C-7), 119.1 (indole C-5), 118.1 (indole C-4), 111.8 
(C(CH
3
)
2
CH=CH
2
), 109.6 (indole C-6), 108.1 (indole C-3), 52.8 (CCH
2
CH
2
NH
2
+CH
3
), 
44.1 (NCH
2
CH=C(CH
3
)
2
), 40.8 (NCC(CH
3
)
2
CH=CH
2
), 35.0 (CCH
2
CH
2
NH
2
+CH
3
), 
29.8 (2C, NCC(CH
3
)
2
CH=CH
2
), 25.4 (NCH
2
CH=C(CH
3
)
2
), 24.6 (CCH
2
CH
2
NH
2
+CH
3
), 
18.2 (NCH
2
CH=C(CH
3
)
2
). 
CF
3
CO
2
193
N
NH
2
Experimental Section  161 
 
IR (ATR): ν~ = 2969 cm-1 (w), 2926 (m), 2868 (w), 2784 (w), 2698 (w), 2468 (w), 2439 
(w), 1632 (w), 1582 (w), 1470 (s), 1379 (w), 1351 (m), 1329 (w), 1308 (m), 1183 (w), 
1115 (w), 1019 (w), 997 (w), 910 (m), 836 (w), 740 (s), 710 (m), 580 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 290 nm (3.95), 240 (4.18), 231 (3.78). 
MS (EI, 70 eV): m/z (%) = 312 (23), 311 (100), 281 (12), 280 (58), 212 (12).  
HRMS (ESI):  calcd. for C
21
H
31
N
2
 [M+H]+  311.2482, 
found      311.2484. 
 
2-(2-(1-(3-Methylbut-2-enyl)-1H-indol-3-yl)ethyl)isoindoline-1,3-dione (208): 
To NaH (60% in mineral oil, 433 mg, 10.82 mmol, 1.5 eq.) was 
added pentane (2 mL) at rt and stirred for 2 min. Pentane was 
removed via syringe. The reaction mixture was cooled on an ice 
bath and phthaloyltryptamine (165, 2.0 g, 7.21 mmol, 1.0 eq.) in 
DMF (25 mL) was added within 2 min and stirred for 1 h at 0 °C. 
To the red colored reaction mixture, prenylbromide (1.32 mL, 
10.82 mmol, 1.5 eq.) in DMF (2 mL) was added drop wise. The 
reaction mixture was allowed to warm to rt and stirred at rt for 24 
h. H
2
O (50 mL) was cautiously added and the reaction mixture was extracted with 
TBME (4 x 100 mL). The combined etherial layers were washed with H
2
O (3 x 100 
mL), brine (100 mL), dried over Na
2
SO
4
, and concentrated in vacuum. The residue 
obtained was purified by column chromatography (silica gel, EtOAc/petrolether (1:4 
to 1:1)) to obtain the title compound 208 (2.32 g, 6.48 mmol, 90%) as a yellow solid. 
TLC [silica gel, EtOAc/petrolether (1:4)]: R
f 
= 0.48. 
Mp: 132-134 °C. 
1H NMR (400 MHz, CDCl
3
): δ = 7.86-7.81 (m, 2H, N(C(=O)CCHCH)
2
), 7.73 (d, 3J = 
7.8 Hz, 1H, indole 4-H), 7.70-7.67 (m, 2H, N(C(=O)CCHCH)
2
), 7.29 (d, 3J = 8.2 Hz, 
1H, indole 7-H), 7.23-7.15 (m, 1H, indole 6-H), 7.11 (ddd, 3J = 7.3, 7.1 Hz, 4J = 1.0 
Hz, 1H, indole 5-H), 6.99 (s, 1H, indole 2-H), 5.38-5.29 (m, 1H, NCH
2
CH=C(CH
3
)
2
), 
4.63 (d, 3J = 6.9 Hz, 2H, NCH
2
CH=C(CH
3
)
2
), 4.02-3.94 (m, 2H, 
N
N
O
O
208
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CCH
2
CH
2
N(phthaloyl)), 3.16-3.08 (m, 2H, CCH
2
CH
2
N(phthaloyl), 1.80 (s, 3H, 
NCH
2
CH=C(CH
3
)
2
), 1.75 (d, 4J = 1.0 Hz, 3H, NCH
2
CH=C(CH
3
)
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 168.3 (2C, N(C(=O)CCHCH)
2
), 136.3 (indole C-7a), 
136.2 (NCH
2
CH=C(CH
3
)
2
) 133.8 (2C, N(C(=O)CCHCH)
2
), 132.3 (2C, 
N(C(=O)CCHCH)
2
), 128.0 (indole C-3a), 125.4 (indole C-2), 123.1 (2C, 
N(C(=O)CCHCH)
2
), 121.5 (indole C-6), 120.0 (NCH
2
CH=C(CH
3
)
2
), 119.0 (indole C-
4), 118.9 (indole C-5), 110.8 (indole C-3), 109.4 (indole C-7), 43.9 
(NCH
2
CH=C(CH
3
)
2
), 38.7 (CCH
2
CH
2
N(phthaloyl)), 25.6 (NCH
2
CH=C(CH
3
)
2
), 24.5 
(CCH
2
CH
2
N(phthaloyl)), 18.0 (NCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~ = 3056 cm-1 (w), 2996 (w), 2941 (w), 2912 (w), 2859 (w), 1766 (w), 1700 
(s), 1611 (w), 1468 (m), 1433 (m), 1397 (s), 1356 (s), 1334 (m), 1272 (w), 1241 (w), 
1220 (w), 1171 (m), 1125 (w), 1083 (s), 1011 (m), 992 (w), 949 (w), 869 (w), 840 (w), 
820 (w), 800 (w), 730 (s), 715 (s), 689 (m), 642 (w), 606 (w), 574 (w).  
UV (CH
3
CN): λ
max
 (log ε) = 292 nm (3.85), 241 (4.24). 
MS (EI, 70 eV): m/z (%) = 359 [M+H]+ (7), 358 [M]+ (24), 199 (7), 198 (48), 161 (8), 
160 (63), 143 (12), 133 (14), 131 (12), 130 (100), 129 (30), 128 (7), 115 (8), 105 
(11), 104 (14), 103 (8), 102 (16), 69 (25).  
GC-HRMS (EI):  calcd. for C
23
H
22
N
2
O
2
 [M]+  358.1676, 
found      358.1691. 
 
2-(2-(2-(3-Methylbut-2-enyl)-1H-indol-3-yl)ethyl)isoindoline-1,3-dione (29): 
To a solution of Nb-phthaloyltryptamine (165, 7.0 g, 25.24 mmol, 
1.0 eq.) and Et
3
N (4.55 mL, 32.82 mmol, 1.3 eq.) in DCM (200 
mL) was added tert-BuOCl (137, 3.71 mL, 32.82 mmol, 1.3 eq.) 
at –78 °C over 10 min and stirred at –78 °C for 45 min. Tri(n-
butyl)prenylstannane137 (203, 32.42 mL, 96.48 mmol, 3.82 eq.) 
was added, followed by rapid addition of BCl
3
 (1.0 M in DCM, 
60.60 mL, 60.60 mmol, 2.4 eq.) within 3 min. The reaction 
                                            
137.  Y. Naruta, Y- Nishigaichi, K. Maruyama, Chem. Lett.1986, 11,1857–1860. 
N
H
N
O
O
29
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mixture was stirred at –78 °C for 1 h, poured into sat. NaHCO
3
 (200 mL) to quench 
and stirred at rt for 10 min. Both layers were filtered through celite-545 and 
separated. The aqueous layer is extracted with DCM (3 x 100 mL). To the combined 
organic layers, sat. KF (200 mL) was added and stirred at rt for 30 min and both 
layers were filtered through celite-545. The separated organic phase was washed 
with sat. KF (1 x 100 mL), dried over Na
2
SO
4
, filtered, and concentrated in vacuum. 
The residue was purified by column chromatography (silica gel + KF (10%, w/w), 
EtOAc/petrolether (1:4 to 1:1)) to afford the title compound 29 (2.4 g, 6.70 mmol, 
27%) as a slightly orange solid. 
TLC [silica gel, EtOAc/petrolether (1:4)]: R
f 
= 0.32. 
1H NMR (400 MHz, CDCl
3
): δ = 7.85 (s, br, 1H, CHCNHCCH
2
), 7.83-7.81 (m, 2H, 
N(C(=O)CCHCH)
2
), 7.70-7.66 (m, 3H, N(C(=O)CCHCH)
2
,
 
indole 4-H), 7.26-7.24 (m, 
1H, indole 7-H), 7.11-7.04 (m, 2H, indole 5-H, indole 6-H), 5.31-5.25 (m, 1H, 
NHCCH
2
CH=C(CH
3
)
2
), 3.91-3.87 (m, 2H, CCH
2
CH
2
N(phthaloyl)), 3.49 (d, 3J = 7.3 
Hz, 2H, NHCCH
2
CH=C(CH
3
)
2
), 3.09-3.05 (m, 2H, CCH
2
CH
2
N(phthaloyl), 1.75 (s, 
6H, NHCCH
2
CH=C(CH
3
)
2
).  
13C NMR (100 MHz, CDCl
3
): δ = 168.3 (2C, N(C(=O)CCHCH)
2
), 135.1 (2C, indole C-
2, indole C-7a), 134.7 (NHCCH
2
CH=C(CH
3
)
2
) 133.8 (2C, N(C(=O)CCHCH)
2
), 132.2 
(2C, N(C(=O)CCHCH)
2
), 128.6 (indole C-3a), 123.1 (2C, N(C(=O)CCHCH)
2
), 121.1 
(indole C-6), 120.2 (NHCCH
2
CH=C(CH
3
)
2
), 119.4 (indole C-5), 118.1 (indole C-4), 
110.3 (indole C-7), 107.2 (indole C-3), 38.4 (NHCCH
2
CH=C(CH
3
)
2
), 25.0 
(CCH
2
CH
2
N(phthaloyl)), 25.7 (NHCCH
2
CH=C(CH
3
)
2
), 23.4 (CCH
2
CH
2
N(phthaloyl)), 
17.8 (NHCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~  = 3385 cm-1 (w), 3057 (w), 2972 (w), 2932 (w), 2863 (w), 1769 (w), 
1701 (s), 1613 (w), 1463 (m), 1441 (m), 1395 (s), 1359 (m), 1187 (w), 1120 (w), 
1099 (w), 1021 (m), 965 (w), 865 (w), 743 (m), 715 (s).  
 UV (CHCl
3
): λ
max
 (log ε) = 352 nm (2.80), 284 (3.85), 241 (4.19), 234 (3.83).  
MS (EI, 70 eV): m/z (%) = 359 [M+H]+ (8), 358 [M]+ (27), 199 (17), 198 (100), 195 
(8), 184 (8), 183 (10), 182 (12), 169 (7), 168 (13), 167 (7), 160 (6), 156 (10), 155 (6), 
143 (10), 130 (10), 77 (5).  
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GC-HRMS (EI):  calcd. for C
23
H
22
N
2
O
2
 [M]+  358.1676, 
found      358.1654. 
 
2-(2-(3-Methylbut-2-enyl)-1H-indol-3-yl)ethanamine (213): 
To a solution of 2-prenyl-phthaloyltryptamine (29, 1.20 g, 3.35 
mmol, 1.0 eq.) in EtOH (110 mL) was added hydrazine 
monohydrate (1.9 mL, 40.17 mmol, 12.0 eq.) at rt. The reaction 
mixture was refluxed for 24 h . After cooling to rt, the reaction 
mixture was diluted with isopropanol/CHCl
3
 (2:1, 400 mL) and 
washed with H
2
O (1 x 200 mL), dried over Na
2
SO
4
, filtered, and concentrated in 
vacuum. The crude reaction mixture was purified by column chromatography (silica 
gel, CHCl
3
/MeOH/NH
4
OH (7:1:0 to 4:1:0.1)) to afford the title compound 213 (623 
mg, 2.73 mmol, 82%) as a yellow oil. 
TLC [silica gel, CHCl
3
/MeOH/NH
4
OH (4:1:0.1)]: R
f 
= 0.64. 
1H NMR (400 MHz, CDCl
3
): δ = 7.99 (s, br, 1H, CHCNHCCH
2
), 7.55 (d, 3J = 7.3 Hz, 
1H, indole 4-H), 7.23 (dd, 4J = 0.9 Hz, 3J = 6.8 Hz, 1H, indole 7-H), 7.07 (dt, 4J = 1.4 
Hz, 3J = 7.5 Hz, 1H, indole 6-H), 7.03 (dt, 4J = 1.3 Hz, 3J = 7.4 Hz, 1H, indole 5-H), 
5.29-5.25 (m, 1H, NHCCH
2
CH=C(CH
3
)
2
), 4.29 (s, br, 2H, CCH
2
CH
2
NH
2
), 3.45 (d, 3J 
= 7.2 Hz, 2H, NHCCH
2
CH=C(CH
3
)
2
), 3.01-2.93 (m, 4H, CCH
2
CH
2
NH
2
), 3.49 (d, 3J = 
7.3 Hz, 2H, 1.74 (s, 3H, NHCCH
2
CH=C(CH
3
)
2
), 1.72 (s, 3H, NHCCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 135.4 (indole C-2), 135.2 (indole C-7a), 134.6 
(NHCCH
2
CH=C(CH
3
)
2
) 128.6 (indole C-3a), 121.0 (indole C-6), 120.2 
(NHCCH
2
CH=C(CH
3
)
2
), 119.2 (indole C-5), 118.0 (indole C-4), 110.4 (indole C-7), 
107.0 (indole C-3), 41.6 (CCH
2
CH
2
NH
2
), 25.9 (NHCCH
2
CH=C(CH
3
)
2
), 25.7 
(NHCCH
2
CH=C(CH
3
)
2
), 25.0 (CCH
2
CH
2
NH
2
), 17.9 (NHCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~  = 3397 cm-1 (w), 3294 (w), 3054 (w), 2967 (m), 2916 (m), 2856 (m), 
1585 (m), 1460 (m), 1375 (w), 1341 (w), 1306 (w), 1241 (w), 1099 (m), 1011 (w), 920 
(w), 741 (s), 619 (w). 
UV (CHCl
3
): λ
max
 (log ε) = 282 nm (3.65), 240 (3.76). 
213
N
H
NH
2
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MS (EI, 70 eV): m/z (%) = 229 [M+H]+ (4), 228 [M]+ (24), 212 (5), 211 (31), 199 (33), 
198 (100), 197 (8), 196 (23), 194 (5), 184 (14), 183 (24), 182 (30), 181 (13), 180 
(12), 170 (7), 169 (19), 168 (30), 167 (23), 157 (6), 156 (22), 155 (13), 154 (11), 144 
(13), 143 (22), 142 (6), 131 (6), 130 (24), 129 (8), 128 (7), 115 (9), 77(8).  
GC-HRMS (EI):  calcd. for C
15
H
20
N
2
 [M]+   228.1621, 
found      228.1625. 
 
N-(2-(2-(3-Methylbut-2-enyl)-1H-indol-3-yl)ethyl)formamide (30): 
A mixture of Ac
2
O (0.21 mL, 2.17 mmol, 5.0 eq.) and HCO
2
H 
(0.08 mL, 2.17 mmol, 5.0 eq.) was stirred at 60 °C for 1 h. After 
cooling to rt, a solution of 2-prenyltryptamine (213, 99 mg, 0.43 
mmol, 1.0 eq.) in DCM (10 mL) was added drop wise. The 
reaction mixture was stirred at rt for 2 h. Upon completion, the 
reaction mixture was added to aqueous NaOH (12 M, 10 mL) and 
ice (15 g). The alkaline mixture was diluted with DCM (50 mL) and the aqueous layer 
was extracted with DCM (3 x 50 mL). The combined organic layers were washed 
with HCl (2 M, 2 x 30 mL), H
2
O (3 x 50 mL), dried over Na
2
SO
4
, filtered, and 
concentrated in vacuum to afford compound 30 (108 mg, 0.42 mmol, 97%) as an oil.  
Ratio of rotamers in CDCl
3
: 1:0.2. 
TLC [silica gel, CHCl
3
/MeOH (8:1)]: R
f 
= 0.66. 
Major Rotamer: 
1H NMR (400 MHz, CDCl
3
): δ = 8.06 (d, 4J = 1.3 Hz, 1H, CCH
2
CH
2
NHCHO), 7.99 (s, 
br, 1H, CHCNHCCH
2
), 7.50 (d, 3J = 7.7 Hz, 1H, indole 4-H), 7.30-7.27 (m, 1H, indole 
7-H), 7.15-7.11 (m, 1H, indole 6-H), 7.10-7.06 (m, 1H, indole 5-H), 5.60 (s, br, 1H, 
CCH
2
CH
2
NHCHO), 5.31-5.26 (m, 1H, NHCCH
2
CH=C(CH
3
)
2
), 3.56 (q, 3J = 6.4 Hz, 
2H, CCH
2
CH
2
NHCHO), 3.45 (d, 3J = 6.7 Hz, 2H, NHCCH
2
CH=C(CH
3
)
2
), 2.95 (t, 3J = 
6.7 Hz, 2H, CCH
2
CH
2
NHCHO), 1.77 (s, 3H, NHCCH
2
CH=C(CH
3
)
2
), 1.76 (s, 3H, 
NHCCH
2
CH=C(CH
3
)
2
). 
30
N
H
HN
O
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13C NMR (100 MHz, CDCl
3
): δ = 161.1 (CH
2
NHCHO), 135.4 (indole C-2), 135.2 
(indole C-7a), 134.8 (NHCCH
2
CH=C(CH
3
)
2
) 128.6 (indole C-3a), 121.3 (indole C-6), 
120.2 (NHCCH
2
CH=C(CH
3
)
2
), 119.5 (indole C-5), 117.9 (indole C-4), 110.7 (indole 
C-7), 107.4 (indole C-3), 38.5 (CCH
2
CH
2
NHCHO), 25.7 (NHCCH
2
CH=C(CH
3
)
2
), 25.1 
(NHCCH
2
CH=C(CH
3
)
2
), 23.9 (CCH
2
CH
2
NHCHO), 17.9 (NHCCH
2
CH=C(CH
3
)
2
). 
Minor Rotamer: 
1H NMR (400 MHz, CDCl
3
): δ = 7.84 (s, 1H, CHCNHCCH
2
), 7.81 (s, 1H, 
CCH
2
CH
2
NHCHO), 7.46 (d, 3J = 7.7 Hz, 1H, indole 4-H), 7.30-7.27 (m, 1H, indole 7-
H), 7.15-7.11 (m, 1H, indole 6-H), 7.10-7.06 (m, 1H, indole 5-H), 5.60 (s, br, 1H, 
CCH
2
CH
2
NHCHO), 5.31-5.26 (m, 1H, NHCCH
2
CH=C(CH
3
)
2
), 3.45 (d, 3J = 6.7 Hz, 
2H, NHCCH
2
CH=C(CH
3
)
2
), 3.43-3.39 (m, 2H, CCH
2
CH
2
NHCHO), 2.90 (t, 3J = 6.6 
Hz, 2H, CCH
2
CH
2
NHCHO), 1.77 (s, 3H, NHCCH
2
CH=C(CH
3
)
2
), 1.76 (s, 3H, 
NHCCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 164.4 (CH
2
NHCHO), 135.5 (indole C-2), 135.0 
(indole C-7a), 134.8 (NHCCH
2
CH=C(CH
3
)
2
) 128.6 (indole C-3a), 121.4 (indole C-6), 
120.0 (NHCCH
2
CH=C(CH
3
)
2
), 119.5 (indole C-5), 117.6 (indole C-4), 110.5 (indole 
C-7), 107.4 (indole C-3), 42.1 (CCH
2
CH
2
NHCHO), 26.3 (CCH
2
CH
2
NHCHO), 25.7 
(NHCCH
2
CH=C(CH
3
)
2
), 25.1 (NHCCH
2
CH=C(CH
3
)
2
), 17.9 (NHCCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~  = 3284 cm-1 (w, br), 3057 (w), 2971 (w), 2928 (w), 2860 (w), 1657 (s, 
br), 1519 (w), 1455 (m), 1381 (m), 1307 (w), 1239 (w), 743 (s). 
UV (CH
2
Cl
2
): λ
max
 (log ε) = 283 nm (3.68), 271 (3.67), 230 (4.19). 
MS (EI, 70 eV): m/z (%) = 257 [M+H]+ (5), 256 [M]+ (28), 211 (17), 199 (17), 198 
(100), 196 (18), 184 (11), 183 (17), 182 (19), 181 (9), 180 (8), 169 (14), 168 (28), 
167 (16), 156 (18), 155 (9), 154 (8), 144 (7), 143 (18), 130 (17), 115 (7), 77(5). 
GC-HRMS (EI):  calcd. for C
16
H
20
N
2
O [M]+   256.1576, 
found      256.1597. 
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2-(2-(1,2-Bis(3-methylbut-2-enyl)-1H-indol-3-yl)ethyl)isoindoline-1,3-dione 
(214): 
To NaH (60% in mineral oil, 84 mg, 2.09 mmol, 1.5 eq.) was 
added pentane (1 mL) at rt and it was stirred for 2 min. Pentane 
was removed via syringe. The reaction mixture was cooled on an 
ice bath and 2-prenyl-phthaloyltryptamine (29, 500 mg, 1.39 
mmol, 1.0 eq.) in DMF (25 mL) was added drop wise and stirred 
for 1 h at 0 °C. To the reaction mixture, prenylbromide (0.25 mL, 
2.09 mmol, 1.5 eq.) in DMF (2 mL) was added drop wise. The 
reaction mixture was allowed to warm to rt and stirred at rt for 48 
h. H
2
O (20 mL) was cautiously added and the reaction mixture 
was extracted with Et
2
O (3 x 100 mL). The combined etherial layers were washed 
with H
2
O (3 x 100 mL), brine (100 mL), dried over Na
2
SO
4
, and concentrated in 
vacuum. The residue obtained was purified by column chromatography (silica gel, 
EtOAc/petrolether (1:5 to 1:1)) to obtain the title compound 214 (188 mg, 0.44 mmol, 
32%) as a yellow solid. 
TLC [silica gel, EtOAc/petrolether (1:4)]: R
f 
= 0.52. 
1H NMR (400 MHz, CDCl
3
): δ = 7.84 (dd, 3J = 5.5, 3.0 Hz, 2H, N(C(=O)CCHCH)
2
), 
7.72-7.69 (m, 3H, N(C(=O)CCHCH)
2
,
 
indole 4-H), 7.21 (dd, 4J = 1.0 Hz, 3J = 7.2 Hz, 
1H, indole 7-H), 7.15-7.06 (m, 2H, indole 5-H, indole 6-H), 5.13-5.07 (m, 2H, 
NCH
2
CH=C(CH
3
)
2
,
 
CCH
2
CH=C(CH
3
)
2
), 4.64 (d, 3J = 6.1 Hz, 2H, NCH
2
CH=C(CH
3
)
2
), 
3.89-3.85 (m, 2H, CCH
2
CH
2
N(phthaloyl)), 3.51 (d, 3J = 6.5 Hz, 2H, 
CCH
2
CH=C(CH
3
)
2
), 3.10-3.06 (m, 2H, CCH
2
CH
2
N(phthaloyl), 1.81 (d, 4J = 0.8 Hz, 
3H, NCH
2
CH=C(CH
3
)
2
), 1.79 (d, 4J = 0.8 Hz, 3H, CCH
2
CH=C(CH
3
)
2
), 1.68 (d, 4J = 
1.2 Hz, 3H, NCH
2
CH=C(CH
3
)
2
), 1.67 (d, 4J = 1.3 Hz, 3H, CCH
2
CH=C(CH
3
)
2
). 
13C NMR (100 MHz, CDCl
3
): δ = 168.3 (2C, N(C(=O)CCHCH)
2
), 136.8 (indole C-2), 
136.0 (indole C-7a), 132.7 (NCH
2
CH=C(CH
3
)
2
), 132.3 (CCH
2
CH=C(CH
3
)
2
), 133.8 
(2C, N(C(=O)CCHCH)
2
), 133.7 (2C, N(C(=O)CCHCH)
2
), 127.9 (indole C-3a), 123.1 
(2C, N(C(=O)CCHCH)
2
), 120.8 (indole C-6), 121.5 (NCH
2
CH=C(CH
3
)
2
), 121.3 
(CCH
2
CH=C(CH
3
)
2
), 119.0 (indole C-5), 118.2 (indole C-4), 109.1 (indole C-7), 107.2 
(indole C-3), 41.6 (NCH
2
CH=C(CH
3
)
2
), 38.7 (CCH
2
CH
2
N(phthaloyl)), 23.88 
214
N
N
O
O
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(CCH
2
CH=C(CH
3
)
2
), 23.86 (CCH
2
CH
2
N(phthaloyl)), 25.6 (CCH
2
CH=C(CH
3
)
2
), 25.5 
(NCH
2
CH=C(CH
3
)
2
), 18.1 (NCH
2
CH=C(CH
3
)
2
), 18.0 (CCH
2
CH=C(CH
3
)
2
). 
IR (ATR): ν~  = 3385 cm-1 (w), 3055 (w), 3028 (w), 2973 (w), 2931 (w), 2913 (w), 
2858 (w), 1765 (w), 1705 (s), 1613 (w), 1463 (m), 1444 (m), 1393 (s), 1365 (s), 1351 
(s), 1284 (w), 1263 (w), 1188 (w), 1169 (w), 1122 (w), 1101 (m), 1017 (s), 920 (w), 
862 (w), 799 (w), 719 (s), 687 (w), 587 (w), 555 (w).  
UV (CHCl
3
): λ
max
 (log ε) = 287 nm (3.97), 241 (4.34), 231 (3.88). 
MS (ESI): m/z (%) = 875 [2M+Na]+ (29), 450 (30), 449 [M+Na]+ (100), 427 [M+H]+ 
(34), 359 (5), 257 (5), 256 (29).  
HRMS (ESI):  calcd. for C
28
H
30
N
2
O
2
 [M+Na]+  449.2199, 
found      449.2194. 
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5 Crystallographic data 
5.1 Crystallographic data of 1 
 
 
 
Identification code: wobrom; Empirical formula: C
17
H
21
BrN
2
O; M
r
 = 349.27; 
Temperature: 100(2) K; Wavelength (λ) = 0.71073 Å; Crystal system: Orthorhombic; 
Space group: P
bca
; a = 14.2247(10) Å, α = 90°, b = 10.8444(5) Å, β = 90°, c = 
21.2757(9) Å, γ = 90°, Volume: 3282.0(3) Å3 ; Z: 8; ρ
calc
: 1.414 Mg/m3; Absorption 
coefficient (µ) = 2.506 mm-1; F(000): 1440; Crystal size: 0.40 x 0.25 x 0.15 mm3; 
Theta range for data collection: 2.39 to 26.37°; Index ranges: -17<=h<=17, -
13<=k<=13, 26<=l<=26; Reflections collected: 28293; Independent reflections: 3350 
[R(int) = 0.0462] ; Final R indices [I>2 σ (I)]: R1 = 0.0455, wR2 = 0.1185; R indices 
(all data): R1 = 0.0771, wR2 = 0.1248; Largest diff. peak and hole:1.130 and -1.010 
e.Å-3; 
 
Table 1. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
N(1) 6132(2) 9628(3) 2855.6(13) 20.2(7) 
C(2) 5861(2) 8622(3) 3212.3(14) 19.0(8) 
C(3) 5917(2) 7583(3) 2849.8(14) 18.7(7) 
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C(3A) 6229(2) 7958(3) 2239.7(14) 18.4(7) 
C(4) 6428(2) 7349(3) 1674.8(15) 26.5(8) 
C(5) 6737(3) 8009(3) 1156.9(16) 31.7(9) 
C(6) 6826(3) 9291(3) 1202.7(15) 27.4(9) 
C(7) 6648(2) 9943(3) 1740.9(15) 21.9(8) 
C(7A) 6351(2) 9255(3) 2259.1(14) 17.5(7) 
N(2) 6315(2) 4196(2) 3259.0(13) 25.9(7) 
O 6303.7(19) 2188(2) 2959.0(12) 41.4(7) 
Br 7214.2(4) 10156.1(4) 465.2(2) 47.1(2) 
C(1') 5681(2) 6271(3) 3017.5(15) 21.7(8) 
C(2') 6548(2) 5471(3) 3108.4(17) 26.5(9) 
C(3') 6465(3) 3277(3) 2858.3(18) 32.2(9) 
C(4') 5885(3) 3929(4) 3873.0(16) 46.3(12) 
C(1") 5527(3) 8797(3) 3885.1(16) 31.2(9) 
C(2") 5878(7) 7801(6) 4298(3)  36.1(18) 
C(3") 5350(6) 7084(6) 4651(3)  64(3) 
C(4") 5788(13) 10050(8) 4147(8)  39(4) 
C(5") 4421(4) 8706(7) 3851(4)  38.2(18) 
C(2'') 6229(11) 8100(15) 4305(8)  41(5) 
C(3'') 6964(9) 7614(13) 4278(6)  52(5) 
C(4'') 5660(20) 10152(14) 4075(18)  28(7) 
C(5'') 4567(11) 8380(20) 4065(11)  90(9) 
 
Table 2. Bond lengths [Å]  
Atoms Distance Atoms Distance 
N(1)-C(7A)  1.368(4) 
N(1)-C(2)  1.383(4) 
C(2)-C(3)  1.368(4) 
C(2)-C(1")  1.520(4) 
C(3)-C(3A)  1.431(4) 
C(3)-C(1')  1.505(4) 
C(3A)-C(4)  1.401(4) 
C(3A)-C(7A)  1.418(4) 
C(4)-C(5)  1.386(5) 
C(5)-C(6)  1.400(5) 
C(6)-C(7)  1.369(4) 
C(6)-Br  1.910(3) 
C(7)-C(7A)  1.396(4) 
N(2)-C(3')  1.328(4) 
N(2)-C(2')  1.457(4) 
N(2)-C(4')  1.471(4) 
O-C(3')  1.222(4) 
C(1')-C(2')  1.521(5) 
C(1")-C(2")  1.479(6) 
C(1")-C(4")  1.515(8) 
C(1")-C(5")  1.579(7) 
C(2")-C(3")  1.316(9) 
 
Table 3. Bond angles [°] 
Atoms Angle Atoms Angle 
C(7A)-N(1)-C(2) 109.9(3) 
C(3)-C(2)-N(1) 108.9(3) 
C(3)-C(2)-C(1") 130.7(3) 
N(1)-C(2)-C(1") 120.4(3) 
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C(2)-C(3)-C(3A) 107.2(3) 
C(2)-C(3)-C(1') 129.2(3) 
C(3A)-C(3)-C(1') 123.6(3) 
C(4)-C(3A)-C(7A) 117.9(3) 
C(4)-C(3A)-C(3) 135.0(3) 
C(7A)-C(3A)-C(3) 107.1(3) 
C(5)-C(4)-C(3A) 120.2(3) 
C(4)-C(5)-C(6) 119.1(3) 
C(7)-C(6)-C(5) 123.7(3) 
C(7)-C(6)-Br 119.1(3) 
C(5)-C(6)-Br 117.2(3) 
C(6)-C(7)-C(7A) 116.1(3) 
N(1)-C(7A)-C(7) 130.1(3) 
N(1)-C(7A)-C(3A) 107.0(3) 
C(7)-C(7A)-C(3A) 122.9(3) 
C(3')-N(2)-C(2') 122.2(3) 
C(3')-N(2)-C(4') 119.3(3) 
C(2')-N(2)-C(4') 118.5(3) 
C(3)-C(1')-C(2') 112.8(3) 
N(2)-C(2')-C(1') 112.6(3) 
O-C(3')-N(2) 125.6(4) 
C(2")-C(1")-C(4") 110.8(7) 
C(2")-C(1")-C(2) 111.3(4) 
C(4")-C(1")-C(2) 112.4(7) 
C(2")-C(1")-C(5") 108.6(5) 
C(4")-C(1")-C(5") 108.5(7) 
C(2)-C(1")-C(5") 105.1(4) 
C(3")-C(2")-C(1") 125.3(8) 
 
Table 4. Hydrogen bonds [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(01)...O#1 0.74(3) 2.09(3) 2.796(4) 159(3) 
 
 
5.2 Crystallographic data of 13 
 
 
 
Identification code: lada; Empirical formula: C
18
H
25
BrCl
2
N
2
; M
r 
= 420.21; 
Temperature: 100(2) K; Wavelength (λ) = 0.71073 Å; Crystal system: Triclinic; Space 
group: P(-1); a = 7.7560(3) Å, α = 73.847(4)°, b = 10.4033(4) Å, = 78.274(4)°, c = 
12.9292(6) Å, γ = 72.065(4)°, Volume: 945.43(7) Å
3; Z: 2; ρ
calc
: 1.476 Mg/m
3; 
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Absorption coefficient (µ) = 2.458 mm-1; F(000): 432; Crystal size: 0.30 x 0.20 x 0.15 
mm3; Theta range for data collection: 2.36 to 30.03°; Index ranges: -10<=h<=10, -
14<=k<=14, -17<=l<=18; Reflections collected: 58212; Independent reflections: 5457 
[R(int) = 0.0300]; Final R indices [I>2sigma(I)]: R1 = 0.0207, wR2 = 0.0511; R indices 
(all data): R1 = 0.0263, wR2 = 0.0516; Largest diff. peak and hole: 0.675 and -0.601 
e.Å-3; 
Table 1. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
N(1) 3556.3(14) 3790.6(10) 3098.4(8) 12.9(2) 
C(2) 5067.3(16) 3706.1(13) 2179.3(10) 14.1(2) 
C(3) 5631.9(16) 2166.3(13) 2133.2(10) 13.4(2) 
C(3A) 3884.0(15) 1682.4(12) 2634.8(9) 10.9(2) 
C(3B) 3920.3(16) 307.5(12) 3450.4(10) 11.9(2) 
C(4) 4746.7(16) -1062.3(13) 3409.5(10) 14.7(2) 
C(5) 4330.3(17) -2113.2(13) 4280.1(11) 17.0(3) 
C(6) 3101.0(17) -1799.6(13) 5176.5(10) 16.6(3) 
C(7) 2279.4(16) -420.7(13) 5243.1(10) 14.7(2) 
C(7A) 2715.0(16) 602.3(12) 4375.4(10) 11.8(2) 
N(8) 2097.4(13) 2066.9(10) 4288.0(8) 11.6(2) 
C(8A) 3022.2(15) 2655.4(12) 3385.2(9) 11.0(2) 
C(9) 2613.4(16) 1891.6(13) 1733.3(10) 12.5(2) 
C(10) 2181.1(16) 3377.5(13) 1071.0(10) 15.3(2) 
C(11) 2573.3(18) 3804.4(15) 7.5(11) 21.4(3) 
C(12) 3584.9(17) 851.0(14) 1025.0(10) 17.1(3) 
C(13) 755.0(17) 1613.9(14) 2265.1(10) 16.8(3) 
C(14) 3005.7(18) 4957.4(13) 3625.9(11) 17.6(3) 
C(15) 967.6(17) 2681.5(13) 5175.8(10) 15.2(2) 
Br 8194.0(2) 5221.4(1) 3119.4(1) 15.6(1) 
C(99) 10217.1(19) 7658.7(15) 1026.5(12) 22.5(3) 
Cl(1) 12604.8(5) 7327.4(4) 968.4(3) 32.7(1) 
Cl(2) 9037.7(5) 9212.2(4) 1440.8(3) 33.6(1) 
 
Table 2. Bond lengths [Å]  
Atoms Distance Atoms Distance 
N(1)-C(8A)  1.3035(15) 
N(1)-C(14)  1.4642(15) 
N(1)-C(2)  1.4906(15) 
C(2)-C(3)  1.5402(17) 
C(3)-C(3A)  1.5469(16) 
C(3A)-C(8A)  1.5096(16) 
C(3A)-C(3B)  1.5187(16) 
C(3A)-C(9)  1.6034(16) 
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C(3B)-C(4)  1.3820(16) 
C(3B)-C(7A)  1.4041(16) 
C(4)-C(5)  1.3971(18) 
C(5)-C(6)  1.3887(18) 
C(6)-C(7)  1.3982(18) 
C(7)-C(7A)  1.3814(17) 
C(7A)-N(8)  1.4285(15) 
N(8)-C(8A)  1.3358(15) 
N(8)-C(15)  1.4659(14) 
C(9)-C(10)  1.5154(17) 
C(9)-C(12)  1.5320(16) 
C(9)-C(13)  1.5418(17) 
C(10)-C(11)  1.3243(18) 
C(99)-Cl(2)  1.7628(14) 
C(99)-Cl(1)  1.7660(14) 
 
Table 3. Bond angles [°] 
Atoms Angle Atoms Angle 
C(8A)-N(1)-C(14) 128.64(10) 
C(8A)-N(1)-C(2) 110.10(10) 
C(14)-N(1)-C(2) 120.89(10) 
N(1)-C(2)-C(3) 103.76(9) 
C(2)-C(3)-C(3A) 103.80(9) 
C(8A)-C(3A)-C(3B) 99.22(9) 
C(8A)-C(3A)-C(3) 99.82(9) 
C(3B)-C(3A)-C(3) 122.60(10) 
C(8A)-C(3A)-C(9) 112.07(9) 
C(3B)-C(3A)-C(9) 109.74(9) 
C(3)-C(3A)-C(9) 111.92(9) 
C(4)-C(3B)-C(7A) 119.03(11) 
C(4)-C(3B)-C(3A) 133.54(11) 
C(7A)-C(3B)-C(3A) 107.22(10) 
C(3B)-C(4)-C(5) 119.05(12) 
C(6)-C(5)-C(4) 121.02(12) 
C(5)-C(6)-C(7) 120.78(12) 
C(7A)-C(7)-C(6) 117.25(12) 
C(7)-C(7A)-C(3B) 122.84(11) 
C(7)-C(7A)-N(8) 126.74(11) 
C(3B)-C(7A)-N(8) 110.38(10) 
C(8A)-N(8)-C(7A) 106.77(9) 
C(8A)-N(8)-C(15) 129.21(10) 
C(7A)-N(8)-C(15) 122.78(10) 
N(1)-C(8A)-N(8) 133.25(11) 
N(1)-C(8A)-C(3A) 113.71(10) 
N(8)-C(8A)-C(3A) 112.08(10) 
C(10)-C(9)-C(12) 112.18(10) 
C(10)-C(9)-C(13) 105.90(10) 
C(12)-C(9)-C(13) 108.50(10) 
C(10)-C(9)-C(3A) 111.01(10) 
C(12)-C(9)-C(3A) 108.24(9) 
C(13)-C(9)-C(3A) 111.01(9) 
C(11)-C(10)-C(9) 126.89(12) 
Cl(2)-C(99)-Cl(1) 111.52(8) 
 
Table 4. Hydrogen bonds [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 C(2)-H(2A)...Br 0.99 2.85 3.8029(12) 162.5 
 C(5)-H(5)...Br#1 0.95 3.01 3.7803(13) 139.7 
 C(6)-H(6)...Br#2 0.95 3.03 3.9337(13) 159.1 
 C(13)-H(13A)...Br#3 0.98 3.11 4.0093(13) 152.5 
 C(14)-H(14A)...Br#3 0.98 3.07 3.8332(13) 136.2 
 C(15)-H(15A)...Br#4 0.98 3.07 3.7647(13) 129.4 
 C(15)-H(15C)...Br#3 0.98 2.93 3.6870(13) 135.3 
 C(99)-H(99B)...Br 0.99 2.65 3.6222(14) 167.2 
 C(2)-H(2B)...Cl(1)#3 0.99 3.00 3.7140(13) 130.3 
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 C(3)-H(3B)...Cl(1)#5 0.99 2.96 3.9074(13) 160.3 
 C(4)-H(4)...Cl(2)#1 0.95 2.99 3.7913(13) 142.6 
 
 
 
5.3 Crystallographic data of 20 
 
 
 
 
Identification code: larder; Empirical formula: C
18
H
25
DBrCl
3
N
2
; M
r
 = 457.68; 
Temperature: 100(2) K; Wavelength (λ) = 0.71073 Å; Crystal system: Monoclinic; 
Space group: P2
1/n
; a = 9.2879(3) Å; α = 90°, b = 22.6454(6) Å, β = 105.571(4)°, c = 
10.3652(3) Å; γ = 90°, Volume: 2100.08(11) Å3; Z: 4; ρ
calc
: 1.444 Mg/m3; Absorption 
coefficient (µ) = 2.342 mm-1; F(000): 936; Crystal size: 0.4 x 0.2 x 0.1 mm3; Theta 
range for data collection 2.23 to 28.28°; Index ranges: -12<=h<=12, -30<=k<=30, -
13<=l<=13; Reflections collected: 68893; Independent reflections: 5197 [R(int) = 
0.0566]; Final R indices [I>2sigma(I)] R1 = 0.0280, wR2 = 0.0613 R indices (all data): 
R1 = 0.0436, wR2 = 0.0627; Largest diff. peak and hole: 0.735 and -0.469 e.Å-3; 
Table 1. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
N(1) 6962.5(18) 2245.2(7) 4956.4(17) 11.6(4) 
C(2) 7362(2) 2677.8(8) 5937.2(19) 11.0(4) 
C(3) 7472(2) 2423.7(8) 7163.2(18) 10.5(4) 
C(3A) 7134(2) 1803.2(8) 6930.6(19) 10.5(4) 
C(4) 7055(2) 1323.4(9) 7759(2) 14.7(4) 
C(5) 6750(2) 771.0(9) 7191(2) 16.1(4) 
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C(6) 6513(2) 682.9(9) 5809(2) 16.8(4) 
C(7) 6555(2) 1149.4(8) 4961(2) 13.1(4) 
C(7A) 6847(2) 1708.4(8) 5532.7(19) 10.9(4) 
N(2) 6805.3(18) 3166.2(7) 10286.8(16) 11.9(4) 
C(1') 7860(2) 2694.4(8) 8541.2(19) 11.6(4) 
C(2') 6495(2) 2969.6(8) 8854.4(19) 13.6(4) 
C(3') 5404(2) 3359.2(9) 10600(2) 19.4(5) 
C(4') 7973(2) 3634.6(9) 10653(2) 18.8(5) 
C(1") 7460(2) 3312.5(8) 5485.9(19) 12.7(4) 
C(2") 8292(2) 3690.0(8) 6647.4(19) 14.7(4) 
C(3") 7766(2) 4150.5(9) 7152(2) 20.3(5) 
C(4") 5867(2) 3532.7(9) 4844(2) 19.2(5) 
C(5") 8373(2) 3344.1(9) 4440.8(19) 17.8(5) 
Br 7474.1(2) 1945.3(1) 1896.7(2) 17.1(1) 
C(99) 7948(2) 370.2(9) 2057(2) 20.0(5) 
Cl(1) 8323.3(8) 250.8(3) 517.2(6) 36.9(2) 
Cl(2) 6296.1(7) 16.1(3) 2141.1(7) 40.4(2) 
Cl(3) 9447.6(8) 120.3(3) 3361.3(6) 46.4(2) 
 
Table 2. Bond lengths [Å]  
Atoms Distance Atoms Distance 
N(1)-C(7A)  1.371(2) 
N(1)-C(2)  1.389(2) 
C(2)-C(3)  1.374(3) 
C(2)-C(1")  1.522(3) 
C(3)-C(3A)  1.446(3) 
C(3)-C(1')  1.506(3) 
C(3A)-C(4)  1.399(3) 
C(3A)-C(7A)  1.418(3) 
C(4)-C(5)  1.379(3) 
C(5)-C(6)  1.404(3) 
C(6)-C(7)  1.381(3) 
C(7)-C(7A)  1.393(3) 
N(2)-C(3')  1.489(2) 
N(2)-C(4')  1.491(2) 
N(2)-C(2')  1.502(2) 
C(1')-C(2')  1.523(3) 
C(1")-C(2")  1.509(3) 
C(1")-C(4")  1.534(3) 
C(1")-C(5")  1.546(3) 
C(2")-C(3")  1.318(3) 
C(99)-Cl(1)  1.744(2) 
C(99)-Cl(3)  1.754(2) 
C(99)-Cl(2)  1.754(2) 
 
Table 3. Bond angles [°] 
Atoms Angle Atoms Angle 
C(7A)-N(1)-C(2) 110.07(16) 
C(3)-C(2)-N(1) 108.71(16) 
C(3)-C(2)-C(1") 133.18(17) 
N(1)-C(2)-C(1") 117.87(16) 
C(2)-C(3)-C(3A) 107.09(16) 
C(2)-C(3)-C(1') 130.26(18) 
C(3A)-C(3)-C(1') 122.65(16) 
C(4)-C(3A)-C(7A) 118.90(17) 
C(4)-C(3A)-C(3) 134.22(18) 
C(7A)-C(3A)-C(3) 106.88(16) 
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C(5)-C(4)-C(3A) 118.76(18) 
C(4)-C(5)-C(6) 121.50(18) 
C(7)-C(6)-C(5) 121.11(18) 
C(6)-C(7)-C(7A) 117.41(18) 
N(1)-C(7A)-C(7) 130.50(17) 
N(1)-C(7A)-C(3A) 107.21(16) 
C(7)-C(7A)-C(3A) 122.27(17) 
C(3')-N(2)-C(4') 110.75(15) 
C(3')-N(2)-C(2') 110.84(15) 
C(4')-N(2)-C(2') 113.31(15) 
C(3)-C(1')-C(2') 111.57(16) 
N(2)-C(2')-C(1') 112.47(15) 
C(2")-C(1")-C(2) 110.48(16) 
C(2")-C(1")-C(4") 112.94(16) 
C(2)-C(1")-C(4") 108.05(16) 
C(2")-C(1")-C(5") 105.85(15) 
C(2)-C(1")-C(5") 110.40(15) 
C(4")-C(1")-C(5") 109.12(16) 
C(3")-C(2")-C(1") 126.84(19) 
Cl(1)-C(99)-Cl(3) 110.07(12) 
Cl(1)-C(99)-Cl(2) 111.51(12) 
Cl(3)-C(99)-Cl(2) 109.79(11) 
 
Table 4. Hydrogen bonds [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(01)...Br 0.806(16) 2.653(17) 3.3991(17) 154.7(17) 
N(2)-H(02)...Br#1 0.855(17) 2.360(17) 3.2027(17) 169.0(19) 
C(99)-H(99)...Br 1.00 2.61 3.593(2) 167.1 
C(2')-H(2'2)...Br#2 0.99 3.16 3.7463(19) 119.4 
C(5")-H(5"1)...Br#3 0.98 3.09 4.027(2) 159.8 
C(5")-H(5"3)...Br 0.98 3.15 4.062(2) 155.2 
 
 
5.4 Crystallographic data of 208 
 
 
 
Identification code:  sachin; Empirical formula : C
23
H
22
N
2
O
2
; M
r 
= 358.43; 
Temperature: 100(2) K; Wavelength (λ) = 0.71073 Å; Crystal system: Monoclinic; 
Space group:  P2
1/n
; a = 4.99523(13) Å; α = 90°, b = 22.8077(6) Å, β = 
92.333(3)°, c = 16.2552(5) Å; γ = 90°, Volume: 1850.42(9) Å3; Z: 4; ρ
calc
 : 1.287 
Crystallographic data  177 
 
Mg/m3; Absorption coefficient (µ) = 0.083 mm-1; F(000): 760; Crystal size: 0.4 x 0.15 
x 0.15 mm3; Theta range for data collection: 2.51 to 30.03°; Index ranges: -7<=h<=7, 
-31<=k<=31, -22<=l<=22; Reflections collected: 67554; Independent reflections: 
5354 [R(int) = 0.0306]; Final R indices [I>2sigma(I)] R1 = 0.0416, wR2 = 0.1049; R 
indices (all data) R1 = 0.0482, wR2 = 0.1091; Largest diff. peak and hole = 0.354 and 
-0.246 e.Å-3. 
Table 1. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
N(1) 8144.5(17) 4869.8(4) 2622.9(5) 16.1(2) 
C(2) 7772(2) 4980.4(4) 3445.1(6) 17.5(2) 
C(3) 5782(2) 5388.7(4) 3530.5(6) 16.3(2) 
C(3A) 4850.3(19) 5541.2(4) 2710.0(6) 15.0(2) 
C(4) 2850(2) 5917.2(4) 2385.7(6) 17.7(2) 
C(5) 2477(2) 5964.4(5) 1540.1(6) 19.9(2) 
C(6) 4081(2) 5644.4(5) 1006.2(6) 19.8(2) 
C(7) 6052(2) 5263.9(4) 1305.5(6) 17.5(2) 
C(7A) 6397.2(19) 5213.1(4) 2160.8(6) 14.7(2) 
N(2) 5304.5(17) 6618.1(4) 5086.4(5) 16.2(2) 
O(1) 8792.4(16) 6270.7(4) 5928.5(5) 23.7(2) 
O(2) 1592.8(16) 7131.1(4) 4584.6(5) 21.9(2) 
C(1') 4945(2) 5676.4(4) 4308.0(6) 18.3(2) 
C(2') 5966(2) 6308.2(4) 4338.7(6) 18.0(2) 
C(3') 6862(2) 6586.2(4) 5819.0(6) 16.6(2) 
C(4') 5670.7(19) 7016.8(4) 6389.2(6) 15.2(2) 
C(5') 6453(2) 7175.8(5) 7184.2(6) 19.1(2) 
C(6') 5003(2) 7623.3(5) 7550.5(6) 21.2(2) 
C(7') 2866(2) 7895.5(5) 7130.5(6) 21.4(2) 
C(8') 2071(2) 7728.6(5) 6329.0(6) 19.3(2) 
C(9') 3515.1(19) 7285.3(4) 5973.7(6) 15.0(2) 
C(10') 3223(2) 7022.3(4) 5136.4(6) 15.4(2) 
C(1") 10120(2) 4471.9(4) 2292.1(6) 18.1(2) 
C(2") 8832(2) 3951.6(4) 1872.8(6) 19.7(2) 
C(3") 9487(2) 3723.7(5) 1152.7(6) 19.2(2) 
C(4") 11619(2) 3969.8(7) 628.4(8) 35.7(3) 
C(5") 8142(3) 3180.3(5) 812.9(8) 32.3(3) 
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Table 2. Bond lengths [Å]  
Atoms Distance Atoms Distance 
N(1)-C(7A)  1.3731(12) 
N(1)-C(2)  1.3801(12) 
N(1)-C(1")  1.4594(12) 
C(2)-C(3)  1.3733(14) 
C(3)-C(3A)  1.4375(13) 
C(3)-C(1')  1.4985(13) 
C(3A)-C(4)  1.4031(14) 
C(3A)-C(7A)  1.4177(13) 
C(4)-C(5)  1.3838(14) 
C(5)-C(6)  1.4089(15) 
C(6)-C(7)  1.3856(14) 
C(7)-C(7A)  1.3989(13) 
N(2)-C(10')  1.3942(13) 
N(2)-C(3')  1.3975(12) 
N(2)-C(2')  1.4557(12) 
O(1)-C(3')  1.2105(13) 
O(2)-C(10')  1.2124(12) 
C(1')-C(2')  1.5287(14) 
C(3')-C(4')  1.4909(13) 
C(4')-C(5')  1.3833(13) 
C(4')-C(9')  1.3897(13) 
C(5')-C(6')  1.3986(15) 
C(6')-C(7')  1.3898(16) 
C(7')-C(8')  1.3991(14) 
C(8')-C(9')  1.3820(14) 
C(9')-C(10')  1.4891(13) 
C(1")-C(2")  1.5003(14) 
C(2")-C(3")  1.3336(14) 
C(3")-C(4")  1.4997(16) 
C(3")-C(5")  1.5042(16) 
 
 
Table 3. Bond angles [°] 
Atoms Angle Atoms Angle 
C(7A)-N(1)-C(2) 108.53(8) 
C(7A)-N(1)-C(1") 125.26(8) 
C(2)-N(1)-C(1") 126.17(8) 
C(3)-C(2)-N(1) 110.39(9) 
C(2)-C(3)-C(3A) 106.18(8) 
C(2)-C(3)-C(1') 127.60(9) 
C(3A)-C(3)-C(1') 125.86(9) 
C(4)-C(3A)-C(7A) 118.96(9) 
C(4)-C(3A)-C(3) 134.04(9) 
C(7A)-C(3A)-C(3) 107.00(8) 
C(5)-C(4)-C(3A) 119.07(9) 
C(4)-C(5)-C(6) 120.96(9) 
C(7)-C(6)-C(5) 121.47(9) 
C(6)-C(7)-C(7A) 117.25(9) 
N(1)-C(7A)-C(7) 129.85(9) 
N(1)-C(7A)-C(3A) 107.89(8) 
C(7)-C(7A)-C(3A) 122.26(9) 
C(10')-N(2)-C(3') 112.05(8) 
C(10')-N(2)-C(2') 124.39(8) 
C(3')-N(2)-C(2') 123.28(9) 
C(3)-C(1')-C(2') 109.64(8) 
N(2)-C(2')-C(1') 113.46(8) 
O(1)-C(3')-N(2) 124.67(9) 
O(1)-C(3')-C(4') 129.48(9) 
N(2)-C(3')-C(4') 105.84(8) 
C(5')-C(4')-C(9') 121.50(9) 
C(5')-C(4')-C(3') 130.45(9) 
C(9')-C(4')-C(3') 108.00(8) 
C(4')-C(5')-C(6') 117.22(9) 
C(7')-C(6')-C(5') 121.18(9) 
C(6')-C(7')-C(8') 121.26(10) 
C(9')-C(8')-C(7') 117.08(10) 
C(8')-C(9')-C(4') 121.76(9) 
C(8')-C(9')-C(10') 130.05(9) 
C(4')-C(9')-C(10') 108.17(8) 
O(2)-C(10')-N(2) 124.91(9) 
O(2)-C(10')-C(9') 129.16(9) 
N(2)-C(10')-C(9') 105.91(8) 
N(1)-C(1")-C(2") 112.05(8) 
C(3")-C(2")-C(1") 126.23(10) 
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C(2")-C(3")-C(4") 123.93(10) 
C(2")-C(3")-C(5") 121.43(10) 
C(4")-C(3")-C(5") 114.63(10) 
 
Table 4. Hydrogen bonds [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
C(1")-H(1"1)...O(1)#1 0.99 2.56 3.3766(13) 139.5 
 C(2')-H(2'1)...O(2)#2 0.99 2.65 3.3897(13) 131.5 
 C(6')-H(6')...O(2)#3 0.95 2.48 3.4153(12) 169.6 
 
 
5.5 Crystallographic data of 2 
 
 
Identification code : flust; Empirical formula: C
17
H
22
N
2
O; M
r 
= 270.37; Temperature: 
100(2) K; Wavelength (λ) = 1.54184 Å; Crystal system: Monoclinic; Space group: Cc; 
a = 21.5126(8) Å; α = 90°, b = 14.3444(4) Å, β = 114.685(4)°, c = 10.8812(4) Å; γ = 
90°, Volume: 3050.95(17) Å3; Z: 8; ρ
calc
: 1.177 Mg/m3; Absorption coefficient (µ) = 
0.575 mm-1; F(000): 1168 ; Crystal size: 0.20 x 0.08 x 0.03 mm3; Theta range for data 
collection: 3.82 to 76.26°; Index ranges: -27<=h<=26, -18<=k<=18, -13<=l<=11; 
Reflections collected: 28569; Independent reflections: 3190 [R(int) = 0.0373]; Final R 
indices [I>2sigma(I)] R1 = 0.0358, wR2 = 0.0975; R indices (all data) R1 = 0.0372, 
wR2 = 0.0990; Largest diff. peak and hole = 0.266 and -0.183 e.Å-3. 
Table 1. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
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Atom x y z U(eq) 
N(1) 2432.5(9) 1270.4(12) -2399.9(17) 26.1(3) 
C(2) 2815.0(11) 1529.1(14) -1070(2) 26.0(4) 
C(3) 2396.0(11) 1556.4(14) -399(2) 25.7(4) 
C(3A) 1723.1(11) 1300.1(14) -1358(2) 26.1(4) 
C(4) 1085.3(11) 1189.8(16) -1305(2) 30.9(4) 
C(5) 525.2(12) 931.7(18) -2465(2) 36.0(5) 
C(6) 582.0(12) 767.4(17) -3688(2) 35.1(5) 
C(7) 1203.4(12) 861.4(15) -3777(2) 30.3(4) 
C(7A) 1765.9(11) 1130.7(14) -2602(2) 25.5(4) 
C(1') 2575.8(11) 1808.7(15) 1054(2) 26.9(4) 
C(2') 2667.0(11) 944.5(14) 1935(2) 27.1(4) 
C(3') 3570.0(12) 1555.9(18) 4113(2) 36.0(5) 
C(4') 2502.6(13) 965.7(16) 4038(2) 31.2(4) 
N(2) 2890.0(10) 1168.7(13) 3376.8(17) 28.6(4) 
O(1) 2674.0(10) 1088.6(12) 5245.0(17) 38.6(4) 
C(1") 3573.1(11) 1736.7(17) -560(2) 30.8(4) 
C(2") 3951.5(12) 1165(2) 707(2) 39.0(5) 
C(3") 4398.0(13) 1462(3) 1896(3) 53.2(8) 
C(4") 3852.3(13) 1431(2) -1594(3) 42.4(6) 
C(5") 3696.4(14) 2789.3(19) -323(3) 44.9(6) 
N(12) 2008.1(9) 3773.0(13) 2083.7(17) 25.8(3) 
C(22) 1642.4(11) 3473.8(14) 2798(2) 25.2(4) 
C(32) 2073.1(11) 3438.2(14) 4157(2) 25.8(4) 
C(3A2) 2733.4(11) 3735.6(14) 4289(2) 27.0(4) 
C(42) 3369.9(12) 3867.8(16) 5382(2) 32.8(5) 
C(52) 3916.5(12) 4172.0(19) 5141(3) 39.1(5) 
C(62) 3847.6(12) 4339.5(18) 3813(3) 38.5(5) 
C(72) 3229.8(12) 4219.8(16) 2713(2) 32.3(4) 
C(7A2) 2676.5(11) 3920.2(15) 2967(2) 26.5(4) 
C(1'2) 1909.2(11) 3166.1(15) 5325(2) 27.1(4) 
C(2'2) 1828.8(11) 4018.8(15) 6085(2) 27.6(4) 
C(3'2) 915.5(12) 3441.7(18) 6735(3) 37.1(5) 
C(4'2) 1986.8(14) 4002.1(16) 8442(2) 34.5(5) 
N(22) 1604.7(10) 3792.9(13) 7147.0(18) 29.2(4) 
O(12) 1806.8(12) 3890.5(13) 9365.3(18) 45.9(5) 
C(1"2) 888.6(11) 3229.2(16) 2066(2) 30.4(4) 
C(2"2) 818.5(12) 2191.8(19) 2273(2) 39.9(5) 
C(3"2) 439.8(17) 1812(2) 2835(3) 56.5(8) 
C(4"2) 623.9(12) 3390(2) 531(2) 37.9(5) 
C(5"2) 466.5(13) 3843(2) 2596(3) 41.5(6) 
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Table 2. Bond lengths [Å]  
Atoms Distance Atoms Distance 
N(1)-C(7A)  1.372(3) 
N(1)-C(2)  1.384(3) 
C(2)-C(3)  1.377(3) 
C(2)-C(1")  1.517(3) 
C(3)-C(3A)  1.434(3) 
C(3)-C(1')  1.506(3) 
C(3A)-C(4)  1.406(3) 
C(3A)-C(7A)  1.416(3) 
C(4)-C(5)  1.383(3) 
C(5)-C(6)  1.406(3) 
C(6)-C(7)  1.386(3) 
C(7)-C(7A)  1.398(3) 
C(1')-C(2')  1.529(3) 
C(2')-N(2)  1.472(2) 
C(3')-N(2)  1.453(3) 
C(4')-O(1)  1.219(3) 
C(4')-N(2)  1.341(3) 
C(1")-C(2")  1.516(3) 
C(1")-C(5")  1.536(3) 
C(1")-C(4")  1.544(3) 
C(2")-C(3")  1.319(4) 
N(12)-C(7A2)  1.372(3) 
N(12)-C(22)  1.385(3) 
C(22)-C(32)  1.380(3) 
C(22)-C(1"2)  1.519(3) 
C(32)-C(3A2)  1.432(3) 
C(32)-C(1'2)  1.506(3) 
C(3A2)-C(42)  1.402(3) 
C(3A2)-C(7A2)  1.416(3) 
C(42)-C(52)  1.378(3) 
C(52)-C(62)  1.411(3) 
C(62)-C(72)  1.379(3) 
C(72)-C(7A2)  1.398(3) 
C(1'2)-C(2'2)  1.526(3) 
C(2'2)-N(22)  1.462(3) 
C(3'2)-N(22)  1.448(3) 
C(4'2)-O(12)  1.228(3) 
C(4'2)-N(22)  1.336(3) 
C(1"2)-C(2"2)  1.522(3) 
C(1"2)-C(5"2)  1.539(3) 
C(1"2)-C(4"2)  1.541(3) 
C(2"2)-C(3"2)  1.323(4) 
 
 
Table 3. Bond angles [°] 
Atoms Angle Atoms Angle 
C C(7A)-N(1)-C(2) 109.41(17) 
C(3)-C(2)-N(1) 109.08(18) 
C(3)-C(2)-C(1") 130.00(19) 
N(1)-C(2)-C(1") 120.92(18) 
C(2)-C(3)-C(3A) 107.00(18) 
C(2)-C(3)-C(1') 128.68(19) 
C(3A)-C(3)-C(1') 124.32(18) 
C(4)-C(3A)-C(7A) 118.32(19) 
C(4)-C(3A)-C(3) 134.77(19) 
C(7A)-C(3A)-C(3) 106.91(18) 
C(5)-C(4)-C(3A) 119.0(2) 
C(4)-C(5)-C(6) 121.5(2) 
C(7)-C(6)-C(5) 121.1(2) 
C(6)-C(7)-C(7A) 117.05(19) 
N(1)-C(7A)-C(7) 129.42(19) 
N(1)-C(7A)-C(3A) 107.60(17) 
C(7)-C(7A)-C(3A) 122.98(19) 
C(3)-C(1')-C(2') 111.89(16) 
N(2)-C(2')-C(1') 112.99(17) 
O(1)-C(4')-N(2) 124.8(2) 
C(4')-N(2)-C(3') 119.69(18) 
C(4')-N(2)-C(2') 121.71(19) 
C(3')-N(2)-C(2') 118.43(18) 
C(2")-C(1")-C(2) 108.25(18) 
C(2")-C(1")-C(5") 112.9(2) 
C(2)-C(1")-C(5") 109.77(19) 
C(2")-C(1")-C(4") 106.5(2) 
C(2)-C(1")-C(4") 111.35(18) 
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C(5")-C(1")-C(4") 108.0(2) 
C(3")-C(2")-C(1") 127.7(3) 
C(7A2)-N(12)-C(22) 109.22(17) 
C(32)-C(22)-N(12) 109.17(19) 
C(32)-C(22)-C(1"2) 130.18(19) 
N(12)-C(22)-C(1"2) 120.65(18) 
C(22)-C(32)-C(3A2) 106.87(19) 
C(22)-C(32)-C(1'2) 128.71(19) 
C(3A2)-C(32)-C(1'2) 124.40(18) 
C(42)-C(3A2)-C(7A2) 118.4(2) 
C(42)-C(3A2)-C(32) 134.6(2) 
C(7A2)-C(3A2)-C(32) 107.01(18) 
C(52)-C(42)-C(3A2) 119.4(2) 
C(42)-C(52)-C(62) 121.0(2) 
C(72)-C(62)-C(52) 121.3(2) 
C(62)-C(72)-C(7A2) 117.2(2) 
N(12)-C(7A2)-C(72) 129.7(2) 
N(12)-C(7A2)-C(3A2) 107.69(18) 
C(72)-C(7A2)-C(3A2) 122.6(2) 
C(32)-C(1'2)-C(2'2) 111.67(17) 
N(22)-C(2'2)-C(1'2) 113.57(17) 
O(12)-C(4'2)-N(22) 124.6(3) 
C(4'2)-N(22)-C(3'2) 120.3(2) 
C(4'2)-N(22)-C(2'2) 121.55(19) 
C(3'2)-N(22)-C(2'2) 117.73(18) 
C(22)-C(1"2)-C(2"2) 107.35(18) 
C(22)-C(1"2)-C(5"2) 109.82(18) 
C(2"2)-C(1"2)-C(5"2) 113.2(2) 
C(22)-C(1"2)-C(4"2) 111.34(19) 
C(2"2)-C(1"2)-C(4"2) 107.01(19) 
C(5"2)-C(1"2)-C(4"2) 108.2(2) 
C(3"2)-C(2"2)-C(1"2) 126.1(3) 
 
 
Table 4. Hydrogen bonds [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(01)...O(1)#1 0.90(2) 1.95(2) 2.831(2) 167(2) 
 N(12)-H(012)...O(12)#1 0.88(2) 1.96(2) 2.810(2) 164(2) 
 
 
5.6 Crystallographic data of 165 
 
 
 
Identification code: skaph ; Empirical formula: C
18
H
14
N
2
O
2 
; M
r 
= 290.31; 
Temperature: 100(2) K; Wavelength (λ) = 0.71073 Å; Crystal system: Monoclinic; 
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Space group: P21; a = 7.2013(2) Å; α = 90°, b = 12.9847(3) Å, β = 97.824(3)°, c = 
15.1782(4) Å, γ = 90°, Volume: 1406.05(6) Å3; Z: 4; ρ
calc
: 1.371 Mg/m3; Absorption 
coefficient (µ) = 0.091 mm-1; F(000): 608; Crystal size: 0.40 x 0.25 x 0.08 mm3; Theta 
range for data collection2.71 to 30.50°; Index ranges: -10<=h<=10, -18<=k<=18, -
21<=l<=21; Reflections collected: 53966; Independent reflection: 4378 [R(int) = 
0.0403]; Final R indices [I>2sigma(I)] R1 = 0.0362, wR2 = 0.0869; R indices (all 
data) R1 = 0.0421, wR2 = 0.0907; Largest diff. peak and hole = 0.335 and -0.233 
e.Å-3 . 
Table 1. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
N(1) -344(2) 6582.7(12) 9872.8(10) 22.2(3) 
C(2) 301(3) 5613.4(15) 9704.3(12) 23.8(4) 
C(3) 525(2) 5512.3(15) 8826.5(12) 20.3(3) 
C(3A) -4(2) 6485.5(14) 8423.0(11) 16.5(3) 
C(4) -65(2) 6883.1(15) 7558.3(11) 20.0(3) 
C(5) -583(3) 7900.9(16) 7401.3(12) 23.4(4) 
C(6) -1099(3) 8534.1(15) 8084.6(12) 22.6(4) 
C(7) -1087(2) 8152.1(14) 8935.3(12) 20.0(3) 
C(7A) -516(2) 7139.2(13) 9097.9(10) 16.5(3) 
C(8) 1139(3) 4574.1(15) 8371.5(13) 24.2(4) 
C(9) -537(2) 3992.8(14) 7883.1(13) 21.2(3) 
N(2) 15(2) 3182.4(12) 7303.3(9) 17.1(3) 
C(10) 391(2) 3367.4(14) 6432.5(11) 17.3(3) 
O(1) 372.6(19) 4210.7(11) 6095.5(10) 25.2(3) 
C(11) 784(2) 2345.6(13) 6064.7(10) 14.6(3) 
C(12) 1229(2) 2075.5(15) 5237.2(11) 18.8(3) 
C(13) 1506(2) 1030.6(16) 5080.0(11) 20.8(4) 
C(14) 1380(2) 298.9(14) 5737.5(12) 20.2(3) 
C(15) 975(2) 577.5(14) 6579.3(11) 17.3(3) 
C(16) 656(2) 1609.1(13) 6719.1(10) 13.8(3) 
C(17) 201(2) 2151.9(14) 7527.0(11) 16.3(3) 
O(2) 35(2) 1786.2(11) 8252.0(8) 25.4(3) 
N(1') 6052(2) 464.1(11) 6271.4(9) 16.2(3) 
C(2') 6442(2) 351.0(13) 5408.3(10) 15.8(3) 
C(3') 6435(2) 1288.8(13) 4997.5(10) 14.2(3) 
C(3A') 6003(2) 2037.5(13) 5636.8(10) 13.3(3) 
C(4') 5807(2) 3114.6(13) 5622.1(11) 16.9(3) 
C(5') 5336(2) 3606.9(14) 6371.6(12) 19.6(3) 
C(6') 5069(2) 3052.0(15) 7137.5(11) 19.5(3) 
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C(7') 5278(2) 1990.5(14) 7176.2(10) 16.7(3) 
C(7A') 5750(2) 1492.3(13) 6419.5(10) 14.1(3) 
C(8') 6769(2) 1497.2(14) 4059.6(10) 16.3(3) 
C(9') 4925(2) 1744.2(14) 3462.8(10) 15.8(3) 
N(2') 5224.2(19) 2084.9(11) 2578.5(9) 14.5(3) 
C(10') 5643(2) 3097.4(13) 2382.5(11) 15.2(3) 
O(1') 5804.6(18) 3795.7(11) 2918.7(8) 21.9(3) 
C(11') 5812(2) 3124.9(14) 1417.5(10) 16.0(3) 
C(12') 6215(3) 3939.9(15) 889.6(12) 22.3(4) 
C(13') 6238(3) 3732.5(17) -14.5(12) 28.1(4) 
C(14') 5888(3) 2748.8(18) -352.0(12) 29.8(4) 
C(15') 5483(3) 1932.2(16) 185.7(11) 23.4(4) 
C(16') 5450(2) 2144.6(14) 1075.6(10) 16.1(3) 
C(17') 5056(2) 1453.7(13) 1819.2(10) 15.2(3) 
O(2') 4660.3(18) 550.2(10) 1809.4(8) 21.3(3)  
 
 
Table 2. Bond lengths [Å]  
Atoms Distance Atoms Distance 
 N(1)-C(7A)  1.371(2) 
N(1)-C(2)  1.377(2) 
C(2)-C(3)  1.370(2) 
C(3)-C(3A)  1.433(3) 
C(3)-C(8)  1.496(2) 
C(3A)-C(4)  1.405(2) 
C(3A)-C(7A)  1.417(2) 
C(4)-C(5)  1.385(3) 
C(5)-C(6)  1.412(3) 
C(6)-C(7)  1.382(3) 
C(7)-C(7A)  1.390(3) 
C(8)-C(9)  1.527(3) 
C(9)-N(2)  1.461(2) 
N(2)-C(17)  1.383(2) 
N(2)-C(10)  1.406(2) 
C(10)-O(1)  1.208(2) 
C(10)-C(11)  1.481(2) 
C(11)-C(12)  1.383(2) 
C(11)-C(16)  1.391(2) 
C(12)-C(13)  1.397(3) 
C(13)-C(14)  1.390(3) 
C(14)-C(15)  1.396(2) 
C(15)-C(16)  1.380(2) 
C(16)-C(17)  1.489(2) 
C(17)-O(2)  1.219(2) 
N(1')-C(7A')  1.376(2) 
N(1')-C(2')  1.384(2) 
C(2')-C(3')  1.368(2) 
C(3')-C(3A')  1.437(2) 
C(3')-C(8')  1.500(2) 
C(3A')-C(4')  1.406(2) 
C(3A')-C(7A')  1.416(2) 
C(4')-C(5')  1.387(2) 
C(5')-C(6')  1.403(3) 
C(6')-C(7')  1.387(3) 
C(7')-C(7A')  1.400(2) 
C(8')-C(9')  1.536(2) 
C(9')-N(2')  1.457(2) 
N(2')-C(10')  1.390(2) 
N(2')-C(17')  1.406(2) 
C(10')-O(1')  1.213(2) 
C(10')-C(11')  1.487(2) 
C(11')-C(12')  1.382(2) 
C(11')-C(16')  1.386(2) 
C(12')-C(13')  1.401(3) 
C(13')-C(14')  1.387(3) 
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C(14')-C(15')  1.393(3) 
C(15')-C(16')  1.382(2) 
C(16')-C(17')  1.499(2) 
C(17')-O(2')  1.207(2) 
 
Table 3. Bond angles [°] 
Atoms Angle Atoms Angle
C(7A)-N(1)-C(2) 108.39(15) 
C(3)-C(2)-N(1) 110.82(16) 
C(2)-C(3)-C(3A) 105.75(15) 
C(2)-C(3)-C(8) 127.45(18) 
C(3A)-C(3)-C(8) 126.78(16) 
C(4)-C(3A)-C(7A) 118.47(16) 
C(4)-C(3A)-C(3) 134.09(16) 
C(7A)-C(3A)-C(3) 107.42(14) 
C(5)-C(4)-C(3A) 119.00(17) 
C(4)-C(5)-C(6) 121.38(16) 
C(7)-C(6)-C(5) 120.55(17) 
C(6)-C(7)-C(7A) 118.00(17) 
N(1)-C(7A)-C(7) 129.85(16) 
N(1)-C(7A)-C(3A) 107.60(15) 
C(7)-C(7A)-C(3A) 122.55(16) 
C(3)-C(8)-C(9) 111.26(15) 
N(2)-C(9)-C(8) 112.71(14) 
C(17)-N(2)-C(10) 111.81(14) 
C(17)-N(2)-C(9) 125.05(15) 
C(10)-N(2)-C(9) 123.12(15) 
O(1)-C(10)-N(2) 124.10(17) 
O(1)-C(10)-C(11) 130.09(16) 
N(2)-C(10)-C(11) 105.81(14) 
C(12)-C(11)-C(16) 121.35(16) 
C(12)-C(11)-C(10) 130.47(15) 
C(16)-C(11)-C(10) 108.18(14) 
C(11)-C(12)-C(13) 117.24(16) 
C(14)-C(13)-C(12) 121.10(15) 
C(13)-C(14)-C(15) 121.48(17) 
C(16)-C(15)-C(14) 116.87(16) 
C(15)-C(16)-C(11) 121.92(15) 
C(15)-C(16)-C(17) 130.23(15) 
C(11)-C(16)-C(17) 107.83(14) 
O(2)-C(17)-N(2) 125.48(16) 
O(2)-C(17)-C(16) 128.22(16) 
N(2)-C(17)-C(16) 106.30(14) 
C(7A')-N(1')-C(2') 108.33(14) 
C(3')-C(2')-N(1') 110.38(15) 
C(2')-C(3')-C(3A') 106.39(14) 
C(2')-C(3')-C(8') 127.01(15) 
C(3A')-C(3')-C(8') 126.59(15) 
C(4')-C(3A')-C(7A') 119.12(15) 
C(4')-C(3A')-C(3') 133.85(15) 
C(7A')-C(3A')-C(3') 107.02(14) 
C(5')-C(4')-C(3A') 118.74(16) 
C(4')-C(5')-C(6') 121.30(17) 
C(7')-C(6')-C(5') 121.27(16) 
C(6')-C(7')-C(7A') 117.50(16) 
N(1')-C(7A')-C(7') 130.09(15) 
N(1')-C(7A')-C(3A') 107.86(14) 
C(7')-C(7A')-C(3A') 122.06(15) 
C(3')-C(8')-C(9') 111.09(13) 
N(2')-C(9')-C(8') 112.47(13) 
C(10')-N(2')-C(17') 111.90(13) 
C(10')-N(2')-C(9') 123.23(14) 
C(17')-N(2')-C(9') 124.83(14) 
O(1')-C(10')-N(2') 124.54(15) 
O(1')-C(10')-C(11') 129.02(16) 
N(2')-C(10')-C(11') 106.43(14) 
C(12')-C(11')-C(16') 122.00(15) 
C(12')-C(11')-C(10') 129.91(16) 
C(16')-C(11')-C(10') 108.08(14) 
C(11')-C(12')-C(13') 116.89(18) 
C(14')-C(13')-C(12') 120.87(18) 
C(13')-C(14')-C(15') 121.80(17) 
C(16')-C(15')-C(14') 116.97(18) 
C(15')-C(16')-C(11') 121.46(16) 
C(15')-C(16')-C(17') 130.30(17) 
C(11')-C(16')-C(17') 108.24(14) 
O(2')-C(17')-N(2') 124.79(16) 
O(2')-C(17')-C(16') 129.88(16) 
N(2')-C(17')-C(16') 105.33(14)
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Table 4. Hydrogen bonds [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 N(1)-H(01)...O(2)#1 0.91(2) 1.98(2) 2.8369(19) 156(2) 
 N(1')-H(01')...O(1')#2 0.90(2) 2.06(2) 2.9050(19) 157(3) 
 C(8)-H(8B)...O(2')#3 0.99 2.59 3.325(2) 130.9 
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6 Abbreviations 
9-BBN  borabicyclo[3.3.1]nonane 
Bp   boiling point 
mCPBA  meta-chloroperbenzoic acid 
DCM   dichloromethane 
DIBAL-H  diisobutylaluminiumhydride 
DMF   dimethylformamide 
DMSO  dimethyl sulfoxide 
EI    electron ionization 
ESI    electrospray ionization 
HV    high vacuum 
HMBC  heteronuclear multiple bond correlation 
HPLC   high performance liquid chromatography 
HSQC  heteronuclear single quantum correlation 
HR   high resolution 
IH   Isohexane 
IC
50   
inhibitory concentration 50% 
MCD   Magnetic Circular Dichroism 
M.p.  melting point 
NBS   N-bromosuccinimide 
NCS   N-chlorosuccinimide 
NMR  nuclear magnetic resonance 
R
f   
retention factor 
RP   reversed phase 
rt   room temperature 
TBAT   tetrabutylammonium difluorotriphenylsilicate 
TBME   tert-Butyl methylether  
TFA   trifluoroacetic acid 
THF   tetrahydrofuran  
TLC   thin layer chromatography 
TMS    tetramethylsilane 
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